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Abstract 
There is a growing recognition that we cannot afford the provision of all new health care 
technologies, even those that are proven to be beneficial.  This is increasingly true in the 
US, where health care spending is on an unsustainable upward trajectory.  US health care 
spending is greatly in excess of that of other countries; however, with respect to key 
health metrics, the US health care system performs relatively poorly.  Despite this, unlike 
many other developed countries economic evaluation, and more specifically cost-
effectiveness evidence, is used sparingly in the US health care system.  Notably, the 
Centers for Medicare and Medicaid Services (CMS), administrators of the Medicare 
programme, state that cost-effectiveness evidence is not relevant to coverage decisions 
for medical technology and interventions evaluated as part of National Coverage 
Determinations (NCDs).  The empirical aspect of this thesis evaluates the current use and 
potential value of using cost-effectiveness evidence in CMS NCDs.  A database was built 
using data obtained from NCD decision memoranda, the medical literature, a Medicare 
claims database, and Medicare reimbursement information.  The findings of the empirical 
work show that, CMS’s stated position notwithstanding, cost-effectiveness evidence has 
been cited or discussed in a number of coverage decisions, and there is a statistically 
significant difference between positive and non-coverage decisions with respect to cost-
effectiveness.  When controlling for factors likely to have an effect on coverage 
decisions, the availability of cost-effectiveness evidence is a statistically significant 
predictor of coverage.  In addition, the quality of the supporting clinical evidence, the 
availability of alternative interventions, and the recency of the decision are statistically 
significant variables.  Further, when hypothetically reallocating resources in accordance 
with cost-effectiveness substantial gains in aggregate health are estimated.  It is shown 
that using cost-effectiveness to guide resource allocation has an effect on resource 
allocation across patient populations and types of technology.   
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CVZ College voor Zorgverzekeringen 
DBS Deep Brain Stimulation 
DERP Drug Effectiveness Review Project 
DoD Department of Defense 
DoH Department of Health 
DPN Diabetic Peripheral Neuropathy 
ECP External Counterpulsation 
EQ-5D EuroQol Group 5-Dimension Self-Report Questionnaire 
ESA Erythropoiesis Stimulating Agents 
ESRD End-Stage Renal Disease 
FDG 2-Fluorodeoxy-D-Glucose 
FOBT Fecal Occult Blood Test 
G-BA Federal Joint Committee (Germany) 
GDP Gross Domestic Product 
HCFA Health Care Financing Administration 
HDA Health Development Agency 
HEED Health Economic Evaluations Database 
HIV Human immunodeficiency virus 
HTA Health Technology Assessment 
HUI Health Utilities Index 
ICD Implantable Cardioverter Defibrillator 
ICD-9 International Classification of Diseases 
ICER Incremental Cost-Effectiveness Ratio 
IDU Intravenous Drug Use 
iFOBT Immunological Fecal Occult Blood Testing 
INR International normalised ratio 
IQWiG Institute for Quality and Efficiency in Health Care 
ISPOR International Society of Pharmacoeconomics and Outcomes Research 
LAGB Laparoscopic Adjustable Gastric Banding 
LOPS Loss of Protective Sensation 
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MBS Medicare Benefits Schedule 
MEDCAC Medicare Evidence Development & Coverage Advisory Committee 
MILP Mixed Integer Linear Programme 
MIPPA Medicare Improvements for Patients and Providers Act 
MRI Magnetic Resonance Imaging 
MSAC Medical Services Advisory Committee 
NA Not applicable 
NCD National Coverage Determination 
NEMA National Electric Manufacturers Association 
NETT National Emphysema Treatment Trial 
NHS National Health Service 
NHS EED National Health Service Economic Evaluations Database 
NICE National Institute for Health and Clinical Excellence 
NNWT Noncontact Normothermic Wound Therapy 
OECD Organisation for Economic Co-operation and Development 
OR Odds Ratio 
OSA Obstructive Sleep Apnea 
OTA Office of Technology Assessment 
P&T Pharmacy and Therapeutics  
PBAC Pharmaceutical Benefits Advisory Committee 
PBS Pharmaceutical Benefits Scheme 
PCORI Patient-Centered Outcomes Research Institute 
PCT Primary Care Trust 
PET Positron Emission Tomography 
PhRMA Pharmaceutical Research and Manufacturers Association of America 
PPACA Patient Protection and Affordable Care Act 
PPP Purchasing Price Parity 
PTA Percutaneous Transluminal Angioplasty 
QALY Quality Adjusted Life Year 
R&D Research and Design 
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ROC Receiver Operating Characteristic 
RYGBP Roux-en-Y gastric bypass 
SBU Swedish Council of Technology Assessment in Health Care 
SG Standard Gamble 
SGB Sendi, Gafni, and Birch 
SNM The Society of Nuclear Medicine 
SSA Social Security Amendments  
TA Technology Assessment 
TEC Blue Cross Blue Shield Association Technology Evaluation Center  
TLV Tandvårds- och läkemedelsförmånsverket (Sweden) 
TTO Time-Trade Off 
UK United Kingdom 
US United States of America  
USPSTF US Preventative Services Task Force 
VA Department of Veterans Affairs 
VBP Value Based Pricing 
VIF Variance Inflation Facor 
WHO World Health Organization 
WTP Willingness To Pay 
 
 
 
 
 
  
23 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
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There is growing recognition that we cannot afford the provision of all new health care 
technologies, even those that are proven to be beneficial.  This is increasingly true in the 
US, where health care spending is on an unsustainable upward trajectory, and where 
current health care spending is twice that of many developed countries in terms of GDP 
per capita.  
 
The US health care system performs poorly in comparison to others.  Ranked 37th by the 
World Health Organization (WHO) in their global rankings of health care systems, and 
placed last in the Commonwealth Fund’s 2010 rankings of health care systems in 
Australia, Canada, New Zealand, the United Kingdom, Germany, the Netherlands and the 
US, the US health care system has much room for improvement.  Despite health care 
spending greatly in excess of that in other developed countries, average life expectancy in 
the US is shorter and infant mortality higher.  Further, with respect to health care 
resources, the US has fewer physicians and hospital beds per capita compared to other 
developed countries.  Most notable, however, is the lack of universal health insurance 
coverage in the US, with many US citizens having either no or insufficient health 
insurance.  
 
There is increasing awareness that resource allocation must be addressed in a systematic 
rather than intuitive manner.  One approach to the prioritisation of resources between 
competing interventions is to use economic evaluation to assess health care technology.  
In Chapter 2, I present the theory underpinning the use of economic evaluation, and more 
specifically cost-effectiveness analysis, to inform resource allocation.  I provide a worked 
example illustrating how a cost-effectiveness decision rule can lead to the efficient 
allocation of scarce resources across multiple health care programmes.  I describe the 
league table and mathematical programming approaches as two frameworks for 
implementing a cost-effectiveness decision rule.  The practicality of both approaches is, 
however, restricted by the requirement for complete knowledge of the costs and benefits 
of available health care programmes.  Therefore, it is necessary to have a benchmark 
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value, or decision rule, with which to interpret the findings of cost-effectiveness studies.  
The remainder of Chapter 2 focuses on the cost-effectiveness threshold.  I present the 
various valuations of the cost-effectiveness threshold, including the threshold operated by 
the National Institute for Health and Clinical Excellence (NICE) in the UK and 
thresholds derived through retrospective evaluation of decisions made by various 
international agencies.  I also present the advantages and disadvantages of hard vs. soft 
and explicit vs. implicit cost-effectiveness threshold valuations, and of cost-effectiveness 
acceptability curves, used to interpret cost-effectiveness evidence while conveniently 
evading the question of the value of the cost-effectiveness threshold.   
 
In Chapter 3, I place the US health care system into an international context with respect 
to spending, abundance of health care resources, and key health statistics.  Comparator 
countries were chosen on the basis that they help illustrate variation in how economic 
evidence and other factors are considered in the evaluation of health care technologies 
across jurisdictions.  I chose the UK, Sweden, Australia, and Canada as examples of 
countries in which cost-effectiveness evidence plays a fundamental role in decision-
making, and Germany and France as examples of countries in which cost-effectiveness 
evidence plays a lesser role.  In spite of health care spending greatly in excess of 
spending in other countries, the US health care system performs poorly across a number 
of key health metrics.  Despite an evident need to increase the return on health care 
spending, cost-effectiveness evidence is used only sporadically in the US health care 
system.  Notably, and of particular relevance to the empirical aspect of this thesis, 
Medicare, the largest payer in the US, states that cost-effectiveness is not a factor 
considered in its coverage decisions.  To provide insight into the resistance to cost-
effectiveness evidence in the US health care system, I review the failed attempts by 
Medicare and the state of Oregon’s Medicaid programme to incorporate cost-
effectiveness evidence into decision-making.  Finally, I discuss the implications of the 
recent Patient Protection and Affordable Care Act (PPACA) legislation for the future use 
of cost-effectiveness evidence in the US, and highlight recent instances in which the 
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Centers for Medicare and Medicaid Services (CMS) used cost-effectiveness evidence in 
coverage decisions for preventative care. 
 
The foundations of my empirical work are presented in Chapter 4.  I chose Medicare, the 
health insurance programme for Americans aged 65 years and over and those with certain 
disabilities, as the aspect of the US health care system on which to focus my research.  
Medicare is the largest payer in the US, providing coverage to 46 million Americans at a 
cost of $6 billion, approximately 5 % of GDP.  Medicare coverage decisions for medical 
technology have far-reaching influence and are thought to affect private payers’ coverage 
decisions.  This research concerns CMS’s national coverage policies, or National 
Coverage Determinations (NCD).  National Coverage Determinations are binding to all 
regional Medicare Administrative Contractors (MACs), and are reserved for interventions 
deemed particularly controversial or projected to have a major impact on the Medicare 
programme.   
 
The research objectives for the empirical component of this thesis are as follows: 
Empirical Research: Part 1 
1. To examine NCD decision memos to determine if the presented evidence 
review is consistent with CMS’s stated position that cost-effectiveness 
evidence is not relevant to coverage decisions.  
2. To determine if there is a difference between the cost-effectiveness of positive 
coverage decisions and non-coverage decisions. 
Empirical Research: Part 2 
1. To determine if cost-effectiveness is an independent predictor of coverage 
decisions included in NCDs when controlling for other factors likely to have 
an effect on coverage decisions. 
Empirical Research: Part 3 
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1. To estimate potential gains in aggregate health achieved from reallocating 
expenditures between interventions covered as part of NCDs in a manner 
consistent with a cost-effectiveness decision rule.  
2. To estimate the impact of reallocation on the distribution of expenditures 
across disease areas (oncology, cardiology, and other) and types of 
intervention (treatment, diagnostic, and other). 
 
Also in Chapter 4, I describe a literature search I performed to identify studies to help 
inform the methodological approach for the empirical work.  First, I performed a search 
to identify studies that evaluated the role of cost-effectiveness evidence in coverage and 
reimbursement decisions, or in recommendations for the efficient use of medical 
technology.  I identified and reviewed studies that evaluated decisions made by NICE in 
the US, the PBAC in Australia, CEDAC in Canada, PHARMAC in New Zealand, and an 
HMO in the US.  Second, I performed a search to identify studies that estimated 
efficiency gains from alternative approaches for resource allocation.     
 
In the remainder of Chapter 4, I describe the development of the database used for the 
empirical work.  Variables in the database include cost-effectiveness, quality of 
supporting clinical evidence, availability of alternative interventions, date of decision, 
coverage requestor, and type of intervention.  I primarily generated the cost-effectiveness 
variable through literature searches, although on occasion a relevant cost-effectiveness 
ratio originated from the decision memo accompanying the NCD.  The variable 
classifying the quality of the supporting clinical evidence was generated through review 
of the decision memo by two researchers at Tufts Medical Center using the US 
Preventative Service Task Force (USPSTF) guidelines for grading evidence.  I generated 
the remaining variables from the information presented in decision memos.  Additional 
variables were required for the third piece of empirical work, including incremental cost 
and incremental QALY gain data, the cost of the intervention in the year following its 
first use, the existing utilisation rate, and the size of the eligible patient population.  The 
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incremental cost and incremental effectiveness data typically originated from the cost-
effectiveness studies; the existing utilisation rate and size of the eligible patient 
population from a Medicare claims database; and the additional cost data required for 
estimation of the intervention in the year following first use from Medicare 
reimbursement codes.  
 
Chapter 5 describes the first piece of my empirical work.  As noted, CMS state that cost-
effectiveness is not a factor it considers when making NCDs.  The first objective of the 
research presented in chapter 5 was to examine NCD decision memos to identify 
instances when cost-effectiveness evidence is cited or discussed, thus assessing the 
consistency of CMS’s behaviour with its stated position on the use of cost-effectiveness 
evidence.  I reviewed each decision memo (n=140) for discussion or citation of cost-
effectiveness evidence relevant to the included coverage decisions (n=255).  On 14 
occasions, a coverage decision was associated with either discussion of cost-effectiveness 
evidence or a citation of a relevant cost-effectiveness study.  Twelve of the 14 coverage 
decisions were positive, and notably, in each instance the estimate of cost-effectiveness 
was favourable (maximum ICER of $27,161 per life year gained).  The second objective 
of this research was to determine if there is a difference between positive and non-
coverage decisions with respect to cost-effectiveness.  I supplemented the estimates of 
cost-effectiveness identified in decision memos with a series of literature searches to 
identify published estimates of cost-effectiveness relevant to included coverage decisions.  
For 64 coverage decisions, an associated cost-effectiveness estimate was identified.  
Findings show that CMS are covering interventions not cost-effective by traditional 
standards; nine covered interventions are associated with an ICER greater than $100,000 
per QALY and three with an ICER greater than $500,000 per QALY.  I used a Mann 
Whitney U test to determine a statistically significant difference between positive 
coverage decisions and non-coverage decision with respect to their cost-effectiveness, 
suggesting that interventions subject to positive coverage decisions tend to be associated 
with more favourable cost-effectiveness evidence. 
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Chapter 6 describes the second piece of empirical work.  This research builds on Chapter 
5 and evaluates whether, when controlling for factors that are likely to have an effect on 
Medicare coverage decisions, cost-effectiveness, or the availability of cost-effectiveness 
evidence, is statistically significantly associated with the coverage decision.  In addition 
to cost-effectiveness, I accounted for a number of aspects thought to be relevant to 
decision-making, with independent variables such as the quality of the supporting clinical 
evidence, the availability of alternative interventions, intervention type, origin of the 
request for coverage, and date of the decision included in the model.  I estimated the 
model using binomial logistic regression, regressing the coverage decision (positive/non-
coverage) against the independent variables.  I performed univariate and multivariate 
regressions.  Compared with interventions estimated to be dominant, those with no 
associated estimate of cost-effectiveness were approximately five times less likely to 
receive a positive coverage decision.  Interventions associated with good quality 
supporting clinical evidence were six times more likely to receive a positive coverage 
decision compared with those associated with insufficient evidence.  Compared to 
interventions with no available alternative, those with an available alternative were 
approximately eight times less likely to be associated with a positive coverage decision.  
Finally, coverage decisions made in 2006-2007 were approximately 10 times less likely 
to be associated with a positive coverage decision than those made in 1999-2001, with 
interventions considered in more recent time periods increasingly less likely to be 
associated with a positive coverage decision.   
 
While the findings are insufficient to conclude that CMS coverage decisions are 
consistent with cost-effectiveness, it is notable that the availability of cost-effectiveness 
evidence estimating the intervention to be dominant is associated with the coverage 
decision.  In addition, this research provides insight into the ‘reasonable and necessary’ 
coverage criterion, suggesting that CMS operate evidence-based coverage policy and 
highlighting that the availability of alternatives is relevant to decision-making.  The 
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findings show that, when controlling for other factors, CMS became more restrictive with 
respect to coverage over the time period considered.   
 
Chapter 7 describes the third piece of empirical work.  In the research presented in 
Chapter 5, I determined that CMS cover a number of interventions not cost-effective by 
traditional standards.  Coverage of interventions with high ICERs is inefficient as it 
consumes considerable resources and produces marginal health gains.  The research 
presented in Chapter 7 considers the question of the inefficient use of resources and 
estimates what gains in aggregate health could be achieved from allocating resources 
using a cost-effectiveness rule.  Specifically, the objectives of the research are to estimate 
potential gains in aggregate health from reallocating existing expenditures, and to 
estimate the impact of reallocation on the distribution of resources across disease areas 
and types of intervention.  To reallocate expenditures between interventions, I simulated 
disinvestment in relatively cost-ineffective interventions and increased investment in 
cost-effective interventions through the manipulation of utilisation rates.  The findings 
estimate that substantial gains in aggregate health are achievable from reallocating 
expenditures to maximise health while maintaining a net change in total expenditure of 
zero.  Further, simply increasing the utilisation of dominant interventions was estimated 
to yield substantial aggregate health gains and cost-savings.  The distribution of 
expenditures across disease areas and types of technology following reallocation of 
resources was different than the existing distribution.   
 
Chapter 8 constitutes the final chapter of this thesis, in which I summarise the empirical 
work and discuss the key findings.  Also, I discuss the limitations of this thesis and the 
steps that can be taken to further develop its empirical aspects.  Finally, I describe how 
this thesis contributes to knowledge and its policy relevance.   
 
This thesis will contribute to knowledge in a variety of ways.  First, it provides the first 
systematic assessment of the cost-effectiveness of interventions evaluated by CMS 
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through NCDs, illustrating that CMS cover interventions that do not represent good 
value, although there is a statistically significant difference between positive and non-
coverage decisions with respect to cost-effectiveness.  Second, it provides the first 
empirical analysis of CMS NCDs that considers a variety of factors likely to have an 
effect on coverage decisions.  This analysis shows that the quality of the supporting 
clinical evidence, the availability of alternative interventions, the date of the decision, and 
the availability cost-effectiveness evidence are associated with coverage decisions.  
Third, it provides the first attempt to estimate efficiency gains in the Medicare 
programme through the hypothetical reallocation of resources using cost-effectiveness 
evidence.  The analysis shows that substantial gains in aggregate health are achievable 
from using a cost-effectiveness rule to inform resource allocation while maintaining 
existing levels of expenditures.   
 
Given the recent passing of the PPACA legislation and the ongoing debate surrounding 
the future of the Medicare programme, this thesis is timely in terms of policy relevance.  
This research sheds light on the value of interventions offered in the Medicare 
programme and shows that CMS have on occasion included cost-effectiveness evidence 
in their review of the evidence base.  The research illustrates the evidence-based nature of 
CMS coverage decisions and provides an insight into the interpretation of the ‘reasonable 
and necessary’ criteria operated by CMS.  This type of research has the potential to lead 
to better and more consistent decision-making and increase the accountability of CMS.  
The research suggests that substantial gains in aggregate health are achievable from 
reallocating existing expenditures, and that cost-effectiveness evidence has the potential 
to inform more efficient resource allocation decisions.   
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2. Background and Theory 
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2.1. Introduction 
In this chapter, I describe the role of economic evaluation in the allocation of scarce 
health care resources.  Unlike other sectors of the economy, market forces cannot be 
relied upon for resource allocation in health care.  Economic evaluation offers an 
approach to help choose between competing health care interventions to prioritise health 
care spending.  
 
In the following sections, I describe two methods of economic evaluation, cost-
effectiveness analysis and cost-benefit analysis, and the key differences between them.  I 
provide a worked example using a scenario including multiple health care programmes to 
illustrate how adherence to a cost-effectiveness decision rule will result in efficient 
resource allocation.  Two frameworks for implementing a cost-effectiveness decision rule 
are described; the league table approach and mathematical programming.  These 
approaches are limited by the magnitude of the information requirements.  Alternative 
frameworks such as the ‘searching for the threshold’ and the ‘Sendi, Gafni, and Birch’ 
are discussed as approaches that are not inhibited by these information requirements.    
 
The requirement of a cost-effectiveness threshold to interpret cost-effectiveness evidence 
is highlighted and a worked example illustrates how a calibrated threshold can lead to 
efficient resource allocation. The last section of this chapter focuses on approaches for 
the derivation of the cost-effectiveness threshold, various valuations of thresholds that are 
used or have been proposed, and various criteria with which thresholds can be 
characterised.  Cost-effectiveness acceptability curves (CEAC) are also shown as a 
method of presenting cost-effectiveness findings that avoids the need for a cost-
effectiveness threshold. 
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2.2. The need for economic evaluation in health care 
2.2.1. The scarcity of health care resources   
Health care resources are scarce.  Consequently, health care systems cannot provide all 
care that would potentially benefit patients.  Decisions must be made as how best to 
allocate available resources to meet health care system goals.  Often referred to as the 
prioritisation or rationing of resources, resource allocation can be emotive and 
contentious.   
 
While currently at the forefront of health care policy debate, the prioritisation of health 
care resources is not only a recent concern.  It has always been the case that doctors have 
had to judge the reasonableness of the care they provide. (Ubel, 2001; Ubel & Goold, 
1997)  Williams, 2002 states, “Time and effort and other health care resources devoted to 
one patient could not be devoted to another, so they had to decide how to allocate these 
scarce resources so as to do the most good, as they saw it.”(Williams, 2002) 
 
How to allocate scarce health care resources remains a challenge.  In many countries 
specialised institutions have been established to provide guidance on resource allocation, 
e.g., the National Institute for Health and Clinical Excellence (NICE) in the UK.  A 
principal role of these institutions is to evaluate the evidence base for new and established 
interventions as a precursor to coverage and reimbursement decisions or to provide 
guidance to practitioners.  It seems reasonable to ask why such institutions are necessary.  
Similar institutions do not exist in other industries in which market forces are relied upon 
to drive down costs and to efficiently allocate resources.  In the following section, I will 
discuss why markets are insufficient and inappropriate for health care resource allocation. 
 
2.2.2. Markets in health care 
In many industries, markets are the mechanism used to ration goods.  The forces that 
determine the price and quantity of goods in a market are supply and demand.  Alone, 
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however, markets are insufficient to ration health care.   
 
In the absence of government intervention, uncertainty, asymmetry of information, and 
risk preferences for health and health care precipitate the need and desire for health 
insurance.  However, for three principal reasons markets do not work well in health care. 
(Donaldson et al. 2005;Donaldson 2008;Donaldson et al. 2008)  First, insurance 
premiums are actuarially unfair.  If health insurance was actuarially fair then premiums 
paid would be equivalent to expenditure incurred.  However, in reality, health insurance 
is actuarially unfair, as the premiums are ‘loaded’ to cover administration costs and 
achieve profit.  Consequently, some who would otherwise have obtained insurance will 
be priced out of the market. (Donaldson et al. 2005;Donaldson 2008)  The second reason 
is ‘moral hazard’.  Moral hazard is the term used to describe how having insurance 
coverage changes individuals’ behaviour.  If a third party, i.e., the insurer, pays for health 
care, individuals have less incentive to avoid illness or injury and thus are more likely to 
use health care than if they were uninsured.  This will result in cost inflation with health 
care becoming more expensive without a corresponding increase in health outcomes. 
(Donaldson et al. 2005;Donaldson 2008)  Finally, a well-functioning health insurance 
market will set premiums in line with individual risk, i.e., low premiums for those at low 
risk and higher premiums for those at higher risk.  This is problematic as individuals at 
higher risk tend to be those who can least afford insurance coverage.  This results in a 
social problem, as those in most need of health care are those without health insurance 
coverage. (Donaldson et al. 2005;Donaldson 2008)   
 
Despite circumventing, at least in part, some of the reasons for market failure, the 
establishment of publicly funded health care systems do not avoid the problem of scarcity 
and the need to prioritise available resources.  Economic evaluation, as part of a broader 
health technology assessment (HTA) programme, is one mechanism by which a health 
care system can work toward achieving value from health care spending.  Through the 
use of economic evaluation, including cost-effectiveness analysis, the relative value of 
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competing interventions can be used to guide resource allocation decisions.  There is 
debate, however, as to the underlying economic framework that should be used when 
evaluating health care programmes.  Debate has focused upon the welfarist and extra-
welfarist frameworks; these are discussed below. 
 
2.3. Economic evaluation in health care 
Economic evaluation forms the basis of informing efficient resource allocation.  Within 
the field of health economics, economic evaluation has been defined as a method of 
‘‘ensuring that the value of what is being gained from an activity outweighs the value of 
what is being sacrificed’’. (Williams 1983) 
 
2.3.1. Efficiency in health care 
To understand the use of economic evaluation in health care, it is necessary to appreciate 
different concepts of efficiency.  Palmer and Torgerson (1999) describe three concepts of 
efficiency; allocative, productive, and technical efficiency. (Palmer & Torgerson 1999)  
Each concept is described below. 
 
Technical efficiency relates to the relationship between resources (capital and labour) and 
health outcome.  An allocation of resources is technically efficient when the maximum 
health outcome is achieved from a set of input resources.  Accordingly, a particular 
allocation of resources is technically inefficient when the same health outcome can be 
achieved with less of any one type of input. (Palmer & Torgerson 1999) 
 
Productive efficiency relates to the relationship between health outcome and the cost of 
input resources.  This differs from technical efficiency, which does not account for 
circumstances where the same health outcome can be achieved with a different 
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combination of inputs.  By considering input costs it is possible to choose between 
different combinations of resources to maximise health outcome within a budget 
constraint.  With respect to health care interventions, the consideration of productive 
efficiency facilitates evaluation of the relative value for money of interventions that 
generate directly comparable health outcomes. (Palmer & Torgerson 1999) 
 
In contrast to technical and productive efficiency, allocative efficiency accounts for the 
efficiency with which outcomes are distributed across society.  Resource use is 
allocatively efficient when any alternative allocation of resources results in at least one 
person being worse off.  Absolute adherence to this principle is difficult, as doing so 
would preclude an allocation of resources resulting in many people benefiting in terms of 
health gain at the expense of few being made worse off.  Consequently, the decision rule 
has been modified; resource allocation is allocatively efficient when the welfare of the 
community is maximised.  Accordingly, allocative efficiency has its roots in welfare 
economics. (Palmer & Torgerson 1999) 
 
2.3.2. The allocation of scarce resources 
Health care decision makers can take two broad approaches when allocating scarce 
resources.  The first approach is to eliminate system waste, i.e., to reduce spending 
without affecting the ability to produce specific health care outputs.  Waste is present in 
varying degrees in all health care systems and its reduction is likely a significant source 
of savings in some health care systems. (Delaune & Everett 2008;Donaldson et al. 2008)  
One approach to waste reduction is to ensure that care is ‘appropriate’, i.e., that the 
potential benefits of care outweigh the potential harms.  Efforts to evaluate the 
appropriateness of care have led to the development of frameworks based upon available 
clinical evidence and expert opinion to guide when care should be provided. (Brook et al. 
1986;Brook 2009;Fitch et al. 2001)  Examples include frameworks for gastrointestinal 
endoscopy, tympanostomy tubes, and coronary angiography. (Froehlich et al. 
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1997;Hemingway et al. 2008;Kleinman et al. 1994)   
 
The second approach is to attempt to prioritise resources in order to maximise return, in 
terms of health gain, from investment.  This requires maximising investment in health 
care programmes that generate most health benefit from investment and minimising 
investment in programmes that generate little, or no, return. (Donaldson et al. 2008)  To 
achieve efficient health care spending the allocation of resources must be done in a 
rational manner.  There is debate, however, as to the most appropriate method for health 
care resource allocation. (Drummond et al. 2005;Gafni & Birch 2006;Holm 1998;Ubel & 
Goold 1997)   
 
Various criteria are likely to be considered when allocating scarce resources between 
health care programmes.  The nature and strength of the available evidence, the potential 
impact of a decision on access to care, relative value for money, and the economic 
consequences of implementation are likely to be criteria in the decision-making process. 
(Drummond et al. 2005;Folland, Goodman, & Stano 2003;Keenan, Neumann, & Phillips 
2006;Neumann 2005)  Society’s preferences for the allocation of resources are also 
important, and may not be in accordance with the maximisation of health.  It has been 
shown that society typically values care for the elderly, the treatment of more severe 
diseases, and the avoidance of discrimination against people with chronic illnesses or 
disabilities highly. (Neumann 2005;NICE 2010c;Ubel 2001)  It is a challenge for health 
care decision makers to concurrently account for each of these criteria and it may be 
necessary for a decision maker to trade off each factor against the magnitude of health 
gain. (Devlin & Sussex 2011)  Across jurisdictions decision makers are, therefore, likely 
to have unique internal criteria and to allocate health care resources differently.   
 
It is necessary to use a consistent decision-making framework.  Without a framework 
with which to make decisions, a decision maker has to rely on judgement or to assume 
that what was done before was the best course of action.  Relying on previous decisions 
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to guide resource allocation is rarely likely to yield more efficient decisions than the 
systematic consideration of relevant criteria. (Drummond et al. 2005)  It has been 
suggested that decisions should be fully transparent, must rest upon criteria that 
stakeholders agree are relevant, and should be revisable following the availability of 
additional evidence. (Daniels 2000) 
 
2.3.3. Welfarism vs. extra-welfarism 
Welfare economics is a branch of economics that uses microeconomic techniques to 
examine individuals’ preferences, the optimal allocation of resources, and the 
consequences of resource allocation on social welfare. (Birch & Donaldson 
2003;Brouwer et al. 2008;Coast 2004;Johannesson 1995)  Cost-benefit analysis has its 
theoretical foundations in welfare economics. (Jonsson 2009a)  Cost-benefit analysis 
requires the consequences of a health care programme to be measured in monetary units, 
facilitating a comparison of costs and benefits in commensurate units.  The decision rule 
is simply that if benefits outweigh costs, the health care programme should be 
implemented, and if not, it should not be implemented.  With its theoretical 
underpinnings in welfare economics, cost-benefit analysis is conceptually appealing.  The 
key criterion when considering a redistribution of resources is whether the redistribution 
represents a potential Pareto improvement (Kaldor-Hicks criterion) in social welfare, i.e., 
those who gain from a policy change compensate the losers and remain in a preferred 
position. (Gafni 2006;Sugden & Williams 1979)  For example, if willingness to pay for 
health care is greatest for the wealthiest in society, then a policy change that results in 
greater health care for the wealthiest would be optimal, as the gainers could compensate 
the losers and remain better off.  Such a policy would therefore benefit society as a 
whole, increasing overall social welfare. (Drummond et al. 2005)  Cost-benefit analysis is 
established as the methodology of choice in sectors of the economy other than health 
care, including transportation and education. (Claxton et al. 2010)   
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2.3.4. Applying cost-benefit analysis to health care 
There are a number challenges to applying cost-benefit analysis to health care.  Placing a 
monetary value on health is associated with a number of difficulties. (Ryan et al. 2001)  
Various techniques exist, including; the human capital, revealed preference, and 
contingent valuation approaches (See Section 2.6.1.1 for further details). (Buxton 
2005;Drummond et al. 2005a)  Each of these approaches has strengths and weaknesses 
and none is universally accepted.  Assigning a monetary value to health is contentious 
and many decision makers find it difficult, or even unethical, to depend on such 
valuations. (Weinstein & Feinberg 1980)  Maybe the most notable challenge is that 
methods that place a monetary value on health intrinsically favour the wealthiest in 
society. (Gold et al. 1996)  To date, cost-benefit analysis has been used infrequently to 
inform resource allocation in health care, with cost-effectiveness analysis the preferred 
approach. (Drummond et al. 2005)  
 
2.3.5. Extra-welfarism and cost-effectiveness analysis 
Given the challenges outlined above, an alternative to the welfarist framework has been 
favoured within health economics. (Weinstein & Stason 1977)  There is a strong ethical 
appeal that life, particularly life enjoyed in good health, is different from other 
commodities.  It is argued that healthy life is necessary in order to carry out all other 
activities and, therefore, should be awarded special moral importance. (Daniels 2008)  
Extra-welfarism, or the non-welfarist approach, has been embraced as the theory 
underpinning much of economic evaluation in health care. (Brouwer & Koopmanschap 
2000;Coast 2004;Culyer 1989;Sugden & Williams 1979;Tsuchiya & Williams 2010)  
Extra-welfarism differs from welfarism, for rather than aiming to maximise social 
welfare, the objective is to maximise aggregate health, irrespective of initial health status, 
age, disability, or indeed, willingness or ability to pay. (Birch & Donaldson 2003;Coast 
2004)  The extra-welfarist approach may be considered ‘utilitarian’ as the distribution of 
health gains is not considered. (Lord, Laking, & Fischer 2004)  However, as the extra-
welfarist framework is uniquely focused on health maximisation, resultant resource 
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allocation may not be consistent with society’s preferences. (Dolan & Cookson 
2000;Nord et al. 1995;Ubel 2001)  The extra-welfarist framework has been suggested to 
be morally superior to the welfarist approach.  As the assigned value of health is 
independent of the distribution of wealth in society, it is considered by many to be 
‘income free’. (Weinstein & Manning, Jr. 1997)  Others suggest, however, that adopting 
cost-effectiveness analysis in preference to cost-benefit analysis does not avoid 
considerations of income distribution. (Donaldson, Birch, & Gafni 2002;Gafni 2006) 
 
The analytical method of choice when considering an extra-welfarist framework is cost-
effectiveness analysis.  Cost-effectiveness analysis estimates the relative cost per unit of 
health gained across competing interventions.(Folland, Goodman, & Stano 2003;Garber 
& Phelps 1997)  This may be in terms of the cost per disease specific unit (e.g., reduction 
in tumour size, reduction in ulcer healing time, etc), the cost per life year, or the cost per 
QALY gained, often referred to as cost-utility analysis.  Cost-utility analysis is the 
preferred methodology for many decision makers, including national HTA bodies in the 
UK, Australia, Canada, and Sweden among others (Section 3.3.1).  The QALY 
incorporates both quality of life and life expectancy into a single unit of health, allowing 
for comparison across disease areas. (Brazier 2008;Drummond et al. 2005;Weinstein et 
al. 1996) 
 
2.3.6. The equivalence of cost-effectiveness analysis and cost-benefit analysis 
A key difference between cost-effectiveness analysis and cost-benefit analysis can be 
illustrated by comparing their objectives.  While the objective of cost-effectiveness 
analysis is to determine the least costly way to achieve a goal, the objective of cost-
benefit analysis is to determine whether the goal is worth achieving. (Bala, Zarkin, & 
Mauskopf 2002;Donaldson 1998)  There have been, however, various attempts to align 
the two methods by grounding cost-effectiveness analysis in a welfarist framework. 
(Garber et al. 1996;Johannesson 1995;Johannesson & O'Conor 1997;Meltzer 1997;Phelps 
& Mushlin 1991)   
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Researchers have attempted to illustrate circumstances when cost-effectiveness analysis 
and cost-benefit analysis can be considered equivalent. (Bala, Zarkin, & Mauskopf 
2002;Johannesson 1995)  Johannesson M (2005) suggests that cost-effectiveness analysis 
can be interpreted as cost-benefit analysis when the willingness to pay (WTP) per unit of 
effectiveness is assumed to be constant and the same for everyone. (Johannesson 1995)  
Bala et al. (2002) suggest less restrictive conditions; WTP for health gain needs to be the 
same in each patient subgroup, and that the WTP per unit of health gain and the 
magnitude of health gain achieved from treatment for a random individual in a given 
subgroup are independent random variables. (Bala, Zarkin, & Mauskopf 
2002;Johannesson 1995)   
 
It has been suggested that an explicit valuation of a unit of health outcome, e.g., the 
QALY, converts an ICER calculation into a quasi-net benefit criterion. (Drummond et al. 
2005)  However, the net benefit approach is ‘quasi’ cost-benefit analysis as its theoretical 
underpinnings remain grounded in an extra-welfarist rather than a welfarist framework; 
society’s valuation of a QALY is preceded by the assumption that the sole objective of 
resource allocation is QALY maximisation.  Further, it also does not avoid the question 
of how to value a QALY. (Brouwer et al. 2008) 
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2.4. Using economic evidence to inform resource allocation  
The primary purpose of economic evaluation is to help decision makers address problems 
due of scarcity in health care resources. (Bryan, Williams, & McIver 2007)  Sweden, 
Australia, and Ontario, Canada were among the first jurisdictions to use economic 
evaluation to inform health care resource allocation. (O'Donnell et al. 2009)  Now, many 
countries have institutions that consider economic evidence for new and established 
interventions as a precursor to coverage and reimbursement decisions, or to issue 
recommendations for the efficient use of health care technology. (Clement et al. 
2009;ISPOR 2011;Raftery 2008)  Cost-effectiveness analysis, with QALYs as the 
preferred outcome measure, is the predominant methodology with the Pharmaceutical 
Benefits Advisory Committee (PBAC) in Australia and NICE in the UK among HTA 
agencies that require such information. (NICE 2008a;PBAC 2010)  
 
Clinical trials often provide incomplete or insufficient information for decision makers.  
It is often infeasible for a clinical trial to include all competing interventions, be of 
sufficient duration, and to include all relevant endpoints. (Drummond et al. 2005)  
Consequently, the use of decision analytic models has become commonplace as decision 
makers synthesise evidence into a single analytic framework to inform resource 
allocation.   
 
Economic evaluation in health care has been defined as, “the comparison of alternative 
options in terms of their costs and consequences”. (Drummond et al. 2005)  Costs and 
consequences should be evaluated over an appropriate time horizon, i.e., one over which 
costs and consequences are likely to differ and thus are discounted accordingly.  The 
fundamental aspects of an economic evaluation are presented in Figure 1.  
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Figure 1. The fundamentals of economic evaluation (Drummond et al. 2005) 
 
An economic model’s structure is dependent on the clinical analytical problem.  For 
example, decision trees are appropriate for acute clinical conditions, i.e., those for which 
a clinical resolution is reached in a short timeframe.  Alternatively, Markov models can 
be used for chronic conditions where patients progress through a number of clinical, or 
Markov, states over a longer period of time. (Barton, Bryan, & Robinson 2004;Briggs, 
Claxton, & Sculpher 2006;Drummond et al. 2005)  Other more complex structures are 
appropriate in certain circumstances. (Caro, Moller, & Getsios 2010;Duintjer Tebbens et 
al. 2008) 
 
Cost-effectiveness is typically expressed using an incremental cost-effectiveness ratio 
(ICER).  An ICER is the ratio of the difference in costs to the difference in effects 
between two competing interventions.  The ICER can be formulated as follows:   
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The findings of cost-effectiveness analysis can be presented using a cost-effectiveness 
plane with each quadrant representing a potential outcome (Figure 2).  Interpretation is 
clear when study findings fall in quadrant II or IV.  In quadrant II the intervention is 
dominant, i.e., more effective and less costly than its comparator.  In quadrant IV the 
intervention is dominated, i.e., less effective and more costly than its comparator.  
However, in order to interpret a study outcome when it falls in quadrants I (intervention 
is more effective and more costly than the comparator) or III (intervention is less 
effective and less costly than the comparator) is less straightforward as the decision 
maker must have some preference for the value of their chosen unit of health gain (e.g., a 
QALY).  This valuation is referred to as the cost-effectiveness threshold (Section 2.6). 
(Buxton 2005;Eichler et al. 2004;McCabe, Claxton, & Culyer 2008) 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cost-effectiveness plane (Black 1990) 
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2.5. Cost-effectiveness analysis 
A worked example of using a cost-effectiveness decision rule based upon Lord et al. 
(2004) is presented below. (Lord, Laking, & Fischer 2004) 
 
Included in this scenario are six health care programmes, Pj(j = 1, 2, 3, 4, 5, 6), indicated 
for patients with a particular diagnosis (type P patients).  Ej is the health gain associated 
with programme Pj and is measured in QALYs.  Cj is the cost of programme Pj and is 
measured in monetary units ($).  Table 1 and Figure 3 present a numerical example for 
10,000 type P patients.  
 
Three assumptions are necessary for this hypothetical example to be valid. (Johannesson 
& Weinstein 1993)  First, available programmes are mutually exclusive, i.e., a patient 
may receive only one of them.  As each patient must receive treatment, one of the 
available health care programmes must be ‘best supportive care’.  Second, health care 
programmes are perfectly divisible, i.e., a health care programme can be partially 
implemented while maintaining the characteristics of the entire programme.  Third, each 
health care programme demonstrates constant returns to scale, i.e., costs and benefits are 
proportional to the scale of implementation.  Therefore, treating half the eligible patient 
population incurs half the costs and yields half the benefits as would be the case if the 
entire patient population was treated.  By maintaining these assumptions the cost-
effectiveness frontier is piecewise-linear and convex in shape (Figure 3).  
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Table 1. Costs and effects of health care programmes available for four groups of 
patients 
Patient 
Group 
  
Health care 
programmes 
 
Mean per patient Total for group Incremental analysis  
Cost ($) 
Effect 
(QALYs) 
Cost ($ 
million) 
Effect 
(QALYs) 
Cost ($ 
million) 
Effect 
(QALYs) 
ICER ($ per 
QALY) 
P-type P1 2,000 0.050 20 500 Baseline   
(n=10,000) P2 3,200 0.065 32 650  Ruled out through simple dominance 
 P3 2,300 0.070 23 700 3 200 15,000 
 P4 3,350 0.106 33.5 1,060 10.5 360 29,167 
 P5 4,100 0.107 41 1,070 Ruled out through extended dominance 
 P6 4,350 0.116 43.5 1,160 10 100 100,000 
         
Q-type Q1 10,000 4.000 10 4,000 Baseline   
(n=2000) Q2 18,000 4.200 18 4,200 8 200 40,000 
 Q3 29,000 4.362 29 4,362 11 162 67,901 
         
R-type R1 1,500 0.200 75 10,000 Baseline   
(n=100,000) R2 1,610 0.210 80.5 10,500 5.5 500 11,000 
 R3 1,700 0.212 85 10,600 4.5 100 45,000 
         
S-type S1 100 0.005 10 500 Baseline   
(n=200,000) S2 105 0.007 10.5 700 0.5 200 2,500 
 S3 130 0.012 13 1,200 2.5 500 5,000 
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Figure 3. Costs and effects of programmes available to ‘type P’ patients 
 
The decision maker’s problem is how to allocate health care resources in a manner that 
maximises health gain.  Two programmes can be immediately eliminated from 
consideration.  First, P2 is both more costly and less effective than P3 ($3,200 vs. $2,300; 
0.065 QALYs vs. 0.070 QALYs) and thus can be eliminated through ‘simple dominance’. 
 Second, P5 can be eliminated through ‘extended dominance’, as a combination of two 
other health care programmes, P4 and P6, will yield greater benefits at less cost.  If all 
10,000 patients received P5, 1,070 QALYs would be gained at a cost of $41 million.  
However, if 5,000 patients are treated with P4 (530 QALYs; $16.75 million) and 5,000 
with P6 (580 QALYs; $21.75 million), aggregate QALYs gained will be greater and 
achieved at a lower cost (1,110 QALYs; $38.5 million).  The remaining non-dominated 
health care programmes form a ‘cost-effectiveness frontier’, represented by the solid lines 
in Figure 3.  The decision maker will maximise health gain by operating at a point on the 
frontier.  The point on the cost-effectiveness frontier where the decision maker acts, and 
hence the composition of the health care programmes offered (where x% of patients will 
receive one programme and (100-x)% will receive the corresponding programme), is 
determined by the available budget.  As the available budget increases or decreases, the 
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decision maker will move from left to right or from right to left on the frontier, 
respectively.   
 
Table 1 includes the results of an incremental analysis of the available interventions.  As 
described above, an ICER represents the additional cost required to generate an 
additional unit of health gain, e.g., a QALY.  With respect to Figure 3, this represents the 
cost of purchasing an additional QALY by moving patients between adjacent non-
dominated treatment options on the cost-effectiveness frontier.  The ICER of programme 
Pk (k>1) in relation to the preceding programme Pj (j<k) can thus be defined as follows: 
jk
jk
k EE
CC
ICER −
−=        
The calculated ICER is equivalent to the slope that joins points Pk and Pj in the cost-
effectiveness space.   
 
2.5.1. Resource allocation across multiple patient populations 
In practice, a decision maker typically must make resource allocation decisions for 
multiple patient populations, each with multiple health care programmes available to 
them.  To illustrate this scenario, Table 1 includes interventions for four patient 
populations; P-type, Q-type, R- type, and S-type patients.  The cost-effectiveness 
frontiers for each of these patient populations can be drawn together in absolute cost-
effectiveness space using incremental effectiveness and incremental cost for the x and y 
axes, respectively, with the least costly options for each population together at the origin 
(Figure 4).  It has been noted, however, that having the least costly options together at the 
origin implies the availability of the ‘costless bullet’ (zero-cost, zero-effective option). 
(Briggs & Fenn 1997)  Consistent with the assumptions presented above, each frontier in 
Figure 4 is piecewise linear and convex in shape.  
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Figure 4. Cost-effectiveness space with cost-effectiveness frontiers for each patient 
population 
 
2.5.1.1 League table approach 
Weinstein and Zeckhauser first demonstrated that total health can be maximised 
(assuming perfect divisibility and constant returns to scale) through a league table 
approach. (Weinstein & Zeckhauser 1973)  In a league table approach, all non-dominated 
interventions are ranked in order of their cost-effectiveness.  Starting with the most cost-
effective programme, health care programmes are implemented in rank order until the 
available budget is exhausted.  This can be demonstrated numerically by extending the 
worked example (Table 2).  The initial set of health care programmes are the least 
expensive (P1, Q1, R1, S1), and yield 15,000 QALYs at a cost of $115 million.  The 
remaining health care programmes are ranked in order of cost-effectiveness with S2 the 
marginal programme.  When the health care budget is increased, patients are switched 
from S1 to S2, yielding in 15,200 QALYs at a cost of $115.5 million.  If the budget is not 
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exhausted, the health care programme with the next lowest ICER is implemented.  This 
process continues until the budget is exhausted.   
 
The value of the ICER of the marginal programme, or the shadow price of the budget 
constraint, is referred to as the cost-effectiveness threshold.  The threshold is a function 
of the costs and benefits of the available health care programmes and the available 
budget.  Increasing the health care budget will result in the implementation of additional 
health care programmes with increasingly higher ICERs.  Accordingly, the value of the 
cost-effectiveness threshold will also increase. 
 
In practice, the league table approach is limited by the magnitude of data requirements.  
To construct a league table it is necessary to have complete knowledge of the costs and 
benefits of each available health care programme.  If available data are incomplete then 
the approach will likely not lead to a QALY maximising resource allocation.  
Consequently, league tables are seldom used in practice.   
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Table 2. League table of available health care programmes 
Set of health care 
programmes 
delivered 
Marginal 
Programme 
Incremental analysis Total set of programmes 
Cost ($ 
million) 
Effect 
(QALYs) 
ICER ($ 
per QALY) 
Cost ($ 
million) 
Effect 
(QALYs) 
P1, Q1, R1, S1 - - - - 115 15,000 
P1, Q1, R1, S2 S2 0.5 200 2,500 115.5 15,200 
P1, Q1, R1, S3 S3 2.5 500 5,000 118 15,700 
P1, Q1, R2, S3 R2 5.5 500 11,000 123.5 16,200 
P3, Q1, R2, S3 P3 3 200 15,000 126.5 16,400 
P4, Q1, R2, S3 P4 10.5 360 27,167 137 16,760 
P4, Q2, R2, S3 Q2 8 200 40,000 145 16,960 
P4, Q2, R3, S3 R3 4.5 100 45,000 149.5 17,060 
P4, Q3, R3, S3 Q3 11 162 67,901 160.5 17,222 
P6, Q3, R3, S3 P6 10 100 100,000 170.5 17,322 
 
2.5.2. Mathematical programming 
2.5.2.1 Overview 
Mathematical programming is a theoretical approach for the comprehensive allocation of 
health care resources.  An algorithm is used to allocate resources using rules consistent 
with those required for the league table approach described above.  The formulation of 
the mathematical programming problem, as illustrated by Epstein DM et al, is presented 
below. 
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2.5.2.2 Mathematical programming formulation 
The objective is to identify the pattern of resource use that maximises gross health benefit 
subject to the following constraints: 
1. Budget constraint is not exceeded; 
2. Each independent health care programme must be selected; 
3. Each population group within the health care programme receives one and only 
one treatment. 
 
The mathematical programming problem can be formulated as follows: 
maxΨ eijk(t)xijk
i=1
Ik∑
j =1
Jk∑
k=1
K∑
t =1
T∑⎛ ⎝ ⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟  
ψ = (xijk , i=1… Ik , j = 1…Jk, k=1… K)         
cijk(t)x
i=1
Ik∑
j =1
Jk∑
k =1
K∑
t =1
T∑ ijk ≤ δ  
0 ≤ xijk ≤ 1 i = 1… Ik, j = 1…Jk, k=1… K 
xijk =
j=1
Jk∑ 1 i = 1… Ik, k=1… K 
 
It is assumed there are K health care programmes, and that each health care programme k 
(k: = 1…. K) has IK population groups (i: = 1… IK) and JK treatments (j: = 1… JK). 
 
Variable xijk varies between zero and one (0 ≤ xijk ≤ 1).  When x = 0 no proportion of 
population group i is allocated treatment j in health care programme k.  When x = 1, the 
entire population group i is allocated treatment j in health care programme k. 
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Costs and benefits from treatment are evaluated over the model’s time horizon (T).  The 
model is static, i.e., the proportion of patients receiving a treatment does not change as a 
function of time.  Variable t is the time index variable, where t: = 1… T.   
 
Variable cijk(t) is the incremental cost of treatment j in health care programme k if the 
treatment is given to all members of population group i (both the pre-existing and newly 
diagnosed patient population) at time t (N.B. cijk(t) must be discounted to a fixed time 
point).  Incremental cost, cijk(t), is defined as the difference in cost between each 
treatment j (j>1), and a comparator treatment (usually current care (j=1) for which costs 
are defined as zero).   
 
Therefore, the total incremental cost in year t of all health care programmes and 
treatments can be formulated as follows: 
)(
1 1 1
)( tcxC ijk
K
k
J
j
I
i
jkt
k k
i∑∑∑
= = =
=   t = 1… T    
 
and, over the time horizon, the total incremental cost is bounded by the budget constraint 
δ.   
 
Treatment benefit eijk(t) is measured in quality adjusted life years (QALYs).  The 
treatment benefit of each treatment j (j>1) is estimated in year t relative to a comparator 
treatment (j=1) for which treatment benefit is defined to be zero (N.B. eijk(t) must already 
be discounted to a fixed time point). 
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It is assumed that the cumulative incremental gain in QALYs is known only over the time 
horizon of the model. It is denoted by the time-invariant parameter bijk, where bijk is the 
gross benefit of treatment j in health care programme k if the treatment is applied to all of 
population group i. 
 
Therefore, the total incremental QALY gain relative to current care may be formulated as 
follows: 
B = eijk(t)
i=1
Ik∑
j =1
Jk∑
k=1
K∑
t =1
T∑ xijk = bijk xijk
i=1
Ik∑
j =1
Jk∑
k=1
K∑   
Thus, above is the formulation of the problem of maximising health benefit while 
assuming that both costs and benefits show constant returns to scale.   
 
2.5.2.3 Relaxation of assumptions in the mathematical programming formulation 
Relaxation of perfect divisibility assumption 
In the initial problem, it is assumed that a treatment can be partially implemented in the 
eligible patient population.  This raises equity concerns as only a proportion of the 
eligible patient population receive treatment.  Through mathematical programming, it is 
possible to relax the assumption of perfect divisibility to disallow the divisibility of 
health care programmes.  This essentially imposes an additional “horizontal equity” 
constraint on the model that requires that people with equal need should have equal 
access to treatment.  The effect of this constraint is that decision variables are binary for 
population i and health care programme j.  This additional constraint can be formulated 
as follows: 
xijk ∈ 0,1{ }  i = 1…Ik, J = 1…Jk, k = 1…K   
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The problem is now defined as a 0-1 mixed integer linear programme (MILP).  
Computationally complex, this method is only feasible for a limited number of decision 
variables taking binary variables. (Birch & Donaldson 1987;Birch & Gafni 1992;Epstein 
et al. 2007) 
 
Accommodating alternative budget rules 
Conventional methods of cost-effectiveness analysis assume no constraints with respect 
to the timing for which the budget can be spent.  Typically, however, budgets exist over 
12-month periods.  Mathematical programming can account for multiple alternative 
budget rules.  First, the available budget can be divided over the time period of the 
analysis.  As per Epstein DM et al, the problem is illustrated below using a time horizon 
of 15 years.  The constraint can be formulated as follows: 
C(t) = δ/15  t = 1….15      
 
Second, in the case of this worked example, the total available budget must be exhausted 
within a 5-year period.  In this scenario, health care programmes incurring a cost after the 
5-year period are permitted only if other programmes generate the necessary cost-savings 
to offset this cost.  This can be formulated as follows: 
∑
=
=
5
1
)(
t
tC δ  
C(t) = 0  t = 6….15   
    
Relaxation of constant returns to scale 
The above approach is insufficient to allow the constant returns to scale assumption to be 
relaxed, i.e., that the costs and benefits of a health care programme are not proportional to 
the scale of its implementation.  As relaxation of the constant returns to scale assumption 
requires nonlinearity, one approach to relax this assumption is to employ non-linear 
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programming.  Non-linear programming increases the flexibility of the model and allows 
the benefits of a health care programme to vary with the scale of programme 
implementation. (Al, Feenstra, & Hout 2005;Elbasha & Messonnier 2004;Stinnett & 
Paltiel 1996)  Another potential approach is mixed integer programming.  This approach 
is appropriate when a number of the unknown variables are required to be integers and 
can be used when both the perfect divisibility and the constant returns to scale 
assumptions require relaxation.  Such an approach is, however, computationally difficult. 
(Lord, Laking, & Fischer 2004;Stinnett & Paltiel 1996)  This methodology can be 
expanded upon to include additional constraints, including the supply of health care 
professionals and the lead time necessary for training. (Earnshaw & Dennett 2003;Lord, 
Laking, & Fischer 2004;Sendi et al. 2003)   
 
2.5.2.4 Summary 
As illustrated above, mathematical programming facilitates relaxation of Johannesson 
and Weinstein’s assumptions and provides an approach for comprehensive resource 
allocation.  However, data requirements are equivalent to those for the league table 
approach, i.e., complete knowledge of the costs and benefits of available health care 
programmes, inhibiting the use of mathematical programming when used for the analysis 
of more than a limited number of programmes.  Computational complexity also inhibits 
its use in practice when considering a multitude of health care programmes.    
 
2.5.3. A cost-effectiveness threshold decision rule 
The practical use of the league table and mathematical programming approaches is 
hindered by the magnitude of data requirements.  Full information regarding the costs and 
benefits of each health care programme is required to comprehensively allocate health 
care resources.  In reality, these data requirements prevent decision makers from 
implementing these methods and alternative approaches have been relied upon. 
(Drummond et al. 2005)  The use of a cost-effectiveness threshold is one of these 
approaches. (Buxton 2005;Eichler, et al. 2004;McCabe, Claxton, & Culyer 2008)  
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If knowledge of the costs and benefits of all available interventions is unknown, a 
comprehensive ranking of health care programmes is unachievable.  Consequently, a 
benchmark value, or cost-effectiveness threshold (λ), is required in order to interpret cost-
effectiveness evidence.  The cost-effectiveness threshold should represent a decision 
maker’s valuation of a unit of health.  If a health care programme is estimated to have an 
ICER greater than the threshold, it is not deemed representative of an efficient use of 
health care resources; alternatively, if the ICER falls below the threshold, it is deemed to 
be sufficiently cost-effective and thus representative of an efficient use of resources.  
Therefore, a health care intervention will be adopted only if the ICER of the programme 
is less than the specified cost-effectiveness threshold.  That is: 
 ICERj ≤ λe      
and 
 ICERk>λe for all k >j 
λe = Estimated threshold 
Using the example presented in Table 1 to evaluate P-type patients, if the estimated value 
of the threshold was $25,000 per QALY, all P-type patients would receive P3, i.e., the 
intervention with the highest ICER less than λe.  Accordingly, if the value of λe was 
increased to $30,000 then P-type patients would receive P4 as this would now be the 
intervention with the highest ICER less than λe.  As demonstrated by Johannesson and 
Weinstein (1993) and Lord et al. (2004), implementation of the threshold decision rule 
will lead to a QALY maximising allocation of health care resources providing the 
following conditions are met (Johannesson & Weinstein 1993;Lord, Laking, & Fischer 
2004): 
1.  The threshold is correctly calibrated; 
2.  Health care programmes demonstrate perfect divisibility; 
3.  Health care programmes demonstrate constant returns to scale; 
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4.  ICERs are correctly calculated. 
 
2.5.4. Importance of the correct calibration of the threshold 
As stated above, correct calibration of the threshold is a necessary condition for the 
threshold decision rule to result in a QALY maximising allocation of resources.  The 
consequence of incorrect threshold calibration can be demonstrated by considering P-type 
patients in Table 1. (Johannesson & Weinstein 1993;Lord, Laking, & Fischer 2004)  If 
the estimated threshold is not equal to the true threshold (λe ≠ λ), i.e., the value of the 
threshold in a perfectly calibrated system, the application of a threshold decision rule will 
lead to inefficient resource allocation.  To illustrate, assume that the correctly calibrated 
threshold is $30,000 per QALY.  If the decision maker uses an estimated threshold of 
$25,000 per QALY, the decision rule will lead to the selection of P3 (the health care 
programme with the highest ICER less than the estimated threshold (ICERj ≤ λe)).  
Treating all 10,000 p-type patients with P3 would result in an aggregate gain of 700 
QALYs at a cost of $23 million.  However, treating patients with P3 will not exhaust the 
budget.  If all p-type patients had instead been treated with P4, the health care programme 
with the highest ICER less than the correctly calibrated threshold, aggregate health gain 
would have been 1,060 QALYs, 360 more than if patients had been treated with P3.  
Similarly, overestimating λ will lead to an inefficient use of resources.  If λe was 
estimated as $100,000 per QALY the decision maker would implement P6 for p-type 
patients.  However, as the available budget ($33.5 million) is insufficient to provide P6 to 
all p-type patients ($43.5 million is required) not all patients would receive care.  In this 
case aggregate health gain would be 893 QALYs, 167 less than if p-type patients were 
treated with P4.   
 
2.5.5. Net benefit approach 
If a decision maker places an explicit value on health, e.g., the QALY, it is possible to 
reorganise the ICER equation to present the same decision in terms of net benefit.  The 
ICER equation is as follows:  
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When using a threshold decision rule the equation can be rearranged as follows: 
ߣ௘ ൌ  
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The threshold can essentially be considered an ‘exchange rate’ to convert units of 
effectiveness into a monetary value.  Rearranging the equation results in the following: 
0 ≤ λe * (Cost Intervention A – Cost Intervention B) – (Effect Intervention A– Effect Intervention B) 
 
If net benefit is positive, implementing the intervention is an efficient use of resources; if 
negative, implementing the intervention is deemed a cost-ineffective use of resources.  
When considering multiple health care programmes, the threshold rule is equivalent to 
selecting the programme with the highest positive net benefit.  This is presented 
geometrically in Figure 5.  Line I0 has a slope equal to the threshold (λe), in this case 
$40,000 per QALY.  The health care programme that will lead to QALY maximising 
resource allocation is that the greatest distance below I0 on each cost-effectiveness 
frontier.  In this scenario, the combination of health care programmes that yields the 
greatest amount of health gain are those shaded points on each frontier (P4, Q2, R2, and 
S3). (Ament & Baltussen 1997;Lord, Laking, & Fischer 2004) 
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Figure 5. Resource allocation using a cost-effectiveness threshold as a decision rule 
 
2.5.6. Relaxation of assumptions 
Lord et al. (2004) illustrate that by relaxing the assumption of perfect divisibility, the 
threshold rule becomes unreliable. (Lord, Laking, & Fischer 2004)  Although for the 
most part the perfect divisibility assumption affects only the marginal health care 
programme, knock-on effects to other cost-effectiveness frontiers may lead to 
inefficiencies when adopting the threshold rule.  At the national level, however, where 
the budget is very large in relation to individual programmes, perfect divisibility is not an 
unrealistic assumption. (Lord, Laking, & Fischer 2004)   
 
Relaxing the constant returns to scale assumption is potentially more problematic.  In 
situations where non-constant returns to scale exist, the costs and benefits associated with 
the implementation of a health care programme will vary with the scale of 
implementation, i.e., the cost-effectiveness frontier would no longer be piecewise linear.  
When non-constant returns to scale exist, to estimate aggregate health gains and incurred 
I0
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costs it is necessary to estimate the entire shape of the cost-effectiveness frontier, i.e., the 
costs and benefits of implementing each programme across all patients in a population.  If 
non-linearities exist the opportunity cost of implementing a programme, and thus the 
value of the cost-effectiveness threshold, will vary at the margin.  Consequently, when 
the constant returns to scale assumption does not hold, using a fixed threshold to guide 
resource allocation may lead to a suboptimal resource allocation. (Lord, Laking, & 
Fischer 2004) 
 
2.5.7. Using cost-effectiveness information with incomplete information 
2.5.7.1 Searching for a threshold 
Culyer et al. (2007) use the example of NICE and the National Health Service (NHS) in 
the UK to illustrate how in the absence of complete information of the costs and benefits 
of available health care programmes, a decision maker should act as a ‘threshold 
searcher’ rather than setting a cost-effectiveness threshold. (Culyer et al. 2007)  
 
As discussed above, if a decision maker with complete knowledge of the costs and 
benefits of all available health care programmes was to rank them in order of their cost-
effectiveness and prioritise resources to the most cost-effective, the cost-effectiveness 
threshold would equal the ICER of the least cost-effective health care programme that the 
health care system could afford.  In the UK the government is responsible for setting the 
NHS budget and, therefore, in this scenario the threshold is, by extension, set indirectly 
by the government.  If the cost-effectiveness threshold was set independently by NICE, 
the health care budget would be a function of the threshold, as all health care programmes 
with an ICER less than or equal to the threshold would be implemented.  Because setting 
the cost-effectiveness threshold is outside of NICE’s mandate, NICE should instead act 
as a ‘threshold searcher’. (Culyer et al. 2007;Karlsson & Johannesson 1996) 
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Figure 6 illustrates the hypothetical scenario of a health care system in which the costs 
and benefits of all health care programmes are known.  The curve Ha represents the 
marginal health gain of currently implemented health care programmes and OE 
represents current expenditure.  Ea represents the marginal health gain, or ICER, 
associated with the least cost-effective health care programme currently implemented.  
The ICER of this programme represents the shadow price of the budget constraint, i.e., 
the cost-effectiveness threshold.    
 
Figure 6. Marginal health gain associated with available interventions in the NHS 
 
Figure 7 illustrates the more realistic analytical problem faced by NICE.  As in Figure 6, 
curve Ha represents the marginal health gain of currently implemented health care 
programmes and OE the current expenditure.  Curve cf represents available health care 
programmes not currently implemented in the NHS.  A composite marginal health gain 
curve, Hde, is the horizontal sum of the curves Ha and ce and combines all available 
health care programmes, i.e., those currently provided in the NHS and those that are 
available but not currently provided.  It is apparent from Figure 7 that there are three 
‘threshold’ values relevant to the decision maker.  The first is Ea, which represents the 
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marginal health gain of the least cost-effective health care programme currently 
implemented.  The second is Ec, the marginal health gain associated with the most cost-
effective health care programme not available in the current health care system.  The 
third is Eb, which lies on curve Hde and is the threshold that would exist in a perfectly 
calibrated health care system.  Implementation of a health care programme with a 
marginal health gain greater than Eb (in the range EE’’), along with the displacement of a 
health care programme with a marginal health gain less than Eb (in the range E’E), will 
increase efficiency.  To maximise health gained from current expenditure, the optimal 
solution is to disinvest in health care programmes that fall in the range E’E on curve Ha 
and substitute them for health care programmes that fall between EE’’ on curve cf.  It is 
suggested that NICE’s role is to act within this range, referred to as the “zone of 
substitution”. (Culyer et al. 2007;McCabe, Claxton, & Culyer 2008)  In order to increase 
efficiency NICE should invest/disinvest in health care interventions that fall in the zone 
of substitution until such a point that additional investment/disinvestment will not result 
in efficiency gain.  Consequently, rather than a constant fixed valuation, the value of the 
cost-effectiveness threshold should fluctuate as a function of the cost-effectiveness of 
currently available health care programmes, both implemented and not, and the health 
care budget. 
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Figure 7.  Representation of all health care programmes available to the NHS 
 
2.5.7.2 The Sendi, Gafni and Birch (SGB) method 
As illustrated above, indivisibilities, non-constant returns to scale, or a poorly calibrated 
threshold may result in the application of a threshold rule leading to suboptimal resource 
allocation.  Proposed methods, such as integer programming, have the potential to 
account for these problems, but they lack feasibility, as they require complete knowledge 
of the costs and benefits of all available health care programmes.  Sendi, Gafni and Birch 
(SGB) (2002) proposed a simple decision rule that eliminates these information 
requirements. (Sendi, Gafni, & Birch 2002)  According to the SGB decision rule, a new 
health care programme should be implemented only after a less effective programme, or 
set of programmes, of equal cost is cancelled.  By acting in accordance with the SGB 
decision rule, incremental improvements in efficiency would be achieved each time a 
new health care programme was implemented.  However, the SGB method would only be 
optimising resource allocation if the marginal programme(s), i.e., the least cost-effective 
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programme(s) available, were displaced.  It is unclear, however, how the marginal health 
care programmes would be identified. 
 
Lord et al. (2004) demonstrate that the SGB decision rule may lead to an inefficient 
allocation of health care resources when the constant returns to scale assumption is 
invalid.  Lord et al. show, however, that by estimating the costs and benefits of 
implementing the programme across all subgroups of the eligible patient population, the 
SGB decision rule can be improved upon and lead to a more efficient allocation of health 
care resources. (Lord, Laking, & Fischer 2004)   
 
2.5.8. Disinvestment of health care programmes 
The league table (Section 2.5.1.1), searching for the threshold (Section 2.5.7.1), and SGB 
(Section 2.5.7.2) approaches all require a disinvestment of existing health care 
programmes along with investment in more cost-effective programmes.  The term 
disinvestment has been defined as, “The processes of (partially or completely) 
withdrawing health resources from existing healthcare practices, procedures, 
technologies, or pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and thus do not represent efficient health resource allocation”. (Elshaug et al. 
2007)  It has been suggested that up to 40% of patients do not receive treatments of 
proven effectiveness and up to 25% of treatments are unnecessary or even harmful. 
(Smith 1991;White 1995)   
 
There are many challenges associated with the disinvestment of health care programmes.  
Notably, it has been suggested that there is a kink in consumers’ threshold value for cost-
effectiveness in health care, i.e., that society’s willingness-to-accept (WTA) monetary 
compensation to forgo a health programme is greater than their willingness-to-pay (WTP) 
for a new health care programme of equivalent benefit. (O'Brien et al. 2002)  This 
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phenomenon has implications for decision makers attempting to allocate resources in a 
manner consistent with societal preferences.   
 
There is an increasing international awareness of the need to disinvest in health care 
programmes that are a relatively poor use of health care resources.  A prominent example 
is NICE’s database of “do not do” recommendations in which health care programmes 
determined to have little or no benefit are listed. (NICE 2010b)  International experience, 
notably in Australia and Canada, has illustrated the challenges of identifying and 
removing candidates for disinvestment. (Elshaug, Hiller, Tunis, & Moss 2007;Elshaug et 
al. 2009;Garner & Littlejohns 2011)   
 
2.5.9. Criticisms of cost-effectiveness analysis 
With its theoretical underpinnings in an extra-welfarist framework, the objective of cost-
effectiveness analysis is to allocate resources in order to maximise aggregate health.  
Given this sole objective, cost-effectiveness analysis does not account for other issues 
that may be important to the decision maker, e.g., equity concerns or societal preferences 
for health care. (Coast 2004;Dolan & Cookson 2000;Drummond et al. 2005;Nord et al. 
1995;Ubel 2001)  A disadvantage of the extra-welfarist framework is that it does not help 
inform resource allocation across industries.  Although possible to compare the cost per 
QALY/life year ratios across the health care industry and some others (e.g., transport), 
cost-effectiveness analysis does not generate the necessary information to fully allocate 
resources at the national level. (Claxton et al. 2010)  As described in Section 2.3.5, cost-
effectiveness analysis considers a single unit of health outcome that typically has a single 
value across the population.  It is possible, therefore, that cost-effectiveness analyses 
result in less favourable findings for treatments for the elderly or the severely ill as these 
populations are unable to accrue as much health as young healthy individuals. (Neumann 
& Greenberg 2009;Torrance 1986;Ubel 2001)  It should be noted, however, that decision-
makers that use cost-effectiveness evidence to inform resource allocation commonly 
account for criteria other than cost-effectiveness in their decisions, including equity and 
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distributional factors. (Anell & Persson 2005;Lopert 2009;NICE 2008a;Ramsberg et al. 
2004) 
 
Much of the criticism concerning cost-effectiveness analysis is that the information 
generated is insufficient to inform resource allocation when the decision maker is 
operating within a budget constraint, i.e., the question of affordability is not addressed. 
(Trueman, Drummond, & Hutton 2001)  Birch and Gafni illustrate how solely 
considering cost-effectiveness evidence is insufficient to fully inform resource allocation.  
Without consideration of the underlying budget constraint, implementing a new health 
care programme with a positive incremental cost while continuing to provide access to all 
other available care will inevitably increase the overall cost of the health care system. 
(Birch & Gafni 2006a;Birch & Gafni 2006b)  The same authors illustrate how accepting a 
programme based upon its ICER provides an indication of how much health gain is 
achieved from a unit of investment without any consideration as to the programmes 
forgone to pay for it.  Thus, accepting a programme based solely on cost-effectiveness 
may not lead to an overall increase in efficiency. (Birch & Gafni 2006b)  It has been 
illustrated, however, that concurrent consideration of cost-effectiveness and affordability 
can lead to health maximising decision resource allocation. (Culyer et al. 2007;Garber & 
Phelps 1997;Nuijten & Rutten 2002;Sendi & Briggs 2001;Trueman, Drummond, & 
Hutton 2001) 
 
It has been suggested that the use of the ICER approach has led to an increase in overall 
health care expenditure in a number of countries. (Birch & Gafni 2004;Gafni & Birch 
2003;Laupacis 2002)  However, increased expenditure on health care is a global 
phenomenon and, to the best of my knowledge, the influence of using cost-effectiveness 
has not been evaluated. (OECD 2011)  Indeed, Gold and Bryan suggest that in the US the 
alternative may be the case, i.e., that the failure to implement a health technology 
appraisal process has allowed health care costs to grow much more than would have been 
the case if a formal process of economic evaluation had been implemented. (Gold & 
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Bryan 2007) 
 
A major drawback to using cost-effectiveness analysis is that, unlike for cost-benefit 
analysis, a clear decision rule does not always exist.  For the most part, new health care 
programmes are associated with a positive incremental cost-effectiveness ratio (ICER), 
i.e., the programme is both more effective and costly than the comparator.  As noted 
above, in the absence of a clear decision rule, it is necessary to compare cost-
effectiveness findings against a benchmark value, or cost-effectiveness threshold.  
However, the value of the threshold and how it should be determined is a matter of 
controversy and debate. (Buxton 2005;Eichler et al. 2004)   
 
In the next section, I review the approaches for the derivation of cost-effectiveness 
thresholds, suggested valuations, and various characteristics of them.   
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2.6. The cost-effectiveness threshold 
In the absence of complete knowledge of the costs and benefits of available health care 
programmes, it is necessary to have a benchmark value, or decision rule, with which to 
interpret the findings of cost-effectiveness studies.  This value, often referred to as the 
cost-effectiveness threshold, is of great importance.  An incorrectly calibrated threshold 
value may have implications for decisions regarding the implementation of new 
technologies, disinvestment of existing technologies, and for the allocative efficiency of 
health care spending (Section 2.5.4).   
 
Broadly, there are two schools of thought with respect to how the cost-effectiveness 
threshold should be valued.  First, the cost-effectiveness threshold should reflect 
society’s valuation of health. (Hirth et al. 2000)  Second, the cost-effectiveness threshold 
should reflect the value of health care programmes displaced by the implementation of 
new programmes, i.e., the threshold should represent the opportunity cost with respect to 
health forgone. (McCabe, Claxton, & Culyer 2008)  
 
The following sections describe approaches for valuing the cost-effectiveness threshold, 
examples of cost-effectiveness thresholds, characteristics of cost-effectiveness 
thresholds, and cost-effectiveness acceptability curves. 
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2.6.1. Deriving the cost-effectiveness threshold 
2.6.1.1 Assigning a monetary value to life 
Three broad approaches have been proposed to assign a monetary value to life; the 
human capital approach, the compensating wage method (revealed preference), and 
contingent valuation. 
 
Human capital approach 
The human capital approach values life by placing a monetary valuation on healthy time 
based upon an individual’s future earnings.  Therefore, use of a health care programme 
can be considered an investment in an individual’s human capital.  This concept of 
human capital can be used as the sole basis of valuing health improvements or as a 
method of valuing benefits accrued from using a health care programme (i.e., changes in 
productivity). (Drummond et al. 2005)  The human capital approach is associated with a 
number of difficulties.  Market wage rates typically vary, and it is difficult to account for 
variations due to race or gender.  Also, it does not value healthy time not sold for a wage 
and thus may undervalue a health care programme’s benefits. (Drummond et al. 2005)   
 
The compensating wage method (revealed preference) 
The compensating wage, or revealed preference, method is often used to estimate the 
value individuals’ place on risk tradeoffs.  This method evaluates individuals’ 
employment behaviour to estimate the value they place on life.  Essentially, the revealed 
preference method works as follows; two individuals are employed in identical jobs with 
the exception that one carries a higher risk of death or injury.  The riskier job provides a 
higher salary than the lower risk job.  The value the individual places on life can be 
estimated by multiplying the wage differential by the inverse of the difference in 
probability of death or injury. (See Appendix 1 for a worked example) (Brannon 2005; 
Drummond et al. 2005)   
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This form of estimation is consistent with welfare economics as it is based upon 
individuals’ choices regarding trade-offs between the risk of death or injury and income.  
A strength of this method is that it is based on actual decisions involving health and 
money, rather than hypothetical scenarios. (Drummond et al. 2005)  This method, though, 
does have a number of drawbacks.  Individuals may not make rational employment 
choices and may not accurately perceive risk. (Brannon 2005)  It is argued that revealed 
preference studies are biased as the wage of a particular job is just enough to entice the 
marginal worker; others require a higher wage to accept the same risk. (Shogren & Stano 
2002)   
 
Contingent valuation studies 
Contingent valuation studies are often used to estimate the demand for non-market goods.  
With respect to health, although individuals are likely to place an infinite amount of 
money on their life, they often value small changes in the risk of death. (Brannon 2005)  
Using contingent valuation, the value of life is estimated by determining how much 
individuals would be willing to pay to avoid a certain level of added risk.   
 
An advantage of contingent valuation is that it allows consideration of hypothetical 
scenarios, which is useful when evaluating health care interventions. (Diener, O'Brien, & 
Gafni 1998)  In addition, this technique incorporates individual preferences into the 
analysis, consistent with welfare economics.  A criticism of the contingent valuation 
technique is that it, as does not require actual cash transactions, it may not reflect 
individuals’ true preferences. (Drummond et al. 2005)  Further, as scenarios are 
hypothetical, responses may not be thoughtful or informed.  It is necessary to control for 
factors that may affect the contingent valuation estimation, e.g., individuals with higher 
incomes are likely to have a higher willingness to pay for health.  Also, the individual 
must understand risk, i.e., if an individual were willing to pay the same amount for a 
reduction in risk of 1/10,000 as for 2/10,000 then it would suggest that they are willing to 
pay for a general reduction in risk rather than valuing changes. (Brannon 2005)  
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2.6.1.2 Linking the threshold to GDP per capita 
A conceptually appealing approach is to benchmark the cost-effectiveness threshold to 
GDP per capita.  This approach allows a country’s wealth to be accounted for in the 
threshold valuation and moves away from the tendency of setting thresholds as round 
numbers. (Weinstein 1996) (Section 2.6.2)  Although arguably, benchmarking the 
threshold to GDP reflects a preference for using ‘convenient’ as opposed to ‘round’ 
numbers.     
 
The cost-effectiveness threshold has been benchmarked to GDP per capita on two notable 
occasions: first, in the report by the WHO Commission on Macroeconomics and Health 
entitled, “Macroeconomics and health: investing in health for economic development”; 
second, in Alan Williams’ 2004 lecture entitled, “What could be nicer than NICE?”. 
(Sachs 2001;Williams 2004)  
 
WHO Commission on Macroeconomics and Health - Macroeconomics and 
health: investing in health for economic development 
In 2000, the Commission on Macroeconomics and Health, a group consisting of leading 
economists and health experts, met to discuss placing health at the centre of the 
development agenda.  As part of the resulting proposed strategy, it was suggested that 
health should be valued explicitly in order to facilitate the economic analysis of health 
care programmes.  The Disability Adjusted Life Year (DALY) was the recommended 
health outcome measure.  The DALY is a unit of health that accounts for the present 
value of future years of lifetime lost through premature mortality adjusted for the severity 
of the illness or injury. (Fox-Rushby & Hanson 2001) 
 
The commission suggested that based upon individuals’ lost economic well-being as a 
result of disease, DALYs should be valued at three times GDP per capita.  The valuation 
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was justified as follows: “this multiple of earnings reflects the value of leisure time in 
addition to market consumption, the pure longevity effect, and the pain and suffering 
associated with disease”. (Sachs 2001)  The valuation was supported by a variety of 
economic analyses. (Cutler et al. 1997;Philipson & Soares 2001;Topel & Murphy 1997)  
Absent from the report, however, is a description of the original analysis used to arrive at 
this figure.  It would appear that rather than being determined from formal analysis, the 
value was derived from an informal meta-analysis of referenced articles.  This was 
confirmed through communication with the authors via email (Appendix 2).  The three-
times-GDP threshold has since been cited in a variety of sources. (Access Economics Pty 
Limited 2004;Baltussen, Knai, & Sharan 2004;Dhanasiri & Puliyel 2007;Hoffman & 
Jackson 2003) 
 
This valuation of a DALY was elaborated on as part of the WHO-CHOICE (CHOosing 
Interventions that are Cost Effective) programme. (Tan-Torres et al. 2003)  Rather than 
taking a single value, the threshold was suggested to exist over a range: interventions 
were deemed highly cost-effective if costing less than one GDP per capita to avert a 
DALY, cost-effective if costing between one and three times GDP per capita to avert a 
DALY, and not cost-effective if costing more than three times GDP per capita to avert a 
DALY. (Tan-Torres et al. 2003;WHO 2005)   
 
Alan Williams: What could be nicer than NICE? 
In 2004, Professor Alan Williams presented a lecture entitled “What could be nicer than 
NICE?”  Featured was discussion of the appropriateness of NICE’s valuation of the cost-
effectiveness threshold.  It was suggested that £30,000 per QALY was “far too high” and 
that the threshold should be no more than 1xGDP per capita, approximately £18,000 in 
2004 GBP. (Williams 2004)  Williams argued that this was a “common sense” approach 
and that as GDP per capita should provide for all the needs of the average citizen (food, 
shelter, transport, education etc), the cost-effectiveness threshold should be no greater 
than this amount.  Although society could afford to pay more than 1xGDP per capita 
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annually for a few individuals’ health needs, it could not do so for many.  Williams 
conceded that setting the threshold in this manner lacks a theoretical rationale, although 
he asserted that this was also the case for the then existing valuation. (Williams 2004) 
 
2.6.1.3 Insight from other industries 
A country’s government must allocate available resources between industries.  These 
investment decisions can provide an insight into how life is valued across sectors of the 
economy.  In various industries it is necessary to place a monetary value on a year of life, 
or a life saved, when making investment decisions.  Referred to as the value of a 
statistical life (VSL), such valuation is often used when evaluating potential investments 
in safety measures. (Viscusi & Aldy 2003)   
 
Consideration of the VSL across industries may inform the appropriate value of the cost-
effectiveness threshold in health care.  It is logical that valuations across industries should 
have some degree of consistency.  Loomes (2010) states, “the cost effectiveness threshold 
should be set at a level consistent with the value attached to life in other parts of the 
public sector”. (Loomes 2010)  For resources to be allocated efficiently across industries, 
the marginal benefit per dollar spent should be the same across programmes. (Tengs et al. 
1995)   
 
In the transport industry, investments are often made in safety measures to prevent 
injuries and fatalities.  Cost-benefit analysis is the analysis of choice in the transport 
industry and, as described in Section 2.3.3, requires both costs and benefits to be 
measured in monetary terms. (Claxton et al. 2010)  As the outcome of interest when 
evaluating safety measures is the prevention of a fatality, a VSL is required.  Included in 
Table 3 are selected examples of VSLs used in the transport industry in the UK and 
Europe. 
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Table 3. Valuation of a statistical life in road and the railway transport industry. 
Industry Country 
Valuation of a 
statistical life 
Year Reference 
Roads Europe €1.1 - €1.3 
million  
2000 European conference of ministers of 
transport. Economic Evaluation of 
Road Traffic Safety Measures: 
Conclusion of round table. (Quinet 
2000) 
Roads UK £1,876,830 2007 Department of transportation – 
Guidance documents. (Department 
for Transport 2009) 
Railways UK £10.8 million 2003 Fatal train accidents on Britain’s 
main line railways: End of 2004 
analysis. (Evans 2007) 
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2.6.2. Valuations of the cost-effectiveness threshold 
Since Kaplan and Bush proposed the first cost-effectiveness threshold in 1982, various 
valuations have been proposed. (Kaplan & Bush 1982)  Valuations may be explicitly 
stated by decision makers, inferred from previous decisions, or proposed by researchers.  
While explicit and implicit thresholds exist only in jurisdictions where economic 
evidence plays a role in decision-making, threshold values have been proposed to 
facilitate the interpretation of cost-effectiveness evidence even in jurisdictions where 
cost-effectiveness evidence plays a minor role (Table 4).  
 
A common characteristic of the cost-effectiveness thresholds presented in Table 4 is that 
they are round numbers.  As noted by Weinstein in reference to the threshold ranges 
proposed by Kaplan and Bush (1982) and Laupacis et al. (1992), although using different 
currencies, the valuations are essentially the same, “in real terms the thresholds have 
changed, but the appeal of round numbers is long lasting”. (Weinstein 1996)  Indeed, it 
is suggested that the endurance of the $50,000 per QALY threshold value in a US health 
care system setting is due in large part to it being a ‘round number’.  This assertion is 
supported by the fact that the second most commonly used threshold in cost-effectiveness 
studies performed in a US health care system setting is $100,000 per QALY. (Greenberg, 
Winkelmayer, & Neumann 2006)  The notion of round numbers is often commented 
upon and used to illustrate the arbitrary nature of many threshold values. (Bridges, 
Onukwugha, & Mullins 2010;Eichler et al. 2004;Evans, Tavakoli, & Crawford 2004) 
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Table 4. Explicit, implicit and assumed ICER threshold values in other countries 
(adapted from Cleemput et al. 2008)  
Country Institution Author Year ICER threshold 
Explicit ICER threshold range 
UK NICE NICE 2008 £20,000 - £30,000 per QALY 
Implicit ICER threshold values or ranges based on past allocation decisions 
Australia PBAC Henry et al. 2005 AU$52,000 (approx) per QALY  
  PBAC George et al. 2001 AU$42,000 - AU$76,000 per QALY  
New 
Zealand 
PHARMAC Pritchard et 
al. 
2002 NZ$20,000 per QALY 
Canada CEDAC Rocchi et al. 2008 Range of acceptance: dominant to 
CAN$80,000 per QALY  
Range of rejection: CAN$31,000 to 
CAN$137,000 per QALY (Rocchi et 
al., 2008) 
UK NICE Towse & 
Pritchard 
2002 £30,000 per QALY 
ICER threshold values or ranges proposed by individuals or institutions 
UK NICE Williams 2004 1x GDP per capita (approx £18,000) 
USA NA Various 
(Section 
2.6.4.1) 
1970s- $50,000 per QALY 
  NA Kaplan & 
Bush 
1982 $20,000 - $100,000 per Well-Year 
  NA Goldman et 
al. 
1992 $20,000 - $100,000 per QALY  
  NA Kanis et al. 2002 $60,000 per QALY ($30,000 per 
QALY when not accounting for future 
costs) 
  NA Braithwaite 
et al.  
2008 $109,000 - $297,000 per QALY 
The 
Netherlands 
College voor 
Zorgverzekeringen 
(CVZ) 
The Council 
for Public 
Health and 
Health Care  
2006 €80,000 per QALY 
Developing 
world 
NA WHO 2003 3x GDP per capita  
New 
Zealand 
PHARMAC Pritchard et 
al. 
2002 NZ$20,000 per QALY (Pritchard, 
2002) 
Canada NA Laupacis et 
al. 
1992 CAN$20,000 to CAN$100,000 per 
QALY 
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2.6.3. Characteristics of a cost-effectiveness threshold 
2.6.3.1 Implicit vs. explicit thresholds 
The decision maker makes explicit thresholds public and must abide by them in their 
decisions.  If a coverage decision were made not in accordance with the explicit cost-
effectiveness decision rule, justification would be required.  In contrast, implicit cost-
effectiveness thresholds are not made public, so identification is possible only through 
retrospective evaluation of established coverage decisions. (Eichler et al. 2004)   
 
There are various theoretical advantages to operating an explicit cost-effectiveness 
threshold. (Coast 2001)  An explicit threshold helps ensure consistency and transparency 
while decreasing burden on the decision maker.  This, in turn, may increase efficiency, 
equity, and public trust.  However, there are also disadvantages associated with explicit 
thresholds.  Setting an explicit threshold would inevitably be politically sensitive and 
would require considerable political will to implement.  Also, as many health care 
decision makers are not familiar with health economics, they may not be comfortable 
with the use of a threshold as a sole criterion, or a principal criterion, for decision-
making. (Buxton 2005;Neumann 2005)  Further, setting an explicit threshold raises issues 
regarding pharmaceutical pricing.  An explicit threshold gives manufacturers information 
regarding the payer’s maximum willingness to pay for a unit of health gain, thus 
providing an incentive to price products in such a way that computed cost-effectiveness is 
equal to the threshold. (Claxton et al. 2008) 
 
To the best of my knowledge, the only institution that currently operates an explicit cost-
effectiveness threshold is NICE in the UK. (NICE 2008a)  This was, however, not always 
the case; rather, NICE originally claimed that a cost-effectiveness threshold was not in 
operation. (National Institute for Health and Clinical Excellence (NICE) 2001;Towse, 
Pritchard, & Devlin 2002)  As discussed in Section 2.6.3.2, NICE’s threshold currently 
ranges from £20,000 to £30,000.  This valuation has been subject to scrutiny, with much 
debate focused on the threshold when used in the context of cancer treatments.  Indeed, 
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pressure on NICE was such that with respect to treatments for end of life care, 
supplementary advice was issued to the Appraisal Committees providing guidance for 
under what circumstances a cost-effectiveness ratio in excess of the £30,000 upper bound 
of the threshold was permissible. (NICE 2009c;Towse 2009) 
 
It is inevitable that use of an implicit threshold will lead to an explicit threshold.  Given a 
sufficient sample size, and a degree of consistency with respect to a fixed decision rule, 
the value of an operated threshold will be identifiable through retrospective analysis.  
Attempts have been made to estimate the value of the threshold operated by decision 
makers in a variety of jurisdictions.  Researchers have evaluated coverage decisions and 
recommendations made by NICE in the UK, the PBAC in the Australia, and CEDAC in 
Canada. (Dakin, Devlin, & Odeyemi 2006;Devlin & Parkin 2004;George, Harris, & 
Mitchell 2001;Henry, Hill, & Harris 2005;Rocchi et al. 2008)  These studies are 
described in Section 4.5.1.  
 
2.6.3.2 Hard and soft cost-effectiveness thresholds 
Thresholds can also be characterised with respect to their rigidity.  A ‘hard’ threshold has 
a fixed valuation and is unaffected by other factors.  A ‘soft’ threshold is flexible and 
may fluctuate within a fixed range depending on the nature of the decision makers’ 
problem. ‘Hard’ thresholds have the advantage of being transparent, consistent and 
predictable.  In contrast, ‘soft’ thresholds allow for factors unrelated to cost-effectiveness 
to be accounted for, e.g., societal preferences. (Eichler et al. 2004)  
 
As illustrated in Table 4, the majority of suggested cost-effectiveness thresholds are ‘soft’ 
in nature.  The thresholds described by Kaplan and Bush (1982), Laupacis et al. (1992), 
Goldman et al. (1992), the WHO-CHOICE programme guidelines, and Braithwaite et al. 
(2008) all have lower and upper values. (Braithwaite et al. 2008;Goldman et al. 
1992;Kaplan & Bush 1982;Laupacis et al. 1992;Tan-Torres et al. 2003)  In the UK, NICE 
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uses a ‘soft’ threshold, ranging from £20,000 to £30,000, when evaluating health care 
programmes.  In NICE’s Guide to the Methods of Technology Appraisal it states, 
“consideration of the cost effectiveness of a technology is a necessary, but is not the sole, 
basis for decision-making”. (NICE 2008a)  With respect to the threshold range, NICE’s 
methods guidance state the following: 
- “Below a most plausible ICER of £20,000 per QALY gained, the decision to 
recommend the use of a technology is normally based on the cost-effectiveness 
estimate and the acceptability of a technology as an effective use of NHS resources.” 
- “As the ICER of an intervention increases in the £20,000 to £30,000 range, the 
Committee’s judgement about the acceptability of the technology as an effective use 
of NHS resources will make explicit reference to the relevant factors listed above.” 
- “Above a most plausible ICER of £30,000 per QALY gained, the Committee will 
need to identify an increasingly stronger case for supporting the technology as an 
effective use of NHS resources, with regard to the factors listed above.”  
 
‘Relevant factors’ include: the degree of certainty around the ICER; whether there are 
strong reasons to indicate that the assessment of the change in HRQL has been 
inadequately captured, and may therefore misrepresent the health utility gained; and the 
innovative nature of the technology. (NICE 2008a) 
 
Rawlins and Culyer (2004) first presented the rationale for NICE’s use of a soft 
threshold, which has been referred to as a ‘smudge’ (Figure 8). (Rawlins & Culyer 
2004;Towse & Pritchard 2002)  An intervention with an ICER below inflection point A 
will almost certainly be deemed acceptable on the grounds of cost-effectiveness; above 
inflection point B, it will be rejected on the grounds of cost-effectiveness and will need to 
be a strong case supporting the technology as an effective use of NHS resources; between 
A and B, it will unlikely be rejected on the grounds of cost-ineffectiveness alone and 
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other factors will be taken into account. (National Institute for Health and Clinical 
Excellence (NICE) 2008;Rawlins & Culyer 2004)  
 
 
 
 
 
 
 
 
Figure 8. Probability of rejection based on the grounds of cost-effectiveness  
 
As noted, NICE will consider other factors in the decision for technologies with an ICER 
above £20,000.  Other than those factors stated in NICE’s 2008 Guide to the Methods of 
Technology Appraisal, a number of special circumstances have been accounted for in 
technology appraisals.  These special circumstances, as presented by Rawlins et al. 
(2010), are as follows: (Rawlins, Barnett, & Stevens 2010) 
1. Severity of underlying illness.   
2. End of life treatments:the public places special value on treatments that prolong 
life at the end of life.  
3. Stakeholder persuasion, i.e., insights provided by stakeholders (e.g., patients, 
patient advocates, clinicians, NHS bodies, industry etc).  
4. Significant innovation, i.e., the technology demonstrates distinct and substantive 
benefits not adequately captured in quality of life measures. 
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5. Disadvantaged populations: special priority to improving the health of the most 
disadvantaged members of the population. 
6. Children: the assessment of improvement in quality of life is methodologically 
challenging; society would prefer to give ‘the benefit of the doubt’ to technologies 
affecting sick children.  
 
Rawlins et al. (2010) presented some of the occasions when the above criteria were 
considered as part of the technology appraisal; these are presented below in Table 5.  
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Table 5. NICE’s application of special circumstances in technology appraisals 
Topic ICER £ ('000s) Severity 
End of 
Life 
Stakeholder 
persuasion 
Significant 
innovation 
Disadvantaged 
population Children 
Riluzole (motor 
neurone disease) 38-40 9 9 9    
Trastuzumab 
(advanced breast 
cancer) 
37.5 9   9   
Imatinib (chronic 
myeloid 
leukaemia) 
36-65 9   9   
Imatinib 
(gastrointestinal 
stromal tumour) 
NA 9 9  9   
Pemetrexed 
(malignant 
mesothelioma) 
34 9 9   9  
Ranizumab (age-
related macular 
degeneration) 
>30   9 9   
Omalizumab 
(severe asthma) >30 9  9 9   
Sunitinib 
(advanced renal 
cancer) 
50 9 9 9 9   
Lenalidomide 
(multiple 
myeloma) 
43 9 9  9   
Somatotropin 
(growth hormone 
deficiency) 
NA   9 9  9 
Chronic 
subcutaneous 
insulin infusion 
(childhood Type 
1 diabetes) 
NA   9   9 
 
2.6.4. ICER threshold values or ranges proposed by individuals or institutions 
Various individuals and institutions have proposed ICER threshold values or ranges.  As 
noted, in 1982 Kaplan and Bush were first to propose a cost-effectiveness threshold. 
(Kaplan & Bush 1982)  The threshold was proposed for use in the setting of the US 
health care system and consisted of three levels: cost-effective by current standards if 
below $20,000 per Well-year; possibly controversial if between $20,000 and $100,000 
per Well-year, but justifiable by many then current examples; and questionable (in 
comparison with other current health care expenditures) if greater than $100,000 per 
Well-year. (Kaplan & Bush 1982) 
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Laupacis et al. (1992) published guidelines for the use of cost-effectiveness evidence in 
the Canadian health care system in 1992. (Laupacis et al. 1992)  As for Kaplan and 
Bush’s proposal, Laupacis et al. (1992) proposed a threshold consisting of three levels:  
cost-effective if less than CAN$20,000 per QALY; moderately cost-effective if between 
$20,000 and $100,000 per QALY; and unlikely to be cost-effective if in excess of 
$100,000 per QALY. 
 
Based in part upon the cost-effectiveness of implemented health care programmes, in 
1992 Goldman et al. (1992) proposed a cost-effectiveness threshold for use in the US 
setting. (Goldman et al. 1992)  The proposed threshold consisted of four levels:  very 
attractive if below $20,000 per QALY; consistent with implemented programmes if 
between $20,000 and approximately $40,000 per QALY; in excess of the majority of 
implemented programmes if between $60,000 and $100,000 per QALY; and unattractive 
if above $100,000 per QALY.  An interpretation of ICERs ranging between $40,000 and 
$60,000 per QALY was not provided.  
 
Kanis et al. (2002) recommended a threshold value of $60,000 per QALY for the 
evaluation of osteoporosis treatments when accounting for future costs.  When future 
costs were excluded a corresponding value of $30,000 per QALY was recommended. 
(Kanis et al. 2005;Kanis & Jonsson 2002) 
 
The Council for Public Health and Health Care (Raad voor de Volksgezondheid en Zorg) 
is an independent body with the role of advising the Netherlands’ government on public 
health and health care.  The Council has stated that it is not entitled to define a cost-
effectiveness threshold and that it should be determined through democratic discussion.  
However, to stimulate debate, in 2006 the Council suggested a value of €80,000 per 
QALY gained as the maximum acceptable cost-effectiveness ratio.  Although the Council 
considers cost-effectiveness evidence when issuing its recommendations, it is claimed 
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that no threshold value is in operation. (Cleemput et al. 2008;Raad voor de 
Volksgezondheid en Zorg 2006)   
 
As noted above (Section 2.6.1.2), on occasion, thresholds benchmarked to GDP per 
capita have been proposed.  Sachs proposed a threshold of 3xGDP per capita per DALY 
averted for use in developing countries.  This threshold was elaborated upon by the 
WHO-CHOICE, which proposed a three-level threshold (Section 2.6.1.2). (Tan-Torres et 
al. 2003;WHO 2005)  Williams proposed a threshold of 1xGDP per capita per QALY for 
use by NICE in the UK. (Williams 2004)   
 
2.6.4.1 The $50,000 per QALY cost-effectiveness threshold 
Approximately half of all cost-utility studies published up to 2003 used the $50,000 per 
QALY benchmark value. (Greenberg, Winkelmayer, & Neumann 2006;Neumann et al. 
2000)  Although suggested that the $50,000 threshold originated in the 1970s or 1980s, a 
recent study claims that it was first used in 1992 in a study evaluating optimal 
management strategies for HIV patients. (Freedberg et al. 1992;Grosse 2008)  However, 
it was not until 1996, following the report from the Panel on Cost-Effectiveness in Health 
and Medicine, that the $50,000 threshold per QALY became routinely used. (Gold et al. 
1996;Grosse 2008;Siegel, Weinstein, & Torrance 1996)  
 
While the origins of the $50,000 per QALY threshold are debated, many suggest that the 
valuation arose from using the cost-effectiveness of haemodialysis for the treatment of 
ERSD as the benchmark. (Hirth et al. 2000;Laufer 2005)  The rationale is that as 
haemodialysis, with a cost-effectiveness ratio of approximately $50,000 per QALY, was 
a Medicare benefit, interventions of similar cost-effectiveness should be deemed 
sufficiently cost-effective.  It should be noted, however, that there is uncertainty whether 
the $50,000 per QALY valuation was ever truly reflective of the cost-effectiveness of 
haemodialysis. (Bridges, Onukwugha, & Mullins 2010;Grosse 2008;Hirth et al. 2000)  
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Although the $50,000 per QALY threshold valuation may not have its foundations in 
society’s willingness to pay for a QALY, or with the opportunity cost associated with 
investing in a new technology, it does provide a “rule of thumb” and some method to 
compare the cost-effectiveness of various health care technologies.  
 
The $50,000 per QALY threshold has been extensively criticised in the literature. 
(Braithwaite, Meltzer, King, Jr., Leslie, & Roberts 2008;Bridges, Onukwugha, & Mullins 
2010;Evans, Tavakoli, & Crawford 2004;Grosse 2008).  If the threshold were 
benchmarked to the cost-effectiveness of haemodialysis, it would be logical to expect its 
value to increase in line with inflation and not remain static over time.  Indeed, as Hirth et 
al. (2000) highlight, in 1997 dollars the value would have increased to an approximate 
value between $74,000 and $95,000. (Hirth et al. 2000)  Also, if the threshold is linked to 
a Medicare benefit, it may be inappropriate to use it across sectors of the health care 
system other than Medicare.  In 2005, Cutler suggested that the threshold should be much 
higher, proposing a value of $100,000. (Cutler 2005)  In 2008, Brathwaite et al. used two 
approaches to assess the consistency of the $50,000 threshold with resource allocation 
decisions. (Braithwaite et al. 2008)  The lower bound of the threshold was estimated 
using a comparison of the incremental cost-effectiveness of recent (2003) versus pre-
“modern era” (1950) medical care in the United States; the upper bound was estimated 
using the incremental cost-effectiveness of unsubsidised health insurance versus self-pay 
for nonelderly adults (ages 21–64) without health insurance.  Lower and upper bounds 
were estimated as $183,000 per life-year and $264,000 per life-year, respectively, notably 
higher than the $50,000 valuation.  Brathwaite et al’s suggested value of the upper bound 
is consistent with that proposed by Ubel et al.  In 2003, Ubel et al. argued that thresholds 
of $50,000 and $100,000 were too low and suggested that medical practice reflects a 
valuation of a QALY much higher than $100,000.  Based upon the median value of their 
review of behavioural and contingent valuation studies, Ubel et al. (2003) suggest a 
higher threshold of approximately $265,000. (Ubel et al. 2003) 
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2.6.5. Empirical work into the value of the threshold 
There have been three notable attempts to empirically estimate the value of the cost-
effectiveness threshold in the UK.  In a series of studies, Martin et al. used a programme 
budgeting approach to model the link between health care spending and life years saved 
across various diseases (Martin S, Rice N, & Smith PC 2008a; Martin S, Rice N, & Smith 
PC 2008a).  Appleby et al. (2009) evaluated coverage/disinvestment decisions made in 
the NHS by local decision makers to estimate the appropriate cost-effectiveness 
threshold. (Appleby et al. 2009)  Baker et al. (2010) attempted to estimate the value of 
the QALY through the use of willingness-to-pay (WTP) and standard gamble approaches. 
(Baker et al. 2010) 
 
Using programme budgeting data from Primary Care Trusts (PCTs) in England, Martin et 
al. performed a series of studies that provide insight into the appropriateness of the cost-
effectiveness threshold operated in the UK.  The authors used a theoretical model in 
which decision-makers are required to allocate a fixed budget across health care 
programmes in order to maximize social welfare while accounting for a health production 
function for each programme.  In the first study, Martin et al. (2008a) used 2004/2005 
PCT data to model the link between health care spending and life years saved for care 
related to cancer and circulatory diseases.  The authors estimated the cost of saving a life 
year in cancer and circulation at approximately £13,000 and £8,000, respectively. (Martin 
S, Rice N, & Smith PC 2008a)  In subsequent studies the same researchers updated the 
analysis using more recent data (2005/2006 and 2006/2007).  In both instances, the 
findings were similar to those of the previous analysis in terms of the estimated cost of 
saving a life year in cancer and circulation. (Martin S, Rice N, & Smith PC 2008a; Martin 
S, Rice N, & Smith PC 2009) 
 
Through the use of structured interviews, Appleby et al. (2009) evaluated coverage 
decisions made by local decision makers in order to gauge the appropriateness of the 
cost-effectiveness threshold operated by NICE.  The research consisted of interviews 
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with senior staff from six NHS purchasers and 18 providers together with financial and 
public health information.  Despite estimating the cost-effectiveness of a number of 
interventions, the researchers could not determine if they were truly the marginal 
available services in the NHS and thus could not definitively draw conclusions regarding 
the appropriateness of the existing value of the cost-effectiveness threshold. (Appleby et 
al. 2009) 
 
The study by Baker et al. (2010) had two objectives: first, to identify characteristics of 
beneficiaries of health care over which relative weights should be derived and to estimate 
these relative weights; second, to determine the feasibility of using willingness-to-pay 
(WTP) and standard gamble approaches to estimate the value of a QALY. (Baker et al. 
2010)  Internet-based surveys were used for both aspects of the study.  With respect to 
the relative weighting aspect of the study, the authors concluded that additional research 
is required to explore the methodological differences with respect to age and severity 
weighting.  With respect to the valuation of a QALY, estimates ranged from values 
within NICE’s existing range for the threshold to extremely high values.  The authors did, 
however, state concerns regarding their measurement approach. (Baker et al. 2010) 
 
2.6.6. Cost-effectiveness acceptability curves 
As described, in the absence of complete information on the costs and benefits of 
available health care programmes, the cost-effectiveness threshold is necessary to 
interpret findings of cost-effectiveness analysis.  However, as this chapter has shown, 
there is much debate with respect to the appropriate threshold value.  Cost-effectiveness 
acceptability curves are proposed as a method for interpreting the findings of cost-
effectiveness studies while conveniently evading the question of the value of the cost-
effectiveness threshold.  Cost-effectiveness acceptability curves present the probability of 
an intervention being the most cost-effective of those considered across a range of 
maximum willingness-to-pay values for a unit of health gain (Figure 9), thus avoiding the 
requirement of a single fixed threshold (Drummond et al. 2005;Fenwick, Claxton, & 
90 
 
Sculpher 2001;Fenwick, O'Brien, & Briggs 2004).  Although a graceful way for analysts 
to avoid the value of a cost-effectiveness threshold, CEACs do not remove the need for 
decision makers to value a unit of health. (Buxton 2005)   
 
Figure 9. Cost-Effectiveness Acceptability Curve (CEAC) 
The presentation of CEACs in published cost-effectiveness analyses is becoming more 
commonplace.  A recent study showed the use of CEACs increasing, with inclusion in 
32.6% of studies published in 2006 compared to only 2.1% of studies published in 2001 
(p<0.0001). (Meckley et al. 2010)  The presentation of CEACs is recommended by a 
number of institutions, including NICE in the UK and the PBAC in Australia. (NICE 
2008a;PBAC 2008)   
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2.7. Chapter summary  
There is increasing awareness that resource allocation must be addressed in a systematic 
rather than intuitive manner.  While the reduction of waste in the health care system will 
allow greater opportunity for investment, this is likely to prove insufficient to curtail the 
rise in health care spending. (Donaldson et al. 2008;Garner & Littlejohns 2011)  Difficult 
resource allocation choices are inevitable, and decision makers must choose between 
available interventions.   
 
In this chapter, I have highlighted that markets are insufficient in health care and that 
economic evaluation offers an approach to the allocation of scarce resources.  I present 
the framework underpinning cost-effectiveness analysis and have shown how cost-
effectiveness information can be used to inform coverage decisions for medical 
technologies.  The requirement for a cost-effectiveness decision rule, along with the 
various approaches to setting its valuation, is illustrated.   
 
In the next chapter I describe various countries with respect to the relationship between 
health care spending and their relative rankings with respect to key health statistics.  
Then, I illustrate how economic evaluation is used to inform health care resource 
allocation in practice.  I have chosen countries that illustrate the varying approaches to 
decision making for health care interventions, some that have embraced cost-
effectiveness evidence in their health care system, i.e., the UK, Australia, Canada, and 
Sweden, and others in which cost-effectiveness evidence has been incorporated into 
decision making to a much lesser extent, i.e., France, Germany, and the US.  Special 
attention is paid to the US health care system, in which, despite an apparent urgent need 
to achieve increased value from health care resources, cost-effectiveness evidence is 
often excluded from review.  To gain insight into the resistance to using cost-
effectiveness evidence, I review attempts to incorporate cost-effectiveness evidence into 
decision-making at Medicare and through the Oregon Health Insurance Experiment. 
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3. Practice 
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3.1. Introduction 
In Chapter 2, I showed that reliance on market forces is insufficient to guide health care 
resource allocation.  Economic evaluation offers an alternative approach and is used in a 
number of jurisdictions to inform the prioritisation of resources between competing 
interventions.  I reviewed the underlying theoretical frameworks for economic evaluation 
in health care and illustrated how cost-effectiveness evidence can guide efficient health 
care resource allocation.  I also illustrated the requirement for a cost-effectiveness 
decision rule, i.e., the cost-effectiveness threshold, described the various approaches for 
setting its value, and presented examples of cost-effectiveness thresholds used in practice. 
 
In Chapter 3, I build on the theory presented in Chapter 2 and review how economic 
evaluation is used in practice to inform health care resource allocation across various 
countries.  I review countries that help to illustrate the different approaches taken to using 
economic evidence, in particular cost-effectiveness evidence, in the prioritisation of 
health care resources.  While some countries, namely the UK, Australia, Canada, and 
Sweden have embraced the use of economic evidence, other countries, namely France, 
Germany, and the US are notable for the limited extent that economic evidence is 
considered.  The decision-making processes employed by these countries are described 
through comparing and contrasting varying approaches. Special attention is paid to the 
US health care system in which, despite a particularly apparent need to improve the 
return from health care spending, the use of economic evidence has a limited role.  
 
To provide some background on the featured health care systems and some perspective 
on the institutions and processes for evaluating health care interventions, I first provide a 
number of comparative statistics.  I describe the health care systems with respect to 
relative health care spending, abundance of resources, and performance, both in terms of 
health outcomes and rankings in terms of overall performance.  
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3.2. Health care system in context 
In this section, I compare the health care systems of the UK, Australia, Canada, Sweden, 
France, Germany, and the US in terms of health care spending, abundance of health care 
resources, and performance. 
 
3.2.1. Health care spending 
While health care spending has increased at a faster rate than economic growth for all 
Organisation for Economic Co-operation and Development (OECD) countries, there is 
great variation between countries with respect to health care spending.  In terms of 
percentage of gross domestic product (GDP), the US is by far the highest spender on 
health care (Figure 10). (Davis, Schoen, & Stremikis 2010;Pearson M 2009)  In 2010, the 
US spent 17.4% of GDP on health care, almost 50% more than France, the next highest 
spender, and twice as much as Australia. (OECD 2011) 
 
Figure 10. Health expenditure as a share of GDP, 2010 (or most recent year 
available) (OECD 2011) 
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In terms of per capita health care spending, the US remains a notable outlier (Figure 11).  
In 2010, per capita health care spending in the US was $7,960, more than twice per capita 
spending in France, Sweden, Australia, and the UK, and approximately $3,500 more than 
the next highest spender, Canada.  Although the US has a higher income per capita than 
other countries, it has been suggested that this does not fully account for relative per 
capita spending. (Davis, Schoen, & Stremikis 2010)   
 
Figure 11.  Health expenditure per capita, US$ PPP, 2010 (or most recent year 
available) (OECD 2011) 
 
There has been much debate as to why US health care spending is much greater than 
spending in other countries. (Anderson et al. 2003;Neumann 2005;Neumann 
2009;Pearson M 2009)  Rather than a single explanation, it would appear that there are 
several contributing factors.  There is evidence suggesting that medical procedures are 
performed much more frequently in the US than elsewhere and that the US pays more for 
medical procedures than other countries. (Antoniou et al. 2004;Peterson & Burton 2007) 
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estimated to represent the greatest difference in spending between the US and other 
nations.  Indeed, elective interventions are estimated to have accounted for a quarter of 
the growth in US health spending between 2003 and 2006. (Farrell et al. 2008)  
Consistent with other developed countries, spending on prescription drugs has increased 
more rapidly than total health spending.  Pharmaceutical spending per capita is, however, 
higher in the US than in other OECD countries. (Danzon & Furukawa 2003;Pearson M 
2009)  Although there are fewer physicians per capita in the US than compared to the UK 
and the OECD average (Section 3.2.2), physicians located in the US, and health care 
professionals in general, are more often paid wages above what would be predicted by 
US national income. (Cutler & Ly 2011;Peterson & Burton 2007)  Administrative costs 
are often cited as a significant contributing factor of the overall cost of health care in the 
US.  The cost of health care administration is twice as high in the US than the OECD 
average and represents 7% of total health care spending. (Cutler & Ly 2011;Pearson M 
2009)  
 
3.2.1.1 Future trends for health care spending 
 Concerns about US health care spending are not only due to the magnitude of current 
spending, but also with respect to the rate of growth.  Globally, there is a trend for growth 
in health care spending as a percentage of GDP.  However, the US has outpaced other 
countries with the percentage of GDP spent on health care almost doubling between 1980 
and 2008 (Figure 12).  Currently, more than 17% of GDP is spent on health care, and 
projections from the congressional budget office (CBO) suggest that by 2050 the 
percentage of GDP spent on health care will have reached 37%. (CBO 2007)  Projected 
future spending on health care increased the urgency for US health care reform. (CBO 
2007;Cutler, Davis, & Stremikis 2009;Orszag & Emanuel 2010;Presidential Executive 
Office 2009;Sutherland, Fisher, & Skinner 2009)  
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Figure 12.  Increase in spending on health care as a percentage of GDP  
 
3.2.2. Abundance of health care resources 
Despite relative levels of spending, it is not necessarily the case that health care resources 
are more abundant in the US than in other countries.  Table 6 illustrates the relative 
abundance of two key health care resources, physicians and hospital beds.  Of the 
countries considered here, the US and Canada equivalently have the fewest physicians 
per 1,000 of the population.  Further, only Sweden has both fewer physician consultations 
per capita and fewer hospital beds per 1,000 of the population than the US.  The US fairs 
marginally better with respect to acute hospital beds but still lags behind other countries, 
with Germany, in particular, having twice as many acute hospital beds. (OECD 2011)   
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Table 6. Abundance of key health care resources 
  Australia Canada France Germany Sweden UK US 
Physicians 
per 1,000 
population 
3.0 2.4 3.3 3.6 3.7 2.7 2.4 
Physician 
consultations 
per capita 
6.5 5.5 6.9 8.2 2.9 5.0 3.9 
Acute 
hospital beds 
per 1,000 
population 
3.5 1.8 3.5 5.7 2.0 2.7 2.7 
Total 
hospital beds 
per 1,000 
population 
3.8 3.3 6.6 8.2 2.8 3.3 3.1 
 
While abundance of physicians and hospital beds is informative, it does not account for 
the intensity of patient interactions with the medical system.  Diagnostic imaging is one 
aspect where care delivery is more intense in the US than elsewhere.  There are many 
more CT and MRI scanners per million of the population in the US than in other 
countries, with scans performed much more frequently as part of routine care. (Cutler & 
Ly 2011;OECD 2011)  Also, the rate of certain surgical procedures is much higher in the 
US, with revascularisation procedures, knee replacements, and caesarean sections 
performed more frequently than in other countries. (Ko et al. 2007)   
 
3.2.3. Key health statistics 
The OECD produces statistics regarding the performance of health care systems using a 
variety of metrics.  The most recent data was published in June 2011. (OECD 2011)   
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Table 7. Inter-country comparison of key health statistics – life expectancy and 
infant mortality 
  Australia Canada France Germany Sweden UK US 
Life 
expectancy* 81.6 80.7 81.5 80.3 81.5 80.4 78.2 
Infant 
mortality* 4.3 5.1 3.7 3.5 2.5 4.6 6.5 
2010 or most recent year available 
 
3.2.3.1 Life expectancy 
Over the latter half of the 20th century many countries achieved significant gains in 
average life expectancy.  From1960 to 2009, average life expectancy increased in OECD 
countries by 11.2 years, from 68.1 to 79.3 years.  In contrast, life expectancy in the US 
increased by only 8.4 years, from 69.8 to 78.2 years.  Notably, average life expectancy in 
the US has fallen from being 1.7 years longer than the OECD average in 1960 to 1.1 year 
less than the OECD average in 2009. (OECD 2011)  Of the countries discussed above, 
the US has the shortest average life expectancy, 3.4 years less than average life 
expectancy in Australia, the country with the highest out of all OECD countries (Table 
7).  
 
3.2.4. Infant mortality 
A pattern similar to average life expectancy emerges when considering infant mortality.  
Considering the OECD average, infant mortality rate has declined drastically from a rate 
of 40.4 deaths per 1,000 live births in 1960 to 4.3 deaths per 1,000 live births in 2009.  In 
the US, infant mortality fell from 26.0 to 6.5 deaths per 1,000 live births (2008 most 
recent data available), notably higher than for other countries considered here (Table 7).  
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3.2.5. Global rankings 
Often claimed to be the world’s best health care system, recent studies have shown that 
the US health care system ranks unfavourably against others across a variety of criteria.  
In 2000, the World Health Organization (WHO) published its widely cited rankings of 
health care systems, and the US health care system placed at number 37.  Ranking was 
based upon ‘overall efficiency’ with a single composite score calculated from five 
indicators: health, health quality, responsiveness-level, responsiveness-distribution, and 
fair-financing.  France was ranked as the health care system with the highest efficiency; 
the UK was ranked 18th (Table 8). (World Health Organization 2000)  
 
Table 8. World Health Organization (WHO) rankings of health care systems 
Country 
WHO 
Ranking 
France 1 
UK 18 
Sweden 23 
Germany 25 
Canada 30 
Australia 32 
US 37 
 
The Commonwealth Fund is a US-based foundation that promotes a high performing 
health care system that achieves better access, improved quality, and greater efficiency. 
(The Commonwealth Fund 2010)  Since 2004, the Commonwealth Fund has made four 
attempts to rank various health care systems. (Davis et al. 2006;Davis et al. 2007;Davis, 
Schoen, & Stremikis 2010;Hussey et al. 2004) The most recent rankings, published in 
June 2010, include seven countries: Australia, Canada, New Zealand, the United 
Kingdom, Germany, the Netherlands, and the US. (Davis, Schoen, & Stremikis 2010)  A 
101 
 
ranking is decided upon using the following criteria:  quality of care; access; efficiency; 
equity; and long, healthy, and productive lives.  The US ranked last in 2010 in terms of 
overall rankings, consistent with the 2006 and 2007 study findings (an overall ranking 
was not presented in the 2004 report). (Davis et al. 2006;Davis et al. 2007)  Despite being 
the most expensive in the world, the comparative analyses by the WHO and 
Commonwealth Fund suggest that the US health care system underperforms relative to 
other countries across the majority of performance dimensions. (Davis, Schoen, & 
Stremikis 2010) 
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3.3. Using economic evaluation to inform resource allocation 
The evaluation of medical technology, commonly referred to as health technology 
assessment (HTA), is a global practice, as an HTA agency exists in virtually every 
developed country.  HTA is a term used to encompass multiple aspects of decision-
making and is defined by the International Network of Agencies for Health Technology 
Assessment (INAHTA) as, “a multidisciplinary field of policy analysis, studying the 
medical, economic, social and ethical implications of development, diffusion and use of 
health technology”. (INAHTA 2011;Luce et al. 2010)   
 
There is, however, much inter-country variation with respect to HTA activity.  A notable 
source of this variation is the type of evidence included in the assessment.  While there is 
broad consistency between HTA agencies with respect to consideration of safety and 
efficacy evidence, there is much variation how, and the extent to which, cost-
effectiveness evidence is considered.  While in some countries cost-effectiveness 
evidence is a fundamental part of technology assessment, in other countries it plays a 
lesser role.  To illustrate, I have chosen countries that best highlight inter-country 
differences with respect to decision-making criteria.  To this end, the UK, Sweden, 
Australia, and Canada serve as examples of countries in which cost-effectiveness 
evidence plays an integral role in decision-making.  In contrast, Germany, France, and 
the US serve as examples of countries in which cost-effectiveness evidence plays less of 
a role in decision-making. 
 
3.3.1. Countries in which cost-effectiveness evidence plays an integral role in 
decision-making 
In a number of countries, cost-effectiveness evidence plays an instrumental role in 
coverage and reimbursement decisions, or in recommendations for the efficient use of 
medical technology.  The use of cost-effectiveness evidence in decision-making in the 
UK, Sweden, Australia, and Canada is presented below. 
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3.3.1.1 UK and NICE 
Health care in the UK is dominated by the National Health Service (NHS) which 
provides health care to approximately 60 million people.  One of the NHS’s fundamental 
principles is universal access to care regardless of ability to pay. (Boyle 2011a;NHS 
2011)  The NHS is funded through general taxation, although approximately 12% of the 
population is also covered through private medical insurance. (Boyle 2011b)  Health care 
spending in the UK consumes 9.8% of GDP (2009 data) and the UK health care system 
was ranked 18th in the WHO’s 2000 global ranking of health care systems. (OECD 2011) 
 
April 1999 saw the introduction of the National Institute for Clinical Excellence (NICE).  
Established as a Special Health Authority, NICE was founded to eradicate the ‘postcode 
lottery’, terminology used to describe NHS patients’ variable access to medical 
technology contingent on where they lived. (NICE 2011c)  In 2005, the institute merged 
with the Health Development Agency (HDA) and was renamed the “National Institute for 
Health and Clinical Excellence”.  NICE’s principal functions are to provide guidance to 
the NHS with respect to public health, health technologies, and clinical practice.  Its most 
notable function is the technology assessment programme through which NICE is 
commissioned by the Department of Health (DoH) to evaluate new and existing medical 
technologies. (NICE 2009a;NICE 2009b;NICE 2011a)  NICE is renowned for its open 
and transparent process, with representatives from the health service, industry, patient 
advocacy groups and the public providing input. (NICE 2009a;NICE 2009b;NICE 2010a)  
NICE does not have the authority to restrict access to medical technologies in the NHS; 
rather, British law dictates that the NHS must provide funding for medical technologies 
for which NICE issues a positive recommendation. (NICE 2011b;Sorenson et al. 2008)  
Further, NICE does not have the authority to negotiate, or set, the price of medical 
technology, though its role is evolving towards a policy of Value Based Pricing (VBP). 
(DoH 2010)  NICE evaluates interventions through one of two processes, single 
technology appraisal (STA) or multiple technology appraisal (MTA).  The STA process 
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is designed to appraise a single product, device, or other technology with a single 
indication for which most of the relevant evidence lies with one manufacturer or sponsor. 
(NICE 2006)  The MTA process is designed to appraise single or multiple products, 
devices, or other technologies with one or more indications.  An independent academic 
group performs the health technology assessment, and additional evidence is sought from 
selected clinical specialists, NHS-commissioned experts, and patient experts. (NICE 
2009a) 
 
Decision-making criteria 
NICE is noted for the significant role that cost-effectiveness plays in its recommendations 
and to the extent to which its methods are in accordance with economic principles.  To 
ensure consistency across appraisals, NICE has adopted the approach of using a 
‘reference case’.  The reference case lays out NICE’s requirements for key aspects of 
their appraisal, e.g., costs should be considered from the perspective of the NHS and the 
Personal Social Services (PSS), health benefits should be measured using QALYs, costs 
and health benefits should be discounted at an annual rate of 3.5%, etc. (NICE 2008a)  
NICE accounts for the opportunity cost of implementing a new technology in the NHS 
through the use of a cost-effectiveness threshold.  To the best of my knowledge, NICE is 
the only agency that operates an explicit cost-effectiveness threshold.  Cost-effectiveness 
is not, however, the only decision-making criterion.  In the Guide to the Methods of 
Technology Appraisal, NICE states, “consideration of the cost effectiveness of a 
technology is a necessary, but is not the sole, basis for decision-making”. (NICE 2008a)  
NICE have laid out the other factors important in the appraisal and described how social 
value judgements should be incorporated. (NICE 2008b) 
 
Although all available evidence is considered in the appraisali, NICE has a strong 
preference for head-to-head RCTs.  In NICE’s appraisals incremental effectiveness data 
                                                 
i NICE’s reference case states that synthesis of evidence on outcomes should be based on a systematic 
review, and, when necessary, indirect and mixed treatment comparisons.  
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are synthesised along with incremental cost data to generate the estimate of cost-
effectiveness.  Potential budget impact does not determine the outcome of NICE 
appraisals, yet in the Guide to the Methods of Technology Appraisal, NICE states, “the 
[Appraisal] Committee will want to be increasingly more certain of the cost effectiveness 
of a technology as the impact of the adoption of the technology on NHS resources 
increases”. (NICE 2008a)  Indicative of the role other factors play in decision-making, 
NICE does not operate a fixed threshold.  Rather cost-effectiveness is considered over a 
range (see section 2.6.3.2).  Below an ICER of £20,000 per QALY gained, the NICE 
Appraisal Committee’s recommendation is normally largely based on cost-effectiveness.  
Above an ICER of £20,000 per QALY gained, other factors are accounted for, including 
degree of certainty around the ICER, whether HRQL has been inadequately captured, and 
the innovative nature of the technology. (NICE 2008a)  Above an ICER of £30,000 per 
QALY gained, the Appraisal Committee needs an increasingly stronger case that the 
technology is an effective use of NHS resources.  As described in Section 2.6.3.2, in 
addition to the factors stated above, special circumstances have been accounted for in a 
number of NICE’ recommendations. (Rawlins, Barnett, & Stevens 2010)   
 
3.3.1.2 Sweden and TLV/SBU 
The Swedish health care system is built around a principle of universal coverage for all 
members of society.  Sweden spends approximately 10% of GDP on health care with 
around 70% of health care services funded through local government taxes. (Anell 
2009;OECD 2011) The vast majority of health care is provided by publicly funded 
entities with only about 10% provided by privately funded entities.(Anell 2009)  Sweden 
was ranked 23rd in the WHO’s 2000 global ranking of health care systems. (OECD 
2011;WHO 2000)  
 
Two agencies perform HTA in Sweden, the Dental and Pharmaceutical Benefits Board 
(Tandvårds- och läkemedelsförmånsverket), or TLV, and the Swedish Council of 
Technology Assessment in Health Care, or SBU.  Established in 2002, the TLV is an 
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independent authority under the Department of Health and Welfare and is financed 
through government grants.  Before a drug can be included in Sweden’s Pharmacy 
Benefit Scheme (PBS), it must first be approved by the TLV. (TLV 2011)  Established in 
1987 by the Swedish government, the SBU was charged with evaluating the effectiveness 
and value of medical technology and providing guidelines for evidence-based medicine 
to the county councils and medical community. (Jonsson 2009b)  Although SBU 
publications have no direct mandate for influencing drug reimbursement, the TLV may 
take their recommendation into account. (TLV 2011)  
 
Decision-making criteria 
The TLV evaluates the clinical and cost-effectiveness of new drugs. (Anell & Persson 
2005)  The evaluation is performed from a societal perspective that includes productivity 
costs and the impact on a patient’s family and carers.  Three broad criteria are used to 
evaluate technologies (Anell & Persson 2005):  first, human value, i.e., health care is to 
be provided equally to all members of society;  second, need and solidarity, i.e., those 
with the greatest need for health care receive more resources than others; third, cost-
effectiveness, i.e., drug costs must be reasonable from medical, humanitarian, and 
socioeconomic standpoints.  Generally, decisions are made at the product level, i.e., the 
cost-effectiveness of a product is evaluated across its indications.  On occasion, 
exceptions are made to this policy with coverage decisions made for certain indications 
or in certain subgroups. (Anell & Persson 2005)  Cost-effectiveness analysis is a “central 
principle” of the TLV’s evaluation. (LFN - Pharmaceutical Benefits Board 2007)  
However, as human need and solidarity are also decision-making criteria necessary, 
trade-offs between them must be made.  Consequently, a single fixed cost-per-QALY 
threshold is not operated. (Anell & Persson 2005;Ramsberg, Odeberg, Engstrom, & 
Lundin 2004)  Although the TLV does not have the authority to negotiate price, if the 
technology is rejected on the basis of cost-effectiveness, the manufacturer may decide to 
reapply for reimbursement using a lower price. (LFN - Pharmaceutical Benefits Board 
2007) 
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The SBU’s remit is to select medical technologies for review and to consider them from a 
number of perspectives, including medical, economic, ethical, and social standpoints. 
(Jonsson 2009b;SBU 2011)  The SBU simultaneously evaluates and compares the 
effectiveness and cost-effectiveness of the alternative technologies. (Jonsson 2010)  One 
of the functions of the SBU’s reports is to aid the efficient allocation of health care 
resources. (O'Donnell et al. 2009) 
 
3.3.1.3 Australia and the PBAC/MSAC 
Australians have universal health care coverage through the Australian health care 
system, the predominant aspect of which is Medicare, the publicly funded insurance 
programme. (Bulfone, Younie, & Carter 2009a)  Health care in Australia is funded 
through a mixture of public and private financing, with the former accounting for 
approximately 70% of total funding.  Australia spends 8.7% of GDP on health care and 
was ranked 32nd in the WHO’s 2000 global ranking of health care systems. (OECD 
2011;WHO 2000)   
 
Two government agencies are responsible for HTA in Australia, the Pharmaceutical 
Benefits Advisory Committee (PBAC) and the Medical Services Advisory Committee 
(MSAC).  The PBAC is a statutory independent expert committee established under the 
National Health Act of 1953 and is appointed by the Health minister. (PBAC 2010)  The 
PBAC committee’s role is to evaluate drugs and to provide recommendations to the 
Minister of Health and Ageing regarding their inclusion on the Pharmaceutical Benefits 
Scheme (PBS), the national formulary that includes drugs and vaccines subsidised by the 
Australian government. (Lopert 2009;PBS 2011)  The PBAC’s recommendations fall into 
one of three categories: unrestricted benefit, restricted benefit, and authority required.  
Only drugs recommended by the PBAC can be added to PBS; the Health Minister may, 
however, decide not to list a recommended drug.  (Lopert 2009;PBS 2011)   
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Established in 1998, the role of the MSAC is to advise the Federal Minister for Health 
and Ageing regarding the strength of evidence relating to new medical technologies and 
procedures and to recommend under what circumstances they should be used. (MSAC 
2010)  Requests for the inclusion of devices on the Medicare Benefits Schedule (MBS) 
are most commonly made by the manufacturer but may also be made by medical 
organisations, individual physicians, or patients. (Bulfone, Younie, & Carter 
2009a;MSAC 2011)  The role of the MSAC is to improve health outcomes for patients by 
ensuring that new and existing medical procedures that attract funding under the MBS are 
supported by evidence of their safety, clinical effectiveness, and cost-effectiveness. 
 
Decision-making criteria 
In 1987, an amendment was made to legislation that required the PBAC to account for 
the effectiveness and cost of a drug relative to other therapies. (National Health Act 
1987)  Since then, consideration of cost-effectiveness has been fundamental in PBAC’s 
review. (Bulfone, Younie, & Carter 2009a)  Multiple factors are, however, considered 
relevant to decision-making and include: cost-effectiveness, including estimation of 
uncertainty; clinical need, including consideration of alternative treatment options; total 
cost of implementation to the PBS; and affordability of the drug to the patient in the 
absence of a subsidy.  Consistent with multiple decision-making criteria, the PBAC does 
not operate a fixed cost-effectiveness threshold but considers and weighs a number of 
relevant factors in deliberations. (Henry, Hill, & Harris 2005;Lopert 2009)  Accordingly, 
although drugs with a lower cost-effectiveness ratio are more likely to be recommended, 
those with a higher ratio may be recommended if indicated for a life threatening 
condition, or if a lack of effective alternatives exist. (Lopert 2009)  
 
The MSAC’s role is to advise the Minister for Health and Ageing on the strength of 
evidence relating to the safety, effectiveness, and cost-effectiveness of medical services 
and technologies and to provide a recommendation as to under what circumstances they 
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should be covered on the MBS. (MSAC 2011)  With respect to the economic evaluation, 
MSAC requests that a societal perspective be adopted. (Bulfone, Younie, & Carter 
2009b)  Consistent with the PBAC, the MSAC does not operate an explicit cost-
effectiveness threshold.  Based upon the strength of the evidence, the MSAC may 
recommend that the technology should receive public funding, recommend that the 
technology should not receive public funding, or deem that the evidence is inconclusive.   
 
3.3.1.4 Canada and CADTH 
Canada has a national health care system, commonly referred to as Medicare.  Canadian 
residents have ‘reasonable access’ to ‘medically necessary’ health-care services 
independent of their ability to pay. (Health Canada 2011;The Commonwealth Fund 
2011a)  Canada spends 11.3% of GDP on health care and the WHO ranked the Canadian 
health care system 30th in their 2000 global health care system rankings.  While 
approximately 70% of health care is publicly funded, approximately two thirds of 
Canadians have some form of supplementary private insurance often gained through 
employment based insurance plans.  Canada has a decentralised health care system with 
13 separate provincial and territorial health insurance plans. (Menon & Stafinski 2009) 
 
Health technology assessment (HTA) is performed at multiple levels throughout the 
Canadian health care system.  While the majority of HTA activity is performed by the 
Canadian Agency for Drugs and Technologies in Health (CADTH), regions often have 
their own HTA programs, e.g., Agence d’évaluation des technologies et des modes 
d’intervention en santé (AETMIS) in Quebec. (AETMIS 2011;Menon & Stafinski 2009)  
Established in 1989, CADTH is a national, independent, not-for-profit organisation 
funded by Canada’s federal, provincial, and territorial ministers of health. (CADTH 
2011b)  Originally named the Canadian Coordinating Office for Health Technology 
Assessment (CCOHTA), the agency is charged with providing credible, impartial advice 
and evidence-based information about the effectiveness and cost-effectiveness of drugs 
and other health care technologies to Canada’s decision makers at the federal, provincial 
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and territorial level. (CADTH 2011b)  In 2002, CCOHTA was given the additional 
responsibility of the Common Drug Review (CDR), the process of evaluating and 
recommending drugs for their inclusion on publicly funded federal, provincial, and 
territorial drug benefit plans.  In 2006, CCOHTA changed its name to CADTH to better 
reflect its roles and responsibilities. (CADTH 2011b)   
 
CADTH has three distinct programs: Health Technology Assessment (HTA), Common 
Drug Review (CDR), and Canadian Optimal Medication Prescribing and Utilization 
Service (COMPUS).  Through its HTA programs, CADTH evaluates technologies 
deemed to be of national interest and performs comprehensive reviews of the clinical 
effectiveness, cost-effectiveness, and broader impact of drugs, drug classes, and health 
technologies. (CADTH 2011a;INAHTA 2011)  The HTA programme’s focus is most 
often on more mature technologies for which there is a larger and higher quality body of 
evidence available. (CADTH 2011a)  In addition to the CADTH’s HTA programme, the 
CDR performs HTAs.  The CDR’s mandate is to evaluate new drugs, except for anti-
cancer agentsii, before they can be listed on federal, provincial, and territorial drug benefit 
plans.  The CDR submits a report to the Canadian Expert Drug Advisory Committee 
(CEDAC), which considers the comparative effectiveness and cost-effectiveness of the 
drug in comparison to the established standard of care.  CEDAC makes one of three 
funding recommendations to participating plans:  list without conditions, list with 
conditions, or do not list.  Each plan considers the recommendation and ultimately makes 
an independent decision as to coverage. (Menon & Stafinski 2009)   
 
Decision making criteria 
For each technology assessment, CADTH produces a comprehensive report that includes 
an evaluation of the technology’s clinical effectiveness, cost-effectiveness, and 
consideration of its various impacts on the health care system, including budget impact, 
                                                 
ii The pan-Canadian Oncology Drug Review (pCODR) was recently established (2010) to assess cancer 
drugs and make recommendations to the provinces and territories to guide their drug funding decisions.  
Although a number of reviews are in process none have yet been completed.(pCODR 2011)   
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legal and regulatory issues, and ethical, equity and psychosocial issues. (CADTH 2011a)  
With respect to clinical effectiveness and efficacy, CADTH typically performs a 
systematic review of the evidence base.  Consideration of all available alternatives must 
be made, with the recommended reference case including comparison with ‘usual care’. 
(CADTH 2006)  The assessment of a technology’s cost-effectiveness is performed from 
the perspective of the publicly funded health care system and typically includes a cost-
utility analysis.  As the broader impact on both patient health and the health care system 
is considered, CADTH does not operate a fixed cost-effectiveness threshold. (CADTH 
2011a) 
 
Fundamental to each CDR submission is evidence of the product’s efficacy, 
effectiveness, and safety.  An appropriate pharmacoeconomic evaluation is required for 
all submissions to the CDR. (CDR 2010)  A cost-effectiveness or cost-utility study is 
required in the following circumstances:  the drug is the first available for a particular 
indication; the drug is the first in a newly established therapeutic class; the drug has 
demonstrated differences in safety or efficacy compared to available alternatives in head-
to-head randomised controlled trials; or, in the absence of head-to-head trials, the drug’s 
manufacturer assumes that differences exist (manufacturer must provide evidence to 
support this assertion).  Cost-effectiveness or cost-utility analyses must be based upon 
final outcomes such as life-years, QALYs, important disease specific units (e.g., 
myocardial infarction, stroke, or fracture), or validated surrogate outcomes. (CDR 2010)  
A cost-consequence analysis may be considered for products demonstrating benefits in 
other outcomes, e.g., those that are patient-reported, non-clinical or surrogate.  In most 
cases budget impact analyses (BIAs) are also required.   
 
3.3.2. Countries in which cost-effectiveness evidence plays less of a role in decision-
making 
Cost-effectiveness is a central component in assessments performed by the HTA agencies 
described in the preceding sections.  Not all countries, however, have HTA agencies that 
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consider cost-effectiveness evidence to the same extent.  Described in the following 
sections are Germany, France, and the US, three countries in which cost-effectiveness 
evidence plays a lesser role.   
 
3.3.2.1 Germany and IQWiG 
In Germany, universal health care coverage is provided through a multi-payer system. 
(The Commonwealth Fund 2011b)  Germany spends 11% of GDP on health care and the 
WHO ranked the German health care system 25th in their 2000 global health care system 
rankings. (OECD 2011;WHO 2000)  Germans whose income is below a certain level 
receive health insurance through the Statutory Health Insurance (SHI) system of private 
non-profit sickness funds.  While the majority of Germans with incomes above the 
threshold opt into the sickness fund system, some purchase private insurance. (The 
Commonwealth Fund 2011b) 
 
The Institute for Quality and Efficiency in Health Care (IQWiG) is an independent 
scientific institute established in July 2004 to provide advice to the Federal Joint 
Committee, the main decision-making body in German health care.  Advice is based 
upon evidence-based evaluations of the costs and benefits of health technologies and 
services. (IQWiG 2011a;Nasser & Sawicki 2009;Perleth, Gibis, & Gohlen 2009)  The 
institute is responsible for the scientific evaluation of the benefits and harms, and the 
quality and efficiency, of health care services. (IQWiG 2011b)  The Federal Joint 
Committee considers IQWiG’s evaluations and issues coverage and payment directives.  
Since January 1st, 2011, all new drugs are subject to assessment with associated medical 
benefit compared against appropriate therapeutic alternatives.  Requests for review topics 
originate from a combination of government sources, patient advocacy groups, or the 
Federal commissioner for patient affairs. (The Commonwealth Fund 2011b)  The Federal 
Joint Committee ultimately selects topics to be considered by IQWiG.   
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Decision making criteria 
IQWiG is responsible for the scientific evaluation of the clinical effects as well as the 
quality and efficiency of health-care services. (Caro et al. 2010)  The assessment is a two-
step process that includes a clinical assessment, and subsequently, a cost-benefit-
assessment. (Fricke & Dauben 2009;Gerber, Stock, & Dintsios 2011)   
 
IQWiG’s assessment considers a new technology’s medical benefit by evaluating both 
comparative and non-comparative clinical studies.  The assessment is based upon a 
dossier submitted to IQWiG by the technology’s manufacturer that must include all 
relevant studies and information regarding the medical benefit relative to therapeutic 
alternatives.  According to regulation, IQWiG categorises the medical benefit of a new 
technology into six categories (Gerber, Stock, & Dintsios 2011): 
1. Remarkable additional benefit 
2. Considerable additional benefit 
3. Minor additional benefit 
4. Additional benefit not quantifiable 
5. No evidence of additional benefit 
6. Less benefit than the comparator 
 
In April 2007, federal law expanded IQWiG’s duties by adding a cost-benefit-assessment 
to the appraisal process.  However, under law a technology cannot be excluded from 
coverage due to its cost.  In January 2008iii, IQWiG published their methods guidance for 
the submission process. (Caro et al. 2010;IQWiG 2009a)  The recommended 
methodology differs somewhat from the requirements of other HTA agencies.  The 
efficiency frontier, a fundamental aspect of this methodology, is a plot of the incremental 
costs and benefits of available technologies, with health benefit in terms of “patient 
                                                 
iii An updated version was published March 2009(IQWiG 2009b)  
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relevant health outcomes” presented on the Y-axis and costs presented on the X-axis 
(Figure 13).   
 
  
Figure 13. Efficiency frontier as used by IQWiG 
 
New technologies falling below and to the right of the frontier are considered less 
efficient; technologies falling above and to the left of the frontier are considered more 
efficient.  However, it is expected that rather than falling in either of these categories, a 
new technology will typically be more effective and more costly than currently available 
care.  The frontier is said to inform whether a new health care programme with a positive 
ICER represents good value for money by providing the “going rate” for the additional 
cost per health benefit, i.e., the ICER associated with programme C, the reciprocal of the 
gradient of the frontier B-C. (Caro et al. 2010)  It is suggested that if there are sufficient 
points on the efficiency frontier, an estimation of the rate at which efficiency has been 
decreasing as a function of increasing value can be made.  This estimate will indicate 
“what is to be expected” with respect to future increases in the value of a unit of health 
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benefit, and will provide a basis for assessing the reasonableness of a decrease in 
efficiency. (Caro et al. 2010)  For example, technology D in Figure 1 represents a new 
technology associated with a positive ICER, i.e., is more effective and more costly than 
technology C.  The ICER associated with technology C represents the “going rate”, i.e., 
the current cost of producing a unit of health gain.  Technology D’s ICER is greater than 
programme C’s, and thus greater than the “going rate”.  Further, it is suggested that a 
willingness to pay approach may inform whether a new technology should be 
implemented, although the challenges associated with this approach are noted.  The 
decision rule is, however, unclear for technologies that are both more effective and more 
expensive than their comparator.  While the Federal Joint Committee may consider the 
“going rate” and WTP estimates, the maximum cost per health outcome that would be 
deemed permissible is uncertain. 
 
 IQWiG do not usually consider the QALY.  Rather, the agency focuses its assessment of 
benefit and harm in terms of patient-relevant health outcomes.  It is stated that due to not 
being a “universally accepted method”, QALYs will not be used as the outcome metric of 
choice. (Caro et al. 2009)  Although the use of disease specific units to quantify health 
benefit is appealing, their use will likely be challenging in therapeutic areas in which 
multiple dimensions of health are affected or for technologies that positively impact 
multiple therapeutic areas. 
 
An important distinction of IQWiG’s methods is that, rather than to serve as a method to 
allocate resources across diseases, the purpose is to recommend maximum reimbursable 
prices.  IQWiG’s methodological approach has been subject to criticism, particularly as 
opportunity cost does not appear to be accounted for. (Sculpher & Claxton 2010)  Similar 
to other HTA agencies, IQWiG publishes reports, rapid reports and working papers, and 
invites input from all stakeholders and the general public. (IQWiG 2011a)  
 
116 
 
3.3.2.2 France and HAS 
In 2000, the French health care system was ranked as the world’s best by the WHO. 
(WHO 2000)  Health care coverage in France is universal and while it is predominantly 
government funded, it is possible to purchase supplementary private insurance. (Rochaix 
& Xerri 2009)  France spends approximately 12% of GDP on health care. (OECD 2011)  
It is said that France’s health care system is characterised by “solidarity and universal 
coverage and responsibility”. (de Pouvourville G. 2010;Weill & Banta 2009)   
 
The Autorité de santé (HAS), or French National Authority for Health, is an independent 
public body established by the French government. (HAS 2011)  HAS was created by the 
National Health Insurance Reform Act of 2004 and was established January 2005, to 
unite under a single entity a number of activities designed to improve the quality of 
patient care and guarantee equity within the health care system. (HAS 2011;Weill & 
Banta 2009)  HAS is mandated by law to carry out particular research projects that it 
reports to the French government and parliament.  While HAS’s recommendations are 
advisory, the decision-making bodies, i.e., the union of sickness funds or the Ministry of 
Health, generally accept its findings.  HAS is responsible for a broad range of activities 
that include: the assessment of drugs, medical devices, medical and surgical procedures, 
and biological tests; physician certification; the generation of clinical guidelines; and 
providing information with respect to the coverage of services and reimbursement. (HAS 
2011;Weill & Banta 2009)   
 
Through its technology evaluation role, HAS performs two types of technology 
assessments; single technology assessments (STA) and multiple technology assessments 
(MTA). (Rochaix & Xerri 2009)  Before a new drug, medical device, or procedure can be 
added to the health insurance benefit list, a mandatory STA is performed.  Product 
manufacturers or professional societies can initiate STAs.  HAS assesses a technology or 
procedure’s intrinsic value and its effectiveness relative to competing therapies. (Rochaix 
& Xerri 2009)   
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HAS gives an “opinion” on the absolute health benefit, i.e., expected or actual benefit and 
the relative health benefit, i.e., effectiveness relative to usual care, of the technology or 
procedure.  HAS’s opinion is given to the Ministry for Health and Social Security and 
union of sickness funds, and is used to support coverage, reimbursement, and pricing 
decisions.  Current regulation dictates that “medicines that neither provide a therapeutic 
added value nor cost savings” may not be included on the benefit list.  Therefore, 
technologies or procedures that do not provide additional clinical benefit will only be 
reimbursed if they are offered at a lower cost.  For technologies or procedures judged to 
provide additional health gain, the pricing committee may grant a higher price.  
Technologies are reassessed by HAS at five year intervals; procedures are reassessed at 
variable time intervals. (Rochaix & Xerri 2009)  
 
In contrast to STAs, MTAs generally review an entire class of technologies or 
procedures.  Also, MTAs may take the form of public health guidelines or concern the 
organisation of care.  Although topics for review may be chosen internally by HAS, 
typically they originate from public agencies or other interested parties.  Rather than 
providing an opinion on certain technologies and procedures, MTAs are designed to 
provide more high level guidance on coverage policy, health care delivery, or health care 
organisation.   
 
Decision making criteria 
With respect to intrinsic value, HAS considers the severity of the condition treated, the 
efficacy/safety ratio, and how treatment fits into the current therapeutic strategy.  With 
respect to relative effectiveness, the incremental clinical benefit of the product is 
categorised on a five-level scale:   
I:  major improvement (new therapeutic area, reduction of mortality) 
II:  significant improvement in efficacy and/or reduction of side-effects 
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III:  modest improvement in efficacy and/or reduction of side-effects 
IV:  minor improvement 
V:  no improvement. 
 
In 2008, HAS’s mission was expanded to include, “recommendations and medico-
economic opinions on the most effective strategies of care, prescription, and disease 
management”. (Rochaix & Xerri 2009)  Although HAS had performed a small number of 
economic analyses prior to 2008 this legislation signalled a change in direction.  To 
perform this function a new department within HAS was created, the Commission for 
Economic and Public Health Evaluation (CEESP).  CEESP is overseen by an 
interdisciplinary committee responsible for evaluating the quality and ethics of completed 
work, providing scoping guidance, and considering potential conflicts of interest.  
Economic evaluations performed by HAS help illustrate the opportunity costs associated 
with reimbursement decisions, thus increasing the efficiency of the use of medical 
technology.  For the most part, economic evaluations are performed as part of MTAs 
rather than STAs.  Therefore, the introduction of economic evaluation has not influenced 
the STA process and so the method for pricing and reimbursing technologies remains 
principally determined through consideration of clinical efficacy. (de Pouvourville G. 
2010)  Economic evaluation may impact the price of medical technologies and 
procedures through a re-examination of treatment classes through MTAs.  Typically, 
economic evaluations consider a whole class of treatments and are used to optimise the 
overall delivery of care, rather than to evaluate individual medical technologies or 
procedures. (de Pouvourville G. 2010)  As economic evaluations are performed in a 
within-class basis, disease specific units are often used, e.g., cost of reduction of 1g/L of 
LDL cholesterol. (de Pouvourville G. 2010)   
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3.3.2.3 US 
The US health care system has been described as fragmented and uncoordinated. 
(Sullivan et al. 2009)  With no single national entity, or set of policies, to guide it, 
multiple agencies administer health care at the national, state, community, and practice 
levels. (Shih et al. 2008)  In contrast to the countries described above, the majority of 
Americans (67.5%) obtain health insurance through private providers. (DeNavas-Walt, 
Proctor, & Smith 2008)  Approximately 28% of Americans receive health insurance 
through government programmes, of which Medicare is the largest.  Prior to the Patient 
Protection and Affordable Care Act (PPACA) legislation in 2010, approximately 15% of 
the population did not have health insurance coverage.iv (PPACA 2010)  As described in 
Section 3.2.1, despite spending considerably more on health care than other countries, the 
US health care system ranked 37th in the WHO’s 2000 global health care system 
rankings. (WHO 2000)   
 
Consistent with the decentralised nature of the health care system, a number of 
independent public and private HTA agencies exist in the US rather than a single HTA 
agency.  Notable publicly funded agencies include Medicare and Medicaid, the Agency 
for Healthcare Research and Quality (AHRQ), the Drug Effectiveness Review Project 
(DERP) in Oregon, and the HTA programme of the Washington State Medicaid 
programme, among others. (AHRQ 2011;CMS 2005a;CMS 2011e;Shih, Davis et al. 
2008;Washington State Health Care Authority 2010)  Other federally funded programmes 
include the Pharmacy Benefits Management Strategic Healthcare Group at the 
Department of Veterans Affairs and the Department of Defense PharmacoEconomic 
Center (PEC) in the Military Health System. (DoD PEC 2010;U.S.Department of 
Veterans Affairs 2010)  The National Institutes of Health, although not having a HTA 
programme, occasionally perform evidence reviews when developing clinical practice 
policies. (NIH 2011)  Private health care plans often make coverage and reimbursement 
decisions, although in many cases Pharmacy Benefit Managers (PBMs) are used to 
                                                 
iv It is expected that the proportion of uninsured individuals will decrease considerably if the recent health 
reform legislation it is fully implemented in 2014. 
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design and administer drug formularies.  However, most private organisations do not 
make information about their HTA programmes readily available.  There is likely 
considerable variation between them. (Sullivan et al. 2009)   
 
Comparative effectiveness research (CER), i.e., the direct comparison of existing health 
care interventions to determine relative effectiveness, has been advocated as an approach 
to improve quality of care while helping to arrest rising costs.  Initial support for CER 
came as part of the American Recovery and Reinvestment Act (ARRA) of 2009, in which 
a provision dedicated $1.1 billion to study CER. (ARRA 2009)  The PPACA legislation 
of 2010 further advocated the use of CER but placed restrictions on how such 
information should be used. (PPACA 2010)  The Patient-Centered Outcomes Research 
Institute (PCORI) was established as part of the PPACA and has the role of coordinating 
CER studies, assisting in their funding, and disseminating study findings. (PPACA 2010) 
 
Cost-effectiveness evidence is not typically part of technology assessment in the US.  The 
Centers for Medicare & Medicaid Services (CMS) are the administrators of Medicare, 
which is the largest payer in the US.  CMS states in its Guidance for the Public, Industry 
and CMS Staff that cost-effectiveness evidence is not a factor CMS considers in making 
national coverage determinations (NCDs), although recent decisions appear to suggest 
that cost-effectiveness evidence plays a role in NCDs for preventative care (Table 9).v 
(CMS 2010e)  Rather, coverage decisions for medical technologies are made using the 
‘reasonable and necessary’ criterion (Section 3.4.2.1).  Both the Department of Defence 
(DoD) and Department of Veterans Affairs (VA) have internal groups that evaluate cost-
effectiveness, but how it is incorporated into decision-making is not described. (DoD 
PEC 2010;U.S. Department of Veterans Affairs 2010)  One of the stated goals of the state 
of Washington’s HTA programme is to make “State purchased health care more cost 
effective by paying for medical tools and procedures that are proven to work”. 
                                                 
v N.B. The empirical work presented in chapters 4 through 7 evaluates CMS NCDs from the perspective of 
cost-effectiveness.  
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(Washington State Health Care Authority 2010)  Again, however, guidance is not given 
as to how cost-effectiveness evidence is factored into decision-making.   
 
Cost-effectiveness analysis is used to a limited extent in the private health care industry.  
The Academy of Managed Care Pharmacy (AMCP) has published guidelines that serve 
as a template for drug companies to submit dossiers to Pharmacy and Therapeutics (P&T) 
Committees.  These guidelines include recommendations regarding cost-effectiveness 
analysis. (FMCP Format Executive Committee 2010)  Wellpoint, one of the largest 
private health insurance companies, has issued guidelines providing a framework for the 
submission of cost-effectiveness evidence. (Wellpoint 2010)  Also, the Drug 
Effectiveness Review Project (DERP) is an alliance of 13 states and private organisations 
that synthesise and judge clinical evidence for drug class reviews. (DERP 2010)  
Consumers Union (CU), an independent, non-profit organisation, adapts DERP reviews 
in developing a consumers “Best Buy” guide.  Recommendations in the guide are based 
upon a comparison of a drug to others in the same therapeutic class.  The criteria used for 
these recommendations include relative effectiveness, safety, side-effect profile, 
convenience, and price.  However, as only drug price is considered and not associated 
costs, CU does not estimate the overall value or cost-effectiveness of drugs. (Consumer 
Reports 2010) 
 
By and large, the use of cost-effectiveness analysis is not established in the US health 
care system.  Although the examples listed above provide evidence that some decision 
makers are aware of the benefits of cost-effectiveness evidence, the fragmented nature of 
the US health care system results in great variability with respect to its use.  When 
decision makers do consider cost-effectiveness evidence, the role that it plays in decision-
making is unclear. 
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3.3.3. Inter-country comparison 
There is noticeable variation in decision-making criteria across agencies in the countries 
described above.  While no country relies solely on cost-effectiveness evidence to guide 
coverage and reimbursement decisions or to make recommendations for the efficient use 
of medical technology, it plays a more important role in some countries than in others.  
Cost-effectiveness evidence plays a fundamental role in technology assessment in the 
UK, Sweden, Australia, and Canada.  However, indicative of the fact that multiple 
criteria are important in decision-making, acceptable cost-effectiveness either exists over 
an explicit range, e.g., the UK, or no range is given, e.g., Sweden, Australia, and Canada.  
Germany and France provide examples of countries in which economic considerations 
play less of a role in decision-making.  It is noteworthy that despite Germany and France 
grounding technology assessment in the clinical evidence, cost-effectiveness evidence 
still features to a limited extent.  In Germany, although IQWiG considers the costs and 
benefits of medical technology, this information may not be used to deny coverage of a 
medical technology.  Rather, cost-effectiveness information is used on the fringe of the 
decision-making process to inform the maximum allowable price.  In France, while the 
consideration of cost-effectiveness evidence has recently been added to HAS’s mandate, 
it is considered in only the minority of instances and resistance to its use remains. (de 
Pouvourville G. 2010) 
 
The US could be considered near the end of the spectrum with respect to its use of cost-
effectiveness information.  The US health care system is largely decentralised and with 
multiple entities evaluating medical technology, decision-making is fragmented and 
uncoordinated.  Although some public and private payers use cost-effectiveness 
information sporadically, the extent to which it informs decision-making is unclear.  
Further, Medicare, the largest payer in the US, states that cost-effectiveness is not a factor 
it considers in national coverage determinations.   
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Why cost-effectiveness evidence plays such a limited role in decision-making in the US 
is not obvious.  In the following sections, I review attempts to incorporate cost-
effectiveness evidence into decision-making in the US and consider reasons why 
resistance to it exists. 
 
3.4. The use of cost-effectiveness evidence in the US health care 
system 
As described in Section 3.2.1, health care spending in the US is greatly in excess of 
spending in other countries, but the US performs relatively poorly when considering key 
health metrics.  Given the comparatively poor return from spending, it would seem that 
the US health care system would benefit greatly from the use of cost-effectiveness 
evidence.  However, as described in Section 3.3.2.3, the US is notable for the minimal 
role that cost-effectiveness evidence plays in decision-making.   
 
There have been, however, a number of prominent attempts to advocate the use of cost-
effectiveness analysis and to incorporate cost-effectiveness information into decision-
making; these are described below.  
 
3.4.1. The US Panel on Cost-Effectiveness in Health and Medicine 
Paradoxically, given the current unwillingness to embrace cost-effectiveness evidence, 
the US was one of first countries to establish methodological guidelines for conducting 
cost-effectiveness analysis.  In 1993, the US Public Health Service convened the U.S. 
Panel on Cost-Effectiveness in Health and Medicine. (Gold et al. 1996)  The Panel’s task 
was to assess the state of the science of cost-effectiveness analysis and to provide 
recommendations for the conduct of cost-effectiveness studies.  In 1996, the Panel 
published its recommendations in a book entitled “Cost-effectiveness in health and 
medicine” and in three summary articles. (Gold et al. 1996;Russell et al. 1996;Siegel et 
al. 1996;Weinstein et al. 1996)  Among the Panel’s recommendations were the 
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appropriateness of analytic techniques (cost-effectiveness analysis was proposed as the 
method of choice), relevant outcome measures (the QALY), the discount rate (3%), and 
the presentation of incremental ratios.  The Panel stated that cost-effectiveness analysis 
should be useful to various audiences, including insurers, managed care organisations, 
policy makers, and the general public, among others.  The Panel’s recommendations 
proved influential among health economic researchers but had only a limited impact on 
the proliferation of the use of cost-effectiveness analysis in the US health care system. 
(Phillips & Chen 2002)    
 
3.4.2. Attempts to incorporate cost-effectiveness analysis into health care 
In the following sections, I present two case studies that provide useful insight into the 
resistance to the use of cost-effectiveness evidence in the US.  
 
3.4.2.1 Cost-effectiveness and Medicare 
As highlighted in Section 3.3.2.3, CMS state that cost-effectiveness evidence is not 
considered in national coverage determinations. (CMS 2010e)  There have been, 
however, attempts to incorporate cost-effectiveness evidence into CMS’s technology 
assessment. 
 
The first attempt to incorporate cost-effectiveness evidence into CMS coverage 
determinations was in the Health Care Financing Administration’s (HCFA) 1989 
proposed regulations. (Federal Register 1989b)  The HCFA supported this intention by 
stating, “We believe the requirement of section 1882(a)(1) that a covered service be 
‘reasonable’ encompasses the authority to consider cost as a factor in Medicare 
coverage determinations”. (Federal Register 1989c)  It was further reasoned that the 
systematic assessment of the cost-effectiveness of technologies would “vastly improve 
our knowledge base and be a deterrent to coverage of procedures that may be costly, but 
have little or no impact on improving health outcomes”. (Federal Register 1989d)  The 
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proposed regulations were scrutinised from a number of sources, e.g., the New York 
Times suggested that it represented “a fundamental shift… the Federal Government will 
explicitly weigh cost as a factor in deciding whether Medicare should pay for new 
medical procedures, devices and drugs for elderly people”. (Pear 1991)  Despite support 
from the Department of Health and Human Services, opposition from the medical device 
industry and consumer groups meant that the proposed regulations were not released in 
final form. (Neumann 2005;Pear 1991)  
 
In the mid-1990s, the HCFA attempted to revive the proposed regulation and publish it as 
a final rule.  Once more, the regulation faced opposition, this time from medical and 
industry groups.  Among those opposing the proposed regulation were the 
Pharmaceutical Research and Manufacturers Association of America (PhRMA), the 
American College of Physicians, the American Medical Association (AMA), and various 
politicians.  The opposition ultimately resulted in the HCFA announcing the formal 
withdrawal of the proposed 1989 regulation in 1999. (Neumann 2005;U.S. Congress 
1997)     
 
Today, coverage decisions remain guided by the legislation that created Medicare, which 
states that “Medicare coverage is limited to items and services that are reasonable and 
necessary for the diagnosis or treatment of an illness or injury”.  Cost-effectiveness 
evidence is effectively excluded from review. (CMS 2010g)  In the Guidance for the 
Public, Industry and CMS Staff states “Cost effectiveness is not a factor CMS considers 
in making NCDs.  In other words, the cost of a particular technology is not relevant in 
the determination of whether the technology improves health outcomes or should be 
covered for the Medicare population through an NCD”. (CMS 2010e) 
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3.4.2.2 The Oregon Experiment  
The Oregon Experiment is an often-cited example of an attempt to introduce cost-
effectiveness into resource allocation decision-making in the US.  Oregon’s proposed 
approach to using cost-effectiveness drew much attention and scrutiny from sources 
inside and outside the US. (Neumann 2005) 
 
Oregon Medicaid Programme 
In the late 1980s, the state of Oregon was struggling to finance its state Medicaid 
programme.  In 1987, in response to ongoing budgetary pressures, the Oregon legislature 
removed major organ transplants as a benefit from the state’s Medicaid programme.  
Later that year, a seven-year-old boy died after not receiving a bone marrow transplant. 
(Buist 1992)  The resultant public outcry prompted a reconsideration of the Medicaid 
benefit with respect to eligibility and service provision.  Attempts to reintroduce bone 
marrow transplants to the Medicaid benefit were opposed by the president of the state 
senate, John Kitzhaber.  Kitzhaber contended that the resources required to provide bone 
marrow transplants to a few individuals would be sufficient to provide basic health 
insurance to many more uninsured individuals. (Fruits, Hillard, & Lewis 2009)  Further, 
it was argued that by restricting the basic services offered as part of the Medicaid 
programme, it would be possible to expand coverage to all uninsured eligible individuals.  
To this end, a bill was proposed in 1989 with the ambitious goal of providing health 
insurance for all Oregon residents.  This was to be achieved through two mechanisms, by 
mandating private employers to provide health insurance to employees and expanding the 
Medicaid programme to all Oregon residents below the poverty line.  Although, attempts 
to mandate employer health insurance were unsuccessful due to political and business 
opposition, reforms to the Medicaid programme with the Oregon Health Plan (OHP) 
were finally implemented in 1994. (Buist 1992;Neumann 2005)  The evolution of the 
OHP from conception to implementation is described below. 
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Prioritisation of services 
The expansion of the Medicaid programme was to be achieved by prioritising services.  
A novel approach was taken to decide what services should be offered as part of the 
Medicaid benefit.  First, a list of 709 condition/treatment pairs was generated by a state 
appointed Health Services Commission by ranking technologies in order of net benefit.  
Through a process that included community meetings, a public survey of quality of life 
preferences, and consideration of treatment cost, interventions were essentially ranked 
with respect to their approximate cost-effectiveness.  The intention was to systematically 
produce an objective list of technologies that represented a ranking based upon cost-
effectiveness, included input from the community, and was consistent with public 
preferences. (Fox & Leichter 1991;Neumann 2005;Ubel 2001)   
 
The initial list met fierce opposition and the plan soon became the subject of intense 
debate.  It was claimed that as Medicaid beneficiaries were predominantly poor, young, 
non-white, and female, the plan discriminated on the basis of class, age, race, and sex. 
(Brown 1991;Neumann 2005)  Others argued that the process used to rank the services 
was neither open nor fair, and that the poor were not represented in the decision-making 
process. (Daniels 1991;Jacobs, Marmor, & Oberlander 1999)  The list was widely 
criticised, particularly since much of the ranking appeared to be counterintuitive.  For 
example, in the original list, tooth capping was ranked above surgery for ectopic 
pregnancy, and splints for temporomandibular joints ranked above appendectomies. 
(Eddy 1991)  Ultimately, the initial list was not submitted to the Health Care Financing 
Administration (HCFA) for approval due to the strong opposition.   
 
In response to the criticisms, the list was amended.  Most notably, the list was rearranged 
in accordance with expert opinion rather than cost-effectiveness.  The amended list was 
submitted to the HCFA in 1992 but was again rejected, this time on the grounds that it 
violated the Americans with Disabilities Act (ADA).  As quality of life measures did not 
have input from disabled patients, it was deemed that potential existed for the programme 
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to discriminate against them.  A third and final list that addressed these concerns, 
excluding the influence of cost-effectiveness evidence, was submitted to the HCFA, and 
the plan was eventually enacted in 1994. (Buist 1992;Neumann 2005)  
 
Success of the Oregon Health Care Experiment 
The OHP achieved its goal of expanding the Medicaid programme and added 100,000 
state residents.  However, expansion came at a high cost. (Leichter 1999)  Expenditures 
increased by 39%, in contrast to 30% nationally, with the additional cost attributed to the 
implementation of the new programme. (Bodenheimer 1997)  Also, evidence suggests 
that the use of the list of services actually reduced access to needed services. (Mitchell et 
al. 2002)   
 
Key lessons from the Oregon Health Plan 
Still relevant today, the underlying rationale of the OHP was to provide universal access 
to health care by prioritising access to health care services.  The plan represented a step 
away from “do everything possible medicine” and shifted the debate away from what 
populations to cover and towards what benefits to cover. (Bodenheimer 1997;Jacobs, 
Marmor, & Oberlander 1999;Leichter 1999)  After a bold attempt to systematically 
allocate resources based on cost-effectiveness while involving the community and taking 
into account public preferences, the OHP was ultimately implemented only after removal 
of the cost-effectiveness provisions.   
 
Why the inclusion of the cost-effectiveness component ultimately failed has been subject 
to much analysis.  Multiple reasons have been suggested for its failure, with a mixture of 
technical, political, legal, and ethical factors playing a role.  It is argued that the list was 
technically flawed with the taken approach lacking methodological rigor (Gold et al., 
1996) and not an actual reflection of cost-effectiveness. (Tengs et al., 1996)  Further, 
despite attempts to incorporate public input into the list, it is thought that the ranking 
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failed to capture public preferences. (Ubel et al., 1996)  The method used to generate 
preference weights has been criticised for relying on a rating scale rather than more 
established techniques such as time trade-off or standard gamble.  Others suggest that the 
principal reason for failure was neither methodological nor legal, rather Americans’ 
ingrained aversion to the imposition of limits and suspicion of governments that impose 
them. (Neumann 2005)  This cultural phenomenon, often referred to as American 
exceptionalism, is discussed in Section 3.5.1.  
 
Notably, no state Medicaid programme has attempted to implement a similar policy to the 
OHP.  Politically, the explicit use of cost-effectiveness evidence to allocate resources 
proved unpalatable.  The OHP was used by politicians to gain political capital and to 
serve as an example of what was wrong with the health care system.  Importantly, the 
OHP exposed the limits of publicly applying explicit rationing policies within the United 
States. (Neumann 2005)  It has been suggested that the enduring lesson from Oregon is 
that the use of cost-effectiveness evidence is unlikely to produce a social or political 
definition of necessary care in the US. (Hadorn 1991)  
 
130 
 
3.5. Resistance to cost-effectiveness evidence in the US health care 
system 
Despite comparing unfavourably with respect to key health metrics, the US health care 
system is substantially more expensive than its international counterparts (Section 3.2.1). 
(Pearson M 2009)  One would expect, therefore, that the US health care system would 
provide the ideal environment for cost-effectiveness analysis to flourish and be of real 
benefit to health care decision makers.  However, as described above, despite attempts to 
consider cost-effectiveness evidence in health care decision-making, such evidence is 
largely excluded from deliberations over the allocation of health care resources.   
 
Resistance to cost-effectiveness evidence, and comparative effective evidence and 
evidence-based medicine in general, is a notable feature of the US health care system.  
Chalkidou and Walley 2010 suggest that “no other developed or developing healthcare 
system and its users view evidence as suspiciously as US stakeholders, including the 
medical technology industry and a large proportion of policy makers”. (Chalkidou & 
Walley 2010;Dhruva et al. 2009)  In many respects, the US health care system is unique.  
The US is the only country in the developed world not to provide universal health care 
coverage to its citizens, although the recent passing of health care reform legislation 
should reduce the number of uninsured considerably.  Further, the composition of health 
care financing in the US is different from the majority of other countries, with a much 
greater proportion coming from private as opposed to public sources. (Davis, Schoen, & 
Stremikis 2010;World Health Organization 2000)  In comparison to other countries’ 
health care systems, the US health care system is fragmented, marked by a mixture of 
multiple public and private payers.  It is unclear, however, why differences in health care 
financing, or structural differences, would lead to the observed resistance to cost-
effectiveness evidence. 
 
It is suggested that the powerful health care lobby is a principal obstruction to the use of 
cost-effectiveness evidence. (Neumann 2005)  The pharmaceutical industry has the 
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largest lobby in Washington, employing more lobbyists than there are Congressmen. 
(Angel 2004)  It is reported that from January 2005 to June 2006, manufacturers of 
pharmaceuticals, medical devices, and other health products spent nearly $182 million on 
federal lobbying. (Ismail 2007)   
 
The competitive nature of the private health insurance market presents a further obstacle 
for the penetration of cost-effectiveness evidence.  A private insurance plan may risk its 
competitive standing in the marketplace by using cost-effectiveness evidence, as it may 
be viewed as rationing care.  There is, therefore, an understandable reluctance to be the 
first private insurance plan to openly use cost-effectiveness evidence. (Sullivan et al. 
2009) 
 
A study by Bryan et al. (2009) evaluated the acceptability of cost-effectiveness evidence 
to US decision makers and provides a useful insight into the lack of use of this type of 
evidence in the US health care system. (Bryan et al. 2009)  Through a series of 
workshops and surveys, Bryan et al. (2009) showed that US decision makers, i.e., 
regulators, and private and public insurers, broadly support the use of cost-effectiveness 
evidence as an input into coverage decisions.  The researchers did, however, identify 
major obstacles preventing the greater use of cost-effectiveness evidence, including; 
litigation fears, concerns of the biased nature of manufacturer funded studies, and the 
failure of studies to address shorter time horizons of more relevance to decision makers.  
Notably, despite the broad support for the use of cost-effectiveness evidence as an input 
in decision-making, the research showed that approximately 40% of decision makers 
remained uncomfortable with the concept of rationing.  
 
The discomfort with the concept of rationing is, along with other aspects of American 
culture, suggested to be an obstacle to the inclusion of cost-effectiveness evidence into 
US health care decision-making.  Often referred to as “American Exceptionalism”, 
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Americans’ supposed uniqueness is thought to help explain why the US health care 
system is different from others. (The Hastings Center 2009)    
 
3.5.1. American Exceptionalism 
The term ‘American exceptionalism’ is used to describe the suggestion that the US is 
different from other nations because of the uniqueness of its origins, evolution, and 
institutions.  The term is also used in reference to the general American attitude to 
business (free markets and long work hours), the environment (national attitudes toward 
energy policy and global warming), consumers (higher birth rates and higher rates of 
obesity), and politics (maintenance of capital punishment and the right to bear arms) 
among other aspects of American life. (Neumann 2009;Reiner et al. 2006)   
 
High spending relative to GDP, the lack of universal coverage, and relatively poor health 
outcomes in the US health system compared to other developed nations are attributed in 
part to the paradigm of American exceptionalism. (Neumann 2009;Rodwin 1987;The 
Hastings Center 2009)  The reluctance to embrace cost-effectiveness analysis has been 
viewed as a symptom of American exceptionalism.  Americans have a clear dislike for 
limit setting and appear to overlook the scarcity of health care resources. (Robinson 
2001)  Also, there is a dislike and mistrust of ‘big government’ and reluctance to accept 
bureaucrats making decisions in lieu of patients and physicians.  (Neumann 2009;The 
Hastings Center 2009)  
 
3.5.2. The Patient Protection and Affordable Care Act  
Passage of the Patient Protection and Affordable Care Act (PPACA) in March 2010 
appears to have further distanced the US health care system from the use of cost-
effectiveness evidence. (Chambers & Neumann 2010;Neumann & Weinstein 
2010;PPACA 2010)  In reference to the PCORI, the legislation states: 
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 “[The PCORI] shall not develop or employ a dollars per quality adjusted life year (or 
similar measure that discounts the value of a life because of an individual’s disability) as 
a threshold to establish what type of healthcare is cost effective or recommended. The 
Secretary shall not utilize such an adjusted life year (or such a similar measure) as a 
threshold to determine coverage, reimbursement, or incentive programs...”.   
- Patient Protection and Affordable Care Act 
(PPACA), March 2010 
 
While the language clearly prohibits the use of cost-per QALY thresholds, it may be 
interpreted as not prohibiting the conduct of cost-utility studies, i.e., cost-per QALY 
ratios can still be calculated as long as they are not compared with a threshold value.  
Also, the excerpt is specific to the PCORI, and does not necessarily affect the evidence 
that is considered by other agencies.  Nevertheless, the absolute nature of the language in 
such a major piece of legislation is noteworthy.  Indeed, Neumann and Weinstein (2010) 
suggest that the language “suggests a broader ban on the use of cost-utility analyses — 
and this could have a chilling effect on the field.”  
 
Consequently, it is surprising that cost-effectiveness evidence has been featured in a 
number of CMS NCDs made after the enactment of the PPACA (Table 9)vi.  Notably, all 
NCDs included in Table 9 pertain to preventative care, a type of intervention that appears 
to have a special relationship with CMS NCDs.  What is driving this phenomenon is the 
Medicare Improvement for Patients and Providers Act (MIPPA) of 2008 
(§1861(ddd)(2)).  Through the MIPPA legislation, Congress authorised the US 
Department of Health and Human Services (DHHS) to add preventive services rated ‘A’ 
or ‘B’ by the US Preventives Services Task Force (USPSTF) to Medicare without 
congressional action.  Accordingly, each of the preventative services included in Table 9 
are associated with a USPSTF ‘A’ or ‘B’ grading.  Further, the MIPPA legislation 
                                                 
vi The empirical aspect of this thesis considers NCDs made from 1999 through 2007.  Therefore, the NCDs 
presented in Table 9 do not feature in the analysis. 
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includes language that is used in these cases to explain CMS’s consideration of cost-
effectiveness.  The MIPPA legislation authorises CMS to “conduct an assessment of the 
relation between predicted outcomes and the expenditures for [preventative] services”.   
 
Still, it is noteworthy that CMS have reviewed cost-effectiveness evidence in each of 
these cases.  While consistent with the MIPPA legislation, the review of cost-
effectiveness evidence seems incongruent with the PPACA.  Also, as these preventative 
interventions are associated with a USPSTF ‘A’ or ‘B’ grading, they are required to be 
covered regardless of CMS’s independent review of the evidence base.  The relevance of 
these cases of CMS considering cost-effectiveness information for preventative 
interventions is discussed in Chapter 8.
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Table 9. National Coverage Determinations including cost-effectiveness evidence made after enactment of the PPACA 
legislation  
Title Date Cost-effectiveness National Coverage Determination 
Counselling to 
Prevent Tobacco Use 
August 
25, 2010 
Study identified from the literature (Solberg et al. 
2006) 
$1100 per QALY when excluding savings from 
smoking-attributable disease prevented. 
Cost saving when including savings from smoking-
attributable disease prevented. 
Positive coverage decision for 
counselling to prevent tobacco use. 
Screening for 
Depression in Adults 
October 
14, 2011 
Study identified from the literature (Simon et al. 2007) 
Intervention estimated to be dominant, accumulating 
61 additional depression free days while accumulating 
savings of $314 per patient 
Positive coverage decision for 
screening for depression in adults is 
reasonable and necessary for the 
prevention or early detection of 
illness or disability. 
Screening and 
Behavioral 
Counseling 
Interventions in 
Primary Care to 
Reduce Alcohol 
Misuse 
October 
14, 2011 
Study identified from the literature (Solberg, Maciosek, 
& Edwards 2008) 
Dominant from societal perspective 
$1755/QALY saved from a health-system perspective 
Positive coverage decision for 
screening and behavioural 
counselling to reduce alcohol 
misuse, in primary care settings, is 
reasonable and necessary for the 
prevention of early illness or 
disability 
Screening for 
Sexually Transmitted 
Infections (STIs) and 
High-Intensity 
Behavioural 
Counselling (HIBC) 
to prevent STIs 
Expected 
November 
2011 
AHRQ study (Glass, Nelson, & Villemyer 2005) 
Screening all women aged 18-31 years more cost-
effective than selective screening. 
For men, standard practice (e.g., history and 
examination) is more cost saving than enhanced 
screening strategies. 
Proposed positive coverage decision 
for screening for chlamydia, 
gonorrhea, syphilis and hepatitis B, 
as well as high intensity behavioral 
counseling (HIBC) to prevent STIs. 
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3.6. Chapter Summary 
In this chapter, I put the US health care system into the perspective of others with respect to 
spending, abundance of health care resources, and key health statistics.  The comparator countries 
were chosen on the basis that they help illustrate different approaches to using cost-effectiveness 
evidence in coverage and reimbursement decisions or in recommendations for the efficient use of 
medical technology.  The UK, Sweden, Australia, and Canada, while all using different processes, 
illustrate countries in which cost-effectiveness evidence plays a fundamental role in decision-
making.  In contrast, Germany and France illustrate countries in which cost-effectiveness 
evidence, and economic evidence more generally, plays less of a role in decision-making.  
 
In spite of health care spending greatly in excess of spending in other countries, the US health 
care system performs poorly across a number of key health metrics, including life expectancy and 
infant mortality.  Further, the US health care system consistently ranks poorly in global health 
care system rankings.  Despite an evident need to increase the return from health care spending, I 
have shown that the US health care system is notable for the limited extent that cost-effectiveness 
evidence is used to inform coverage and reimbursement decisions.  Although in the US some 
public and private payers use cost-effectiveness evidence sporadically, how, and the extent to 
which, it informs decision-making is unclear.  Notably, Medicare, the largest payer in the US, 
states that cost-effectiveness is not a factor considered in their coverage decisions. 
 
To provide insight into the resistance to cost-effectiveness analysis in the US health care system, I 
described in this chapter attempts by Medicare and the state of Oregon’s Medicaid programme to 
incorporate cost-effectiveness evidence into decision-making.  Further, I described ‘American 
exceptionalism’, a term used to describe the suggestion that the US is different from other nations 
because of the uniqueness of its origins, evolution, and institutions, and how this may help 
explain such resistance.  Lastly, I highlight the restrictions that the PPACA legislation imposed on 
the PCORI with respect to the use of cost-per QALY thresholds, and yet the recent trend of cost-
effectiveness evidence featuring in decision memos for NCDs pertaining to preventative care.  
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The remainder of this thesis describes my empirical work, which focuses on CMS NCDs.  Given 
the prominence of Medicare in the US health care system and its stated position on the use of 
cost-effectiveness evidence, CMS NCDs are a particularly attractive aspect of the US health care 
system to evaluate.   
 
Chapter 4 forms the foundation for my empirical work.  Here, I present some background of the 
Medicare programme and Medicare coverage policies.  Also, I present the research questions and 
review the relevant literature that helped inform the methods I use for the research and analyses 
presented in chapters 5 through 7.  Finally, I describe the database I created for the analyses 
presented in the following chapters, including the literature search I performed to identify relevant 
estimates of the cost-effectiveness of interventions considered in coverage decisions included in 
NCDs.    
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4. Introduction to Empirical Work  
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4.1. Introduction 
In Chapter 2, I presented the underlying theory and rationale for the use of economic evaluation to 
allocate scarce health care resources and illustrated how cost-effectiveness information can guide 
efficient health care resource allocation.  In Chapter 3, I put the US health care system into the 
perspective of others with respect to spending, abundance of health care resources, and key health 
care statistics.  I also described that despite health care spending greatly exceeding the spending 
in other countries, the US health care system performs poorly across key health metrics.  
 
In spite of the US’s poor return from health care spending, the US is notable for the limited extent 
that cost-effectiveness evidence is used to inform coverage and reimbursement decisions.  This is 
particularly evident when considering Medicare.  The Centers for Medicare and Medicaid 
Services (CMS), the administrators of Medicare, state that cost-effectiveness is not a factor 
considered in National Coverage Determinations (NCDs). 
 
This chapter introduces the empirical component of this thesis.  The overarching purpose of the 
empirical work is to study the use of cost-effectiveness evidence in the US health care system. 
Given its importance in the US health care system, I chose the Medicare programme as the 
empirical component of this thesis.   
 
This chapter has three components:  first, background is given on the Medicare programme and 
the coverage policies described; second, the research questions that constitute the empirical work 
are presented; and third, the database that I created for this research is described, including a 
description of the included variables. 
 
     
   
 140
4.2. Introduction to Medicare 
The empirical aspect of this thesis focuses on CMS national coverage determinations (NCDs).  
CMS administers Medicare, the largest health insurance programme in the US.  Established in 
1965, Medicare provides coverage for US citizens aged 65 years and older, certain people with 
disabilities under age 65, and people of all ages with end-stage renal disease (ESRD). (CMS 
2005a)  More than 46 million Americans (almost one sixth of the population) receive health 
insurance coverage through Medicare. (CMS 2011a) Medicare is a major health care payer and its 
coverage decisions may have far reaching effects, influencing the coverage policies of other 
public and private payers. (Neumann 2005)   
 
With an annual cost of upwards of $600 billion, the Medicare programme is a major part of the 
US economy. (CMS 2011a)  It is estimated that one in five dollars used to purchase health 
services in 2006 came through the Medicare programme, and it finances about one-third of all 
hospital stays nationally. (The Henry J.Kaiser Family Foundation 2008)  As a percentage of GDP, 
total expenditure on the Medicare programme is projected to increase from 3.5% to 4.6% between 
2009 and 2020, spending that will exceed $1 trillion. (CMS 2009a;Medicare 2010) A major driver 
of these increasing costs is medical technology. (Ginsburg 2004;Ginsburg 2008)  Consequently, 
as exemplified by recent examples, e.g., autologous cellular immunotherapy treatment of 
metastatic prostate cancer and screening computed tomography colonography (CTC) for 
colorectal cancer, CMS’s rulings regarding medical technology are increasingly scrutinised and 
debated. (Chambers & Neumann 2011;CMS 2009b;CMS 2011c;Dhruva, Phurrough, Salive, & 
Redberg 2009;Garg & Ahnen 2010) 
 
4.2.1. Coverage of medical technology in Medicare 
In the Social Security Amendments (SSA) that established Medicare, Congress broadly defined 
the services to be covered by the programme: (Foote 2002;Marmor 1970) 
1. Benefit categories covered – e.g., hospital services and physician services; 
2. Services with severe limitations – e.g., dental or chiropractic care; 
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3. Categories excluded – e.g., personal comfort items or cosmetic surgery. 
 
Within these broad categories, CMS adjudicates payment for specific items and services through 
its coverage processes.vii   
 
4.2.2. Medicare coverage policies 
The statutory language that established Medicare did not provide an all-inclusive list of items and 
services to be covered by Medicare.  Rather, the legislation provided the criteria to be used to 
guide the coverage of items and services.  The legislation (1862(a)(1)(A) of Social Security Act) 
states that Medicare may not reimburse “items and services which are not reasonable and 
necessary for the diagnosis and treatment of an illness or injury or to improve the functioning of a 
malformed body member”. (Social Security Act 1965)  Throughout the first two decades of the 
programme, how this language should be interpreted was not clarified and was generally 
considered to mean safe, effective, non-investigational, and appropriate. (Neumann 2005)  
Indeed, text included in the US Federal Register in 1989 stated that the HCFA did not “think it 
possible, or advisable, to try to set quantitative standards or develop formula for the applications 
of those criteria”. (Federal Register 1989a;Neumann 2005) How to interpret ‘reasonable and 
necessary’ has remained unclear. (Foote 2002;Garber 2001;Neumann 2005)  However, as noted 
in Section 3.4.2.1, one clarification that has been made is with respect to the use of cost and cost-
effectiveness evidence.  The Guidance for the Public, Industry and CMS Staff states “Cost 
effectiveness is not a factor CMS considers in making NCDs.  In other words, the cost of a 
particular technology is not relevant in the determination of whether the technology improves 
health outcomes or should be covered for the Medicare population through an NCD”. (CMS 
2010e)  While attempts have been made to incorporate cost-effectiveness evidence into the review 
process (Section 3.4.2.1), this remains CMS’s stated position on the use of cost-effectiveness 
evidence.    
 
                                                 
vii Most services available in Medicare are not subject to formal coverage policies.  Prospective payment policies, i.e., 
diagnosis-related groups (DRGs) for inpatient care and ambulatory service payment categories (APCs) for outpatient 
hospital care, facilitate payment of services not formally evaluated by CMS. 
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As decisions regarding the availability of interventions in the Medicare programme are becoming 
increasingly contentious, uncertainty regarding CMS’s decision-making criteria is increasingly 
the focus of debate. (Chambers & Neumann 2011;Dhruva et al. 2009;Fox 2010;Garg & Ahnen 
2010)   
  
4.2.2.1 Coverage Determinations 
Formal coverage determinations for health services are made by the CMS at either the local or the 
national level.  Local coverage policies, or local coverage determinations (LCDs), are made by 14 
independent regional Medicare Administrative Contractors (MACs) in the absence of a national 
coverage policy and represent the majority of Medicare coverage policies. (CMS 2010b;Foote, 
Halpern, & Wholey 2005)  National coverage policies, or National Coverage Determinations 
(NCD), are binding to all MACs and are reserved for interventions deemed particularly 
controversial or projected to have a major impact on the Medicare programme. (CMS 2003d)  
Medicare Administrative Contractors are bound by NCDs.  CMS make approximately 15 NCDs 
each year and since 1999, a total of 171 have been made.  For the most part, NCDs are made by 
CMS’s internal coverage group.  On occasion, CMS supplements their review with an external 
technology assessment (TA) and/or consultation with the Medicare Evidence Development and 
Coverage Advisory Committee (MEDCAC). (CMS 2010f;CMS 2010h)  
 
Within a NCD CMS often evaluates multiple similar technologies, or more commonly, a single 
technology for multiple indications.  Typically, a proposed NCD is subject to a one month 
comment period before the final NCD is made.  The final coverage policy may be coverage 
without restrictions, coverage with restrictions, non-coverage, or a referral to regional Medicare 
contractors.  On occasion, CMS has utilised a coverage with evidence development (CED) policy, 
which provides access to technologies while additional evidence is generated to establish whether 
expanded coverage is warranted.  Each NCD is published in the Federal Register, and a decision 
memorandum, often referred to as a decision memo, is made available on CMS’s website. (CMS 
2010a;Federal Register 2010)  The decision memo is a structured document and is used to 
communicate CMS’s decision.  A decision memo presents a brief clinical background of the 
disease, a review of the history of Medicare’s coverage policies for the intervention, a review and 
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analysis of the relevant scientific and clinical literature, and CMS’s reasoning for the ultimate 
coverage policy. 
 
4.3. Empirical work 
Medicare is a fundamental part of the US health care system.  The programme is estimated to cost 
upwards of $600 billion dollars with costs rising at an unsustainable rate.  It is suggested that a 
major cost driver is medical technology. (Ginsburg 2004;Ginsburg 2008) 
 
As stated above, Medicare coverage decisions have far reaching effects and may influence 
coverage policies of other public and private payers. (Neumann 2005)  The criteria CMS use 
when evaluating medical technology is vague, with decisions guided by the ‘reasonable and 
necessary’ criterion.  Importantly, one aspect of decision-making that is clear is the use of cost-
effectiveness evidence, which CMS state is not a factor considered in making NCDs. 
 
CMS coverage decisions, and in particular NCDs, are an attractive aspect of the US health care 
system from a research perspective. NCDs are typically made for interventions expected to have 
the most significant impact on the Medicare programme and thus could be considered CMS’s 
most important coverage decisions.  Although much has been written about NCDs, to the best of 
my knowledge they have not been subject to empirical analysis. (Gillick 2004;Neumann, Rosen, 
& Weinstein 2005)  An advantage of focusing on CMS NCDs is that the publicly available 
decision memos provide a rich source of information regarding CMS’s review of the evidence 
base and ultimate coverage decision.    
 
Given these factors, the empirical aspect of this thesis focuses on CMS NCDs.  The empirical 
work considered in Chapters 5 through 7 is described below. 
 
4.3.1. Chapter 5 
The first piece of empirical work is presented in Chapter 5 and has two research questions. 
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As highlighted above, in the Guidance for Public, Industry and CMA Staff, the CMS state that 
cost-effectiveness is not a factor considered in making NCDs. (CMS 2010e)  The first objective 
of this research is to evaluate NCDs to determine if they are consistent with CMS’s stated 
position. The second part of this research is to evaluate the cost-effectiveness of coverage 
decisions made as part of NCDs.  The data are evaluated to determine if there is a difference 
between the cost-effectiveness of positive and non-coverage decisions.   
 
The objectives for the empirical work presented in Chapter 5 are as follows: 
Objective one 
• To examine NCD decision memos to determine if they are consistent with CMS’s stated 
position on the use of cost-effectiveness evidence. 
Objective two 
• To determine if there is a difference between positive and non-coverage decisions with 
respect to cost-effectiveness. 
 
4.3.2. Chapter 6 
The empirical work presented in Chapter 6 builds on that presented in Chapter 5.  While the 
approach in Chapter 5 evaluates whether there is a relationship between coverage decisions and 
cost-effectiveness, it does not control for other factors and thus is insufficient to determine if cost-
effectiveness is independently associated with coverage decisions.  The approach taken in Chapter 
6 attempts to control for these factors in the analysis.  The objective for the empirical work 
presented in Chapter 6 is as follows: 
Objective one 
• To determine if cost-effectiveness is an independent predictor of coverage when 
controlling for other factors that may be considered to influence coverage decisions. 
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4.3.3. Chapter 7 
The third piece of empirical work is presented in Chapter 7.  The empirical work in Chapter 5 
concerns the evaluation of the cost-effectiveness of coverage decisions in CMS NCDs.  The 
empirical work in Chapter 7 builds on this research to estimate the potential efficiency gains in 
terms of health gains and cost-savings from a hypothetical reallocation of expenditures between 
interventions subject to NCDs, using a criterion of cost-effectiveness.  Potential benefits in terms 
of aggregate health gain and cost-savings, along with the effects of using a cost-effectiveness 
decision rule on the distribution of resources between disease areas and types of interventions, are 
estimated.  The objective for the empirical work presented in Chapter 7 is as follows: 
Objective one 
• To estimate potential gains in aggregate health achieved from reallocating expenditures 
between interventions covered as part of NCDs in a manner consistent with a cost-
effectiveness decision rule.  
Objective three 
• To estimate the impact of reallocation on the distribution of expenditures across disease 
areas (oncology, cardiology, and other) and types of intervention (treatment, diagnostic, 
and other). 
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4.4. Choice of a quantitative approach 
I decided to use a quantitative approach for the empirical aspect of this thesis.  The factors that 
decision makers consider relevant in decision-making have been evaluated qualitatively by a 
number of researchers. (Bryan et al. 2009;Gold MR et al. 2007;Fischer KE et al. 2011;Williams I 
et al. 2008; Al MJ, Feenstra T, & Brouwer WB. 2004)  These studies used surveys and focus 
groups to gain an insight into the importance of various decision-making criteria.  Studies of 
particular relevance to this thesis include Bryan et al. (2009) and Gold MR et al. (2007), both of 
which evaluated the use of cost-effectiveness evidence in decision-making.   
 
While a qualitative approach would provide useful insights, I chose a quantitative approach for 
the empirical component of this thesis for two principal reasons.  First, unlike for agencies in 
other countries, CMS’s coverage decisions for medical technologies and interventions have not 
been evaluated in a quantitative manner and I considered this to be a significant gap in the 
literature.  Second, the availability of decision memos for each CMS NCD provided a rich data 
source amenable to quantitative evaluation.   
 
4.5. Literature review 
To help inform the methodological approach taken for the empirical aspect of this thesis, I 
reviewed the relevant literature.  First, I review the literature pertinent to the research objectives 
in Chapter 5 and Chapter 6.  These chapters were considered together in the literature review as, 
in spite of having different objectives, both concern the retrospective evaluation of coverage 
decisions.  Second, I review the literature pertinent to the research objectives in Chapter 7.   
 
4.5.1. Literature pertaining to Chapter 5 and Chapter 6 
The broad objective of the empirical work presented in Chapters 5 and 6 was to evaluate the use 
of cost-effectiveness evidence in CMS NCDs.  A literature search was performed using the 
PubMed database to identify studies with similar objectives that evaluated how decision makers 
elsewhere had incorporated cost-effectiveness information into decision-making.  The search 
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criteria included the terms: “Health technology assessment”; “cost-effectiveness”; “cost-
effectiveness threshold”; “regression analysis”; “coverage decisions”; “reimbursement 
decisions”; “recommendations”; “decision-making criteria”; “decision-making framework”.  
Searches were limited to English-language articles only and included studies published before 
October 15th, 2011. 
 
I included studies that used a quantitative approach to retrospectively evaluate coverage decisions 
for medical technologies and interventions made by various agencies.  I excluded studies that 
used a qualitative approach to evaluate decision-making criteria or that did not concern the 
coverage or reimbursement of medical technologies or interventions.   
 
Given that the objective of the literature search was to identify studies that evaluated how cost-
effectiveness evidence had been used in coverage decisions, the identified studies were relevant to 
institutions that use cost-effectiveness in decision-making.  The studies evaluated coverage 
decisions by national agencies in the UK, Australia, Canada, and New Zealand, although one US-
based study was also identified.  The reference lists of the identified studies were also reviewed 
for relevant publications.  In addition, I became aware of relevant research presented at a 
scientific conference.  This study, Devlin et al. 2010, is also reviewed below. 
 
4.5.1.1 George et al. 2001 
As described in Section 3.3.1.3, the Australian government subsidises the price that consumers 
pay for drugs listed on the national drug formulary, the Pharmaceutical Benefits Schedule (PBS).  
The Pharmaceutical Benefits Advisory Committee (PBAC) evaluates submissions by 
manufacturers and recommends drugs to be listed on the PBS.  Manufacturers voluntarily 
submitted economic evaluations between 1991 and 1993, after which point the inclusion of an 
economic evaluation in their submission has been mandatory, although no guidance as to what 
constitutes an acceptable level of cost-effectiveness was communicated.  
The objective of the study by George et al. (2001) was to generate a league table of drugs 
considered by the PBAC ranked in order of cost-effectiveness.  The league table was used to test 
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the hypothesis that the PBAC’s decisions were consistent with a maxim of economic efficiency.viii  
Further, coverage decisions were explored to determine if they revealed a cost-effectiveness 
threshold.   
 
Submissions to the PBAC from January 1991 through 1996 were reviewed, with those 
incorporating ICERs reporting a cost-per life year or cost-per QALY ratios identified.  PBAC 
recommendations were considered dichotomously: ‘recommended’, and ‘recommended at a lower 
price/‘not recommended’.  Cost-per life year studies (n=26) and cost-utility studies (n=9) were 
considered separately.   
 
For recommendations associated with cost-effectiveness studies reporting cost-per life year 
gained ratios, ICERs for recommended drugs ranged from $AU 5,517 to $AU $75,286; ICERs for 
drugs rejected or recommended at a lower price ranged from $AU 42,679 to $AU 256,950.  For 
recommendations associated with cost-effectiveness studies reporting cost-per QALY gained 
ratios, ICERs for recommended drugs ranged from $AU 4,690 to $AU 24,343.  Only two drugs 
associated with cost-effectiveness studies reporting cost-per QALY gained ratios were not 
recommended.  One, with an ICER of $AU 17,937 per QALY gained was recommended at a 
lower price, and a second, with an ICER of $AU 133,337 per QALY gained was rejected.   
 
A Mann-Whitney test was used to evaluate whether there was a difference between the cost-
effectiveness of drugs recommended and those not recommended for listing.  It was reported that 
there was a statistically significant difference between the cost per life-year gained for drugs that 
were recommended for listing and those that were not (p=0.0008).  The small number of studies 
associated with cost-per QALY ratios and a relatively narrow range of ratios prevented the 
researchers from drawing conclusions for these studies.    
 
The findings were deemed consistent with the hypothesis that PBAC’s decisions were consistent 
with a maxim of economic efficiency.  The authors did not identify a fixed threshold value of 
                                                 
viii The authors’ definition of economic efficiency was not presented. 
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cost-effectiveness for which the PBAC appeared less likely to recommend a drug for listing, 
although stated that the PBAC was less likely to recommend a drug if associated with an ICER 
greater than $AU 76,000 (1998/1999 values) and was unlikely to reject a drug if associated with 
an ICER less than $AU 42,000.   
 
The authors conclude that while it is clear that economic efficiency plays a large role, it is not the 
only factor that influences PBAC’s recommendations.  
  
4.5.1.2 Towse and Pritchard 2002 
Recommendations made by the National Institute for Health and Clinical Excellence (NICE) have 
been the subject of a number of studies.  In 2002, NICE had not clarified their position on the 
value of the cost-effectiveness threshold.  To evaluate whether an implicit cost-effectiveness 
threshold could be inferred from NICE’s recommendations, Towse and Pritchard (2002) reviewed 
all appraisals featuring a cost-utility study from 1999 through May 2002. (Towse, Pritchard, & 
Devlin 2002)  Also included were cost-effectiveness studies that reported ICERs using cost-per 
life year gained or cost-per-episode avoided ratios that could be converted into a cost-per QALY 
estimate using “eminently reasonable assumptions”. (Towse, Pritchard, & Devlin 2002)     
 
In contrast to George et al. (2001), rather than generating a league table based upon cost-
effectiveness, recommendations were categorised using the reported cost-per QALY ratio; 
<£20,000 per QALY, £20-£30,000 per QALY, and >£30,000 per QALY.  These categories were 
chosen because NICE had previously given some indication in appraisal determinations that the 
range £20-£30,000 per QALY was significant, and that £30,000 per QALY was approaching the 
highest acceptable cost-effectiveness.  Technologies were further categorised with respect to 
NICE’s recommendation (Table 10): 
1. Those in which a cost-per QALY range was given and the technology was accepted; 
2. Those in which a cost-per QALY range was given and access to the technology was 
restricted to a proportion of the patient group; 
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3. Those in which a cost-per QALY range was given and the technology was rejected. 
 
Table 10. Findings of Towse and Pritchard (2002) 
Cost per QALY 
estimate 
Technology accepted Technology restricted Technology rejected 
<£20,000 15 3 2 
£20-£30,000 4 5 1 
>£30,000 3 4 4 
 
The authors use a chi-squared test to test a null hypothesis that there was no relationship between 
the cost-per QALY estimate and whether the technology was accepted, restricted, or rejected.  
The findings suggested that there was a positive relationship between the cost-per QALY and 
recommendations (p<0.05).  The authors report that the findings were sensitive to their 
assumptions regarding relationship between cost-per QALY and cost-per life year gain.  It is clear 
from Table 10 that there were exceptions to these findings, i.e., that it is not necessarily the case 
that technologies are accepted if associated with a cost-per QALY ratio less than £20,000, 
restricted if in the range of £20,000 to £30,000, and rejected if more than £30,000.  The authors 
reported instances when severity of disease and short survival time lead to NICE accepting a 
technology with an ICER greater than £30,000 per QALY.  
 
4.5.1.3 Dranove et al. 2003 
In their study, Dranove et al. (2003) evaluated health maintenance organisation (HMO) formulary 
adoption decisions.  Their objective was to identify economic and organisational characteristics 
that affect the likelihood of HMOs, including new drugs on their formularies. (Dranove, Hughes, 
& Shanley 2003)   
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Data was obtained from a survey of pharmacy directors and drug-specific data taken from an 
industry trade journal.  Respondents reported on seven drugs and reported information with 
respect to economic and organisational factors, administrative factors, relationship with 
pharmaceutical companies, and ‘other’ factors that included HMO size and per member per 
month pharmacy costs.   
 
Multivariate logistic regression analysis, adjusting for fixed-drug effects and random-HMO 
effects, was used to estimate models of formulary inclusion.  Five models were estimated.  The 
first included only HMO-specific economic factors, models two through four added various 
administrative factors, and model five included two drug-specific measures.  The dependent 
variable was dichotomous, taking a value of one if the HMO included the drug on the formulary 
and zero if they did not.  Factor analysis was used to limit the number of predictors.   
 
A number of characteristics were identified as affecting formulary adoption.  These included non-
profit status (for-profits were estimated to have lower adoption rates); incentives facing the 
pharmacy director (e.g., if the importance of meeting the drug budget was part of the pharmacy 
director’s performance evaluation, the probability of adoption was reduced); the size of the P&T 
committee (larger P&T committees tended to approve fewer drugs); the make-up of the P&T 
committee (replacing two medical personnel on the P&T committee with two nonmedical 
personnel reduced the likelihood of adoption to 50 percent); the relationship between the HMO 
and the pharmaceutical company (HMOs tended to favour manufacturers whose representatives 
pay more visits); and member satisfaction (if the relative importance of member satisfaction 
increased by 0.8 percent, the chances of adoption increased to 78 percent). 
 
Notably, a number of HMO-specific economic factors, including size, drug expenditures, and 
whether the primary care physicians were at financial risk for drug costs, did not affect the 
likelihood of adoption.   
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4.5.1.4 Devlin and Parkin 2004 
In the first of a number of similar studies, Devlin and Parkin (2004) evaluated coverage decisions 
made by NICE in the UK. (Devlin & Parkin 2004)  The primary objective of this research was to 
explore NICE’s cost-effectiveness threshold(s) and the trade-offs made between cost-
effectiveness and other factors pertinent to decision-making.  The methodological approach taken 
also facilitated an exploration of NICE’s preferences and considered the consistency of 
recommendations. 
 
NICE’s recommendations made prior to May 2002 were considered and comprised of 39 
technologies and 51 recommendations.  Data were abstracted from the publicly available NICE 
Technology Appraisals.  The recommendation was the dependent variable and took the value 0 if 
NICE recommended the use of the technology, and the value 1 if NICE recommended against the 
use of the technology.  Recommendations originating from the same technology appraisal were 
considered independent.  Independent variables included:  the estimated cost-effectiveness 
reported as cost-per life year or cost-per QALY gained ratios; uncertainty regarding cost-
effectiveness; the burden of disease; the availability of alternatives to the technology under 
review; and specific factors indicated by NICE (e.g., severity of condition, short life expectancy, 
etc).  For the cost-effectiveness variable, cost-per life year gained ratios were included when cost-
per QALY gained ratios were unavailable.  The authors acknowledge the weakness of this 
approach, i.e., assuming a one-to-one correspondence between life years gained and QALYs 
gained, but claimed that this was necessary to ensure sufficient degrees of freedom.   
 
Recommendations were divided into those with associated cost-effectiveness evidence and those 
without.  Those with cost-effectiveness evidence (n=33) were deemed amenable to quantitative 
analysis and were explored using logistic regression.  A binary choice logistic regression model 
was used. The value of the cost-effectiveness threshold was estimated by calculating the 
probability of a favourable recommendation for each ICER, while holding other variables 
constant at their mean value.  Four different models were considered.  Model 1 was univariate and 
included only the cost-effectiveness variable.  The other three models increasingly added 
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explanatory variables, including uncertainty regarding cost-effectiveness (Model 2), burden of 
disease (Model 3), and availability of alternatives (Model 4). 
 
A chi square test was used to determine that none of the four models could be rejected.  The 
authors reported that Model 4 was ‘preferred’ as it was associated with the highest pseudo R2 and 
sensitivity (although specificity was slightly lower than for other models).  The results indicated 
that the likelihood of a positive coverage recommendation decreased as the cost-effectiveness 
ratio increased.  Cost-effectiveness along with other variables better explained NICE’s decisions 
than cost-effectiveness alone.  The findings also indicated that the threshold appeared to be 
somewhat higher than the £20-30,000 per QALY range, NICE’s then stated ‘range of acceptable 
cost-effectiveness’. 
 
4.5.1.5 Dakin et al. 2006 
Dakin et al. (2006) built on the previous approach by Devlin and Parkin (2004) and tested an 
alternative model of decision-making.  Rather than modelling decision-making using a binary 
choice model, this paper used a multinomial dependent variable to better reflect NICE decision-
making.  The aim of this study was to gain additional insight into the determinants of NICE 
decisions and trade-offs between them.  
 
NICE Technology Appraisals published up to December 31st, 2003 were evaluated, with data 
abstracted from 73 appraisals, constituting 94 recommendations (a number of appraisals were 
subdivided into 2-4 separate recommendations).  Recommendations were categorised as 
“recommended for routine use”, “recommended for restricted use”, or “not recommended”.  No 
ranking was assumed in the dependent variable; the authors believed that the three categories 
were qualitatively different and “recommended for restricted use” did not represent an 
intermediate point between the other categories.  Various independent variables were considered, 
including: quantity/quality of clinical evidence; cost-effectiveness; decision date; existence of 
alternative treatments; budget impact; and intervention type.  Variables concerning clinical 
effectiveness included those pertaining to the number, type, quality, and outcome of reviewed 
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studies.  The primary analysis included only estimates of cost-effectiveness reporting cost-per 
QALY gained, although a secondary analysis pooled cost-per QALY studies along with cost-per 
life year studies.  
 
The model was estimated using multinomial logistic regression.  Univariate and multivariate 
regressions were performed.  Results showed that high cost-effectiveness ratios increased the 
likelihood of technologies being rejected rather than recommended for restricted use.  Pooling 
cost-per life year studies along with cost-per QALY studies increased the reported pseudo R2 
compared to the reported value when only cost-per QALY studies were included.  The authors 
suggested that this finding confirms that cost-effectiveness evidence is an important factor in 
NICE decision-making.  With respect to the clinical evidence base, the study showed that the 
number of RCTs and systematic reviews were statistically significant, i.e., technologies with a 
larger evidence base were more likely to be recommended for routine use.  The results also 
suggested that pharmaceuticals and technologies evaluated earlier were also less likely to be 
rejected.  Patient group submissions increased the likelihood of a recommendation for routine 
rather than restricted used. 
 
The authors concluded that the factors affecting the recommendation between routine and 
restricted use, but not that between routine use and rejection, suggests that that the model was an 
improvement over the binary-choice model reported by Devlin and Parkin (2004), and that 
modelling the three outcomes as opposed to a binary choice model more closely reflects NICE 
decision-making.  
 
 
4.5.1.6  Harris et al. 2008 
Similar to George et al. (2001), Harris et al. (2008) evaluated PBAC recommendations.  However, 
in contrast to George et al. (2001), Harris et al. (2008) considered a range of additional 
independent variables rather than solely focusing on the cost-effectiveness of recommendations.   
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The objective of the study was to evaluate the relative influence of factors in PBAC’s 
recommendations.  PBAC recommendations from February 1994 through December 2004 were 
considered (n=858). (Harris et al. 2008)  Following exclusion of submissions with insufficient 
data, the final sample included 103 submissions reporting a cost-per QALY gained ratio and 123 
submissions reporting a cost-per life year gained ratio.   
 
In addition to cost-effectiveness, a variety of variables were considered, including; an assessment 
of the clinical evidence base (clinical importance of treatment effect, precision of clinical 
evidence, relevance of evidence, etc), severity of the condition (whether condition is associated 
with premature mortality), availability of alternatives, and the associated budget impact of the 
technology.   
 
The probability of the PBAC recommending a drug was estimated using a probit multiple 
regression model.  The dependent variable was dichotomous: recommendation and non-
recommendation.  Two models were estimated, the first including all explanatory variables, the 
second excluding non-significant groups of variables (determined using a Wald test p>0.05).  The 
predictive power of the model was assessed by its pseudo R2, Hosmer and Lemeshow’s goodness 
of fit test, and the area under the receiver operating characteristic.  
 
The results of the regression when including cost-per QALY studies were presented.  It was 
determined that clinical significance, cost-effectiveness, budget impact, and severity of disease 
were significant predictors of PBAC’s recommendation.  In comparison to the average 
submission, drugs estimated to be clinically significant were associated with an increased 
probability of coverage of approximately 0.2, and drugs indicated for a life-threatening condition 
were associated with an increased probability of coverage of approximately 0.4.  From the mean 
reported cost-per QALY ratio of $AU 46,400, an increase of $AU 10,000 corresponded to a 
decrease in the likelihood of a positive recommendation by 0.06.  The authors did not report the 
results of the analysis with submissions reporting cost-per life year ratios included.  However, it 
was reported that this analysis confirmed the findings of the primary analysis.   
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The authors concluded that while there was evidence of the probability of a positive 
recommendation decreasing with higher ICERs, there is no evidence of a fixed cost-effectiveness 
threshold.  
 
4.5.1.7 Rocchi et al. 2008 
As described in Section 3.3.1.4, the Common Drug Review (CDR) is the central review agency 
for new outpatient medications in Canada.  As part of the drug review process, the CDR submits a 
report to the Canadian Expert Drug Advisory Committee (CEDAC), which considers the drug’s 
effectiveness and cost-effectiveness relative to the standard of care.  Rocchi et al. (2008) reviewed 
CEDAC recommendations published from September 2003 through March 2007 to evaluate the 
role that cost-effectiveness evidence played in oncology reimbursement decision-making. (Rocchi 
et al. 2008)   
 
The results of the research were not presented in a league table as per George et al. (2001), nor 
categorised into categories of cost-effectiveness as per Towse and Pritchard (2002).  Rather, for 
the 25 recommendations with accompanying cost-effectiveness data, drugs were categorised as to 
whether CEDAC considered the drug to be attractive or unattractive from a cost-effectiveness 
perspective and whether the drug was listed.  For each category the reported range of cost-
effectiveness for the respective drugs was listed.  The authors did not separate studies reporting 
cost-per life year gained and cost-per QALY gained ratios in their presentation of study findings.  
 
On four occasions the ICER was considered attractive and the drug listed, with ICERs ranging 
from dominant to $CAN 71,000 per life year gained.  Nine drugs were listed with ICERs deemed 
unattractive, with ICERs ranging from $CAN 50,000 to $CAN 80,000 per QALY.  Twelve drugs 
were not listed with ICERs deemed to be unattractive, with the ICERs ranging from $CAN 
32,000 to $CAN 137,000 per QALY.   
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Of the drugs considered, oncology medications were recommended for listing with the highest 
ICERs, with the highest $CAN 80,000 per QALY.  Anti-retrovirals were another evaluated 
subset, with the highest ICER of a recommended drug $52,000 per QALY.  Only one drug not 
classified as an oncology medication or an anti-retroviral was listed with an ICER substantially 
more than $50,000 per QALY.  In this instance it was noted that the ICER was “in excess of 
traditional standards”.   
 
The authors conclude that oncology drugs seem to be adopted at the higher thresholds of 
acceptability than non-oncology drugs.  However, as no hypothesis test was performed, it is not 
possible to conclude with any level of certainty that this was the case.   
 
4.5.1.8 Chim et al. 2010 
Chim et al. (2010) also evaluated PBAC recommendations. (Chim et al. 2010)  The background 
to the study was concern that existence of a cost-effectiveness hurdle for the reimbursement of 
drugs in Australia may limit access to new cancer treatments because of their high cost and 
modest benefits.  The primary objective of this study was to test the hypothesis that ceteris 
paribus, cancer drugs were less likely be recommended by the PBAC for reimbursement on the 
PBS than non-cancer drugs.  
 
Public summary documents (PSDs) on major submissions to the PBAC from July 2005 to March 
2008 were reviewed (n=227), corresponding to 243 recommendations (on occasion multiple 
recommendations originated from a PSD).  Only drugs used to treat cancer were classified as 
cancer drugs; those indicated for cancer related nausea and vomiting, or neutropaenia or anaemia 
were classified as non-cancer drugs.  All PSDs reported cost-per QALY information as a range or 
as a single estimate.  When reported as a range, the highest value was used for the analysis.   
 
Cost-effectiveness was included as a categorical variable with the type of model (cost-
minimisation analysis or cost-effectiveness analysis/cost-utility analysis) and cost-per QALY 
ratio (≤$AU 45,000 per QALY; >$AU 45,000 to ≤$AU 75,000 per QALY; >$AU 75,000 per 
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QALY) accounted for.  The estimated annual cost of the drug to the PBS was included.  Whether 
the PBAC accepted the manufacturer’s clinical claim was included as a binary variable, as was 
whether the PBAC accepted the manufacturer’s nominated comparator.  With respect to predicted 
utilisation of the drug, the number of patients that would use the drug in a year was considered.  
Further, submissions were categorised as to their type of application, i.e., whether they pertained 
to a new drug, new indication, or other.   
 
The PBAC recommendation, i.e., whether the drug was approved or non-approved, was classified 
as a dichotomous variable by merging instances when a drug was rejected with instances when a 
drug was partially accepted.   
 
The model was estimated using a binomial logistic regression.  Univariate and multivariate 
analyses were performed.  In the multivariate model, type of application, cost-effectiveness, and 
estimated cost to the PBS were statistically significant.  For all submissions, it was reported that 
the likelihood of a positive recommendation decreased with higher estimates of cost-
effectiveness.  Submissions for cancer drugs were associated with higher cost-per QALY ratios 
than non-cancer drugs.  However, after adjusting for other factors, there was no statistical 
difference between cancer and non-cancer with respect to PBAC’s recommendation for PBS 
listing.   
 
4.5.1.9 Devlin et al. 2010 
Devlin et al. (2010) was a podium presentation presented at the International Society for 
Pharmacoeconomics and Outcomes Research’s (ISPOR) 13th Annual European Congress in 
November 2010. (Devlin et al. 2010b)  The full study is yet to be published in the peer-reviewed 
medical literature, and the following information is based upon the material in the presentation.  
As for Devlin and Parkin (2004) and Dakin et al. (2006) the researchers evaluated NICE 
Technology Appraisals, although the study time period was not presented.   
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Study aims were to build upon previous modelling approaches to determine the role of cost-
effectiveness and other factors on NICE decisions.  Specific research questions were:  Has 
NICE’s cost-effectiveness threshold or decision-making process changed over time?  What effect 
does evidence and factors other than cost-effectiveness exert on NICE’s decisions?   
 
The researchers used data obtained from HTAInSite, a proprietary database of NICE decisions, 
supplementing this with data from NICE Technology Appraisal documents when required.  
Technology appraisals were sub-divided into sub-decisions, with the unit of analysis the 
individual coverage decision.   
 
Variables considered included cost-effectiveness, patient numbers in RCTs, availability of 
treatment alternatives, whether the decision pertained to children, whether the submission 
originated from a patient group, and date of decision.  Estimates of technologies that were 
dominant or dominated were excluded from review, i.e., all technologies included were associated 
with a positive ICER (more effective and more expensive than comparator).  Only studies 
reporting cost-per QALY ratios were included.   
 
Logistic regression was used to estimate the model, with the dependent variable coded 
dichotomously as positive or non-coverage.  The authors found that cost-effectiveness evidence 
alone explained the majority of NICE’s decisions.  Cancer treatments were estimated to have a 
higher probability of recommendation ceteris paribus.  Date of decision was not a significant 
predictor of coverage, suggesting that the decision-making process had not significantly changed 
over time.  With respect to estimation of the cost-effectiveness threshold (when probability of 
rejection = 50%), cancer treatments were estimated to be associated with a higher threshold 
(approximately £50,000 per QALY) than non-cancer treatments (approximately £38,000 per 
QALY).   
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4.5.2. Literature pertaining to Chapter 7 
The objective of the third piece of empirical work was to hypothetically reallocate expenditures 
between interventions considered in CMS NCDs in accordance with available cost-effectiveness 
evidence.  A literature search was performed using the PubMed database to identify studies with 
similar objectives that estimated efficiency gains in terms of aggregate health from a hypothetical 
reallocation of resources.  The search criteria included the terms: “priority setting”; “resource 
allocation”; “cost-effectiveness”; “cost-effectiveness threshold”; “optimisation”; 
“disinvestment”.  Searches were limited to English-language articles only and included studies 
published before October 15th, 2011. 
 
I included studies that estimated that consequences of using alternative resource allocation criteria 
to estimate aggregate health gains across multiple interventions and/or indications.  I excluded 
studies that focused on a single intervention or technology; that did not provide an estimate of 
aggregate health gain, e.g., burden of illness studies; and cost-effectiveness analyses. 
 
While the search strategy identified a number of studies, only three met my inclusion criteria.  
The majority of identified studies were cost-effectiveness analyses that evaluated various 
individual health care technologies or policies.  While a body of literature was identified 
concerning evidence-based priority setting, this literature was largely descriptive in nature and did 
not provide an empirical framework for the research presented in Chapter 7. (Foglia et al. 
2008;Mitton & Donaldson 2003)  A number of burden of illness studies featured in the literature 
search results, including some that quantified health using QALYs, e.g., van Hoek et al. (2011)  
However, as these studies did not evaluate the consequences of using alternative resource 
allocation criteria, they did not help inform the empirical framework for the research presented in 
Chapter 7.  Tengs et al. (1995) was an example of a study that was excluded because an 
estimation of efficiency gain was not provided.  In this study the authors gathered information on 
587 life-saving interventions across a range of industries.  However, as an estimation of aggregate 
health gain achievable from a reallocation of resources was not presented, this study was not 
reviewed.   
   
 161
 
Three studies, Cromwell et al. (1998), Zaric and Brandeau (2001) and Ratcliffe et al. (2005), were 
identified with similar objectives to those employed in Chapter 7 and are described below. 
 
4.5.2.1 Cromwell et al. (1998) 
Cromwell et al. (1998) was a demonstration project set in Australia that used an integer 
programming approach to allocate resources across acute inpatient services.  The objective of the 
study was to find the mix of services that would maximise health gain from available resources.  
The authors derived effectiveness data from the Oregon Health Services Commission (measured 
in QALYs) and resource use data from Australian National Diagnosis Related Groups (AN-
DRG).  Utilisation data was derived from regional activity data.  Over a one-year timeframe, the 
model estimated potential gains of approximately 353,000 QALYs from the treatment of 45,000 
patients.   
 
In the study discussion, Cromwell et al. (2008) suggest that this research makes visible the trade-
offs implicit in health policy decision-making, and the opportunity costs in terms of health gain.  
However, they acknowledge a number of challenges that would need to be overcome before such 
a model could be implemented in practice.  The principal hurdle is the requirement for high 
quality data regarding the costs and benefits of interventions.  Also, for the set of included 
interventions, there were small differences in the cost-effectiveness of interventions close to the 
margin, i.e., those immediately above and below the cut-off value of cost-effectiveness.  This 
would prove problematic in practice, as it would be challenging to operate a rigid cost-
effectiveness decision rule with little to distinguish between interventions in terms of cost-
effectiveness.  The authors note that expanding the model beyond acute inpatient services would 
likely have an inhibitive effect on model complexity.   
 
The study had a number of characteristics that restricted its applicability to the empirical work 
considered here.  For example, Cromwell et al. (1998) did not employ the cost-effectiveness 
literature; rather, they used separate sources for the evidence regarding cost and effect.  Also, 
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included interventions were limited to forms of acute inpatient care.  Finally, costs were limited to 
a one-year time horizon. 
 
4.5.2.2 Zaric and Brandeau (2001) 
The objective of Zaric and Brandeau (2001) was to determine the optimal allocation of resources 
for HIV prevention and to investigate the impact of alternative patterns of resource allocation on 
health outcomes.  The patient population considered for this research were a hypothetical cohort 
of 1 million injection drug users (IDUs) and non-IDUs.  High prevalence and low prevalence 
communities were considered, each with differing numbers of IDUs, methadone treatment slots, 
and HIV prevalence.  Three HIV prevention interventions were considered: a needle exchange 
programme, methadone maintenance treatment, and condom availability programmes.  With a 
hypothetical budget of $1 million, the set of expenditures that maximised aggregate QALYs 
gained and the number of infections averted was determined.  A dynamic epidemic model was 
used to model the spread of HIV and the flow of IDUs into and out of methadone maintenance 
over a two-year time horizon.  In the low prevalence community, the model resulted in an 
additional 45.0 QALYs gained, and in the high prevalence community, 7.9 QALYs were gained. 
 
A number of characteristics limited the applicability of this research to the empirical work 
considered here.  Zaric and Brandeau (2001) focused solely on HIV prevention, with only three 
interventions included.  Also, the model was limited to a short time horizon (two years).  Cost-
effectiveness evidence was not used in Zaric and Brandeau’s model, and thus their framework had 
limited applicability to this research. 
 
4.5.2.3 Ratcliffe et al. (2005) 
The literature search identified Ratcliffe et al. (2005) as a potentially relevant study.  This study 
estimated the consequences in terms of costs and aggregate health of using alternative allocation 
rules for donor liver grafts.  A discrete choice experiment was used to generate relative weights 
for several key factors that might be used to prioritise patients for liver transplantation.  These 
weights were used to develop a “patient-specific index” for patients who received a liver 
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transplant from centres in England and Wales.  The patient-specific index was used to guide 
resource allocation on the basis of equity.  Costs and aggregate health resulting from this 
allocation were compared to when resources were allocated in order to maximise efficiency, i.e., 
to maximise health from available resources.  The authors used a Wilcoxan signed rank test to 
show that there was a statistically significant difference in ranks (p<0.001) between when patients 
were ranked in order of efficiency and equity.  The authors of the study concluded that the general 
public’s priorities may not be in accordance with a pure efficiency objective and using them to 
guide resource allocation may lead to an increase in costs and a decrease in aggregate health.    
 
While Ratcliffe et al. (2005) provided a useful insight into the estimation of hypothetical 
efficiency gains/losses when using alternative resource allocation rules it was of limited 
applicability to the empirical work considered here.  The study focused solely on the allocation of 
liver grafts and the study’s limited scope prevented me from emulating the approach for the 
empirical work presented in Chapter 7. 
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4.6. Methodological approach  
The studies reviewed above informed the methods used for the empirical work presented in 
Chapters 5 through 7.  Although the objectives of the empirical work, particularly Chapter 5 and 
Chapter 6, have a degree of similarity with a number of the reviewed studies, due to a number of 
data limitations it was not possible to emulate the studies precisely.  Nevertheless, a number of 
the reviewed studies provided a framework with which to approach the research objectives stated 
in Section 4.3.   
 
For example, the broad objective of George et al. (2001), Towse et al. (2002), and Rocchi et al. 
(2008) was to evaluate aspects of the cost-effectiveness of coverage decisions or 
recommendations.  These studies were particularly relevant to the empirical work presented in 
Chapter 5 in which one objective is to assess if there is a difference between positive and non-
coverage decisions with respect to cost-effectiveness.  George et al. (2001) proved particularly 
useful with respect to the presentation of cost-effectiveness studies and statistical approach.  
 
The remainder of the studies described in Section 4.5.1, i.e., Dranove et al. (2003), Devlin and 
Parkin (2004), Dakin et al. (2006), Harris et al. (2008), Chim et al. (2010), Devlin et al. (2010), 
helped provide a framework for the empirical work presented in Chapter 6.  These studies used 
variations on a regression approach to evaluate the influence of cost-effectiveness on coverage 
decisions or recommendations while controlling for other factors.  Further, these studies provided 
useful insight into what factors are important to decision makers and helped inform the variables I 
included in the database (Section 4.7.4).   
 
Unfortunately, it was not possible to find studies that proved as helpful to inform the 
methodological approach for the empirical work presented in Chapter 7.  Cromwell et al. (1998) 
and Zaric and Brandeau (2001) illustrated different approaches to estimating aggregate health 
gains from alternative resource allocations, but their complexity and data requirements restricted 
their applicability to the empirical work considered here.  In contrast, the narrow scope of 
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Ratcliffe et al. (2005), i.e., its focus on the allocation of liver transplantations limited its 
applicability to this research. 
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4.7. Methodology - Generation of database 
This section describes the development of the database used for the empirical work presented in 
chapters 5, 6 and 7. 
 
4.7.1. Identification of NCDs 
As noted above, since 1999 CMS have posted a decision memo for each completed NCD on their 
website.  I included decision memos relevant to NCDs made from 1999 through 2007 in this 
research. 
 
4.7.2. Decision memoranda 
I downloaded and reviewed each decision memo.  I included only decision memos relevant to 
national coverage policies, excluding those pertaining to instances when MACs were granted 
coverage discretion.  I also excluded incomplete memoranda, or those that pertained to minor 
language changes.  For example, the NCD for external counterpulsation (ECP) therapy (CAG-
00002N) was opened to clarify the language used to describe the device and thus was not 
included in the database.  Finally, I excluded NCDs pertaining to the coverage of medical 
technology in clinical trials (coverage with evidence development (CED)), as CED policies were 
not deemed equivalent to either positive or non-coverage decisions.   
 
4.7.3. Unit of analysis 
At the outset of the research, my expectation was that the NCD would be the unit of analysis.  
However, upon review of the decision memos it became apparent that few NCDs represented a 
single coverage decision.  A multiplicity of decisions arose in a single NCD for several reasons.  
First, two or more related but distinct technologies were considered.  One example of this is the 
NCD for image guidance for breast biopsy in which both stereotactic and ultrasound image 
guidance were considered. (CMS 1999a)  Second, a single technology was considered for 
multiple indications, as was the case with the NCD for Positron Emission Tomography (PET) 
imaging for various forms of cancer. (CMS 2000)  Third, the NCD may consider multiple uses of 
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a technology for a particular indication, such as the NCD for PET which considered technologies 
for both diagnosis (first use) and staging (second use) of cancer. (CMS 2000)  Finally, a 
“coverage with conditions” decision implicitly gives rise to two or more coverage decisions:  a 
positive decision for the covered indication or population and a negative decision for the non-
covered applications.  Rarely is a positive coverage decision made without restrictions.  In the 
majority of NCDs, CMS placed restrictions on the eligible patient population.  For these NCDs, 
an entry was made in the database for the population deemed eligible for the medical technology 
or intervention, with additional entries included for the populations deemed ineligible (Figure 14).  
An example of this scenario was the NCD for bariatric surgery.  In this case, a positive coverage 
decision was made only for Medicare beneficiaries who have a body-mass index (BMI) >35, at 
least one obesity-related co-morbidity, and for whom previous obesity treatment proved 
unsuccessful. (CMS 2006a)  Accordingly, a non-coverage decision was included for Medicare 
beneficiaries who did not meet the stipulated criteria. 
 
  
Figure 14.  Separate coverage restrictions in a single decision memo 
 
4.7.4. Database 
I developed a database in Microsoft Excel and included various data pertaining to each coverage 
decision.  I downloaded one hundred and forty decision memos from the CMS website. (CMS 
2010f)  Following review, I excluded 37 decision memos based on the exclusion criteria (Section 
4.7.2).  From the 103 decision memos included in the database, I identified 255 coverage 
decisions. 
Coverage with 
restrictions
Positive coverage
Patient population who meet 
restrictions
Non-coverage
Patient population who do not 
meet restrictions
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The process I used to review each decision memo is illustrated using a worked example for the 
NCD for deep brain stimulation for Parkinson’s disease (Appendix 3). The variables considered 
in this review and for inclusion in the database are presented below.   
 
4.7.4.1 Coverage decision 
I reviewed each decision memo to identify included coverage decisions.  I categorised coverage 
decisions as either positive coverage or non-coverage and thus coded Coverage decision as a 
dichotomous variable.  This approach is consistent with Dranove et al. (2003), Devlin and Parkin 
(2004), and Harris et al. (2008).   
 
As it was often the case that a decision memo was the source of multiple coverage decisions, it 
was necessary to account for the possibility that these coverage decisions may be related, i.e., 
there may have been overlap in the reviewed evidence, and that the coverage decisions were made 
by the same reviewers under the same circumstances.  I numbered NCDs chronologically to allow 
for the ‘clustering’ of coverage decisions to be accounted for.   
 
I also categorised coverage decisions as implicit and explicit.  Explicit coverage decisions were 
those for which a review of the evidence was presented in the decision memo.  Implicit decisions 
were those for which while it was clear CMS had made a coverage decision a review of the 
evidence was not presented in the decision memo.  An example of this was the NCD for foot care 
for diabetic patients. (CMS 2001)  The NCD included a positive coverage decision for foot care 
for diabetic patients with peripheral neuropathy with loss of protective sensation (LOPS).  For this 
coverage decision a review of the evidence base was presented in the decision memo.  Implicit in 
the NCD was a non-coverage decision for diabetic patients with peripheral neuropathy but 
without LOPS, despite the absence of a review of the supporting evidence base. (CMS 2001)   
 
On occasion, coverage decisions were reconsidered at a later date.  As CMS revisit a coverage 
decision only when the body of evidence is sufficient to warrant reconsideration, I considered 
these to represent unique observations.  
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I coded Coverage decision ‘1’ for positive coverage decisions, and ‘0’ for non-coverage 
decisions.   
 
4.7.4.2 Quality of evidence 
Evaluating the relationship between coverage decisions and the evidence base was an important 
aspect to this work.  Quality of Evidence is a categorical variable included in the database that 
characterises the clinical evidence supporting the coverage decision.  This classification is based 
on an independent review of each decision memo using a grading scale adapted from the United 
States Preventative Services Task Force (USPSTF) guidelines.  The USPSTF classification 
criteria are presented in Table 11.   
 
Table 11. Grading evidence according to net benefit and quality of evidence (USPSTF 
Guidelines) 
  Magnitude of net benefit, recommendation grade 
Quality of 
evidenceix 
Substantial Moderate Small
Zero/ 
negative
Insufficient 
information 
Good A B C D I 
Fair B B C D I 
Poor I I I I I 
 
                                                 
ix The USPSTF guidelines used the following criteria : 
Good: Evidence includes consistent results from well-designed, well-conducted studies in representative 
populations that directly assess effects on health outcomes. 
Fair: Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is 
limited by the number, quality, or consistency of the individual studies, generalisability to routine practice, 
or indirect nature of the evidence on health outcomes. 
Poor: Evidence is insufficient to assess the effects on health outcomes because of limited number or power 
of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information 
on important health outcomes. 
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The USPSTF classification criteria captures two dimensions of the evidence base, the magnitude 
of net clinical benefit and evidence quality.  For each coverage decision, two trained reviewers 
from Tufts Medical Center independently reviewed CMS’s evaluation of the evidence as 
presented in the decision memo and assigned a grade using the USPSTF classification criteria 
(Table 11).  The Tufts Medical Center researchers clarified any discrepancies during a consensus 
meeting.  I reviewed the grading assigned to each coverage decision to ensure consistency with 
the evidence base.  On two occasions I spoke with the researchers at Tufts Medical Center to gain 
clarification before finalising the database.  In the database, I classified evidence as “Good” when 
graded as “A” or “B”, “Poor” when graded as “C”, and “Insufficient” when graded “I”.  No 
evidence was classified with a ‘D’ grading.   
 
Although combining the magnitude of net clinical benefit and the quality of evidence dimensions 
is not ideal, evidence grading using the USPSTF classification criteria was the only approach 
taken by the researchers at Tufts Medical Center.  Another critique of this variable is its 
subjectivity.  Clinical studies included within CMS’s review were not independently reviewed by 
the Tufts Medical Center researchers; rather, their grading was based upon the presentation of 
CMS’s review of the evidence in the decision memo.  In spite of these limitations, using this 
approach was deemed defensible and appropriate given the limited resources.  Potential 
approaches that may be taken in the future to improve on this variable and to classify the evidence 
in an objective manner are discussed in Section 6.4.5.  
 
4.7.4.3 Alternative intervention 
Alternative intervention is a dichotomous variable (Alternative available; No alternative 
available) that captures whether or not an alternative intervention was available for the indicated 
patient population.  A number of the studies reviewed above (Section 4.5.1), including Devlin and 
Parkin (2004), Dakin et al. (2006), and Harris et al. (2008), accounted for the availability of 
alternatives in the model.  Based upon information presented in the decision memo, I made a 
judgment as to the availability of alternative interventions.  I coded the coverage decision as No 
alternative available in situations when it was clear from the decision memo that there were no 
alternative interventions available.  Also, I coded a coverage decision as No alternative available 
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in situations where it was clear from the decision memo that the intervention was permitted only 
after failure of all available alternatives, because in this usage no further alternatives are available.  
Therefore, for the purposes of this research I deemed that best supporting care was not an 
independent treatment option.  Abarelix for the treatment of prostate cancer is an example of a 
coverage decision when no alternative was available.  In this case, treatment with abarelix was 
deemed ‘reasonable and necessary’ only for patients with advanced symptomatic prostate cancer 
in whom gonadotropin-releasing hormone (GnRH) agonist therapy is not appropriate, who 
decline surgical castration, and meet other clinical restrictions. (CMS 2005b) 
 
4.7.4.4 Type of intervention 
Various types of intervention are considered through the NCD programme.  At the outset, I 
attempted to categorise the intervention as to its modality, i.e., pharmaceuticals, medical devices, 
surgeries, and health education and counselling.  This categorisation proved unsuitable, as often 
the intervention did not fit precisely into a single category.  Examples are cardiac stents and 
bariatric surgery, which could be categorised as either surgeries or medical devices.  
Consequently, I categorised interventions as to their broad indication; those used to treat disease, 
those used for diagnosis, screening or staging, and those that did not fit into either category, i.e., 
health education, preventative care, and mobility assistive equipment.  Accordingly, I categorised 
the interventions as Treatment, Diagnostic test, or Other.  
 
4.7.4.5 Coverage requestor 
A request for a NCD may originate externally or be internally generated by CMS.  An external 
request for coverage can be made from an individual or entity (e.g., the manufacturers, health 
plans, providers, etc) who “identifies an item or service as a potential benefit (or to prevent 
potential harm) to Medicare beneficiaries”. (CMS 2010e)  Alternatively, CMS may internally 
initiate a NCD in the interest of “the general health and safety of Medicare beneficiaries”. (CMS 
2010e)  CMS are prompted to initiate a NCD for an intervention already in use based on several 
factors, including uncertainty of risks and benefits, the availability of new evidence suggesting a 
required amendment of existing policies, and non-uniform local coverage policies. (Neumann, 
Kamae, & Palmer 2008) 
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I included Coverage requestor in the database to account for differences in the origin of the 
coverage request.  Coverage requestor is a categorical variable including the following 
categories:  Manufacturer (medical device or pharmaceutical company); Internally generated 
(decision to consider the intervention for coverage made by CMS); and Other (medical or 
professional societies and organisations, patient groups, etc).  I used information presented in the 
decision memo and the accompanying ‘tracking sheet’ to generate Coverage requestor. (CMS 
2010a) 
 
4.7.4.6 Date of decision 
I included the date of the coverage decision in the database.  Consideration of the date of decision 
allowed me to control for unobserved factors that affect the outcome of NCDs that change over 
time (e.g., composition of decision-making body).  I used the date reported in the decision memo.  
Date is a categorical variable including the following categories:  1999-2001, 2002-2003, 2004-
2005, and 2006-2007.  I considered a number of alternative ways to code Date, including:  coding 
as a continuous variable; coding as a categorical variable using each year as a separate category; 
and coding as a categorical variable categorising the observations into quartiles.  I coded Date as 
a categorical variable because odds ratios for continuous variables are less straightforward to 
interpret.  It coded the variable in groups of years as I thought this to be the most intuitive 
approach to present the findings.  I also investigated the impact of alternative coding on the 
findings of the analysis (Section 6.3.3).  
 
4.7.4.7 Cost-effectiveness 
The inclusion of cost-effectiveness evidence was an important aspect of this research.  In the 
following sections, the development of the cost-effectiveness variable is described.   
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4.7.4.8 Identification of cost-effectiveness analyses 
The first objective for the research presented in Chapter 5 is to examine NCD decision memos to 
determine if they are consistent with CMS’s stated position on the use of cost-effectiveness 
evidence.  Therefore, the first step in identifying relevant estimates of cost-effectiveness was to 
review each decision memo to determine if a cost-effectiveness analysis had been discussed or 
cited. (CMS 2010e)  In addition, I reviewed accompanying commissioned technology 
assessments and/or MEDCAC meeting documentation.  If no cost-effectiveness analysis was 
discussed or cited in the decision memo, or conducted as part of a commissioned technology 
assessment or MEDCAC, I performed a literature search to identify pertinent studies.  Primary 
sources used included the PubMed database, Tufts Medical Center CEA Registry, the Health 
Economic Evaluations Database (HEED), and the NHS Economic Evaluation Database (NHS 
EED). (CEA Registry 2010;HEED 2010;NHS-EED 2011;U.S.National Library of Medicine 
2011)  Secondary sources included internet search engines, conference abstracts, and 
manufacturers’ websites.  I performed a literature search for each coverage decision (n=255).  
Search terms included; generic and brand names of the intervention, all synonyms, and “economic 
evaluation,” “cost-effectiveness,” “cost-utility,” “cost-minimisation,” “decision analysis”, 
“decision model”, and “decision analytic model” (See Section 4.7.4.10, for a worked example).  
Studies were obtained through the Brunel University library.  When the electronic copy was not 
accessible, a paper copy was obtained through the British Library.  I included cost-effectiveness 
studies irrespective of date of publication, although those available at the time of the decision 
were recorded as such.  The search included articles published through December 31st, 2007.   
 
I included cost-effectiveness studies reporting cost-per QALY gained or cost-per life year gained 
ratios.  Also, I included cost-effectiveness studies reporting clinical outcomes measured in disease 
specific units, such as reduction in blood pressure or decrease in ulcer surface area, when the 
intervention was dominant, i.e., more effective and less expensive than its comparator, or 
dominated, i.e., less effective and more expensive than its comparator.  I reviewed cost-
effectiveness analyses that were a good match to the coverage decision with respect to the 
intervention, comparator, indication, and patient population.   
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4.7.4.9 Evaluation of cost-effectiveness studies 
I extracted data from each cost-effectiveness study and presented it using a table format 
(Appendix 3).  I chose review criteria based upon the suggested checklist for assessing the quality 
of decision analytic models reported in Drummond et al. (2005).  The criteria were selected to 
best reflect the aims and objectives of this research, i.e., to select the highest quality cost-
effectiveness study most relevant to the coverage decision.  To this end, I extracted the following 
data: 
Year of study  
• Price year reported in study.  If the price year was not reported, the study was reviewed to 
determine the time period over which data was collected and this was reported 
accordingly.  
Perspective of study 
• The perspective of the analysis, e.g., a societal perspective, a health care system 
perspective, or a patient perspective, was reported. 
Comparator 
• Each intervention and comparator included in the cost-effectiveness analysis was reported.  
Only cost-effectiveness analyses that included interventions and comparators relevant to 
the coverage decision, as determined from review of the decision memo, were included.  
Country setting  
• The country setting of the cost-effectiveness study was reported. 
Study population 
• Characteristics of the patient population evaluated in the cost-effectiveness study were 
reported, e.g., average age, nationality, comorbidities, etc 
Incremental cost-effectiveness ratio (ICER) 
• ICERs presented in the cost-effectiveness study were reported.  As noted above, studies 
reporting cost-per QALY and cost-per life year ratios were included.  Instances when the 
intervention was estimated to be dominant or dominated were reported accordingly.   
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Uncertainty associated with reported ICER(s) 
• Estimates of uncertainty surrounding the ICER(s) were reported when available.  The 
methodology used for sensitivity analysis, i.e., deterministic or probabilistic, was also 
reported.   
Date of study publication 
• The date of study publication was reported.  Studies published through December 31st, 
2007 were considered.x  
The purpose of the cost-effectiveness analysis 
• The purpose of the cost-effectiveness analysis, i.e., whether the study was prepared for 
submission to a regulatory body, written for publication, etc, was reported. 
Other comments 
• Any other aspects of the study deemed important to this research were reported.  
Examples of reported information included the source of study funding, origin of the 
clinical evidence, appropriateness of model time horizon, discount rate, etc. 
 
Adjustment of ICER (currency and year) 
For cost-effectiveness analyses performed in a country other than the US, I converted the reported 
ICER into US dollars.  I used the purchasing price parity (PPP), available on the OECD website, 
to convert non-US estimates of cost-effectiveness into US dollars. (OECD 2010)  The PPP is a 
conversion factor that represents how much of a country's currency is needed in that country to 
buy what $1 would buy in the United States. (World Bank 2010)  When necessary, I 
inflated/deflated the reported ICER to the year in which the NCD was made.  I used the health 
care component of the US consumer price index (CPI) available on the US Bureau of Labor 
Statistics website for this adjustment. (U.S.Bureau of Labor Statistics 2010b)  The CPI is a 
measure of the average change over time in the prices paid by consumers for a market basket of 
goods and services. (U.S.Bureau of Labor Statistics 2010a) 
                                                 
x December 31st, 2007 was chosen as the cut-off date to ensure consistency between literature 
searches. 
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Selection of pertinent study 
As noted, I reviewed only cost-effectiveness analyses that were a good match to the coverage 
decision with respect to intervention, comparator, indication, and patient population.  The 
intervention was clearly described in each decision memo.  The background section of decision 
memos includes description of the disease and available therapeutic management options and was 
used to evaluate the relevance of the comparator included in the cost-effectiveness study.  For 
some interventions, such as some screening and diagnostic tests, there was no obvious 
comparator, and so in these cases it was assumed that the appropriate study comparator was no 
screening/diagnostic test.  For others, however, I had to make a decision regarding the appropriate 
comparator.  An example is the NCD for aprepitant for the treatment of chemotherapy-induced 
nausea. (CMS 2005c)  The identified cost-effectiveness analysis compared three treatment 
strategies; conventional treatment (treatment with a 5-HT3 antagonist and a corticosteroid), 
conventional treatment plus aprepitant, and conventional treatment with aprepitant added after the 
onset of chemotherapy-induced nausea and vomiting. (Moore et al. 2007)  Review of the decision 
memo made clear that the CMS considered conventional treatment with a 5-HT3 antagonist and a 
corticosteroid as the relevant comparator. (CMS 2005c)   
 
I expected that in some cases I would identify multiple relevant estimates of cost-effectiveness.  I 
considered various approaches if this were the case:  take an average of the identified estimates of 
cost-effectiveness; take the median estimate of cost-effectiveness; or, combine the results of 
studies using meta-analysis.  Ultimately, these approaches were not required.  In the majority of 
cases, a single relevant estimate of cost-effectiveness was identified.  When multiple estimates of 
cost-effectiveness were available identified, the best estimate could be selected using the grading 
system described below.   
 
Study grading 
I graded each cost-effectiveness study using an ordered rating scale designed for this research.  
The scale ranges from “A” to “E,” with “A” deemed the most relevant to CMS (Table 12).  The 
objective was to find the study most relevant to the coverage decision.  Therefore, I assigned 
estimates made as part of the NCD or originated from a cost-effectiveness study discussed or 
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cited in the decision memo an ‘A’ grade.  I assigned a cost-effectiveness study submitted to CMS 
as part of the submission process but not made reference to in the decision memo a ‘B’ grade.  I 
assigned relevant studies set in the US and not reviewed by CMS a ‘C’ grade.  Within this 
grading, studies funded from sources other than the manufacturer were given precedence.  In the 
absence of studies set in the US, studies set in other health systems were considered.  I assigned 
studies set in health systems other than the US and were conducted by a regulatory agency in that 
country a ‘D’ grade.  Finally, I assigned studies set in health systems other than the US and not 
conducted by regulatory agencies an ‘E’ grade.   
 
When multiple estimates of cost-effectiveness were available, I gave priority to the cost-
effectiveness analysis with the best grading.  I used the recency of the study to the coverage 
decision to choose between studies tied on rank.   
   
 178
Table 12. Grading of cost-effectiveness analyses 
Ranking Description 
A 
Estimate of cost-effectiveness made as part of the NCD.  Includes discussion 
of the cost-effectiveness of the intervention, reference to a cost-effectiveness 
analysis, or when a cost-effectiveness analysis was commissioned as part of 
a TA or MEDCAC. 
B 
Cost-effectiveness analysis submitted to the CMS as part of the submission 
process. 
C 
Cost-effectiveness analysis set in the US health care system that the decision 
memo does not reference. 
D Cost-effectiveness estimate made by a regulatory body in another country. 
E Relevant cost-effectiveness analysis not set in the US health care system. 
 
4.7.4.10 An example of the literature search for cost-effectiveness studies 
I searched for a cost-effectiveness study relevant to each coverage decision (n=255).  To illustrate 
the approach taken to identify relevant estimates of cost-effectiveness, the results of the PubMed 
search strategy used for the NCD for deep brain stimulation (DBS) to treat essential tremor and 
Parkinson’s disease are presented in Table 13. 
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Table 13. Search strategy and literature search results for the NCD for deep brain 
stimulation 
Search  Search terms Results 
#1 Deep brain stimulation OR DBS OR Globus pallidus deep 
brain stimulation OR Subthalamic deep brain stimulation OR 
Thalamic deep brain stimulation 
3,416 
#2 Economic evaluation OR Cost-effectiveness OR Cost-utility 
OR Cost-minimisation OR Decision analysis OR Decision 
model OR Decision analytic model 
146,033 
#3 #1 AND #2 42 
Limits English, Publication Date through 2007/12/31  
 
I reviewed titles and abstracts for the 42 results of search #3, and judged whether to include them 
for further review.  I obtained and reviewed three full text studies and abstracted data from them.  
I performed a search of the additional economic databases, i.e., CEA Registry, NHS EED and 
HEED, to ensure that all pertinent studies were identified through the PubMed search.  This 
search yielded one additional study.  A search of the secondary databases did not yield any 
additional studies.  In total, I reviewed four studies, and data was extracted from them using a 
data extraction table (data extraction tables are presented in Appendix 3).  Of the four studies 
Tomaszewski and Holloway (2001) was assigned the highest grade and was included in the 
database. 
 
4.7.4.11 Overview of the cost-effectiveness variable 
Using the search strategy described above, I often identified multiple potentially relevant 
abstracts.  As noted above, I reviewed each abstract and the full text article was obtained for those 
deemed a satisfactory match with the coverage decision in terms of intervention, comparator, and 
patient population.  Of the 103 NCDs, 43 included at least one coverage decision for which an 
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appropriate cost-effectiveness analysis was identified.  In total, I reviewed 87 cost-effectiveness 
studies pertaining to 64 coverage decisions.  Of the 64 cost-effectiveness studies included, 48 
pertained to positive coverage decisions and 16 to non-coverage decisions.  Of the 191 coverage 
decisions without an associated estimate of cost-effectiveness, 75 were positive coverage 
decisions and 116 were non-coverage decisions.  An overview of the generation of Cost-
effectiveness is presented in Figure 15. 
 
 
Figure 15. Overview of the generation of Cost-effectiveness 
 
For the research presented in Chapter 6, it was necessary to code Cost-effectiveness as a 
categorical variable.  While for some studies reviewed above (Section 4.5.1) the researchers 
included cost-effectiveness evidence in the model as a continuous variable, this meant that 
dominant and dominated estimates of cost-effectiveness were either dropped from the analysis, 
e.g., Devlin et al. (2010), or, in the case of dominant estimates, coded as zero, e.g., Dakin et al. 
(2006).  For the research in Chapter 6, I coded the cost-effectiveness data categorically, as it 
140 decisions
memos
64 coverage decisions 
with pertinent 
economic evaluation
255 individual 
coverage decisions
103 decisions 
memos reviewed
191 coverage decisions
for which no economic 
evaluation identified
37 decision 
memos excluded
48 positive coverage
decisions
16 non-coverage
decisions
75 positive coverage
decisions
116 non-coverage
decisions
   
 181
allowed for the more straightforward interpretation of odds ratios and facilitated the inclusion of 
coverage decisions associated with dominant or dominated estimates of cost-effectiveness.  
 
4.7.4.12 Additional variables not included in database 
I attempted to develop a number of variables that were ultimately were not included in the 
database.  These variables, and reasons for their ultimate exclusion, are discussed below. 
 
Nature of clinical benefit 
Interventions subject to NCDs vary with respect to the nature of benefit they provide.  Some 
interventions primarily affect patient survival, others patient quality of life.  An attempt was made 
to capture the nature of benefit that interventions provide in the database.  Nature of benefit was a 
categorical variable that included the following categories: Direct effect on survival; Indirect 
effect on survival; Uncertain effect on survival; Quality of life increasing; and Not applicable.   
 
Development of Nature of benefit was challenging.  Rarely was an intervention solely survival or 
quality of life increasing, and categorising interventions was complex.  Further, for diagnostic and 
screening tests any positive effect on health is indirect, attributable to treatment as a result of 
diagnosis of disease.  To try to account for this, I included the category Indirect effect on survival.  
 
Despite best efforts to include this variable, I deemed that its imprecise nature would prevent 
meaningful interpretation and I ultimately excluded it from the final database.  It is likely that 
successful inclusion of this variable would require additional input from clinicians or other health 
care professionals. 
 
Prevalence 
NCDs are performed for interventions deemed to have a significant impact on the Medicare 
programme.  Therefore, I attempted to include a variable to capture the potential impact of the 
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intervention on the Medicare programme.  One approach taken was to determine the number of 
Medicare beneficiaries potentially affected by the coverage decision.  Prevalence was coded as a 
continuous variable.  
 
On rare occasions, the prevalence of disease was reported in the decision memo.  However, the 
reported statistics were typically not specific to the precise patient population affected by the 
coverage decision.  For example, in the decision memo for cochlear implantation it states, “… 
more than 25 million Americans have hearing loss, including one out of four people older than 
65”. (CMS 2005d)  However, the positive coverage decision was made for a population with a 
number of restrictions, and the reported prevalence statistics do not correlate with the number 
eligible to receive the intervention.  In the vast majority of decision memos, prevalence of disease 
is not reported, and I performed a search of the medical literature in an attempt to identify 
estimates.  However, in most cases it was not possible to identify an estimate of the number of 
Medicare beneficiaries affected by the coverage decision.  Given the frequency with which 
estimates could not be identified, Prevalence was ultimately not included in the final database.   
 
I used a version of this variable for the research described in Chapter 7.  This version relied upon 
the reporting of ICD-9 codes to estimate the number of eligible beneficiaries in a Medicare claims 
database.  Unfortunately, this information was insufficient to include Prevalence here.  I found 
that ICD-9 codes often lacked the precision to identify beneficiaries who met the NCD 
specifications.  Given the imprecise nature of this approach, I ultimately excluded Prevalence 
from the database.  I present further details on a version of this variable used for the research 
presented in Chapter 7 in Section 4.7.5.5. 
 
Budget impact 
I used a second approach to attempt to capture the potential impact of the intervention on the 
Medicare programme by considering the potential budget impact of the coverage decision.  
Budget impact was coded as a continuous variable.   
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On rare occasions, the potential budget impact of an intervention was reported in the decision 
memo.  However, the reported estimates were typically imprecise.  For example, in the decision 
memo for smoking and tobacco use cessation counseling it states, “In 1993, smoking cost the 
Medicare program about $14.2 billion, or approximately 10 percent of Medicare’s total budget.”  
In the vast majority of decision memos, an estimated budget impact is not reported, thus I 
performed search of the medical literature in an attempt to identify estimates.  However, as was 
the case with Prevalence, in most cases it was not possible to identify a relevant estimate of the 
budget impact associated with the coverage decision.  Given the frequency that a relevant 
estimate of cost-effectiveness could not be identified, Budget impact was ultimately not included 
in the final database. 
 
I used a version of Budget impact for the research described in Chapter 7 (4.7.5.2).  As for 
Prevalence, I used a Medicare claims database to estimate the number of Medicare beneficiaries 
receiving an intervention and those eligible for it.   
 
First line technology 
To account for instances when CMS recommended the intervention as the standard of care, I 
attempted to include First line technology in the database.  I reviewed each decision memo and 
made a judgement with respect to how CMS recommended the intervention should be 
incorporated into clinical practice.  I coded First line technology as a dichotomous categorical 
variable including the following categories; First line technology and Not first line technology.  
First line technology differed from Alternative intervention as rather than the absolute availability 
of alternatives, I accounted for how the intervention is prioritised in therapeutic management.   
 
Unfortunately, information provided in decision memos was insufficient for this purpose.  While 
in some cases it was clear that the intervention was not to be used as the first line treatment, i.e., 
when restrictions on coverage were that the intervention was only permitted after the failure of 
other interventions, in most cases such information was not presented.  Ultimately, despite best 
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efforts to include this variable, I deemed that its imprecise nature would prevent meaningful 
interpretation, and it was ultimately excluded from the final database.   
 
4.7.5. Additional variables required for empirical work presented in Chapter 7 
The database described above was insufficient for the research presented in Chapter 7.  For this 
research I developed a second smaller database including only coverage decisions with an 
associated estimate of cost-effectiveness that included the data necessary to perform a 
hypothetical reallocation of expenditures between interventions subject to NCDs.  
For each intervention, the following information was required. 
1. Estimate of cost-effectiveness, including incremental cost and incremental effectiveness 
data; 
2. Estimate of intervention and comparator cost in the year following implementation; 
3. Estimate of existing utilisation rate (served population), i.e., the utilisation of the 
intervention within the Medicare population in 2007; 
4. Estimate of the size of the total patient population eligible for the intervention in 2007 (to 
facilitate estimation of the unserved patient population). 
 
4.7.5.1 Cost-effectiveness data 
Only interventions with an associated estimate of cost-effectiveness were included.  The methods 
used to identify and evaluate the cost-effectiveness evidence are described in Section 4.7.4.7.  In 
summary, I performed a literature search to identify relevant cost-effectiveness studies for each 
coverage decision featuring in CMS NCDs from 1999 through 2007.  To be included, the cost-
effectiveness analysis had to include an intervention matching the coverage decision and also a 
realistic and relevant comparison intervention.  I assessed each cost-effectiveness study using a 
number of criteria and when multiple studies were available I included the most relevant in the 
database (Section 4.7.4.9).  When necessary, I converted cost-effectiveness estimates to US 
dollars using the PPP and adjusted them to a 2007 valuation using the health component of the 
CPI (Section 4.7.4.9).  I considered studies reporting cost-per QALY and cost-per life year gained 
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ratios.  Also considered were cost-effectiveness studies reporting the cost-per disease-specific unit 
when the intervention was estimated to be dominant.  Interventions estimated to be dominated, all 
of which pertained to non-coverage decisions, were excluded from the dataset.  I included cost-
effectiveness studies irrespective of publication date.   
 
4.7.5.2 Incremental costs 
To estimate the consequence of reallocating expenditures between competing interventions in 
terms of programme costs, incremental cost data was required.  I extracted incremental cost data 
from the cost-effectiveness study when possible.  This was possible for the majority of cost-
effectiveness studies set in the US.  When incremental cost was reported in US dollars other than 
a 2007 valuation I adjusted the estimate using the health component of the CPI.  When the cost-
effectiveness study was set in a country other than the US, I performed a search of the medical 
literature to identify costing studies set in the US that provided the necessary data.  Primary 
sources included the PubMed database and NHS EED. (Centre for Reviews and Dissemination 
2011;U.S.National Library of Medicine 2011)  If a relevant US-based costing study could not be 
identified, I converted the incremental cost reported in the cost-effectiveness study into US 
dollars using the PPP and, when necessary, adjusted it to a 2007 valuation using the health 
component of the CPI (Section 4.7.4.9).  
 
4.7.5.3 Cost of an intervention in the first year of its use 
In addition to incremental costs, estimates of the cost of competing interventions in the year 
following their first use were required.  On occasion, the necessary information was presented in 
the included cost-effectiveness study and was incorporated accordingly.  When not directly 
reported, it was on occasion possible to calculate the cost from data reported in the cost-
effectiveness study, e.g., when cost data was presented graphically.  When this was not possible, I 
estimated the cost of the competing treatments in the year following first use from Medicare and 
physician reimbursement codes (Section 4.7.5.6).  Generally, it was possible to identify the 
pertinent reimbursement codes from official Medicare documentation, the included cost-
effectiveness study, or the manufacturer’s website.  For interventions subject to non-coverage 
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decisions, it was possible to either obtain the relevant information from the cost-effectiveness 
study or from a costing study performed in the US setting. 
 
4.7.5.4 Incremental effectiveness data 
Incremental QALY data were necessary to estimate aggregate population health gain/loss from 
the hypothetical reallocation of expenditures.  Quality adjusted life years are an ideal metric for 
this research as they facilitate a comparison of health gain across interventions and disease areas.  
The majority of cost-effectiveness studies included in this research included QALYs as the 
outcome measure, and I extracted the incremental QALY gain accordingly.  Consistent with the 
research presented in Chapters 5 and 6, cost-effectiveness studies reporting cost-per life year 
gained ratios were considered in the absence of cost-per QALY studies.  To maintain consistency 
with cost-per QALY studies, estimates of incremental life year gains were adjusted with a utility 
weight, 0.76, for Americans aged 65-69 as reported by Erickson P et al. (1995). (Erickson, 
Wilson, & Shannon 1995)  This adjustment may underestimate incremental QALY gain as it only 
accounts for years of survival gain, not prior years of treatment when quality of life may have 
differed between intervention arms.  However, I used this approach to facilitate the measurement 
of aggregate health gains using a single metric.   
 
Cost-effectiveness studies that reported health gain using disease specific units were considered 
for interventions estimated to be dominant.  Although these studies do not provide estimates of 
incremental QALY gain, they do provide incremental cost data.  Separate analyses were 
performed for the inclusion and exclusion of studies that report health gain using disease-specific 
units.  
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4.7.5.5 Utilisation rates 
Interventions associated with a positive coverage decision 
I estimated utilisation rates from a Medicare claims database obtained for a broader research 
project performed by researchers at Tufts Medical Center.xi  The database included both inpatient 
and outpatient data from a 5% sample of the Medicare population.  ICD-9 diagnostic codes, the 
standard format used to identify illness, injury, or disease, were included in this database.  Upon 
receiving care, Medicare beneficiaries are assigned an ICD-9 diagnostic code that best categorises 
their ailment.  Medicare beneficiaries eligible for an intervention, as defined by the parameters of 
the NCD, were identified through the reported ICD-9 diagnostic codes.  Also included in the 5% 
Medicare claims database are ICD-9 procedural codes, used for documenting and recording 
performed medical procedures, and Common Procedural Terminology (CPT) codes, used for 
physician reimbursement for services performed while working for Medicare, Medicaid, and a 
majority of private health care payers. 
 
I obtained utilisation rates by estimating the number of beneficiaries that had matching relevant 
ICD-9 diagnostic codes and CPT or ICD-9 procedural codes.  As a 5% Medicare claims database 
was used, I adjusted the identified utilisation rate by a factor of 20 to estimate of the total number 
of beneficiaries receiving the intervention.   
 
Separate data files were used for the inpatient and outpatient data, and it was not possible to 
ensure that beneficiaries did not feature in both datasets.  Consequently, it is possible that a 
beneficiary who received the same therapy on both an inpatient and an outpatient basis in the 
same year would be counted twice.  This double counting is, however, unlikely to be a significant 
problem.  In the majority of cases, interventions are reimbursed exclusively on either an inpatient 
(e.g., bariatric surgery, transmyocardial revascularisation, ventricular assist devices, etc) or an 
outpatient basis (e.g., cardiac rehabilitation, PET for various oncology indications, foot care, etc), 
and the possibility of double counting is minimal. 
 
                                                 
xi See Acknowledgements. 
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ICD-9 diagnostic codes were used to estimate the size of the eligible patient population.  
Important in this research was identification of the size of the unserved eligible population, i.e., 
beneficiaries eligible for the intervention as defined by the NCD parameters but who did not 
receive the intervention.  I calculated the size of the unserved population as the difference 
between the number of beneficiaries who were a match for both ICD-9 diagnostic codes and 
CPT/ICD-9 procedural codes, and those who were match solely when considering ICD-9 
diagnostic codes (Table 14).   
 
Table 14. Identification of served and unserved populations from Medicare claims 
 ICD – 9 Diagnostic codes 
Reimbursement code/ICD 
procedural code 
Match with NCD Not a match with NCD 
Match with NCD Currently served population NA 
Not a match with NCD Unserved population NA 
 
Non-covered interventions  
Interventions subject to non-coverage decisions are unavailable to Medicare beneficiaries for the 
indication defined by the NCD parameters.  For interventions subject to non-coverage decisions, 
the utilisation rate was assumed zero in all cases.  In order to include non-covered interventions in 
the reallocation, it was necessary to estimate the size of the potential eligible patient population if 
the intervention was offered as a Medicare benefit.  As for interventions subject to positive 
coverage decisions, the size of the eligible patient population was estimated through ICD-9 
diagnostic codes.  For each non-coverage decision, I reviewed the decision memo to determine 
the patient population for which the non-coverage decision pertained.  This patient population 
was then categorised using ICD-9 diagnostic codes using an online database. (Centers for Disease 
Control and Prevention 2011)  In turn, I used these diagnostic codes to estimate the size of the 
potentially eligible patient population through the Medicare 5% claims database. 
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4.7.5.6 Reimbursement codes 
As described above, I used reimbursement codes to estimate current utilisation rate, i.e., the 
served population, and the cost of the intervention in the first year of its use.  The price year was 
2007.  I describe the sources of these reimbursement codes below. 
 
Physician reimbursement 
Common Procedural Terminology codes are developed, published, and licensed by the American 
Medical Association (AMA).  The reimbursement rate associated with each CPT code is available 
on CMS’s website. (CMS 2010c)  As reimbursement rate varies by geographic region, the 
‘neutral’ code (Carrier/ Locality code 0000000) was used to maintain consistency in each 
instance.   
 
Outpatient services 
Ambulatory Payment Classifications (APCs) are reimbursement codes used for outpatient 
services within the Medicare programme.  Ambulatory Payment Classifications are a prospective 
payment system for hospitals and cover all services performed in an outpatient setting, with the 
exception of physician reimbursement. (MedPAC 2007)  This information was obtained for the 
most part through coding information available on the manufacturer’s website.  When unavailable 
through the manufacturer’s website, or indeed when the intervention was not associated with a 
medical technology, APCs were available through published Medicare documentation.   
 
Inpatient services 
The Medicare Inpatient Prospective Payment System (IPPS) is a prospective payment system 
used to reimburse hospitals for inpatient care.  This system categorises patients into specific 
diagnostic categories (MS-DRG) and provides reimbursement accordingly. (MedPAC 2008)  
Similar to APC codes, this information is most readily accessible through coding information 
available from manufacturers’ websites or through published Medicare documentation. 
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4.7.5.7 Categorisation of interventions 
To facilitate evaluation of the effect of reallocation on the distribution of expenditures, I 
categorised interventions with respect to disease classification, type, and the size of the associated 
untreated population.  The approach to classifying intervention type is presented in Section 
4.7.4.4.  Classifications pertaining to disease and size of the associated untreated population are 
presented below. 
 
Disease classification  
• Interventions were categorised as those related to; cardiology, oncology, other (i.e., those 
unrelated cardiology or oncology). 
 
Size of the associated untreated population 
• Interventions were classified as those for which the size of the untreated patient population 
was large (>1 million beneficiaries), medium (50,000 – 1 million beneficiaries), or small 
(<50,000 beneficiaries). 
 
4.7.5.8 Software 
I used SAS to identify utilisation rates from the Medicare 5% database and Microsoft Excel to 
perform the hypothetical reallocation of resources. 
 
4.8. Chapter summary 
This chapter lays the foundation for the empirical work presented in Chapters 5 through 7.  The 
Medicare programme is described, highlighting its size and importance in the US health care 
system.  The process for coverage of interventions in the Medicare programme is explained, along 
with the circumstances in which interventions are evaluated through NCDs.   
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The three pieces of research that constitute the empirical aspect of this thesis are described above, 
with the objective(s) for each stated.  A literature search was performed to identify studies that 
would help inform the methodological approach for each piece of empirical work.  First, a search 
was performed to identify studies that evaluated the role of cost-effectiveness evidence in 
coverage and reimbursement decisions, or in recommendations for the efficient use of medical 
technology.  A body of literature was identified and reviewed that evaluated how cost-
effectiveness has been used in decision-making by NICE in the UK, the PBAC in Australia, 
CEDAC in Canada, PHARMAC in New Zealand, and an HMO in the US.  Second, a literature 
search to identify studies that estimated efficiency gains, in terms of aggregate health gains and 
cost savings, through the hypothetical reallocation of resources was performed.  Two studies that 
estimated hypothetical gains from alternative approaches to resource allocation were reviewed.   
 
A database was developed including the variables required for the empirical work.  Variables in 
the database included cost-effectiveness, quality of supporting clinical evidence, availability of 
alternative interventions, date of decision, coverage requestor, and type of intervention.  The cost-
effectiveness variable was primarily generated through literature searches, although on occasion a 
relevant cost-effectiveness ratio originated from the decision memo.  The variable classifying the 
quality of the supporting clinical evidence was generated through review of the decision memo by 
two researchers at Tufts Medical Center using the USPSTF guidelines for grading evidence.  The 
remaining variables were generated from review of the decision memos. 
 
Additional variables were required for the third piece of empirical work, including incremental 
cost and incremental QALY gain data, the cost of the intervention in the first year of its use, the 
existing utilisation rate, and size of the eligible patient population.  For the most part, the 
incremental cost and incremental effectiveness data originated from the included cost-
effectiveness studies.  The cost of the intervention and the comparator was captured from a 
number of sources, including the cost-effectiveness literature, costing studies, or from Medicare 
reimbursement codes.  Utilisation rate and the size of the eligible patient population were 
estimated from Medicare claims data. 
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In the next chapter, I describe the first piece of empirical work. The first objective is to evaluate if 
NCDs are consistent with CMS’s stated position on the use of cost-effectiveness evidence, i.e., 
that cost-effectiveness is not a factor that is considered in NCDs.  The second objective is to 
evaluate the cost-effectiveness of positive coverage and non-coverage decisions and to determine 
if there is a statistically significant difference between the two groups. 
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5. Empirical Research: Part 1 
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5.1. Introduction 
In this chapter, I present the first piece of empirical work.  In Chapter 2, I described the theory 
underpinning cost-effectiveness analysis.  In Chapter 3, I illustrated how cost-effectiveness 
evidence is used to inform decision-making in a range of jurisdictions.  In some cases, cost-
effectiveness analysis has a fundamental role in coverage and reimbursement decisions, or in 
recommendations for the efficient use of medical technology; in others it plays a lesser role.  In 
particular, despite maintaining levels of health care spending grossly in excess of other countries 
and faring noticeably worse with respect to health outcomes, cost-effectiveness analysis has not 
been embraced by the US health care system.  This is particularly noticeable when examining the 
Centers for Medicare and Medicaid Services (CMS), an agency whose stated position is that cost-
effectiveness is not a factor considered in national coverage determinations (NCDs).   
 
Chapter 4 provides the foundation for the empirical aspect of this thesis.  A background to the 
Medicare programme and the processes for the coverage of medical technology were summarised.  
The objectives of the empirical component of this thesis were presented and key studies identified 
from a literature search that helped inform the methodological approach reviewed.  The 
development of the database necessary for the empirical work is described. 
 
The purpose of this chapter is to examine CMS’s use, or lack of use, of cost-effectiveness 
evidence, and to evaluate the cost-effectiveness of coverage decisions made as part of NCDs.  To 
the best of my knowledge, although the cost-effectiveness of CMS NCDs has been commented 
upon in the literature, a systematic assessment has not been performed. (Neumann, Rosen, & 
Weinstein 2005)  The research objectives are presented below.  
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5.2.  Objectives and Methods 
The empirical work presented in this chapter has two specific objectives:  
1. To examine NCD decision memos to determine if they are consistent with CMS’s stated 
position on the use of cost-effectiveness evidence, i.e., that cost-effectiveness is not a 
factor considered in making NCDs. 
2. To determine if there is a difference between positive coverage decisions and non-
coverage decisions with respect to cost-effectiveness. 
 
5.2.1. Objective 1 
For the first research objective, I scrutinised the decision memos accompanying NCDs made from 
1999 through 2007 (n=140) for any discussion or citation of cost-effectiveness evidence.  Also, I 
reviewed documentation accompanying the NCD, which included that pertaining to associated 
MEDCAC meetings or external technology assessments.  I recorded each instance that cost-
effectiveness evidence featured in a decision memo or the accompanying documentation (Section 
4.7.4.8).   
 
5.2.2. Objective 2 
For the second research objective, the methodological approach was informed by the review of 
the methods used in the research described in Section 4.5.1.  Three studies, George et al. (2001), 
Towse and Pritchard (2002), and Rocchi et al. (2008), evaluated coverage decisions solely from a 
cost-effectiveness perspective.  An important distinction between the studies and the research 
described in this chapter is that they evaluated agencies in which cost-effectiveness evidence 
plays an established role in decision-making.  Indeed, rather than evaluating whether there is a 
difference between positive and non-coverage decisions with respect to cost-effectiveness, the 
objective of the studies was to identify a threshold value of cost-effectiveness above which a 
technology is less likely to be covered.  Nevertheless, the methodological approaches of the 
reviewed studies provided a framework with which to perform this research.  In particular, 
George et al. (2001) used a similar methodology to that employed here.  Specifically, the study 
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similarly used tabular presentation of the cost-effectiveness studies as well as a statistical test to 
evaluate if there was a statistically significant difference between positive and non-coverage 
decisions with respect to cost-effectiveness.   
 
For coverage decisions made in NCDs from 1999 through 2007, I attempted to identify estimates 
of cost-effectiveness.  As described above, I reviewed each decision memo for discussion or 
citation of cost-effectiveness evidence.  In addition, I performed a literature search for each 
coverage decision to identify estimates of cost-effectiveness available in the peer-reviewed 
literature.  I considered only cost-effectiveness studies that were a good match with respect to 
intervention, comparator, indication, and patient population.  When I identified multiple relevant 
cost-effectiveness estimates, the estimate deemed most relevant to the coverage decision was 
included.  A more detailed description of the process used to generate the data used in this 
research is described in Section 4.7.4.9.  
 
Consistent with the methodological approach taken by George et al. (2001), I performed a Mann 
Whitney U test to determine if there was a statistically significant difference between the cost-
effectiveness of positive coverage decisions and non-coverage decisions.  The Mann Whitney U 
test was deemed the most appropriate statistical test for this analysis.  The data take the form of 
two independent random samples taken from two populations, i.e., positive and non-coverage 
decisions, and have the necessary characteristics for the Mann Whitney U test, i.e., they are 
unpaired, categoricalxii and ordinal.  To perform the test, the two samples were pooled and the 
observations ranked in order of their cost-effectiveness, with ties assigned the average of the next 
available ranks.  The Mann Whitney U statistic (U) can be presented algebraically as follows: 
1
11
21 2
)1( RnnnnU −++=  
n1 = Number of observations available from the first population (positive coverage decisions) 
n2 = Number of observations available from the second population (non-coverage decisions) 
                                                 
xii I considered the data to be categorical as the inclusion of observations that were dominant and dominated 
prevented me from using a numerical variable. 
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R1 = Sum of ranks of the observations from the first population 
 Assuming the null hypothesis that the central locations of the two population distributions 
are the same, the Mann Whitney U, has mean and variance as presented below: 
( )
2
21nnUE U == μ  
( ) ( )
12
121212 ++== nnnnUVar Uσ  
 
Further, given the available sample sizexiii (total coverage decisions, n=64; positive coverage, 
n=48; non-coverage, n=16), it is possible to assume that the distribution of the random variable is 
approximated by the normal distribution: 
  
U
UUZ σ
μ−=  
The decision rule for the Mann Whitney U test is to reject H0 if: 
2/ασ
μ
z
U
Z
U
U −<−=      or       2/ασ
μ zUZ
U
U >−=  
 
                                                 
xiii Approximation to a normal distribution is appropriate if each sample contains at least 10 observations, i.e., n1 ≥ 10 
and n2 ≥ 10 (Newbold, Carlson, & Thorne 2003) 
   
 198
5.3. Results 
In this section, I present the findings of the literature search, illustrating how I arrived at the final 
sample of cost-effectiveness studies.  Also, I describe the distribution of cost-effectiveness studies 
with respect to study grading (Section 4.7.4.9), and country of study.  Next, I present the findings 
of the research pertinent to the first research objective, i.e., to examine NCD decision memos to 
determine if the reviewed evidence is consistent with CMS’s stated position on the use of cost-
effectiveness evidence.  Finally, I present the findings of the research pertinent to the second 
research objective, i.e., to determine if there is a difference between positive and non-coverage 
decisions with respect to cost-effectiveness. 
 
5.3.1. Literature search findings  
An overview of the review process and the final sample of coverage decisions and corresponding 
cost-effectiveness studies are presented in Figure 16. Thirty-seven of the 140 NCDs made from 
1999 through 2007 were excluded based upon the exclusion criteria (Section 4.7.2).  From the 
remaining 103 NCDs, 255 coverage decisions were identified.  A relevant estimate of cost-
effectiveness was identified for 64 coverage decisions, 48 positive coverage decisions (Table 15), 
and 16 non-coverage decisions (Table 16).  Of the 191 coverage decisions for which no relevant 
estimate of cost-effectiveness was identified, 75 were positive coverage decisions and 116 non-
coverage decisions.  
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Figure 16. Review process and final sample of coverage decisions with associated estimate of 
cost-effectiveness 
N.B. QALY = Quality Adjusted Life Year; Life years = Life years gained 
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Table 15. Positive coverage decisions associated with an estimate of cost-effectiveness 
No. Technology - Coverage 
decision 
Year Ranking 
of  
evidence 
ICER (US$) Outcome 
measure* 
Study 
country 
Reference: 
1 Cryosurgery Ablation for 
Prostate - Primary 
treatment for clinically 
localised prostate cancer. 
(Stages T1-T3) 
1999 C Dominant Other USA Benoit RM et al. 
(1998) 
2 Breast Biopsy - 
Stereotactic core needle 
image guidance 
1999 C Dominant Other USA Lee et al. (1997)
3 Breast Biopsy - Ultrasound 
image guidance 
1999 C Dominant Other USA Liberman L et al. 
(1998)  
4 Diabetic Peripheral 
Neuropathy with Loss of 
Protective Sensation - 
Coverage for diabetic 
patients who meet 
specified conditions 
2001 E Dominant QALY Sweden Ragnarson 
Tennvall G et al. 
(2001)  
5 Positron Emission 
Tomography - Lung 
Cancer (non-small cell) 
2000 C Dominant Other USA Valk PE et al. 
(1996) 
6 Positron Emission 
Tomography - Colorectal 
Cancer 
2000 C Dominant Other USA Valk PE et al. 
(1996) 
7 Positron Emission 
Tomography - Melanoma 
2000 C Dominant Other USA Valk PE et al. 
(1996) 
8 Ambulatory blood pressure 
monitoring - Use in 
patients with high blood 
pressure who meet 
specified criteria 
2001 E Dominant Other UK Aitken (1996) 
9 Prothrombin Time (INR) 
Monitor for Home 
Anticoagulation 
Management - Patients 
with mechanical heart 
valves that meet specific 
criteria 
2001 E Dominant Other Germany Völler H et al. 
(2001) 
10 Cardiac rehabilitation 
programs - Acute 
Myocardial Infarction 
2006 C Dominant QALY USA Yu C et al. 
(2004) 
11 Cardiac rehabilitation 
programs - Percutaneous 
2006 C Dominant QALY USA Yu C et al. 
   
 201
No. Technology - Coverage 
decision 
Year Ranking 
of  
evidence 
ICER (US$) Outcome 
measure* 
Study 
country 
Reference: 
Transluminal Coronary 
Angioplasty 
(2004) 
12 Positron Emission 
Tomography (FDG) for 
Breast Cancer - Detection 
of Locoregional 
Recurrence or Distant 
Metastasis/Recurrence 
(Staging and Restaging) 
2002 E Dominant Other Canada Sloka JS et al. 
(2005) 
13 Positron Emission 
Tomography (FDG) for 
Myocardial Viability - PET 
as a primary or initial 
diagnostic study 
2002 E Dominant Other Australia Miles KA (2001) 
14 Intravenous Immune 
Globulin for Autoimmune 
Mucocutaneous Blistering 
Diseases - Pemphigus 
Vulgaris 
2002 C Dominant Other USA Daoud YJ (2006) 
15 Intravenous Immune 
Globulin for Autoimmune 
Mucocutaneous Blistering 
Diseases - Bullous 
Pemphigoid 
2002 C Dominant Other USA Daoud YJ (2006) 
16 Intravenous Immune 
Globulin for Autoimmune 
Mucocutaneous Blistering 
Diseases - Mucous 
Membrane Pemphigoid  
2002 C Dominant Other USA Daoud YJ (2006) 
17 Magnetic Resonance 
Angiography of the 
Abdomen and Pelvis - 
Imaging the renal arteries 
and the aortoiliac arteries 
when using MRA is 
expected to avoid 
obtaining contrast 
angiography 
2003 C Dominant Other USA Levy MM et al. 
(1998)  
18 Positron Emission 
Tomography (N-13 
Ammonia) for Myocardial 
Perfusion - Diagnosis of 
myocardial perfusion 
2003 E Dominant Other Switzerland Siegrist PT et al. 
(2007) 
19 Smoking & Tobacco Use 2005 A Dominant Other USA CMS Decision 
Memo (CAG-
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No. Technology - Coverage 
decision 
Year Ranking 
of  
evidence 
ICER (US$) Outcome 
measure* 
Study 
country 
Reference: 
Cessation Counseling 00241N)  
20 Screening Immunoassay 
Fecal-Occult Blood Test 
(Hemoccult II  FOBT) 
2003 A $1,072 Life years USA Report to the 
Agency for 
Healthcare 
Research and 
Quality (2003) 
21 Positron Emission 
Tomography - Head and 
Neck Cancers 
2000 C $2,395 QALY USA Hollenbeak CS 
et al. (2001)  
22 Continuous Positive 
Airway Pressure (CPAP) 
Therapy for Obstructive 
Sleep Apnea (OSA)   
2001 C $3,079 QALY USA Ayas NT et al, 
(2006)  
23 Hyperbaric Oxygen 
Therapy - Diabetic 
Wounds of the Lower 
Extremities that fit 
specified criteria 
2002 C $5,409 QALY USA Guo S et al. 
(2003)  
24 Cochlear implantation - 
Post lingually hearing 
impaired patients 
2005 C $10,729 QALY USA Francis HW et 
al. (2002)  
25 Cochlear implantation - 
Pre lingually hearing-
impaired patients  
2005 C $10,953 QALY USA Francis HW et 
al. (2002)  
26 Bariatric Surgery for the 
Treatment of Morbid 
Obesity - Open Roux-en-Y 
gastric bypass (RYGBP) 
2006 E $12,733 QALY UK Clegg A et al. 
(2003)  
27 Bariatric Surgery for the 
Treatment of Morbid 
Obesity - Laparoscopic 
adjustable gastric banding 
(LAGB) 
2006 E $17,264 QALY UK Clegg A et al. 
(2003)  
28 Erythropoiesis Stimulating 
Agents (ESAs) for non-
renal disease indications - 
Treatment of 
chemotherapy induced 
anaemia for patients who 
meet specified criteria 
2007 E $18,713 QALY UK Martin SC et al. 
(2003)  
29 Screening Immunoassay 
Fecal-Occult Blood Test 
2003 A $21,001 Life years USA Report to the 
Agency for 
Healthcare 
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No. Technology - Coverage 
decision 
Year Ranking 
of  
evidence 
ICER (US$) Outcome 
measure* 
Study 
country 
Reference: 
(iFOBT) Research and 
Quality (2003)  
30 Autologous Stem Cell 
Transplantation (AuSCT) 
for Multiple Myeloma - 
Treatment of multiple 
myeloma for patients who 
meet certain conditions 
2000 C $27,687 Life years USA Trippoli S et al. 
(1998)  
31 Implantable Cardioverter 
Defibrillators (ICDs) - 
Documented sustained 
ventricular 
tachyarrhythmia 
2003 C $36,396 Life years USA Mushlin AI et al. 
(1998)  
32 Deep Brain Stimulation for 
Parkinson's Disease (PD) - 
PD patients that meet 
specified criteria 
2003 C $55,826 QALY USA Tomaszewski et 
al. (2001)  
33 Microvolt T-wave 
Alternans - diagnostic 
testing for patients at risk 
of sudden cardiac death 
when the spectral analytic 
method is used 
2007 C $55,126 QALY USA Chan PS et al. 
(2006) 
34 Positron Emission 
Tomography - Esophageal 
Cancer 
2000 C $60,544 QALY USA Wallace MB et 
al. (2002)  
35 Implantable Defibrillators 
2 - NIDCM, documented 
prior MI, Class II and III 
heart failure 
2005 C $70,200 QALY USA Sanders G et al. 
(2005) 
36 Implantable Cardioverter 
Defibrillators (ICDs) - 
Documented familial or 
inherited conditions with a 
high risk of ventricular 
tachyarrhythmias 
2003 C $84,439 Life years USA Larsen G et al, 
(2002)  
37 Pancreas Transplants - 
Patients that meet the 
specified criteria (type 1 
diabetes etc) 
2007 C $90,159 QALY USA Kiberd BA et al. 
(2000)  
38 Ultrasound Stimulation for 
Nonunion Fracture Healing 
- Tibial 
2005 D $94,848 QALY Australia MSAC 
application 1030 
2001)  
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No. Technology - Coverage 
decision 
Year Ranking 
of  
evidence 
ICER (US$) Outcome 
measure* 
Study 
country 
Reference: 
39 Aprepitant for 
Chemotherapy-Induced 
Emesis - For use following 
specified chemotherapies 
2005 C $97,429 QALY USA Moore S et al. 
(2007)  
40 Liver transplantation in 
patients suffering from 
hepatitis B 
1999 C $145,749 QALY USA Dan YY et al. 
(2006)  
41 Ocular Photodynamic 
Therapy with Verteporfin 
for Macular Degeneration - 
Predominately classic 
subfoveal CNV lesions 
2004 D $172,770 QALY UK Meads et al. 
(2002) 
42 Lung Volume Reduction 
Surgery - Severe upper 
lobe emphysema 
2003 C $175,790 QALY USA Ramsey et al. 
(2003)  
43 Transmyocardial 
revascularisation for 
Severe Angina - Patients 
with severe angina (stable 
or unstable), refractory to 
standard medical therapy. 
1998 E $337,568 QALY UK Campbell HE et 
al. (2001)  
44 Lung Volume Reduction 
Surgery - Non high risk 
patients suffering from 
non-upper lobe 
emphysema with low 
exercise capacity 
2003 C $343,259 QALY USA Ramsey et al. 
(2003)  
45 Ultrasound Stimulation for 
Nonunion Fracture Healing 
- Radius 
2005 D $446,384 QALY Australia MSAC 
application 1030 
(2001)  
46 Ultrasound Stimulation for 
Nonunion Fracture Healing 
- Scaphoid 
2005 D $570,379 QALY Australia MSAC 
application 1030 
(2001) 
47 Insulin Infusion Pump - 
Type 1 diabetic patients 
1999 D $511,683 QALY UK Colquitt et al. 
(2004)  
48 Ventricular Assist Devices 
as Destination Therapy - 
Chronic end-stage heart 
failure patients that meet 
specified criteria 
2003 C $834,924 QALY USA Samson D 
(2004)  
* QALY = Quality Adjusted Life Year; Life years = Life years gained; Other = Study-specific 
clinical outcome 
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Table 16. Non-coverage decisions associated with an estimate of cost-effectiveness 
No. Technology - Coverage 
decision 
Year Ranking 
of 
evidence 
ICER Outcome 
measure* 
Study 
country 
Reference: 
1 Positron Emission 
Tomography (FDG) for 
Breast Cancer - Initial 
Staging of Axillary 
Lymph Nodes 
2002 E Dominant Other Australia Miles KA 
(2001)  
2 Warm-Up Wound 
Therapy aka Noncontact 
Normothermic Wound 
Therapy (NNWT) 
2002 C Dominant QALY USA Macario A et al. 
(2002)  
3 Positron Emission 
Tomography (FDG) for 
Brain, Cervical, Ovarian, 
Pancreatic, Small Cell 
Lung, and Testicular 
Cancers - Ovarian cancer 
2005 C Dominant Other USA Smith GT et al. 
(1999)  
4 External 
Counterpulsation (ECP) 
Therapy 
2006 B $3,126 QALY USA (Varricchione 
2006) 
5 Electrical Bioimpedance 
for Cardiac Output 
Monitoring 
2006 B $6,137 QALY USA CMS Decision 
memo – (CAG-
00001R2)  
6 Bariatric Surgery for the 
Treatment of Morbid 
Obesity - BMI of 50 and 
no comorbidites 
2006 C $11,524 QALY USA Craig BM et al. 
(2002)  
7 Lumbar Artificial Disc 
Replacement 
2007 D $16,957 QALY Australia MSAC 
application 
1090 (2000)  
8 Acupuncture - 
Osteoarthritis 
2003 E $17,249 QALY Germany Reinhold et al. 
(2007) 
9 Bariatric Surgery for the 
Treatment of Morbid 
Obesity - Stated 
treatments indicated for 
obesity alone BMI of 40 
2006 C $31,861 QALY USA Craig BM et al. 
(2002)  
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No. Technology - Coverage 
decision 
Year Ranking 
of 
evidence 
ICER Outcome 
measure* 
Study 
country 
Reference: 
10 Diabetic Peripheral 
Neuropathy with Loss of 
Protective Sensation - 
Coverage for diabetics 
without loss of protective 
sensation) 
2001 E $187,472 QALY Austria Rauner MS et 
al.  (2005)  
11 Percutaneous 
Transluminal Angioplasty 
(PTA) of the Carotid 
Artery Concurrent with 
Stenting 
2001 C Dominated Other USA Jordan WD et 
al. (1998)  
12 Lung Volume Reduction 
Surgery - High-risk 
patients suffering from 
severe emphysema 
2003 C Dominated QALY USA Ramsey et al. 
(2003)  
13 Lung Volume Reduction 
Surgery - Non high risk 
patients suffering from 
non-upper lobe 
emphysema with low 
exercise capacity 
2003 C Dominated QALY USA Ramsey et al. 
(2003) 
14 Implantable Cardioverter 
Defibrillators (ICDs) - 
Acute Myocardial 
Infarction 
2003 C Dominated QALY USA Sanders G et al. 
(2005)  
15 Implantable Cardioverter 
Defibrillators (ICDs) - 
Patients who have 
undergone a coronary 
artery bypass graft 
2003 C Dominated QALY USA Sanders G et al. 
(2005)  
16 Positron Emission 
Tomography (FDG) - For 
Alzheimer's 
Disease/Dementia 
2003 A Dominated QALY USA Matchar DB et 
al.  (2001)  
* QALY = Quality Adjusted Life Year; Life years = life years gained; Other = Study-specific 
clinical outcome 
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5.3.2. Characteristics of cost-effectiveness studies 
As described in Section 4.7.4.7, I considered cost-effectiveness studies reporting cost-per QALY 
ratios or cost-per life year gained ratios.  In addition, I considered cost-effectiveness studies 
incorporating disease-specific units when the intervention was estimated to be dominant or 
dominated.  Of the 64 cost-effectiveness studies, 40 (62.5%) reported cost-effectiveness using 
cost-per QALY ratios, 19 (29.7%) in cost-per disease-specific unit, and five (7.8%) in cost-per 
life year gained.  
 
Using the criteria described in Table 12 in Section 4.7.4.9, I graded cost-effectiveness studies 
with respect to relevance.  Four cost-effectiveness studies were classified as grade “A” evidence, 
two as grade “B,” 39 as grade “C,” six as grade “D,” and 14 as grade “E.”  The distribution with 
respect to awarded grade was qualitatively similar across positive and non-coverage decisions 
(Figure 17).   
   
Figure 17. Grading of cost-effectiveness studies 
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Of studies associated with positive coverage decisions (n=48), 33 (69%) were performed in a US 
setting; of those associated with non-coverage decisions (n=16), 12 (75%) were performed in a 
US setting.  The distribution with respect to setting was qualitatively similar across positive and 
non-coverage decisions (Figure 18). 
  
Figure 18. Country of setting of cost-effectiveness studies 
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consistent with CMS’s stated position on the use of cost-effectiveness evidence.  For 14 coverage 
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pertained to positive coverage decisions, and two to non-coverage decisions.  Of the positive 
decisions, seven were associated with a cost-effectiveness study that estimated the intervention to 
be dominant, and five with an ICER less than $30,000 per QALY/life year gained. 
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Table 17. Decision memos including discussion regarding cost-effectiveness or citation of a 
cost-effectiveness analysis  
No. Technology - Coverage decision ICER Outcome 
measure* 
Reference: 
Positive coverage decisions 
1 Cryosurgery Ablation for Prostate - Primary 
treatment for clinically localised prostate 
cancer. (Stages T1-T3) 
Dominant Other Benoit RM et al. 
(1998)  
2 Positron Emission Tomography - Lung Cancer 
(non-small cell) 
Dominant Other Valk PE et al. (1996) 
3 Positron Emission Tomography - Colorectal 
Cancer 
Dominant Other Valk PE et al. (1996)  
4 Positron Emission Tomography – Melanoma Dominant Other Valk PE et al. (1996)  
5 Cardiac rehabilitation programs - Acute 
Myocardial Infarction 
Dominant QALY Yu C et al. (2004)
6 Cardiac rehabilitation programs - Percutaneous 
Transluminal Coronary Angioplasty 
Dominant QALY Yu C et al. (2004) 
7 Smoking & Tobacco Use Cessation 
Counseling 
Dominant Other CMS Decision Memo 
(CAG-00241N) 
8 Screening Immunoassay Fecal-Occult Blood 
Test  
$1,072 Life Years Report to the Agency 
for Healthcare 
Research and Quality 
(2003)  
9 Cochlear implantation - Post lingually hearing 
impaired patients 
$10,729 QALY Francis HW et al. 
(2002)  
10 Cochlear implantation – Pre lingually hearing-
impaired patients  
$10,953 QALY Francis HW et al. 
(2002)  
11 Screening Immunoassay Fecal-Occult Blood 
Test 
$21,001 Life Years Report to the Agency 
for Healthcare 
Research and Quality 
(2003) 
12 Autologous Stem Cell Transplantation 
(AuSCT) for Multiple Myeloma - Treatment of 
multiple myeloma for patients who meet 
certain conditions 
$27,687 Life Years Trippoli S et al. 
(1998)  
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No. Technology - Coverage decision ICER Outcome 
measure* 
Reference: 
Non-coverage decisions 
1 Positron Emission Tomography (FDG) - 
Positron Emission Tomography (FDG) for 
Alzheimer's Disease/Dementia 
Dominant QALY Matchar DB et al. 
(2001) 
2 Electrical Bioimpedance for Cardiac Output 
Monitoring 
$6,137 QALY CMS Decision memo 
(CAG-00001R2)  
* QALY = Quality Adjusted Life Year; Life years = Life years gained; Other = Study-specific 
clinical outcome 
 
5.3.4. Findings – Research Objective 2 
The second objective of this research was to determine if there is a difference between positive 
and non-coverage decisions with respect to cost-effectiveness.  An overview of the findings is 
presented in Figure 19. 
 
Figure 19. Overview of findings - Cost-effectiveness of coverage decisions 
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The graphical presentation of the findings is insufficient to determine that there is a statistically 
significant difference between positive and non-coverage decisions with respect to cost-
effectiveness.  To evaluate if this was the case, a Mann Whitney U test, as described in Section 
5.2.2, was performed.  The null hypothesis was defined as there being no difference between the 
sample of positive coverage decisions and the sample of non-coverage decisions, or, more 
specifically, that the two population distributions have the same central locations.xiv  The test 
showed that there was a statistically significant difference between the cost-effectiveness of 
interventions subject to positive coverage decisions compared to those subject to non-coverage 
decisions (p<0.05), i.e., the null hypothesis was rejected.  This test was repeated when the five 
studies reporting cost-per life year gained were excluded.  The conclusion of the test remained the 
same, i.e., that there was a statistically significant difference between positive coverage decisions 
and non-coverage decisions (p<0.05) with respect to cost-effectiveness. 
                                                 
xiv In formulating the null hypothesis that the central locations of the two population distributions 
are the same, I assume that apart from any possible differences in central location, the two 
population distributions are identical (Newbold, Carlson, & Thorne 2003) 
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5.4.  Discussion 
Although CMS NCDs have been discussed in the literature, as far as I am aware this is the first 
empirical study of its kind. (Gillick 2004;Neumann, Rosen, & Weinstein 2005)  The research 
described in this chapter provides important insights into the relationship between CMS NCDs 
and cost-effectiveness evidence.  
 
5.4.1. Cost-effectiveness evidence featuring in decision memos 
Given CMS’s stated position on the use of cost-effectiveness evidence, my expectation was that 
few, if any, decisions memos would include an indication that CMS had considered cost-
effectiveness evidence in their review.  It was somewhat surprising that for 14 coverage decisions, 
estimates of cost-effectiveness originated from the decision memo (Table 17). The discussion of 
cost-effectiveness evidence or citation of a cost-effectiveness study pertained to a positive 
coverage decision and non-coverage decision in 12 and two of these instances, respectively.  
 
Of the positive coverage decisions, seven were estimated to be dominant.  The remaining five had 
favourable estimates of cost-effectiveness with the highest ICER $27,161 per life year gained.  
Two decision memos that feature a particularly comprehensive review and discussion of cost-
effectiveness evidence refer to screening immunoassay fecal-occult blood test and smoking 
cessation counselling. (CMS 2003b;CMS 2005e)  The decision memo for screening immunoassay 
fecal-occult blood test included a detailed account of the cost-effectiveness of the intervention.  
Incremental cost-effectiveness ratios were presented, e.g., “Hemoccult II® at $4.50 had a cost-
effectiveness ratio of $1,071 per life year gained.” (CMS 2003b) 
 
 In the decision memo for smoking and tobacco use cessation counselling, estimates of the cost, 
cost-effectiveness, and resultant savings associated with the intervention are presented as follows:  
“Evidence suggests that smoking cessation interventions are highly cost-effective when 
 compared with other medical treatments and prevention programs…. The average annual 
 Medicare cost would be $11.2 million, with a ten-year Medicare cost of $112 million. The 
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 ten-year Medicare savings would be $75 million, with a ten-year non-Medicare savings of 
 $62 million. Over this time, the combined savings to Medicare, state government 
 healthcare programs, third party payers, and to health consumer’s out-of-pocket costs, the 
 total savings of the benefit would exceed the costs.” (CMS 2005e) 
 
The two non-coverage decisions for which the decision memo contained an estimate of cost-
effectiveness were electrical bioimpedance for cardiac output monitoring (estimated ICER of 
$6,341 per QALY gained) and PET for Alzheimer’s disease/dementia (estimated to be dominant).  
In the decision memo for electrical bioimpedance for cardiac output monitoring, it is stated that 
the manufacturer submitted a cost-effectiveness study to CMS. (CMS 2006c)  However, CMS 
excluded this study from their review and in response to its submission CMS stated, “CMS does 
not consider cost in making NCDs”.  In the decision memo for PET for Alzheimer's 
disease/dementia, it states that CMS reviewed and made a then unpublished cost-effectiveness 
study by Silverman et al. available to the Medicare Evidence Development and Coverage 
Advisory Committee (MEDCAC) convened for the NCD. (CMS 2003a)  The now-published 
study is a reformulated analysis of a previously published cost-effectiveness analysis by the same 
author. It estimates the use of PET in the early evaluation of dementia patients to increase 
diagnostic accuracy and reduce the need for nursing home care and unnecessary drug therapy. 
(Silverman et al. 2002;Silverman et al. 2003)  However, these findings are in contrast to a 
technology assessment (TA) commissioned by CMS for the same NCD, which concluded that 
using PET in the early evaluation of dementia patients actually decreased aggregate QALYs while 
increasing costs compared to standard care, i.e., it was a dominated strategy.  The findings of the 
commissioned TA were included in the database in preference to Silverman et al. (2003).   
 
Each decision memo that included discussion of cost-effectiveness evidence or citation of a cost-
effectiveness study was re-reviewed to better understand the extent that cost-effectiveness 
evidence informed the NCD.  It was consistently the case that coverage decisions appeared to be 
guided predominantly by the clinical evidence and that the cost-effectiveness evidence did not 
appear to have a particularly influential role.  Despite this, it is perhaps telling that of the 14 
coverage decisions for which the estimate of cost-effectiveness originated in the decision memo, 
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12 pertained to positive coverage decisions and only two to non-coverage decisions.  It is possible 
that rather than helping inform the coverage decision, the presentation of cost-effectiveness 
evidence for positive coverage decisions was to justify or support the coverage decision that was 
based predominantly on clinical evidence.  
 
On occasion, although cost-effectiveness evidence did not explicitly feature in the decision 
memo, the concept of cost-effectiveness appeared relevant to the coverage decision.  In one 
instance, the NCD for diabetic peripheral neuropathy with loss of protective sensation, CMS 
made two coverage decisions for the provision of foot care consistent with cost-effectiveness 
evidence. (CMS 2001)  For the first decision, positive coverage for diabetics who suffer from a 
loss of protective sensation, a cost-effectiveness study estimating foot care to be dominant was 
identified. (Ragnarson & Apelqvist 2001)  For the second decision, non-coverage for diabetics 
who have not lost protective sensation, a cost-effectiveness study was identified estimating the 
intervention to be associated with an ICER of approximately $190,000 per QALY. (Rauner, 
Heidenberger, & Pesendorfer 2005)  While the decision memo does not attribute non-coverage 
directly to cost-effectiveness evidence -- neither cost nor cost-effectiveness is discussed in the 
decision memo -- given that foot care has some degree of a clinical benefit in this population, 
evidence of relative value appears to have been considered. 
 
As noted, in CMS’s Guidance for the Public, Industry and CMS Staff it states that cost-
effectiveness is not a factor in NCDs, and in some cases decision memos are consistent with this 
stated policy. (CMS 2010e)  For example, in one decision memo it states, “From the initial 
PubMed yield, CMS then excluded abstracts, case reports, review articles, meta-analyses, cost-
effectiveness studies…”. (CMS 2010d)  On multiple occasions, CMS note that they do not 
consider cost or cost-effectiveness evidence when making NCDs. (CMS 2002b;CMS 2006b;CMS 
2006c;CMS 2006e;CMS 2007)  Further, in one case, the NCD for external counterpulsation 
(ECP) therapy, an intervention’s manufacturer submitted cost-effectiveness evidence during the 
comment period. (CMS 2006d;Varricchione 2006)  This evidence, however, did not feature in the 
decision memo.  On other occasions, CMS is inconsistent with respect to their stated policy.  For 
example, as illustrated above for the NCDs for screening immunoassay fecal-occult blood test and 
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smoking cessation counselling, cost-effectiveness evidence has been explicitly discussed in 
decision memos and appears to have played some role in coverage determinations. (CMS 
2003b;CMS 2005e) 
 
Notably, in the decision memo for screening immunoassay fecal-occult blood test, it states, “A 
ratio of $50,000 or less per life saved is often accepted by health economists as indicating that the 
intervention is ‘cost-effective’”. (CMS 2003b)  Although this valuation of a cost-effectiveness 
threshold is said to be acceptable to ‘health economists’, and not necessarily CMS, it illustrates 
CMS’s awareness of it.  Interestingly, CMS used the same language regarding the cost-
effectiveness threshold in a recent NCD (2009) for computed tomography colonography (CTC) 
for colorectal cancer. (CMS 2009b)  Reference to the cost-effectiveness threshold is qualified 
with the language that the value is often accepted by ‘health economists’ as indicating that the 
intervention is “cost-effective”.  This is consistent with the decision memo for screening 
immunoassay fecal-occult blood test.  
 
NCDs made from 1999 through 2007 were considered in this research.  As discussed in Chapter 
3, the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008 authorises CMS 
to consider cost-effectiveness evidence for preventative interventions. (MIPPA 2008)  In a 
number of recent NCDs for preventative care, CMS have justified their consideration of cost-
effectiveness evidence with the MIPPA legislation. (CMS 2009b;CMS 2009c;CMS 2011d)  
However, as these NCDs were made after 2007, they were not included in this research.  The 
MIPPA legislation is discussed further in Chapter 3. 
 
5.4.1.1 Other indications of the relevance of cost-effectiveness evidence 
The NCD for PET for Alzheimer's disease/dementia was unique among those included in the 
database as it included discussion of QALYsxv. (CMS 2003a) As noted above, as part of this NCD 
CMS commissioned a technology assessment from the Agency for Healthcare Research and 
                                                 
xv As discussed in Section 3.5.2, CMS have considered cost-utility studies in NCDs for preventative interventions in 
recent years outside the timeframe this research.  
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Quality (AHRQ).  Along with life expectancy and severe dementia-free life expectancy, QALYs 
were included as an outcome measure in the agency’s evaluation. (Matchar et al. 2001) It is 
notable, however, that, although QALYs were considered, they were not used as part of a cost-
effectiveness analysis.  Reasons why QALYs were considered in this case are not provided.  The 
NCD for PET for Alzheimer's disease/dementia sets an important precedent, suggesting that CMS 
values and is willing to use QALYs.  
 
Notably, a cost-effectiveness analysis identified through my literature search was partly funded by 
CMS.xvi  Ramsey et al. (2003) conducted a cost-effectiveness analysis of lung-volume-reduction 
surgery for patients with severe emphysema. (Ramsey et al. 2003)  The findings of this study are 
not, however, presented in the decision memo for lung volume reduction surgery. 
 
5.4.2. Statistically significant difference between positive and non-coverage decisions with 
respect to cost-effectiveness  
Between positive coverage decisions and non-coverage decisions, the results of the Mann 
Whitney U test described above (Section 5.3.4) show a statistically significant difference with 
respect to cost-effectiveness, suggesting that interventions subject to positive coverage decisions 
tend to be associated with more favourable cost-effectiveness evidence than those subject to non-
coverage decisions.  The results of the Mann Whitney U test remained the same when cost-
effectiveness studies reporting cost-per life year gained ratios were included in the dataset.  There 
does not appear, however, to be an upper bound on the value of acceptable cost-effectiveness, i.e., 
a fixed cost-effectiveness threshold.  The highest ICER associated with a non-coverage decision 
was approximately $190,000 per QALY, for foot care for diabetics who have lost protective 
sensation in their feet.  However, six positive coverage decisions were associated with an ICER 
greater than this value, with the highest approximately $835,000 per QALY, for ventricular assist 
devices as destination therapy for chronic end-stage heart failure patients.   
 
                                                 
xvi The cost-effectiveness study performed by the National Emphysema Treatment Trial Research Group was 
supported by contracts with the National Heart, Lung, and Blood Institute, the Centers for Medicare and Medicaid 
Services, and the Agency for Healthcare Research and Quality. 
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It is apparent that CMS covers a number of interventions that do not appear cost-effective by 
traditional standards.  Seventeen interventions subject to positive coverage decisions are 
associated with an ICER greater than $50,000 per QALY, nine of which are greater than 
$100,000 per QALY, and three of which are greater than $500,000 per QALY.  Notably, often 
within positive coverage decisions for interventions with high estimates of cost-effectiveness, the 
language used in the decision memo suggested that the CMS had been aware of the economic 
implications of the coverage decision.  For example, within the decision memos for insulin 
infusion pumps for diabetic patients (ICER of $558,522) and ventricular assist devices as 
destination therapy in chronic end-stage heart failure patients (ICER of $820,967), CMS note the 
high cost of the technology. (CMS 1999b;CMS 2003c) 
 
5.4.3. Challenges and limitations 
Identifying cost-effectiveness studies relevant to the coverage decisions was challenging.  In 
contrast to the studies reviewed in Section 4.5.1, estimates of cost–effectiveness were not readily 
available from the regulatory agency’s published documentation, in this case from decision 
memos.  Of the 64 cost-effectiveness studies included in this review, only 14 (22%) originated 
from the decision memo, with the remainder identified from literature searches.   
 
Of the 103 NCDs included in this research, 43 (42%) included at least one coverage decision for 
which a relevant cost-effectiveness study was identified.  Of the total sample of 255 coverage 
decisions, a relevant cost-effectiveness estimate was available for 64 (25%).  Given the proportion 
of coverage decisions for which a relevant cost-effectiveness estimate was unavailable, there is a 
possibility that those associated with a cost-effectiveness estimate are unrepresentative of the 
overall sample.  Of positive coverage decisions (n=123), 48 (39%) were associated with a cost-
effectiveness estimate.  Of non-coverage decisions (n=132), 16 (12%) were associated with a 
cost-effectiveness estimate, noticeably less than for positive coverage decisions.  This was not 
entirely unexpected as typically the volume of supporting literature reviewed in the decision 
memo was much greater for positive coverage decisions than for non-coverage decisions.  Also, 
evidence suggests that there is bias towards the publication of favourable cost-effectiveness 
estimates that, if CMS NCDs are consistent with the clinical evidence, may increase the 
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likelihood of a cost-effectiveness study being available for positive coverage decisions. (Bell et al. 
2006)  
 
Of the 64 cost-effectiveness studies, 40 (62.5%) reported cost-effectiveness using cost-per QALY 
gained ratios, 19 (29.7%) using cost-per disease-specific unit, and five (7.8%) using cost-per life 
year gained ratios.  The five cost-effectiveness studies reporting the ICER in terms of cost-per life 
year reported positive ICERs ranging from $1,072 to $84,439 (Table 15).  In some instances, 
adjusting survival gain with quality of life will decrease the magnitude of the denominator of the 
ICER equation, causing estimates of cost-effectiveness to be higher when reporting cost-per 
QALY gained as opposed to a cost-per life year gained ratios.  Although not directly comparable, 
cost-effectiveness studies reporting cost-per life year gained ratios were considered along with 
those reporting cost-per QALY ratios to maximise the quantity of cost-effectiveness evidence 
available for this research.  For the second research objective, the effect of excluding cost-
effectiveness studies reporting cost-per life year gained ratios from the sample was observed.  
Consistent with the findings when studies reporting cost-per life year gained ratios were included, 
there was a statistically significant difference (p<0.05) between positive coverage decisions and 
non-coverage decisions with respect to cost-effectiveness.  
 
Although care was taken to ensure that included estimates of cost-effectiveness were high quality 
and representative of the coverage decision, it was inevitable that there would be some degree of 
variability among them.  For example, while the majority of cost-effectiveness analyses identified 
were cost-utility analyses, there was variability between them in how the utility weights were 
calculated.  Utilities can be measured either directly (e.g., Standard Gamble [SG] and Time-Trade 
Off [TTO]) or indirectly (e.g., EuroQol [EQ-5D] and Health Utility Index [HUI]). The method of 
elicitation will affect their valuation. (Brazier 2008)  Research has shown, however, that 
adjustment of the quality of the utility estimate often does not substantially alter cost-
effectiveness estimates. (Chapman et al. 2004)  Another source of variation among the included 
cost-effectiveness analyses was with respect to funding source.  Evidence suggests that cost-
effectiveness studies funded by the pharmaceutical and medical device industry are more likely to 
report ICERs below accepted thresholds. (Bell et al. 2006)  Although priority was given to non-
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industry-funded studies, it was not possible to find a non-industry-funded cost-effectiveness 
analysis for each coverage decision. 
 
It is possible that, on occasion, CMS considered the intervention to be more or less effective or 
costly than the inputs used in the corresponding cost-effectiveness analysis.  This is illustrated in 
the example noted above for PET for Alzheimer’s disease/dementia.  In this instance, while a 
cost-effectiveness study (Silverman et al. (2003)) estimated the intervention to be dominant, the 
technology assessment commissioned by CMS estimated the intervention to be dominated. (CMS 
2003a;Matchar et al. 2001;Silverman et al. 2003)  Nevertheless, in the absence of CMS routinely 
performing cost-effectiveness studies as part of NCDs, relying on the peer-reviewed literature is a 
practical and manageable approach. 
 
5.4.4. Next Steps 
Future research can build upon the approach used here.  I considered NCDs made from 1999 
through 2007, and it is possible that updating the research to include subsequent NCDs would 
increase the number of coverage decisions associated with a relevant estimate of cost-
effectiveness.  Notably, as discussed in Section 3.5.2, since 2007 CMS have often considered 
cost-effectiveness evidence in their evaluation of preventative interventions.  Expanding the 
research to include these additional NCDs may allow a comparison between the preventative and 
non-preventative interventions with respect to cost-effectiveness. 
 
This research was limited to the Medicare programme.  It would be valuable to expand the scope 
to include a broader range of public and private payers.  For example, as described in Section 
3.3.2.3, the health care programmes in the Department of Defense (DoD) and U.S. Department of 
Veterans Affairs (VA) state that economic factors are considered when evaluating interventions.  
A comparison between these agencies with respect to the cost-effectiveness of coverage decisions 
would prove insightful.  As private health care represents the majority of the US health care 
system, expanding this research to consider private payers would also be of interest.  As discussed 
in Section 3.3.2.3, private payers such as Wellpoint, one of the largest private health insurance 
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companies, has issued guidelines providing a framework for the submission of cost-effectiveness 
evidence, and thus may represent a useful starting point for such research.   
 
While NCDs could be considered the most important of CMS’s coverage determinations, local 
coverage policies, or local coverage determinations (LCDs), made in the absence of a national 
coverage policy by MACs represent the majority of Medicare coverage decisions. (CMS 
2010b;Foote, Halpern, & Wholey 2005) To more completely understand the cost-effectiveness of 
CMS’s coverage decisions, this research could be expanded to consider LCDs.  
 
As noted above, one limitation of this research is the relatively small proportion of coverage 
determinations for which it was possible to identify a relevant cost-effectiveness estimate.  One 
approach to get around the limitations of the cost-effectiveness literature would be to gain input 
from clinicians, health economists, and other health services researchers.  Using an expert panel 
to make judgements with respect to the cost-effectiveness of interventions for which the available 
cost-effectiveness literature proved insufficient, while not ideal, would be one potential approach.   
 
Cost-effectiveness is only one economic parameter of potential relevance to CMS.  This analysis 
does not account for the budget impact of the intervention, which may have factored into 
decisions.  It is possible that cost-ineffective interventions are more likely to receive a positive 
coverage decision if they are associated with a relatively small budget impact.  Also, I did not 
consider reimbursement decisions, which may, in addition to coverage, have an important effect 
on actual use of a technology, i.e., despite a positive coverage decision, the mode of 
reimbursement could provide an incentive or disincentive for a physician to prescribe an 
intervention or for a hospital to offer it. (Neumann, Rosen, & Weinstein 2005) 
 
5.4.5. Policy relevance 
Given the current financial difficulties faced by the US health care system, and specifically the 
Medicare programme, this research is timely and relevant.  It provides an insight into the value of 
many interventions offered by Medicare and the relationship between NCDs and cost-
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effectiveness evidence.  Importantly, however, this research highlights the lack of knowledge 
regarding the value of many of the interventions offered by Medicare.  Therefore, this research 
identifies a potential research agenda to better understand the value of interventions offered by the 
Medicare programme.  Highlighted in this research are a number of interventions offered in the 
Medicare programme that are not cost-effective by traditional standards.  Offering these 
interventions generates relatively little health gain for the expenditure and suggests that resources 
could provide greater benefits if directed towards alternative interventions.  
 
This research highlights CMS’s experience with cost-effectiveness evidence.  CMS has helped 
fund a cost-effectiveness study and has used ‘tools’ of cost-effectiveness analysis, e.g., QALYs, 
to inform NCDs.  Further, discussion of a cost-effectiveness threshold suggests an awareness of 
the magnitude of cost-effectiveness ratios that are generally considered to be indicative of value.  
Therefore, despite CMS’s stated position on the use of cost-effectiveness evidence, this research 
suggests that CMS has considered such evidence worthy of review on occasion. 
 
It is notable that there is a statistically significant difference between positive coverage decisions 
and non-coverage decisions with respect to cost-effectiveness, suggesting that interventions 
subject to positive coverage decisions tend to be associated with more favourable cost-
effectiveness evidence.  While this research is insufficient to suggest cost-effectiveness evidence 
is an independent factor in CMS coverage, the finding is encouraging. 
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5.4.6. Chapter summary 
As noted in Section 3.4.2.1, in their “Guidance for the Public, Industry and CMS Staff”, CMS 
state that cost-effectiveness is not a factor CMS considers in making NCDs. (CMS 2010e)  To the 
best of my knowledge, the research presented in this chapter is the first systematic attempt to 
evaluate NCDs from the perspective of cost-effectiveness. 
 
The first objective of this research was to examine NCD decision memos to identify instances 
when cost-effectiveness evidence was cited or discussed, thus assessing the consistency of CMS’s 
behaviour and its stated position on the use of cost-effectiveness evidence.  In 14 instances, the 
identified estimate of cost-effectiveness associated with a coverage decision originated from the 
decision memo.  It was notable that 12 of these occasions pertained to positive coverage 
decisions, and the estimate of cost-effectiveness was favourable in each case (maximum ICER of 
$27,161 per life year gained). 
 
The second objective of this research was to determine if there is a difference between positive 
and non-coverage decisions with respect to cost-effectiveness.  The methodological approach 
built upon the published studies reviewed in Section 4.5.1.  The findings show a statistically 
significant difference between positive coverage decisions and non-coverage decision with 
respect to their cost-effectiveness, suggesting that interventions subject to positive coverage 
decisions tend to be associated with more favourable cost-effectiveness evidence. 
 
While the findings of the research presented in this chapter show that CMS have on occasion 
considered cost-effectiveness evidence in the review of the evidence base, and that positive 
coverage decisions tend to be associated with more favourable estimates of cost-effectiveness, the 
approach taken here is insufficient to determine if cost-effectiveness, or the availability of cost-
effectiveness evidence, is an independent factor in CMS NCDs.  To evaluate this research 
question, it is necessary to account for other potentially relevant factors in the NCD process in the 
analysis.  Further, it is necessary to restrict the included cost-effectiveness evidence to only that 
available at the time of the NCD, i.e., that which CMS may realistically have had the opportunity 
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to consider.  To this end, the research in Chapter 6 presents a logistic regression analysis that 
includes the independent variables described in Section 4.7.4 to evaluate the factors relevant to 
CMS when making NCDs.   
 
This research also shows that CMS cover a number of interventions that are not cost-effective by 
traditional standards.  Coverage of cost-ineffective interventions results in a financial burden on 
the programme, while generating relatively little health gain.  Consequently, a reallocation of 
resources from cost-ineffective interventions to more cost-effective interventions will generate 
additional health gain for existing levels of expenditure.  In an attempt to quantify potential 
benefits of using cost-effectiveness evidence, a hypothetical reallocation of expenditures between 
interventions subject to CMS NCDs using a cost-effectiveness decision rule is presented in 
Chapter 7.  
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6. Empirical Research: Part 2 
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6.1. Introduction 
In Chapter 4, I provided the foundation for the empirical aspect of this thesis, including a 
background to the Medicare programme and the processes for the coverage of medical technology 
in it.  Also, I presented the objectives of the empirical work and reviewed the relevant literature 
that helped inform the methodological approach.  Lastly, I described the development of the 
database and set of variables available for this research. 
 
Chapter 5 constituted the first piece of empirical work.  This research had two objectives:  to 
identify instances when cost-effectiveness evidence was cited or discussed in CMS national 
coverage determinations (NCDs), and to determine if there is a difference between positive and 
non-coverage decisions with respect to cost-effectiveness.  With respect to the first objective, 14 
coverage decisions were identified for which cost-effectiveness evidence was cited or discussed 
in the decision memo, with 12 pertaining to positive coverage decisions and two to non-coverage 
decisions.  Notably, the estimate of cost-effectiveness in each case was favourable (maximum 
ICER of $27,161 per life year gained).  With respect to the second objective, findings show a 
statistically significant difference between positive coverage decisions and non-coverage 
decisions with respect to their cost-effectiveness, suggesting that covered interventions tend to be 
associated with more favourable cost-effectiveness evidence. 
 
The research presented in this chapter builds on Chapter 5 and constitutes my second piece of 
empirical work.  While the findings of the research presented in Chapter 5 show that CMS have 
on occasion reviewed cost-effectiveness evidence and that positive coverage decisions tend to be 
associated with more favourable estimates of cost-effectiveness, the methodological approach was 
insufficient to determine if cost-effectiveness, or the availability of cost-effectiveness evidence, is 
an independent factor in CMS NCDs.   
 
The objective of the research presented in this chapter is to determine if cost-effectiveness is an 
independent predictor of coverage, i.e., when controlling for other factors, is cost-effectiveness, or 
the availability of cost-effectiveness evidence, statistically significantly associated with coverage.   
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6.2. Objective and Methodology 
6.2.1. Objective 
The empirical work presented in this chapter has the following objective: 
1. To determine if cost-effectiveness is an independent predictor of coverage when 
controlling for other factors that may be considered to influence coverage decisions. 
 
6.2.2. Methodology 
As described in Section 4.5.1, a body of literature exists that describes the evaluation of coverage 
and reimbursement decisions, or recommendations for the efficient use of medical technology, 
made by agencies across a number of countries.  The methodological approaches taken in 
conducting these studies helped inform the research presented here.   
 
I included NCDs made from 1999 through 2007 in the dataset.  The unit of analysis was the 
coverage decision, with all coverage decisions made within NCDs considered separately.  The 
variables I considered for inclusion in this research are discussed in Section 4.7.4 and were 
chosen in an attempt to account for the key aspects of decision-making.  The final set of 
independent variables included; Quality of evidence, Alternative intervention, Cost-effectiveness, 
Type of intervention, Coverage requestor, and Date (Table 18).  Full details of the methodology 
used to generate the database are presented in Section 0. 
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Table 18.  Variables included in the analysis 
Variable Description 
Variable 
Construction Definition % of observations 
Dependent variable    
Coverage 
decision 
Outcome of the coverage 
decision. 
Dichotomous 
variable 
Positive coverage 54% 
Non-coverage 
decision 46% 
Independent variables    
Quality of 
evidence 
A review of the supporting 
clinical evidence as presented 
in the decision memo 
performed independently by 
two reviewers. 
Categorical variable 
– Categorised using 
USPSTF guidelines 
(Table 2) 
Good 53% 
Poor 10% 
Insufficient 37% 
Alternative 
intervention 
The availability of an 
alternative intervention for the 
same indication. 
Dichotomous 
variable 
Alternative available 83% 
No alternative 
available 17% 
Cost-
effectiveness 
Estimate of cost-effectiveness 
for the intervention. 
Categorical 
variable** 
No estimate 79% 
Dominates 8% 
ICER <$50k/QALY 6% 
ICER >$50k/QALY 8% 
Type of 
intervention 
The broad indication of the 
intervention. Categorical variable 
Treatment 67% 
Diagnostic test 
(includes staging/ 
screening/ 
monitoring) 
28% 
Other (including 
health education, 
preventative care, and 
mobility assistive 
equipment) 
5% 
Coverage 
requestor 
The group or individual that 
requested coverage. Categorical variable 
Manufacturer 32% 
Internally generated 37% 
Other (includes 
medical/professional 
society or 
organization) 
41% 
Date Decisions grouped into years Categorical variable 
1999-2001 22.6% 
2002-2003 36.9% 
2004-2005 14.9% 
2006-2007 25.6% 
* Percentages may not add to 100% due to rounding 
** Percentages represent those cost-effectiveness studies available at the time of the NCD 
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6.2.3. Exploratory analysis of interaction effects 
The independent variables (Table 18) were chosen as I considered them to represent factors likely 
to have an effect on coverage decisions.  Despite the relevance of the variables to various aspects 
of the coverage decision, it was important to evaluate whether there was any interaction between 
them that may influence the findings of the model.  The term “interaction” describes the instance 
when the combined effects of two variables are not a sum of their individual effects.  Interaction 
effects can have important implications for the interpretation of the findings of the statistical 
model as the changing value of one variable will have unpredictable consequences on the result of 
the model.   
 
For the included independent variables there are various sources of potential interaction.  Cost-
effectiveness is the aggregate of clinical and cost data.  Consequently, I considered it a possibility 
that interaction would exist between Cost-effectiveness and Quality of evidence.  Similarly, as 
cost-effectiveness analyses typically compare two or more competing interventions I considered it 
a possibility that interaction would exist between Cost-effectiveness and Alternative intervention.  
Also, evidence suggests that the number of cost-effectiveness studies published each year is 
increasing (Neumann PJ et al. 2005).  Therefore, I considered it a possibility that an interaction 
effect would exist between Cost-effectiveness and Date. 
 
For each possible combination of variables I included their interaction term, i.e., the product of 
the two independent variables, in a multivariate regression including all independent variables.  In 
each instance the interaction term was not significant.  Therefore, I deemed that interaction 
between independent variables did not have an important effect on the results of the model.   
 
6.2.4. Analyses 
The model was estimated using binomial logistic regression, regressing the coverage decision 
against the independent variables (Table 18).  I chose logistic regression primarily as a 
dichotomous decision output was used.  I considered a production function to be the conceptual 
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framework that best represented CMS’s decision-making process (Figure 20).  As described in 
Section 4.2.2, NCDs are guided by the ‘reasonable and necessary’ criterion, with little guidance 
provided regarding the relative importance of different decision inputs.  In a production function 
model, decision-making inputs are considered concurrently.  An alternative approach would be to 
consider decision-making as a hierarchical process.  However, greater knowledge regarding how 
CMS prioritises different decision inputs would be required to facilitate this approach.  
 
 
Figure 20. Conceptual framework - Production model of CMS decision-making 
 
For multivariate regressions, I assessed model goodness of fit using a number of statistics.  The 
pseudo R2 statistic is automatically estimated when performing a multivariate regression.  The 
closer the pseudo R2 is to 1.0, the better the model fits the data.  I also performed the Hosmer-
Lemeshow test.  This test divides observations into deciles based on predicted probabilities, and 
then computes a chi-square from observed and expected frequencies.  The null hypothesis that 
there is no difference between observed and predicted values is tested.  When the test result is 
non-significant, the null hypothesis is rejected and the model can be considered to ‘fit’ the data.  
The final test I used is the area under the receiver operating characteristic (ROC) curve, or C-
statistic.  This summary measure of predictive power plots sensitivity versus 1 - specificity.  The 
area under the ROC line is estimated, which ranges between 0.5 and 1.0, with values close to 1.0 
representing good predictive power and a high degree of goodness-of-fit. 
 
Inputs into decision 
• Clinical evidence 
• Cost-effectiveness 
evidence 
• Disease- and 
treatment-specific 
characteristics 
Decision process 
Judgment if the medical 
technology is ‘reasonable 
and necessary’ for the 
diagnosis or treatment of 
an illness or injury 
Decision output 
Positive coverage 
Non-coverage 
   
 230
I performed both univariate and multivariate regression analyses.  Following each regression, the 
predicted probability of a positive coverage decision was computed for each variable.  A 
predicted probability is the estimated probability of a positive coverage decision associated with 
each category in each independent variable while controlling for the other included variables.  In 
multivariate models, the covariates were fixed at their sample mean values to facilitate the 
calculation of this statistic.   
 
In the primary set of analyses, univariate and multivariate analyses were performed.  First, I 
performed a univariate analysis that included each independent variable (Table 19).  Next, I 
performed a multivariate analysis that included all independent variables (Table 20).  Lastly, I 
performed a second multivariate analysis that included only those variables with at least one 
significant category in the initial multivariate analysis (Table 20).   
 
In the primary analyses, I categorised the date of decision variable (Date) into groups of years 
(Table 18).  However, it was uncertain how best to code Date, and therefore I performed a set of 
analyses to evaluate the impact of alternative coding approaches on study findings.   
 
I performed a number of analyses to examine the cost-effectiveness variable (Cost-effectiveness). 
In the primary analyses, only cost-effectiveness studies available at the time of the NCD were 
included.  Further, cost-effectiveness studies reporting cost-per life years gained were included 
along with studies reporting cost-per QALY gained.  This approach assumes equivalency between 
the two metrics.  To evaluate if the inclusion of cost-per life year studies affected study findings, I 
performed univariate and multivariate regressions using a dataset excluding cost-per life year 
gained studies.  Analyses were also performed using a version of Cost-effectiveness that included 
cost-effectiveness data from studies published after the NCD (under the theory that CMS may 
have had access to unpublished data on cost-effectiveness or could have independently calculated 
cost-effectiveness in the absence of published studies).  Also, I deconstructed the cost-
effectiveness variable into the numerator and denominator of the ICER to evaluate to what extent 
incremental costs or incremental effectiveness was driving the results.  Finally, I performed a set 
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of regressions using a dataset including only coverage decisions with an associated estimate of 
cost-effectiveness.   
 
A p-value below the 5% level is regarded as statistically significant, and between 5% and 10% is 
regarded as weakly significant. Analyses were undertaken using Stata SE version 11. (Stata 2009)  
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6.3. Results 
6.3.1. Primary analyses 
6.3.1.1 Univariate analyses 
In the univariate analyses, Quality of evidence (p<0.01), Alternative intervention (p<0.01), Cost-
effectiveness (p<0.05), and Date (p<0.01) were statistically significantly associated with the 
coverage decision (Table 19).  Type of intervention and Coverage requestor were non-significant.  
For Quality of Evidence, interventions associated with good quality supporting evidence (Good), 
compared to interventions associated with insufficient evidence (Insufficient), were approaching 
seven times more likely to receive a positive coverage decision (over twice as likely when 
considering predicted probabilities).  Interventions with an available alternative were 
approximately seven times less likely to be associated with a positive coverage decision 
(approaching half as likely when considering predicted probabilities) than those without an 
available alternative.  Compared with interventions estimated to be dominant, those for which 
there was no estimate of cost-effectiveness were approximately six times less likely to be 
associated with a positive coverage decision (approaching half as likely when considering 
predicted probabilities); the categories ICER<$50k/QALY and ICER>$50k/QALY were not 
statistically significant.  Coverage decisions made after 2001 were significantly less likely to be 
associated with a positive coverage decision than those made prior to that year, with those made 
in 2006-2007 over 13 times less likely to be associated with a positive coverage decision than 
those made from 1999 through 2001 (less than half as likely when considering predicted 
probabilities). 
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Table 19. Results of univariate logistic regression   
Summary statistics 
Number of observations = 195  
Variable OR 95% CI 
Predicted 
probability 
Quality of evidence     
Good  6.678*** 3.418 13.049 0.777 
Poor 0.686 0.222 2.122 0.263 
Insufficient Reference category   0.342 
Joint significance p<0.001     
     
Alternative intervention     
No Reference category  0.879 
Yes 0.138*** 0.046 0.41 0.500 
     
Cost-effectiveness     
No estimate 0.173** 0.038 0.800 0.510 
Dominates Reference category    0.857 
ICER<$50k/QALY gained 0.444 0.060 3.285 0.727 
ICER>$50k/QALY gained 0.458 0.070 3.017 0.733 
Joint significance p=0.035      
     
Date     
1999-2001 Reference category  0.864 
2002-2003 0.176*** 0.066 0.469 0.528 
2004-2005 0.258** 0.082 0.809 0.621 
2006-2007 0.074*** 0.026 0.212 0.320 
Joint significance p<0.001     
     
Type of intervention 
Treatment  Reference category 0.557 
Diagnostic 0.856 0.453 1.615 0.519 
Other 7.151* 0.880 58.076 0.900 
Joint significance p=0.149  
  
Coverage requestor 
Manufacturer  Reference category 0.565 
Internally generated  1.106 0.557 2.194 0.589 
Other 0.882 0.432 1.800 0.533 
Joint significance p=0.813  
*p<0.1, **p<0.05, ***p<0.01 
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6.3.1.2 Multivariate analyses 
The results from the multivariate analysis when including all variables are presented in Table 20.  
This model had an adjusted pseudo R2 of 0.312, indicating room for improvement.  However, the 
C statistic is reasonably high (0.86) and the null hypothesis was rejected when using the Hosmer- 
Lemeshow goodness-of-fit test, indicating that the model fits the data reasonably well.  Quality of 
evidence (p<0.01), Alternative intervention (p<0.05), and Date (p<0.01) were significantly related 
to the coverage decision.  Although the cost-effectiveness variable was not significant (p=0.143), 
the category “No estimate” was (p<0.1).  Type of intervention and Coverage requestor were non-
significant variables.  Consistent with the univariate findings, interventions associated with good 
quality supporting evidence were estimated to be approximately six times more likely to be 
associated with a positive coverage decision compared to interventions associated with 
insufficient evidence (approximately twice as likely when considering predicted probabilities).  
Interventions with an available alternative were seven times less likely to be associated with a 
positive coverage decision than those without an alternative intervention available (approximately 
two-thirds as likely when considering predicted probabilities).  With respect to Cost-effectiveness, 
interventions not associated with an estimate of cost-effectiveness were almost six times less 
likely to be associated with a positive coverage decision compared with those estimated to be 
dominant (approaching half as likely when considering predicted probabilities); the categories 
ICER<$50k/QALY and ICER>$50k/QALY were not statistically significant.  Coverage decisions 
made after 2001 were significantly less likely to be associated with a positive coverage decision 
than those made prior to that year, with those made from 2006 through 2007 approximately 10 
times less likely to be associated with a positive coverage decision than those made from 1999 
through 2001 (approaching half as likely when considering predicted probabilities). 
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Table 20. Results of multivariate logistic regression 
  
Multivariate logistic regression including all 
variables 
Multivariate logistic regression including 
those variables identified as significant  
  Summary statistics Summary statistics     
  Pseudo R2 = 0.312 Pseudo R2 = 0.304 
  Number of observations = 195 Number of observations = 195 
  Area under ROC curve = 0.858 Area under ROC curve = 0.850 
 Hosmer-Lemeshow goodness-of-fit = 0.137 Hosmer-Lemeshow goodness-of-fit test = 0.421 
Variable Adj. OR 95% CI Predicted probability Adj. OR 95% CI 
Predicted 
probability 
Quality of evidence 
Good  5.900*** 2.602 13.354 0.715 6.040*** 2.762 13.209 0.715 
Poor 1.218 0.300 4.951 0.424 1.423 0.367 5.522 0.445 
Insufficient Reference category  0.389 Reference category  0.381 
 Joint significance p<0.01  Joint significance p<0.01 
  
Alternative intervention 
No Reference    0.809 Reference    0.823 
Yes 0.147** 0.031 0.686 0.521 0.130*** 0.035 0.483 0.515 
                  
Cost-effectiveness 
No estimate 0.185* 0.032 1.085 0.529 0.190* 0.035 1.024 0.527 
Dominates Reference category  0.781 Reference category  0.779 
ICER<$50k/QALY gained 0.653 0.052 8.159 0.724 0.646 0.055 7.589 0.719 
ICER>$50k/QALY gained 0.319 0.035 2.893 0.616 0.375 0.046 3.021 0.637 
 Joint significance p=0.143 Joint significance p=0.110 
 
Date 
1999-2001 Reference category  0.761 Reference category  0.765 
2002-2003 0.334* 0.110 1.018 0.578 0.311** 0.103 0.937 0.569 
2004-2005 0.324* 0.085 1.228 0.572 0.310* 0.084 1.144 0.569 
2006-2007 0.101*** 0.024 0.375 0.365 0.109*** 0.031 0.383 0.380 
 Joint significance p<0.01 Joint significance p<0.01 
         
Type of intervention        
Treatment Reference category  0.575       
Diagnostic 0.759 0.328 1.754 0.532       
Other 1.676 0.117 24.014 0.653       
 Joint significance p=0.744       
       
Coverage requestor       
Manufacturer Reference category  0.572     
Internally generated  1.156 0.434 3.074 0.594     
Other 0.721 0.270 1.927 0.522     
 Joint significance p=0.610         
*p<0.1, **p<0.05, ***p<0.01 
 
Comparing the results of the univariate and multivariate analyses suggests that there may be some 
degree of collinearity in the model.  In the univariate logistic regression results for Type of 
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intervention, the Other category had an odds ratio (OR) of 7.15 (95% CI 0.880 – 58.076).  
However, in the multivariate analysis the OR dropped to 1.68 (0.117 – 24.014), suggesting that 
collinearity may be causing the change.  To investigate the possibility that two or more of the 
predictors were non-significant because of collinearity, a number of diagnostic tests were 
performed.  First, various specifications of the model were tested.  Dropping individual variables 
from the model did not produce a noticeable shift in the results, consistent with the presence of 
collinearity.  Coding the variables differently (e.g., coding Date as a continuous variable) also did 
not have a noticeable effect on the results.  The Variance Inflation Factor (VIF) was calculated for 
each coefficient following each multivariate regression.  The VIF provides an estimate of how 
much of the variance of the coefficient estimate is being inflated by multicollinearity.  A 
commonly used rule of thumb is that VIFs≥10 may be a reason for concern and suggest that 
multicollinearity is a problem. (O'Brien 2007)  Following a multivariate regression, the VIFs were 
calculated and none were approaching a value of 10.  Finally, following a multivariate regression 
the correlations of the estimated coefficients were evaluated.  A high correlation (0.8 or higher) 
between pairs of coefficients indicates that problematic collinearity may exist. (Grewal, Cote, & 
Baumgartner 2004)  No high correlations between any pairs of coefficients were identified.  An 
additional method of determining the presence of multicollinearity is to include different samples 
in the dataset and observe any large changes in the results of the model.  However, given the 
limited size of the dataset, it was not possible to use this method.  The tests described above 
suggest that despite the rather large difference in the magnitude of the OR for the category Other 
in Type of intervention between the univariate and multivariate analyses, multicollinearity is not 
problematic.  Nevertheless, the impact of simply dropping Type of intervention from the analysis 
was evaluated.  Compared to the multivariate logistic regression including Type of intervention, 
excluding this variable did not have a notable effect on the results. 
 
When considering a model that included only variables in which at least one category was 
statistically significant, the model had a pseudo R2 of 0.304, indicating room for improvement.  
However, the C statistic is reasonably high (0.850) and the null hypothesis was rejected when 
using the Hosmer- Lemeshow goodness-of-fit test, indicating that the model fits the data 
reasonably well.  Quality of evidence (p<0.01), Alternative intervention (p<0.01), and Date 
(p<0.01) were significantly associated with the coverage decision.  Although Cost-effectiveness 
   
 237
was not significant (p=0.110), the category No estimate was (p<0.1).  Interventions associated 
with good quality supporting evidence were six times more likely to receive a positive coverage 
decision compared with those associated with insufficient evidence (approximately twice as likely 
when considering predicted probabilities).  Compared to interventions with no available 
alternative, those that had an available alternative were approximately eight times less likely to be 
associated with a positive coverage decision (approaching half as likely when considering 
predicted probabilities).  Compared with interventions estimated to be dominant, those with no 
associated estimate of cost-effectiveness were approximately five times less likely to receive a 
positive coverage decision (approximately two thirds as likely when considering predicted 
probabilities); the categories ICER<$50k/QALY and ICER>$50k/QALY were not statistically 
significant.  Each of the categories in Date was significant.  Interventions considered in more 
recent time periods were increasingly less likely to be associated with a positive coverage 
decision.  Coverage decisions made from 2006 through 2007 were approximately 10 times less 
likely to be associated with a positive coverage decision than those made from 1999 through 2001 
(half as likely when considering predicted probabilities).   
 
6.3.2. Controlling for multiple coverage decisions from a single decision memo 
It was often the case that multiple coverage decisions were made in a single NCD.  It may be the 
case that coverage decisions made in the same NCD are not independent as they are made using 
similar or related evidence and by the same committee.  In order to control for this potential 
relationship, univariate and multivariate regressions were performed using cluster analysis, i.e., 
the estimated standard errors were adjusted for within-decision memo clustering of decisions 
(Table 21 and Table 22).  To perform a cluster analysis, observations are assigned to a particular 
subset in which it there may be some similarity between decisions.  In this case, coverage 
decisions were clustered with respect to the NCD in which they were made.  Clustering 
observations does not have an effect on estimated OR or predicted probabilities, but it does affect 
the estimated 95% CI and the statistical significance.  The findings from the cluster analyses did 
not vary greatly from the findings of the models when observations were unclustered.  A notable 
change in the univariate analysis was that Type of intervention was statistically significant 
(p<0.01) which was not the case in the unclustered analysis.  In the multivariate clustered 
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analysis, a noticeable change from the unclustered analysis was that in Date, 2002-2003 
(p=0.143) and 2004-2005 (p=0.152) were non-significant.  Also, Cost-effectiveness was jointly 
significant (p<0.1), which was not the case in the unclustered analysis. 
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Table 21. Univariate regression clustering sub-decisions from the same decision memo 
Summary statistics 
Number of observations = 195  
Independent variable  OR 95% CI Predicted probability 
Quality of evidence     
Good  6.678*** 2.330 19.138 0.777 
Poor 0.686 0.134 4.524 0.263 
Insufficient Reference category 0.342 
Joint significance p<0.01     
     
Alternative intervention     
No Reference category 0.879 
Yes 0.138*** 0.053 0.357 0.500 
     
Cost-effectiveness     
No estimate 0.173** 0.037 0.843 0.510 
Dominates Reference category 0.857 
ICER<$50,000/QALY gained 0.444 0.056 3.546 0.727 
ICER>$50,000/QALY gained 0.458 0.064 3.297 0.733 
Joint significance p<0.1      
     
Date     
1999-2001 Reference category 0.864 
2002-2003 0.176*** 0.053 0.590 0.528 
2004-2005 0.258* 0.058 1.158 0.621 
2006-2007 0.074*** 0.019 0.287 0.320 
Joint significance p<0.01    
     
Type of intervention 
Treatment Reference category 0.557 
Diagnostic 0.856 0.304 2.407 0.519 
Other 7.151*** 2.759 18.535 0.900 
Joint significance p<0.01  
  
Coverage requestor 
Manufacturer Reference category 0.565 
Internally generated  1.106 0.370 3.300 0.589 
Other 0.882 0.274 2.832 0.533 
Joint significance p=0.926  
*p<0.1, **p<0.05, ***p<0.01 
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Table 22. Multivariate regression clustering sub-decisions from the same decision memo  
  
Multivariate logistic regression including all 
variables 
Multivariate logistic regression including 
those variables identified as significant  
  Summary statistics Summary statistics     
  Pseudo R2 = 0.312 Pseudo R2 = 0.305 
  Number of observations = 195 Number of observations = 195 
  Area under ROC curve = 0.858 Area under ROC curve = 0.850 
 Hosmer-Lemeshow goodness-of-fit test = 0.137 Hosmer-Lemeshow goodness-of-fit test = 0.421 
Independent variable Adj. OR 95% CI Predicted probability Adj. OR 95% CI 
Predicted 
probability 
Quality of evidence 
Good  5.900*** 1.819 19.102 0.715 6.040*** 1.825 19.987 0.715 
Poor 1.218 0.182 8.142 0.424 1.423 0.239 8.459 0.445 
Insufficient Reference category 0.389 Reference category 0.381 
 Joint significance p<0.05  Joint significance p<0.05  
  
Alternative intervention 
No Reference 0.809 Reference category 0.8233 
Yes 0.147** 0.036 0.601 0.521 0.130*** 0.042 0.404 0.515 
                  
Cost-effectiveness 
No estimate 0.185** 0.037 0.933 0.529 0.190* 0.045 0.803 0.527 
Dominates Reference category 0.781 Reference category 0.779 
ICER<$50,000/QALY 
gained 0.653 0.104 4.123 0.724 0.646 0.115 3.631 0.719 
ICER>$50,000/QALY 
gained 0.319 0.029 3.460 0.616 0.375 0.046 3.089 0.637 
 Joint significance p<0.1  Joint significance p<0.1  
 
Date 
1999-2001 Reference category 0.761 Reference category 0.765 
2002-2003 0.334 0.077 1.447 0.578 0.311 0.071 1.363 0.569 
2004-2005 0.324 0.069 1.514 0.572 0.310 0.073 1.324 0.569 
2006-2007 0.101*** 0.024 0.434 0.365 0.109*** 0.029 0.405 0.380 
 Joint significance p=0.021 Joint significance p<0.05 
         
Type of intervention        
Treatment Reference category 0.575       
Diagnostic 0.759 0.220 2.612 0.532       
Other 1.676 0.349 8.061 0.653       
 Joint significance p=0.745       
       
Coverage requestor       
Manufacturer Reference category 0.572     
Internally generated  1.156 0.358 3.734 0.594     
Other 0.721 0.228 2.284 0.522     
 Joint significance p=0.752         
*p<0.1, **p<0.05, ***p<0.01 
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6.3.3. Alternative specification of the Date variable   
There were a number of alternative available approaches to code Date.  Initially, I coded Date as 
a continuous variable, using a day as the unit of analysis.  Although significant, the OR was so 
close to 1.0 that it was difficult to interpret in a meaningful way.  Date was then included as a 
continuous variable, with a year as the unit of analysis.  In this case, the estimated OR was 0.71 
(p<0.01) for the univariate analysis and 0.70 (p<0.01) for the multivariate analysis.  However, 
reporting ORs for continuous variables is not ideal as interpretation is not straightforward.  
Including Date as a categorical variable as opposed to a continuous variable is less restrictive 
because it allows the effect of a unit change in the variable (e.g., a year) to be not constant across 
the values of the variable.  NCDs made from 1999 through 2007 were included in the analysis.  A 
number of options were available to code this variable categorically.  First, an analysis was 
performed using each year as a separate category.  When running a multivariate analysis that 
included all variables, the years 2003, 2006, and 2007 were significant (p<0.1).  Although these 
findings show that in these particular years the likelihood of coverage is less than in 1999, the 
approach is insufficient to establish a temporal trend in the data.  Consequently, to develop the 
variable, coverage decisions were grouped together with respect to the year, or order, in which 
they were made.  When grouped together into quartiles and using the first quartile as the reference 
category, the second, third and fourth quartiles were associated with ORs of 0.39 (p<0.01), 0.20 
(p<0.01), and 0.08 (p<0.01), respectively, in a multivariate analysis including all variables.  
Alternatively, when grouped with respect to the year in which the coverage decision was made 
and using years 1999-2001 as the reference category, the years 2002-2003, 2004-2005, and 2006-
2007 were associated with ORs of 0.33 (p<0.1), 0.32 (p<0.1), and 0.10 (p<0.01), respectively, in 
a multivariate analysis including all variables.  Specifying Date with groupings of years was 
chosen for the final model, as I considered these results to be the most intuitive and 
straightforward to interpret. 
 
6.3.4. Evaluation of the cost-effectiveness variable 
The cost-effectiveness variable was evaluated in a numbers of ways.  These are described below. 
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6.3.4.1 Exclusion of cost-per life year studies 
In the primary analyses, cost-effectiveness studies reporting cost-per life year gained ratios were 
included along with those that reported cost-per QALY gained.  This approach assumes 
equivalency between these metrics, which is not correct in the majority of scenarios.  To evaluate 
the effect of including cost-effectiveness studies that report cost-per life year gained ratios, 
analyses were performed excluding these studies from the dataset.  Five studies were excluded, 
each associated with a positive coverage decision (Table 23). 
 
Excluding cost-effectiveness studies reporting cost-per life year gained ratios did not greatly 
impact the findings, with the results qualitatively the same as when these studies were included 
(Table 24 and Table 25).   
 
Table 23. Cost-effectiveness studies reporting cost-per life year gained ratios 
Technology - Coverage decision Year ICER 
(US$) 
Reference: 
Screening Immunoassay Fecal-Occult 
Blood Test (Hemoccult II FOBT) 
2003 $1,072 Report to the Agency for 
Healthcare Research and Quality 
(2003) 
Screening Immunoassay Fecal-Occult 
Blood Test (iFOBT) 
2003 $21,001 Report to the Agency for 
Healthcare Research and Quality 
(2003)  
Autologous Stem Cell Transplantation 
(AuSCT) for Multiple Myeloma - 
Treatment of multiple myeloma for 
patients who meet certain conditions 
2000 $27,687 Trippoli S et al. (1998)  
Implantable Cardioverter Defibrillators 
(ICDs) - Documented sustained 
ventricular tachyarrhythmia 
2003 $36,396 Mushlin AI et al. (1998)  
Implantable Cardioverter Defibrillators 
(ICDs) - Documented familial or 
inherited conditions with a high risk of 
ventricular tachyarrhythmias 
2003 $84,439 Larsen G et al. (2002)  
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Table 24. Univariate regression with cost-per life year studies excluded from the dataset 
Summary statistics 
Number of observations = 195  
Variable OR 95% CI Predicted probability 
Cost-effectiveness     
No estimate 0.184* 0.040 0.850 0.525 
Dominates Reference category  0.857 
ICER<$50k/QALY gained 0.222 0.027 1.846 0.571 
ICER>$50k/QALY gained 0.417 0.063 2.768 0.714 
Joint significance p=0.102     
*p<0.1, **p<0.05, ***p<0.01 
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Table 25. Multivariate regression with cost-per life year studies excluded from the dataset 
  
Multivariate logistic regression including all 
variables 
Multivariate logistic regression including 
those variables identified as significant  
  Summary statistics Summary statistics     
  Pseudo R2 = 0.306 Pseudo R2 = 0.298 
  Number of observations = 195 Number of observations = 195 
  Area under ROC curve = 0.852 Area under ROC curve = 0.846 
 Hosmer-Lemeshow goodness-of-fit test =0.109 Hosmer-Lemeshow goodness-of-fit test = 0.116 
Variable Adj. OR 95% CI Predicted probability Adj. OR 95% CI 
Predicted 
probability 
Quality of evidence 
Good  6.166*** 2.731 13.924 0.721 6.376*** 2.929 13.880 0.723 
Poor 1.171 0.290 4.722 0.410 1.362 0.354 5.238 0.429 
Insufficient Reference category  0.382 Reference category  0.373 
 Joint significance p<0.01 Joint significance p<0.01 
  
Alternative intervention 
No Reference category  0.809 Reference category   0.819 
Yes 0.149** 0.032 0.689 0.512 0.139*** 0.038 0.509 0.516 
                  
Cost-effectiveness 
No estimate 0.196* 0.034 1.141 0.538 0.195* 0.036 1.057 0.536 
Dominates Reference category  0.780 Reference category  0.782 
ICER<$50k/QALY gained 0.387 0.022 6.780 0.645 0.364 0.022 6.029 0.636 
ICER>$50k/QALY gained 0.288 0.031 2.646 0.600 0.330 0.040 2.692 0.621 
 Joint significance p=0.284 Joint significance p=0.233 
 
Date 
1999-2001 Reference category  0.760 Reference category  0.764 
2002-2003 0.343* 0.113 1.040 0.580 0.317** 0.105 0.952 0.569 
2004-2005 0.313* 0.083 1.185 0.563 0.303* 0.082 0.112 0.561 
2006-2007 0.106*** 0.029 0.391 0.367 0.116*** 0.033 0.406 0.345 
 Joint significance p<0.01 Joint significance p<0.01 
         
Type of intervention        
Treatment Reference category  0.574       
Diagnostic 0.792 0.346 1.813 0.537       
Other 1.626 0.115 23.002 0.647       
 Joint significance p=0.794       
       
Coverage requestor       
Manufacturer Reference category  0.580     
Internally generated  1.097 0.416 2.890 0.594     
Other 0.655 0.248 1.728 0.514     
 Joint significance p=0.526         
*p<0.1, **p<0.05, ***p<0.01 
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6.3.4.2 Addition of cost-effectiveness data from studies published after the NCD 
In the primary set of analyses, the dataset was restricted to include only estimates of cost-
effectiveness available at the time of the NCD, i.e., those to which CMS may feasibly have had 
access.  Nineteen estimates of cost-effectiveness were identified that were published following the 
NCD, and additional analyses were performed including these studies.  One hundred and thirty-
six (69.7%) coverage decisions were included in the category No estimate, 22 (11.3%) in 
Dominates, 16 (8.2%) in <$50k per QALY, and 21 (10.8%) in >$50k per QALY.  Considering the 
univariate analysis, and including Dominates as the reference category, the estimated ORs for No 
estimate, <$50k per QALY, and >$50k per QALY were 0.13 (p<0.01), 0.47 (p=0.378), and, 0.67 
(p=0.632), respectively.  These findings are qualitatively similar to those from the univariate 
analysis, in which case only estimates of cost-effectiveness available at the time of the NCD were 
included.  The findings of the multivariate analysis are presented in Table 26.  As for the 
univariate analysis, with respect to Cost-effectiveness, the results of the multivariate regression 
when including cost-effectiveness evidence published after the NCD were qualitatively similar to 
when only cost-effectiveness evidence available at the time of the NCD was included.  One 
notable change, however, is that the categories in Cost-effectiveness were jointly significant when 
estimates published following the NCD were included (p<0.01).  The ORs for the other 
independent variables included in the multivariate analyses were qualitatively the same as those 
when only cost-effectiveness evidence available at the time was included. 
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Table 26. Results of multivariate logistic regression – inclusion of cost-effectiveness studies 
published following the coverage decision 
  
Multivariate logistic regression including all 
variables 
Multivariate logistic regression including 
those variables identified as significant  
  Summary statistics Summary statistics     
  Pseudo R2 = 0.357 Pseudo R2 = 0.347 
  Number of observations = 195 Number of observations = 195 
  Area under ROC curve = 0.877 Area under ROC curve = 0.877 
 Hosmer-Lemeshow goodness-of-fit test = 0.239 Hosmer-Lemeshow goodness-of-fit test = 0.049 
Independent 
variable Adj. OR 95% CI 
Predicted 
probability Adj. OR 95% CI 
Predicted 
probability 
Quality of evidence 
Good  6.275*** 2.633 14.956 0.706 6.275*** 2.755 14.292 0.704 
Poor 1.169 0.249 5.494 0.419 1.457 0.326 6.516 0.450 
Insufficient Reference category 0.393 Reference category 0.387 
 Joint significance p<0.01 Joint significance p<0.01 
  
Alternative therapy available  
No Reference category 0.824 Reference category 0.829 
Yes 0.107*** 0.0267 0.428 0.515 0.103*** 0.026 0.408 0.511 
                  
Cost-effectiveness 
No estimate 0.106*** 0.024 0.463 0.483 0.115*** 0.028 0.471 0.482 
Dominates Reference   0.810 Reference   0.805 
ICER<$50,000 per 
QALY gained 0.708 0.088 5.683 0.768 0.701 0.094 5.220 0.760 
ICER>$50,000 per 
QALY gained 0.290 0.041 2.022 0.641 0.362 0.058 2.272 0.665 
 Joint significance p<0.01 Joint significance p<0.01 
 
Date 
1999-2001 Reference category 0.739 Reference category 0.747 
2002-2003 0.339* 1.10 1.045 0.568 0.308** 0.101 0.940 0.561 
2004-2005 0.378 0.095 1.504 0.587 0.349 0.091 1.341 0.582 
2006-2007 0.107*** 0.027 0.428 0.380 0.111*** 0.029 0.417 0.391 
 Joint significance p<0.05 Joint significance p<0.05 
         
Type of intervention        
Treatment Reference category 0.575       
Diagnostic 0.771 0.324 1.832 0.538       
Other 1.321 0.082 21.231 0.614       
 Joint significance p=0.818       
       
Coverage requestor       
Manufacturer Reference category 0.569     
Internally generated  1.284 0.461 3.581 0.604     
Other 0.672 0.244 1.849 0.512     
 Joint significance p=0.443         
*p<0.1, ** p<0.05, ***p<0.01 
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6.3.4.3 Subdividing the ICER into incremental cost and incremental benefit 
To examine the cost-effectiveness variable, regressions were performed including the numerator 
(incremental cost) and denominator (incremental effectiveness) as separate variables.  The version 
of the cost-effectiveness variable including estimates of cost-effectiveness published after the 
NCD and cost-effectiveness studies reporting cost-per life year gained ratios was used for this 
analysis to maximise the number of observations associated with an estimate of cost-
effectiveness.   
 
Incremental cost was coded as a categorical variable using the following categories: No estimate 
(n=138), Cost-saving (n=23), Incremental cost <$5,000 (n=15), and Incremental cost >$5,000 
(n=19).  Incremental effect was coded as a categorical variable using the following categories:  
No estimate (n=158), Negative incremental benefit (n=4), 0-0.1 QALY gain (n=13), 0.1-1.0 QALY 
gain (n=13), and >1.0 QALY gain (n=7).  These categorisations were used in both cases to ensure 
a sufficient number of observations in each category. The findings of the univariate analyses are 
presented in Table 27. 
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Table 27. Univariate analysis – Incremental costs and effectiveness 
Summary statistics 
Variable OR 95% CI Predicted probability 
Incremental cost (n=195)     
No estimate 0.119*** 0.034 0.419 0.442 
Cost-saving Reference category  0.870 
<$5,000 0.600 0.104 3.463 0.800 
>$5,000 1.275 0.190 8.545 0.895 
Joint significance p<0.01     
     
Incremental benefit (n=191)     
No estimate 0.180 0.021 1.528 0.519 
Negative effect Dropped from analysis (perfectly predicts model outcome) 
0-0.1 QALYs 0.917 0.682 12.322 0.846 
0.1-1.0 QALYs 0.917 0.682 12.322 0.846 
>1.0 QALYs Reference category  0.857 
Joint significance p<0.05    
*p<0.1, **p<0.05, ***p<0.01 
 
The categories in Incremental cost were jointly significant (p<0.01).  The likelihood of a positive 
coverage decision when there is no estimate of incremental cost is approximately eight times less 
than when the intervention is estimated to be cost-saving (reference category).  Neither 
Incremental cost <$5,000 nor Incremental cost >$5,000 were significant.  The categories in 
Incremental benefit were jointly significant (p<0.05).  As those interventions associated with 
negative incremental benefit perfectly predicted a non-coverage decision, Negative Effect was 
dropped from the regression.  Compared to the reference category, >1.0 QALY, all other 
categories were associated with an OR of less than 1.0, indicating a decreased likelihood of 
coverage.  No categories in Incremental effectiveness were significant. 
 
Incremental cost and Incremental effectiveness were included along with all other variables in a 
multivariate logistic regression (Table 28).  The findings of this analysis suggested the presence 
of multicollinearity.  The ORs for a number of the categories in Incremental cost and Incremental 
effectiveness were exceptionally high and associated with uncalculated 95% confidence intervals.  
To evaluate the potential presence of multicollinearity, the VIF was estimated for each coefficient 
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generated from the multivariate regression.  In Incremental cost, the VIFs for <$5,000 and 
>$5,000 were 6.44 and 5.45, respectively.  In Incremental effectiveness, the values for No 
estimate and 0-0.1 QALYs were 12.64 and 5.44.  These relative high estimates, in particular the 
VIF for No estimate, suggested the presence of multicollinearity.  Further, I estimated the 
correlation between coefficients.  Although no correlations were greater than 0.8, those between 
the incremental cost and incremental effectiveness variables ranged up to a value of 6.7.  Given 
the concerns and uncertainty regarding the presence of multicollinearity, separate regressions 
were performed when including Incremental cost and Incremental effectiveness. 
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Table 28. Multivariate regression including incremental cost and incremental effectiveness 
  Multivariate logistic regression including all variables 
  Summary statistics 
  Pseudo R2 = 0.448 
  Number of observations = 191 
  Area under ROC curve = 0.913 
 Hosmer- Lemeshow goodness-of-fit test = 0.442 
Variable Adj. OR 95% CI Predicted probability 
Quality of evidence 
Good  7.812*** 2.922 20.882 0.705 
Poor 2.285 0.345 15.144 0.528 
Insufficient Reference category   0.413 
  Joint significance p<0.01 
  
Alternative intervention 
No Reference category   0.829 
Yes 0.079*** 0.013 0.503 0.526 
          
Incremental cost 
No estimate 0.068*** 0.012 0.377 0.393 
Cost-saving Reference category   0.733 
<$5,000 34.951 0.195 6253.629 0.935 
>$5,000 3.10 x 107 Not estimated 0.995 
 Joint significance p<0.01 
 
Incremental effectiveness 
No estimate 1.99 x 107 Not estimated 0.601 
Negative effect Dropped from analysis (perfectly predicts model outcome) 
0-0.1 QALYs 298975.100 Not estimated 0.226 
0.1-1.0 QALYs 488113.400 Not estimated 0.253 
>1.0 QALYs Reference category   0.087 
  Joint significance p=0.480 
  
Date 
1999-2001 Reference category   0.767 
2002-2003 0.297* 0.086 1.021 0.598 
2004-2005 0.268* 0.059 1.217 0.582 
2006-2007 0.053*** 0.010 0.285 0.359 
  Joint significance p<0.01 
  
Type of intervention  
Treatment Reference category   0.585 
Diagnostic 0.744 0.284 1.948 0.550 
Other 1.737 0.089 34.038 0.651 
  Joint significance p=0.774 
  
Coverage requestor 
Manufacturer Reference category   0.575 
Internally generated  1.591 0.468 5.408 0.629 
Other 0.636 0.206 1.960 0.521 
  Joint significance p=0.292 
*p<0.1, **p<0.05, ***p<0.01 
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A multivariate logistic regression was performed including Quality of evidence, Alternative 
intervention, Date, Type of intervention, Coverage requestor, and Incremental cost.  With Cost-
saving serving as the reference category in Incremental cost, only the category no estimate was 
significant (OR=0.09, p<0.01).  The categories <$5,000 and >$5,000 were not significant (Table 
29). 
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Table 29. Multivariate regression including incremental cost 
  Multivariate logistic regression including all variables 
  Summary statistics 
  Pseudo R2 = 0.390 
  Number of observations = 195 
  Area under ROC curve = 0.893 
 Hosmer- Lemeshow goodness-of-fit test = 0.144 
Variable Adj. OR 95% CI Predicted probability 
Quality of evidence 
Good  6.061*** 2.508 14.648 0.695 
Poor 1.111 0.209 5.907 0.425 
Insufficient Reference category  0.409 
  Joint significance p<0.01 
  
Alternative intervention 
No Reference  0.824 
Yes 0.095*** 0.018 0.492 0.514 
          
Incremental cost 
No estimate 0.093*** 0.021 0.404 0.466 
Cost-saving Reference category  0.809 
<$5,000 0.729 0.084 6.294 0.771 
>$5,001 1.110 0.103 11.938 0.821 
  Joint significance p<0.01 
  
Date 
1999-2001 Reference category  0.735 
2002-2003 0.338** 0.108 1.057 0.572 
2004-2005 0.343 0.083 1.411 0.574 
2006-2007 0.094*** 0.021 0.411 0.377 
  Joint significance p<0.05 
  
Type of intervention  
Treatment Reference category  0.570 
Diagnostic 0.848 0.350 2.059 0.548 
Other 1.468 0.089 24.175 0.621 
  Joint significance p=0.897 
  
Coverage requestor 
Manufacturer Reference category  0.567 
Internally generated  1.330 0.463 3.822 0.604 
Other 0.689 2.245 1.943 0.517 
  Joint significance p=0.450 
*p<0.1, **p<0.05, ***p<0.01 
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Similarly, a multivariate logistic regression was performed including Quality of evidence, 
Alternative interventions, Date, Type of intervention, Coverage requestor, and Incremental 
effectiveness (Table 30).  With >1.0 QALYs serving as the reference category, only No estimate 
was significant (OR=0.05, p<0.05).  As all interventions associated with a deleterious effect on 
health were non-covered, Negative effect perfectly predicted the final coverage decision and was 
dropped from the regression.  The remaining variables, 0-0.1 QALYs, and 0.1-1.0 QALYs, were 
not significant.  As Quality of evidence takes into account both quality of evidence and degree of 
clinical benefit (Table 11, Section 4.7.4.2), it was assumed that there may be some collinearity 
between it and incremental effectiveness.  This was evaluated through the calculation of VIFs and 
the correlation between coefficients.  Although no evidence of collinearity was identified, an 
additional multivariate logistic regression was performed excluding Quality of evidence.  
Consistent with the previous regression, only No estimate was significant (OR=0.03, p<0.01), 
with the remaining variables either dropped or not significant (Table 31).   
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Table 30. Multivariate regression including incremental effectiveness 
  Multivariate logistic regression including all variables 
  Summary statistics 
  Pseudo R2 = 0.3728 
  Number of observations = 191 
  Area under ROC curve = 0.874 
 Hosmer- Lemeshow goodness-of-fit test = 0.231 
Variable Adj. OR 95% CI Predicted probability 
Quality of evidence 
Good  6.689*** 2.766 16.177 0.719 
Poor 1.442 0.300 6.923 0.469 
Insufficient Reference category   0.409 
  Joint significance p<0.01 
  
Alternative intervention 
No Reference category   0.797 
Yes 0.141** 0.026 0.758 0.539 
          
Incremental effectiveness 
No estimate 0.053** 0.035 0.787 0.530 
Negative effect Dropped from analysis (perfectly predicts model outcome) 
0-0.1 QALYs 0.261 0.010 6.621 0.748 
0.1-1.0 QALYs 0.489 0.019 12.553 0.817 
>1.0 QALYs Reference category   0.881 
  Joint significance p<0.05 
  
Date 
1999-2001 Reference category   0.828 
2002-2003 0.202*** 0.061 0.669 0.589 
2004-2005 0.169** 0.042 0.687 0.559 
2006-2007 0.037*** 0.008 0.170 0.319 
  Joint significance p<0.01 
  
Type of intervention  
Treatment Reference category   0.565 
Diagnostic 1.096 0.471 2.549 0.578 
Other 2.937 0.222 38.841 0.709 
  Joint significance p=0.705 
  
Coverage requestor 
Manufacturer Reference category   0.555 
Internally generated  2.027 0.670 6.133 0.649 
Other 0.752 0.269 2.103 0.516 
  Joint significance p=0.166 
*p<0.1, **p<0.05, ***p<0.01 
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Table 31. Multivariate regression including incremental effectiveness and excluding quality 
of evidence 
  Multivariate logistic regression including all variables 
  Summary statistics 
  Pseudo R2 = 0.296 
  Number of observations = 191 
  Area under ROC curve = 0.844 
 Hosmer- Lemeshow goodness-of-fit test = 0.554 
Variable Adj. OR 95% CI Predicted probability 
Alternative intervention 
No Reference   0.846 
Yes 0.108*** 0.021 0.574 0.534 
          
Incremental effectiveness 
No estimate 0.028*** 0.002 0.321 0.518 
Negative effect Dropped (perfectly predicts model outcome) NA 
0-0.1 QALYs 0.152 0.008 2.765 0.776 
0.1-1.0 QALYs 0.236 0.013 4.406 0.827 
>1.0 QALYs      Reference 0.940 
  Joint significance p<0.01 
  
Date 
1999-2001 Reference   0.867 
2002-2003 0.213*** 0.071 0.640 0.624 
2004-2005 0.190** 0.051 0.701 0.602 
2006-2007 0.021*** 0.005 0.085 0.240 
  Joint significance p<0.01 
  
Type of intervention  
Treatment Reference   0.565 
Diagnostic 0.906 0.413 1.985 0.549 
Other 7.304 0.597 89.382 0.840 
  Joint significance p=0.280 
  
Coverage requestor 
Manufacturer Reference   0.606 
Internally generated  1.000 0.394 2.539 0.606 
Other 0.588 0.225 1.5436 0.520 
  Joint significance p=0.412 
*p<0.1, **p<0.05, ***p<0.01 
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6.3.4.4 Including only observations with an associated estimate of cost-effectiveness 
As noted above, when including estimates of cost-effectiveness published after the date of the 
NCD, 59 coverage decisions (approximately 30% of the total sample) were associated with an 
estimate of cost-effectiveness.  Univariate and multivariate logistic regressions were performed 
using a dataset that included only coverage decisions with an associated estimate of cost-
effectiveness (Table 32 and Table 33).  
 
In this restricted dataset, all interventions without an available alternative were associated with 
non-coverage decisions.  Consequently, Alternative intervention perfectly predicted the outcome 
of the model and was dropped from the analysis.  Also, in Type of intervention the category 
“Other” perfectly predicted coverage and was dropped from the analysis.   
 
In the univariate analysis, Quality of evidence was the only significant variable (p<0.05). 
Compared to interventions associated with insufficient evidence, those associated with good 
quality evidence were approximately seven times more likely to be associated with a positive 
coverage decision (p<0.05).   
 
The findings of the multivariate analysis had a similar pattern to the univariate analysis, with 
Quality of evidence the sole significant variable (p<0.05).  As for the univariate analysis, 
compared to interventions associated with insufficient evidence, those associated with good 
quality evidence were more likely to be associated with a positive coverage decision, albeit with a 
much greater OR (59.4 vs. 7.2). 
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Table 32. Univariate logistic regression – Only coverage decisions with associated estimate 
of cost-effectiveness 
Summary statistics 
Number of observations in dataset = 59  
Independent variable OR 95% CI Predicted probability 
Quality of evidence (n=59)    
Good  7.200** 1.524 34.022 0.923 
Poor 0.600 0.066 5.447 0.500 
Insufficient Reference category 0.625 
 Joint significance p<0.05  
     
Alternative intervention (n=51)    
No Reference category NA 
Yes Dropped (perfectly predicts model outcome) NA 
     
Cost-effectiveness (n=59)     
Dominates Reference category 0.864 
ICER<$50,000/QALY gained 0.474 0.090 2.497 0.750 
ICER>$50,000/QALY gained 0.671 0.131 3.438 0.810 
 Joint significance p=0.678  
     
Date (n=59)     
1999-2001 Reference category 0.941 
2002-2003 0.167 0.018 1.546 0.727 
2004-2005 0.563 0.031 10.117 0.900 
2006-2007 0.146 0.013 1.658 0.700 
 Joint significance p=0.303  
     
Type of intervention (n=55) 
Treatment Reference category 0.800 
Diagnostic 1.00 0.253 3.949 0.800 
Other Dropped (perfectly predicts model outcome) NA 
  
Coverage requestor (n=59) 
Manufacturer Reference category 0.842 
Internally generated  0.50 0.106 2.355 0.727 
Other 1.50 0.220 10.218 0.889 
 Joint significance p=0.411  
*p<0.1, **p<0.05, ***p<0.01 
 
  
 
   
 258
Table 33. Multivariate logistic regression – Only those variables with an associated cost-
effectiveness estimate  
  Multivariate logistic regression including all variables 
  Summary statistics 
  Pseudo R2 = 0.367 
  Number of observations = 55 
  Area under ROC curve = 0.812 
 Hosmer-Lemeshow goodness-of-fit test = 0.716 
Independent variable Adj. OR 95% CI Predicted probability 
Quality of evidence 
Good  59.406** 2.014 1,751.867 0.937 
Poor 0.910 0.027 30.679 0.461 
Insufficient Reference category 0.474 
 Joint significance p<0.05  
     
Cost-effectiveness 
Dominates Reference category 0.898 
ICER<$50,000 per QALY gained 0.135 0.003 5.914 0.733 
ICER>$50,000 per QALY gained 0.173 0.007 4.242 0.756 
  Joint significance p=0.518 
  
Date 
1999-2001 Reference category 0.953 
2002-2003 0.060 0.002 2.031 0.730 
2004-2005 0.123 0.003 6.003 0.813 
2006-2007 0.057 0.001 2.804 0.723 
  Joint significance p=0.444 
  
Type of intervention  
Treatment Reference category 0.769 
Diagnostic 3.035 0.167 55.184 0.865 
Other Dropped   NA 
  
Coverage requestor 
Manufacturer Reference category 0.828 
Internally generated  0.248 0.023 2.718 0.698 
Other 7.346 0.146 370.927 0.934 
  Joint significance p=0.224 
*p<0.1, **p<0.05, ***p<0.01 
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6.4. Discussion 
In Chapter 5, I evaluated the cost-effectiveness of coverage decisions made in NCDs from 1999 
through 2007.  The findings show a statistically significant difference between positive coverage 
decisions and non-coverage decisions with respect to cost-effectiveness, suggesting that 
interventions subject to positive coverage decisions tend to be associated with more favourable 
cost-effectiveness evidence.  However, this approach is insufficient to determine if cost-
effectiveness, or the availability of cost-effectiveness evidence, is an independent factor in CMS 
NCDs.  The research presented in this chapter builds on the research in Chapter 6 and evaluates 
whether cost-effectiveness, or the availability of cost-effectiveness evidence, is an independent 
predictor of coverage, i.e., is statistically significantly associated with coverage when controlling 
for other factors that may be considered to influence coverage decisions. 
 
Medicare law dictates that coverage of interventions is limited to those that are ‘reasonable and 
necessary’ for the diagnosis or treatment of an illness or injury. (CMS 2010e)  Other than the 
notable exclusion of cost or cost-effectiveness evidence from the decision-making process 
(Section 4.2.2), CMS has not provided comprehensive guidance as to how this language should be 
interpreted.  Although interpretation of the ‘reasonable and necessary’ terminology has been 
discussed qualitatively at some length in the literature, to the best of my knowledge this is the first 
time that CMS NCDs have been evaluated in an empirical manner. (Foote 2002;Neumann 2005)   
 
6.4.1. Methodology 
As described in Section 4.5.1, coverage and reimbursement decisions, or recommendations for the 
efficient use of medical technology, made by agencies across the globe have been subject to 
evaluation.  Although their research objectives vary, e.g., exploration of a cost-effectiveness 
threshold vs. the relative likelihood of positive recommendations for cancer vs. non-cancer 
treatments, essentially the studies share the goal of gaining a better understanding of the role of 
cost-effectiveness evidence in decision-making.  A number of these studies have used variations 
of logistic regression to evaluate the role of cost-effectiveness evidence while controlling for 
other factors.   
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The development of the database used for this research is described in Chapter 4.  For the most 
part, information used to generate the variables originated from the decision memo published for 
each NCD.  This approach was consistent with similar studies that also used publicly available 
documentation to obtain the necessary data. (Chim et al. 2010;Dakin, Devlin, & Odeyemi 
2006;Devlin & Parkin 2004;Harris et al. 2008)  Unfortunately, decision memos do not provide the 
same breadth of information as documentation provided by other decision makers.  For example, 
information regarding budget impact and prevalence of disease are often reported in NICE 
technology appraisals but are rarely reported in NCD decision memos.  Variables considered for 
inclusion but did not feature in the research are described in Section 4.7.4.12.   
 
The coverage decision was the dependent variable in this analysis, i.e., positive coverage and non-
coverage.  This approach was taken because multiple coverage decisions often were made in 
NCDs.  Prior to the decision to use a dichotomous dependent variable, various alternative 
approaches to model CMS coverage decisions were considered.  For example, if using a 
dependent variable that allowed for more than two coverage outcomes, e.g., positive coverage, 
coverage with restrictions and non-coverage options, potential approaches include multinomial 
logistic or ordered logistic regression.  An advantage of the coverage decision being coded as a 
dichotomous variable is that it facilitates use of a binomial logistic regression model, modelling 
the dependent variable as simply positive or non-coverage.   
 
As multiple coverage decisions were made in a single NCD, it may be the case that they are not 
truly independent.  To evaluate whether this had an effect on the findings of the analysis, I 
performed an additional regression in which I clustered coverage decisions together. 
 
The model was estimated using binomial logistic regression, regressing the coverage decision 
against the independent variables. 
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6.4.2. Overview of research findings 
Findings show that the quality of supporting clinical evidence, the availability of alternative 
interventions, the available of cost-effectiveness evidence, and the date of the decision are 
statistically significantly associated with coverage decisions.  Neither Type of intervention or 
Coverage requestor was statistically significant in the primary analyses.  Findings were broadly 
consistent across the univariate model, the multivariate model including all variables, and the 
multivariate model including only variables that had at least one statistically significant category 
in the multivariate model including all variables.  Findings remained qualitatively the same when 
alternative constructions of Cost-effectiveness and Date were evaluated.  With respect to model 
fit, although the pseudo-R2 statistics indicated that there was room for improvement, the C-
statistics were reasonable high, indicating that the model fits the data reasonably well (0.85 for the 
primary multivariate analysis).  
 
6.4.2.1 Quality of the supporting clinical evidence 
Within each decision memo, CMS presents a review of the supporting clinical evidence and 
discusses its strengths and weaknesses.  The impression gained from reviewing the decision 
memos is that CMS are careful to ensure that the ultimate coverage decision is supported by their 
review of the clinical evidence.  The findings of the regression analysis are consistent with this 
impression, as the quality of evidence is statistically significantly associated with coverage 
decisions.  In the primary multivariate analyses, interventions associated with good quality 
evidence were estimated to be approximately six times more likely to be associated with a 
positive coverage decision than interventions associated with insufficient evidence when 
considering ORs (twice as likely when considering predicted probabilities).  Good quality clinical 
evidence was consistently a significant predictor of the coverage decision across analyses. 
 
This finding is encouraging, illustrating the evidence-based approach taken for NCDs.  It is 
important to note that Quality of evidence has a number of limitations (Section 6.4.3), including 
the subjective nature of the variable along with the fact that the USPSTF guidelines used to grade 
the evidence combine quality of evidence and net benefit into a single measure.  These limitations 
will be addressed in future work.   
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6.4.2.2 Availability of alternative interventions 
Alternative intervention was a statistically significant variable.  In the primary multivariate 
analyses, interventions with available alternatives were approximately seven times less likely to 
be to be covered than those for which no alternative was available (approaching two times less 
likely when considering predicted probabilities).  Alternative intervention was consistently a 
statistically significant variable across the various analyses.   
 
A number of the reviewed studies (Section 4.5.1) included a variable similar to Alternative 
therapy. (Dakin, Devlin, & Odeyemi 2006;Devlin et al. 2010a;Devlin & Parkin 2004;Harris et al.  
2008)  Alternative therapy accounts for the importance a decision maker attributes to ensuring a 
patient population has access to care.  In this case, the results for Alternative therapy show that 
CMS have a strong preference for the coverage of interventions for indications for which no 
alternatives exist.  The finding also indicates that CMS do not consider interventions in isolation 
and do account for the treatment landscape when making NCDs.   
 
6.4.2.3 Cost-effectiveness 
The objective of this work was to determine if cost-effectiveness was an independent predictor of 
coverage.  To facilitate the interpretation of categorical variables, typically one of the extreme 
categories is chosen as the reference category.  In the case of Cost-effectiveness, Dominates was 
chosen.  Therefore, the estimated ORs are interpreted as the likelihood of positive coverage 
relative to interventions estimated to be both more effective and less costly than their comparator.    
 
In the primary univariate and multivariate regressions, the category No estimate was statistically 
significant, with ORs of approximately 0.18 and 0.19, respectively.  This finding indicates that 
compared to interventions estimated to be dominant, those with no associated estimate of cost-
effectiveness are approximately five times less likely to be associated with a positive coverage 
decision.  In the primary analyses, the categories <$50k per QALY and >$50k per QALY were not 
statistically significant.  While in the multivariate analyses the ORs were less than 1.0, consistent 
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with a hypothesis that interventions with more favourable estimates of cost-effectiveness are more 
likely be covered, the lack of statistical significance prevented any conclusions to be drawn.   
 
Under the theory that CMS may have had access to unpublished data on cost-effectiveness or 
could have independently calculated cost-effectiveness in the absence of published studies, cost-
effectiveness data from studies published after the NCD were included in an additional set of 
analyses.  The findings of these analyses were qualitatively similar to those including only 
estimates of cost-effectiveness available at the time of the NCD. 
 
Cost-effectiveness combines estimates of both the costs and effectiveness of the intervention.  It 
may be the case that any impact of cost-effectiveness on positive coverage decisions 
demonstrated in the analysis is actually due to the impact of effectiveness on the decision rather 
than cost or cost-effectiveness.  The quality of evidence variable included in the analysis 
simultaneously accounts for evidence quality and the magnitude of the clinical benefit shown by 
the intervention.  I attempt to control, albeit imperfectly, for the clinical effectiveness of each 
intervention and analyse the impact of cost-effectiveness conditional on this variable. 
 
The cost-effectiveness variable was further explored by subdividing the ICER into incremental 
cost and incremental effectiveness components.  When considered in univariate analyses, 
Incremental cost and Incremental effect were jointly significant (Table 27).  However, while No 
estimate was a significant category in Incremental cost, No estimate was not significant in 
Incremental effect.  When including Incremental cost and Incremental effectiveness together as 
independent variables in a multivariate regression, the presence of collinearity hindered the 
interpretation of the findings.  Therefore, separate multivariate regressions were performed 
including Incremental cost and Incremental effectiveness, and in each case, the variable was 
significant.  For both variables, the category No estimate was significant; no estimate of 
incremental cost was associated with an OR of 0.09 (p<0.01), and no estimate of incremental 
effectiveness was associated with an OR of 0.05 (p<0.01).  For both variables, all other categories 
were non-significant.  This analysis provided little insight into the association of incremental cost 
or incremental effectiveness with coverage.  As categories other than No estimate were not 
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statistically significant, no relationship between magnitude of incremental cost or incremental 
effectiveness with coverage was identified.     
 
The majority (approximately 70%) of coverage decisions in the dataset were not associated with 
an estimate of cost-effectiveness.  To further evaluate Cost-effectiveness, an additional set of 
analyses was performed including only coverage decisions with an associated estimate of cost-
effectiveness.  The small size of this restricted dataset (n=59) led to a number of difficulties.  
Most notably, Alternative intervention was dropped from the model as it perfectly predicted 
model outcome.  Of the remaining variables, Quality of evidence was the only significant 
variable; Date and Cost-effectiveness were not significant.  While this analysis further confirms 
the significance of Quality of evidence, it is not informative with respect to the other variables.  
This analysis would likely provide a greater insight if the dataset were extended to include more 
recent coverage decisions, or if additional estimates of cost-effectiveness were available for 
interventions in the current dataset. 
 
In summary, across the primary analyses interventions for which there were no available 
estimates of cost-effectiveness were less likely to be associated with a positive coverage decision 
compared with interventions estimated to be dominant.  This is an important finding and suggests 
that, controlling for other factors, the availability of dominant estimates of cost-effectiveness, or 
lack thereof, impacts the likelihood of a positive coverage decision.   
 
6.4.2.4 Date of decision 
The date of decision variable was significant across the primary analyses.  As described in 
Section 4.7.4.6, various alternative approaches for coding Date were considered.  Ultimately, in 
the primary analyses, Date was included as a categorical variable, with coverage decisions 
grouped into the years they were made, i.e., 1999-2001, 2002-2003, 2004-2005, and 2006-2007.  
Notably, for the multivariate analyses each category was statistically significant, and the reported 
OR decreased for consecutive groups of years, suggesting that CMS became increasingly 
restrictive throughout the considered time period.  This trend was confirmed when including a 
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version of Date in the multivariate analysis in which coverage decisions were ordered with 
respect to year and grouped into quartiles (Section 4.7.4.6).  
 
While it is apparent that CMS coverage decisions have become increasingly restrictive, this 
research does little to explain why this was the case.  Date was included to control for unobserved 
factors that affect the outcome of NCDs that change over time.  It may be that Medicare’s ever 
greater fiscal challenges – the cost of Medicare more than doubled from $213 billion in 1997 to 
$431 billion in 2007 – influenced the outcome of NCDs. (CMS 2011a)  Alternatively, the 
changing composition of CMS’s coverage team may have influenced the likelihood of coverage. 
     
6.4.3. Limitations and challenges 
The principal challenge of this research was obtaining the necessary data.  Unfortunately, CMS 
do not present the same breadth of information in decision memos typically presented by agencies 
in other countries.  For example, unlike NICE’s Technology Appraisals, CMS decision memos do 
not present a budget impact estimate or the number of beneficiaries likely to receive the 
intervention.  This made emulating the methods used in the studies reviewed in Section 4.5.1 
difficult, and restricted the number of variables available for analysis.  Most notably, the majority 
of included cost-effectiveness studies were obtained from a literature search and thus, there is 
inevitably variability between with respect to quality.  Also, it may be the case that CMS 
considered the intervention to be more or less effective or costly than the inputs used in the 
corresponding cost-effectiveness analysis.  Nevertheless, as CMS do not routinely perform cost-
effectiveness analysis as part of NCDs, relying on the peer-reviewed literature is a practical and 
manageable approach. 
 
As described in Section 4.7.4.2, the USPSTF guidelines were used to grade the quality of the 
supporting clinical evidence for each coverage decision.  The USPSTF grading scale accounts for 
magnitude of net clinical benefit and evidence quality in terms of study design and conduct.  Two 
researchers from Tufts Medical Center independently performed the grading of the clinical 
evidence considered here.  The grading was based upon an evaluation of CMS’s review of the 
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clinical evidence presented in the decision memos.  Combining net clinical benefit and evidence 
quality into a single variable is not ideal, and unfortunately this was the only approach used by the 
Tufts Medical Center researchers.  Further, while the grading was based on independent reviews, 
Quality of evidence is a subjective review of the evidence base.  Quality of evidence would prove 
more informative if considered in an objective manner, i.e., the assessment of the evidence base 
was quantifiable and not based on interpretation.  Potential approaches to achieving this goal are 
described in Section 6.4.5 below. 
 
The significance of the No estimate category in Cost-effectiveness was notable.  However, as only 
21% of coverage decisions, or 30% when studies published after the NCD were included, were 
associated with a cost-effectiveness estimate, the cost-effectiveness of the majority of coverage 
decisions was unavailable.  As described in Section 6.3.4.4, analyses were performed that 
included only coverage decisions for which an estimate of cost-effectiveness was available.  
However, the small sample size limited the interpretability of the findings.  
 
In contrast to a number of reviewed studies (Section 4.5.1), Cost-effectiveness was coded as a 
categorical variable.  The principal reason for this approach was to include all available cost-
effectiveness evidence in the research.  Including interventions estimated to be dominant or 
dominated in the dataset would have proved challenging if Cost-effectiveness was coded as a 
continuous variable.  Researchers have gotten around this problem by dropping observations that 
were dominant or dominated from the dataset. (Devlin et al. 2010)  However, this approach was 
not an option given the available sample size, and the exclusion of relevant data in this way is 
questionable.  Other researchers have gotten around this problem by coding dominant 
interventions with a zero value. (Dakin, Devlin, & Odeyemi 2006)  Again, however, this approach 
is questionable and requires manipulation of the data.  Ultimately, Cost-effectiveness was coded 
as a categorical variable.  Unfortunately, I was unable to include as many categories in Cost-
effectiveness as I would have liked.  The categories were chosen to ensure a sufficient number of 
positive and non-coverage decisions in each category.  This necessitated interventions associated 
with an ICER >$50,000 per QALY to be pooled with interventions estimated to be dominated.  
This approach is not ideal as it includes interventions that are more effective than their 
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comparator (ICER >$50,000 per QALY) in the same category as interventions that are less 
effective than their comparator (dominated).  It is expected that as the available sample increases, 
more categories will be included.  As a result, pooling interventions with an ICER of >$50,000 
per QALY with those that are dominated can be avoided.   
 
Finally, when evaluating cost-effectiveness evidence, it is important to consider uncertainty in the 
estimate. (Claxton, 2008)  As described in 4.7.4.9, I reported estimates of uncertainty when 
reviewing the studies.  However, given the inconsistent nature of reporting estimates of 
uncertainty, it proved infeasible to include here.  
 
6.4.4. Policy relevance 
As far as I am aware, this is the first study of its kind to quantitatively evaluate CMS NCDs.  This 
study is particularly important given the uncertainty surrounding the interpretation of the 
‘reasonable and necessary’ criterion and, thus, CMS coverage of medical technology.  Recent 
NCDs, e.g., autologous cellular immunotherapy treatment of metastatic prostate cancer, serve to 
underline the importance of CMS NCDs and the emotion and debate that surrounds them. 
(Chambers & Neumann 2011)   
 
The findings of the analyses presented above provide insight into CMS’s decision-making process 
and the factors important in CMS decision-making.  First, they underscore that CMS has adopted 
evidence-based medicine, with interventions associated with good quality evidence several times 
more likely to be covered than those associated with insufficient evidence.  Second, the findings 
highlight the importance of the availability of alternative interventions at the time of NCDs, with 
interventions with an available alternative much less likely to be covered than those without an 
alternative available.  This may provide an insight into how CMS considers the “necessary” 
component of the ‘reasonable and necessary’ criterion.  Third, the findings suggest that the 
availability of cost-effectiveness evidence plays a role in CMS coverage.  However, as the 
categories <$50,000 per QALY and >$50,000 per QALY were not statistically significant, the 
findings are insufficient to conclude that CMS NCDs are consistent with cost-effectiveness.  If 
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CMS coverage decisions were consistent with cost-effectiveness, one would expect that these 
categories would be significant, and the respective ORs would reflect a decreased likelihood that 
interventions associated with higher ICERs are associated with positive coverage.  Nevertheless, 
when controlling for other factors, the absence of an associated estimate of cost-effectiveness, 
when compared to instances when a dominant estimate is available, reduces the likelihood of 
coverage by approximately a factor of five.  While preference for the coverage of dominant 
interventions is intuitive, the finding is contradictory to CMS’s stated position, that “Cost 
effectiveness is not a factor CMS considers in making NCDs. In other words, the cost of a 
particular technology is not relevant in the determination of whether the technology improves 
health outcomes or should be covered for the Medicare population through an NCD.” (CMS 
2010e)  Finally, the findings suggest that, when controlling for the other factors in the model, 
CMS has become more restrictive over time with respect to the coverage of interventions.   
 
Studies like this have the potential to increase the transparency of coverage decisions and increase 
the accountability of CMS.  This study has the potential to help the entire medical community 
better understand the evidence that CMS considers, thus reducing uncertainty associated with 
NCDs.  The findings of this research go some way to reveal CMS’s interpretation of the 
‘reasonable and necessary’ criterion.  
 
6.4.5. Next steps 
While the findings of this research provide important insights, there is much room for 
improvement with respect to the data and methodological approach.  Expanding the dataset to 
include NCDs made after 2007 will increase the sample size and likely improve results.  In 
particular, this may be the case for the cost-effectiveness variable as a number of NCDs have 
featured cost-effectiveness evidence since 2007 (see Section 3.5.2 for further discussion).  Adding 
a number of variables to the model will also likely prove beneficial.   
 
As noted above, a limitation of the quality of evidence variable is its subjectivity.  An objective 
review of the supporting evidence could be achieved by categorising the evidence base using a 
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number of criteria pertaining to:  study design (e.g., randomised studies, non-randomised study, 
retrospective study, etc); study outcomes (‘hard’ endpoints vs. surrogate endpoints); inclusion of 
active comparators; consistency of findings across studies; patient population (e.g., whether the 
study included Medicare beneficiaries); country of study (e.g., US-based vs. non-US-based); and 
recency of study publication. 
 
The availability of alternative interventions proved to be a significant predictor of the final 
coverage decision.  While it was included here as a binary variable, it is possible that the 
likelihood of a positive coverage decision decreases for interventions with multiple available 
alternatives.  Unfortunately, information presented in the decision memos was insufficient to code 
the variable in this manner.  However, it may be possible to develop the variable along these lines 
with input from health care practitioners. 
 
As described in Section 4.7.4.12, the inclusion of a number of variables proved difficult, and they 
were ultimately excluded from this research.  Variables pertaining to budget impact and 
prevalence would be particularly useful to include, as both would give an insight into the impact 
of the coverage decision on the Medicare programme, something that is currently not accounted 
for in the model.  Again, one approach to help develop these variables would be to gain input 
from clinicians or other health services researchers.  
 
It has been suggested that social values, e.g., disease severity and equitable access to care, should 
play a role in health care resource allocation and therefore should be accounted for in coverage 
decisions. (Dolan et al. 2005)  Severity of disease could be included by gaining input from health 
care practitioners to categorise diseases based upon whether they are life threatening.  Another 
approach would be to use utility weights as a proxy to disease severity.    
 
Also, although challenging to source the information, it would be useful to include the extent of 
lobbying to CMS in support of a positive coverage decision that occurred throughout the NCD 
time period.  A potential proxy for this would be to count the number of comments submitted to 
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CMS during the NCD’s comment period.  Although a somewhat tenuous link to lobbying, this 
approach would at least account for the amount of public input into the decision.   
 
As described in Section 6.2.3, a ‘production function’ formed the conceptual framework for this 
research.  This approach was deemed appropriate as CMS provides little guidance on their 
decision-making criteria.  As noted above, alternative frameworks could be considered, including 
the use of hierarchical models.  When decision-making is viewed as a hierarchical process, multi-
level models can used to reflect the decision-making process.  For example, if hypothesised that 
clinical evidence is the most important aspect of decision-making, this can be reflected in the 
model structure.  Interviews with staff from the CMS coverage group may offer additional insight 
into how CMS prioritises different decision-making criteria and thus help inform different 
modelling approaches. 
 
The objective of a number of the studies reviewed in Section 4.5.1 was to identify an implicit 
cost-effectiveness threshold from coverage decisions.  It is important to note, however, that these 
studies evaluated decisions by agencies for which cost-effectiveness evidence played an 
established role.  While CMS do not routinely use cost-effectiveness evidence, a similar 
evaluation could be performed here.  However, the lack of a sufficient number of non-coverage 
decisions associated with high ICERs inhibits such an analysis with the current data.  
Nevertheless, such an evaluation may be feasible as the sample of cost-effectiveness studies 
grows.   
 
As described above, I used cluster analysis to control for the fact that coverage decisions made in 
the same NCD may not be independent because they are made by the same committee and use 
similar or related evidence (Section 6.3.2).  A similar approach could be used to group coverage 
decisions that are reconsiderations together with the initial NCD.  In the current dataset, 
reconsiderations of previous coverage decisions were considered independent.  However, as the 
evidence reviewed for reconsiderations is likely related to the evidence reviewed for the 
preceding NCD, it would be interesting to control for this using cluster analysis.  It is important to 
note that reconsiderations do not typically concern an identical coverage decision to the preceding 
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NCD; rather, they result in coverage determinations for different indications and/or patient 
populations.  Thus, simply including the most recent NCD would exclude a number of unique 
coverage decisions. 
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6.5. Chapter summary 
In Chapter 5, I identified occasions when CMS had cited or discussed cost-effectiveness evidence 
in the decision memo and showed a statistically significant difference between positive coverage 
decisions and non-coverage decisions with respect to their cost-effectiveness. This suggested that 
covered interventions tend to be associated with more favourable cost-effectiveness evidence.  
The research presented in this chapter builds on these findings.  The objective was to determine if 
cost-effectiveness is an independent predictor of coverage, i.e., when controlling for other factors, 
cost-effectiveness, or the availability of cost-effectiveness evidence, is statistically significantly 
associated with coverage.   
 
A number of variables were included in the model, including; Quality of evidence, Alternative 
intervention, Cost-effectiveness, Type of intervention, Coverage requestor, and Date. The model 
was estimated using binomial logistic regression, regressing the coverage decision (positive/non-
coverage) against the independent variables.  Univariate and multivariate regressions were 
performed. 
 
Across the primary analyses, the quality of supporting clinical evidence, availability of alternative 
interventions, and the date of decision were statistically significantly associated with the coverage 
decision.  Although the cost-effectiveness variable was not significant overall, the category No 
estimate was.  Key findings are summarised below: 
• Interventions associated with good quality supporting evidence were six times more likely 
to receive a positive coverage decision compared to those associated with insufficient 
evidence (approximately twice as likely when considering predicted probabilities);   
• Compared to interventions with no available alternative, those with an available 
alternative were approximately eight times less likely to be associated with a positive 
coverage decision (approaching half as likely when considering predicted probabilities); 
• Compared with interventions estimated to be dominant, those with no associated estimate 
of cost-effectiveness were approximately five times less likely to receive a positive 
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coverage decision (approximately two thirds as likely when considering predicted 
probabilities); 
• Coverage decisions made in 2006-2007 were approximately 10 times less likely to be 
associated with a positive coverage decision than those made in 1999-2001 (half as likely 
when considering predicted probabilities).  Interventions considered in more recent time 
periods were increasingly less likely to be associated with a positive coverage decision. 
 
While the findings are insufficient to conclude that CMS coverage decisions are consistent with 
cost-effectiveness, they are notable given CMS’s stated position on the use of cost-effectiveness 
evidence.  As the available sample increases, it will be interesting to re-evaluate the data to gain a 
greater insight into the association of cost-effectiveness with coverage decisions made in NCDs.  
This research provides insight into CMS’s interpretation of the ‘reasonable and necessary’ 
criterion.  The findings suggest that CMS operate an evidence-based coverage policy and that the 
availability of alternatives is relevant to decision-making.  It is interesting that a trend was 
identified that showed that CMS became more restrictive with respect to coverage over the time 
period considered.  While the research does not provide insight into why this is the case, it may 
reflect Medicare’s ever greater fiscal challenges or the changing composition of CMS’s coverage 
team. 
 
The research presented in Chapter 7 is the final piece of empirical work and builds on the research 
presented in Chapter 5 and Chapter 6.  The findings of the research presented in Chapter 5 
illustrate that CMS are covering interventions that are not cost-effective by traditional standards, 
e.g., nine with ICERs greater than $100,000 per QALY and three with ICERs greater than 
$500,000 per QALY.  Offering these interventions generates relatively little health gain for the 
expenditure and suggests that resources could provide greater benefits if directed towards 
alternative interventions.  The research in this chapter support this finding and shows that CMS 
coverage decisions are not entirely consistent with cost-effectiveness.  The primary objective of 
the research in Chapter 7 is to estimate potential gains in aggregate health from a hypothetical 
reallocation of expenditures between interventions subject to NCDs, using a criterion of cost-
effectiveness.  Also, the impact of using a cost-effectiveness decision rule to hypothetically 
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reallocate expenditures between interventions subject to NCDs on the distribution of resources 
among disease areas and types of intervention is evaluated. 
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7. Empirical Research: Part 3 
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7.1. Introduction 
In Chapter 4, I provided the foundation for the empirical aspects of this thesis, including a 
background to the Medicare programme and the processes for the coverage of medical 
technology.  Also, I presented the objectives of the empirical work and reviewed the relevant 
literature that helped inform my methodological approach.  Lastly, I described the development of 
the database used for this research and the included set of variables. 
 
In Chapters 5 and 6, I evaluated coverage decisions made in CMS national coverage 
determinations (NCDs).  In Chapter 5, I found that on occasion CMS have discussed or cited cost-
effectiveness evidence in NCDs.  Also, while findings show a statistically significant difference 
between positive coverage decisions and non-coverage decisions with respect to cost-
effectiveness, suggesting that covered interventions tend to be associated with more favourable 
cost-effectiveness evidence, interventions have been covered in NCDs that are not cost-effective 
by traditional standards.  Indeed, seventeen covered interventions are associated with an ICER 
greater than $50,000 per QALY, nine of which greater than $100,000 per QALY and three of 
which greater than $500,000 per QALY.  The research presented in Chapter 6 built on these 
findings and evaluated whether, when controlling for other factors likely to influence coverage 
decisions, cost-effectiveness, or the availability of cost-effectiveness evidence, is an independent 
predictor of coverage outcome.  The findings showed that compared with interventions estimated 
to be dominant, those with no associated cost-effectiveness estimate were approximately five 
times less likely to be covered.  However, as the categories including ICERs with positive values 
were not statistically significant, it was not possible to conclude that CMS coverage decisions 
were consistent with cost-effectiveness, i.e., the likelihood of coverage decreased with higher 
estimates of cost-effectiveness.  Other independent variables included those concerning the 
quality of the supporting clinical evidence, availability of alternative interventions, and the date of 
decision.  
 
The research presented in this chapter represents the final piece of my empirical work.  As 
described in Chapter 3, the US health care system is under financial strain, with health care costs 
rising at an unsustainable rate.  Spending on Medicare represents a large proportion of total US 
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health care spending, approximately 5% of GDP, with projections suggesting an increase to 5.9% 
by 2017. (Orszag & Ellis 2007)  It is claimed that Medicare is underperforming, with 
approximately 30% of administered care either inappropriate or unnecessary. (Bentley et al. 
2008;Fisher et al. 2003;Garber, Goldman, & Jena 2007;Orszag 2008)  
 
The primary objective of the research presented in this chapter is to estimate potential gains in 
aggregate health from a hypothetical reallocation of expenditures between interventions subject to 
NCDs using a cost-effectiveness decision rule.  In addition, the impact of this hypothetical 
reallocation on the distribution of resources across disease areas and types of intervention is 
evaluated.   
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7.2. Objective and Methods 
The empirical work presented in this chapter has two specific objectives:  
1. To estimate potential gains in aggregate health from a hypothetical reallocation of 
expenditures using a cost-effectiveness decision rule between interventions subject to 
NCDs in terms of the net present value of future commitments and expenditures 
associated with interventions in the year following first use.  
2. To estimate the impact of reallocation on the distribution of resources across disease areas 
and types of intervention. 
 
7.2.1. Sample of interventions 
The database used for this research is described in Section 4.7.5.  For each coverage decision the 
following information were required: 
1. Estimate of cost-effectiveness, including incremental cost and incremental effectiveness 
data; 
2. Estimate of the cost of the intervention and comparator in the year following first use; 
3. Estimate of the existing utilisation rate (served population), i.e., the number of Medicare 
beneficiaries using the intervention in 2007; 
4. Estimate of the number of Medicare beneficiaries eligible for the intervention in 2007. 
 
I reviewed each cost-effectiveness study to extract reported incremental cost and incremental 
effectiveness data.  With respect to incremental effectiveness, incremental QALY gained data was 
used when available.  Incremental life-years gained data were included by adjusting incremental 
survival gain with a reported utility weight for Americans aged 65-69.  (Erickson, Wilson, & 
Shannon 1995)  Cost-effectiveness studies that estimated the intervention to be dominant and 
reported health outcome using disease-specific units were included.  While the inclusion of these 
studies did not provide incremental health gain data in an appropriate form, the reported estimates 
of cost-savings were relevant to this work.  Separate analyses were performed when including and 
excluding these studies.   
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I obtained estimates of the costs associated with the interventions and comparators in the year 
following first use from the cost-effectiveness study when available.  When not reported, I 
estimated the values from Medicare reimbursement codes (Section 4.7.5.6).     
 
I estimated inpatient and outpatient utilisation rates from a Medicare claims database that 
included data from a 5% sample of the Medicare population.  I used ICD-9 diagnostic codes to 
identify beneficiaries eligible for the intervention as specified by the parameters in the NCD, and 
CPT codes and ICD-9 procedural codes to identify beneficiaries who had received the 
intervention in the dataset.  I estimated the existing utilisation rate by identifying beneficiaries 
who were a match for both ICD-9 codes and CPT codes.  I calculated the size of the unserved 
patient population, i.e., Medicare beneficiaries who were eligible for the intervention but did not 
receive it, as the difference between the two estimates (Section 4.7.5.5).  For non-coverage 
decisions, I assumed existing utilisation of the intervention to be zero in all cases.  I estimated the 
size of the potentially eligible patient population, i.e., the population for which the non-coverage 
decision was made, using ICD-9 codes.  A more complete description of the database used for 
this research is presented in Section 4.7.5. 
 
Only interventions for which all the required data were available were included in this research.   
 
7.2.2. Analytic approach 
I performed a literature search and review to identify studies with a similar objective to the 
research considered here (Section 4.5.2).  While two studies, Cromwell et al. (1998) and Zaric 
and Brandeau (2001), appeared to be relevant, neither provided a suitable framework with which 
to perform this research.  Cromwell et al. (1998) used integer programming to allocate resources 
across acute inpatient services in an Australian setting.  The limited scope of this research – it 
focused solely on inpatient services – facilitated the authors’ approach.  Unfortunately, the scope 
of my research, i.e., the inclusion of interventions indicated for a much broader range of 
indications, prevented me from using a similar framework.  Zaric and Brandeau (2001) used a 
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dynamic model to estimate optimal resource allocation for HIV prevention in a hypothetical 
cohort of injection drug users (IDUs) and non-IDUs.  A dynamic model was used to account for 
the infectious nature of the disease.  A similar approach was not applicable to my research.  Also, 
the focus of the study was narrow, and although the objective of estimating optimal resource 
allocation was similar to the objective considered here, the limited number of alternative 
interventions (three) reduced the applicability of the methods to this research.  
 
7.2.2.1 Objective 1 
The first research objective was to estimate potential gains in aggregate health from a 
hypothetical reallocation of expenditures using a cost-effectiveness decision rule between 
interventions subject to NCDs in terms of the net present value of future commitments and 
expenditures associated with interventions in the year following first use.  To achieve this 
objective, I ranked the interventions in order of cost-effectiveness and simulated 
disinvestment/increased investment by adjusting intervention utilisation rates.   
 
It was necessary to make a number of assumptions in this analysis:  
1. The comparator included in the cost-effectiveness study was the only true alternative to 
the intervention, i.e., in all cases, beneficiaries not receiving the intervention would 
instead receive the study comparator. 
2. The following assumptions consistent with a league table approach (Section 2.5.1.1). 
(Johannesson & Weinstein 1993) 
a. Perfect divisibility, i.e., a health care programme can be partially implemented and 
still maintain the characteristics of the entire programme. 
b. Constant returns to scale, i.e., costs and effects are proportional to the scale of 
implementation.  
3. When considering the net present value of future commitments, unrestricted finance is 
available.      
4. Supply of organs is not a limited factor in the delivery of transplant related interventions.  
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Included were all non-dominated interventions with complete data.  Reallocations were required 
to be expenditure-neutral, i.e., no net change in total expenditure was permitted.  Also, all eligible 
beneficiaries must have received either the intervention or the comparator. 
 
A worked example of the reallocation using a simplified scenario is shown below.  For simplicity, 
the worked example includes four interventions (A, B, C, and D) and costs are presented in terms 
of the net present value of future commitments.  Table 34 presents the state of the world prior to 
the reallocation of expenditures.  The ICER (cost-per QALY gained), the existing utilisation 
level, the total number of eligible beneficiaries, the number of unserved eligible beneficiaries, the 
incremental cost and QALY gain associated with the intervention, and the aggregate incremental 
cost and QALY gain across the population, is included for each intervention in Table 34. 
 
Table 34. Worked example – Existing distribution of expenditures across available 
interventions 
Intervention 
ICER 
($/QALY) 
Existing 
utilisation 
Eligible 
beneficiaries 
Unserved 
eligible 
beneficiaries 
Inc. 
Cost 
Inc. 
QALYs 
Total inc. 
cost 
Total 
inc. 
QALYs 
A 250,000 100 250 150 25,000 0.10 2,500,000 10 
B 80,000 200 350 150 20,000 0.25 4,000,000 50 
C 30,000 50 400 350 15,000 0.50 750,000 25 
D 25,000 100 200 100 20,000 0.80 2,000,000 80 
  450     9,250,000 165 
 
Step 1 - Decrease utilisation of least cost-effective intervention (Intervention A) 
The first step is to disinvest in the least cost-effective intervention available, in this case 
intervention A (ICER = $250,000 per QALY).  This is achieved by decreasing the existing 
utilisation of the intervention by 50%.  In this case the utilisation of intervention A is reduced 
from 100 to 50.  The consequences of this change are shown by the highlighted text in Table 35.  
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Table 35. Worked example – Step 1 
Intervention 
ICER 
($/QALY) 
Existing 
utilisation 
Eligible 
beneficiaries 
Unserved 
eligible 
beneficiaries 
Inc. 
Cost 
Inc. 
QALYs 
Total 
inc.cost 
Total 
inc. 
QALYs 
A 250,000 50 250 200 25,000 0.10 1,250,000 5 
B 80,000 200 350 150 20,000 0.25 4,000,000 50 
C 30,000 50 400 350 15,000 0.50 750,000 25 
D 25,000 100 200 100 20,000 0.80 2,000,000 80 
  400     8,000,000 160 
 
Step 2 - Increase utilisation of most cost-effective intervention (Intervention D) 
The second step is to increase investment of the most cost-effective intervention available, in this 
case intervention D (ICER = $25,000 per QALY).  This is achieved by decreasing the size of the 
unserved patient population by 50%.  In this case the number of unserved eligible beneficiaries 
was decreased from 100 to 50, with utilisation of intervention D increasing from 100 to 150.  The 
consequences of this change are shown by the highlighted text in Table 36.  
 
Table 36. Worked example – Step 2 
Intervention 
ICER 
($/QALY) 
Existing 
utilisation 
Eligible 
beneficiaries 
Unserved 
eligible 
beneficiaries 
Inc. 
Cost 
Inc. 
QALYs 
Total 
inc.cost 
Total 
inc. 
QALYs 
A 250,000 50 250 200 25,000 0.10 1,250,000 5 
B 80,000 200 350 150 20,000 0.25 4,000,000 50 
C 30,000 50 400 350 15,000 0.50 750,000 25 
D 25,000 150 200 50 20,000 0.80 3,000,000 120 
  450     9,000,000 200 
 
Step 3 - Decrease utilisation of next least cost-effective intervention (Intervention B) 
The third step is to disinvest in the second least cost-effective intervention available, in this case 
intervention B (ICER = $80,000 per QALY).  This is achieved by decreasing the existing 
utilisation of the intervention by 50%.  In this case the utilisation of intervention B is reduced 
from 200 to 100.  The consequences of this change are shown by the highlighted text in Table 37. 
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Table 37. Worked example – Step 3 
Intervention 
ICER 
($/QALY) 
Existing 
utilisation 
Eligible 
beneficiaries 
Unserved 
eligible 
beneficiaries 
Inc. 
Cost 
Inc. 
QALYs 
Total 
inc.cost 
Total 
inc. 
QALYs 
A 250,000 50 250 200 25,000 0.10 1,250,000 5 
B 80,000 100 350 250 20,000 0.25 2,000,000 25 
C 30,000 50 400 350 15,000 0.50 750,000 25 
D 25,000 150 200 50 20,000 0.80 3,000,000 120 
  350     7,000,000 175 
 
Step 4 - Increase utilisation of next most cost-effective intervention (Intervention C) to 
achieve expenditure neutrality 
The fourth and final step is to increase utilisation of the second most cost-effective intervention in 
order to achieve expenditure neutrality, in this case intervention C (ICER = $30,000 per QALY).  
Expenditure neutrality was achieved by decreasing the size of the unserved patient population 
from 350 to 200, a decrease of approximately 43%.  Net change in expenditure is zero (total 
incremental cost of $9,250,000) with a gain in aggregate health of 85 QALYs (Table 38).    
 
Table 38. Worked example – Step 4 
Intervention 
ICER 
($/QALY) 
Existing 
utilisation 
Eligible 
beneficiaries 
Unserved 
eligible 
beneficiaries 
Inc. 
Cost 
Inc. 
QALYs 
Total 
inc.cost 
Total 
inc. 
QALYs 
A 250,000 50 250 200 25,000 0.10 1,250,000 5 
B 80,000 100 350 250 20,000 0.25 2,000,000 25 
C 30,000 200 400 200 15,000 0.50 3,000,000 100 
D 25,000 150 200 50 20,000 0.80 3,000,000 120 
  500     9,250,000 250 
 
The worked example illustrates the stepwise approach.  The process was continued until there was 
no further opportunity for reallocation between interventions.   
 
For each hypothetical reallocation, I present the aggregate health gain in terms of QALYs and the 
number of additional beneficiaries receiving the most effective treatment option, i.e., of the pair 
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of treatments available, those that received the intervention as opposed to the comparatorxvii.  In 
the worked example, 50 additional beneficiaries received the most effective available treatment 
option following the reallocation of expenditures.  I also report the ICER of the marginal 
intervention, i.e., the intervention with the highest ICER for which utilisation was increased.  
Lastly, I report the average incremental QALY gain per beneficiary affected by the reallocation, 
i.e., the average incremental QALY gain per beneficiary for whom the reallocation changed the 
intervention they received.    
 
In the worked example, the reallocation of expenditures is illustrated using the net present value 
of future commitments.  An identical process was used when considering expenditures in the year 
following first use of the intervention.  This more restrictive analysis considered the difference in 
cost between the intervention and comparator in the first 12 months of use.   
 
Also reported are the findings of an additional analysis when the utilisation of dominant 
interventions was increased while maintaining the existing utilisation of non-dominant 
interventions, i.e., those associated with a positive ICER.  As dominant interventions are more 
effective and less costly than their comparator, this hypothetical reallocation results in aggregate 
health gains and cost-savings. 
 
From a practical standpoint, I concluded it was infeasible to increase utilisation of the intervention 
to 100%.  Despite Medicare covering a particular intervention, patients may be reluctant to 
receive it.  Also, it may often be the case that physicians are reluctant to change their approach to 
care and will be resistant to offering a different intervention.  Cost-effectiveness studies report the 
cost-effectiveness of an intervention when used for the average patient in a population.  However, 
populations are often likely to be heterogeneous, with interventions of high value for some 
patients but of low value for others.  Therefore, in the base-case analysis a maximum of a 50% 
shift in patients between competing interventions was allowed, with a range of 10%-90% 
reported.  For example, if 400,000 beneficiaries were eligible for a relatively high value 
                                                 
xvii N.B. As noted, an assumption was that each eligible beneficiary received care.  If the beneficiary did not receive 
the intervention, it was assumed they received the comparator.  
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intervention, and 100,000 received it, it was assumed that further investment could increase 
utilisation by 50% of the 300,000 eligible beneficiaries not currently receiving it, i.e., 150,000 
beneficiaries.  If 200,000 beneficiaries received a relatively low value service, I assumed that 
utilisation could only be reduced by 50% (10% to 90% range), i.e., to 100,000 beneficiaries.   
 
Hypothetical reallocations were performed using Microsoft Excel. 
 
7.2.2.2 Objective 2 
The second research objective was to estimate the impact of the hypothetical reallocation of 
expenditures between interventions on the distribution of expenditures across disease areas and 
types of intervention.  As described in Section 4.7.5.7, interventions were characterised with 
respect to disease area, magnitude of incremental health gain, type of intervention, size of patient 
population, cost of intervention, and potential budget impact.  To determine the impact of the 
reallocation on the distribution of expenditures between the aforementioned categories, I made a 
comparison between the distribution of expenditures prior to and following the hypothetical 
reallocation. 
 
7.2.3. Datasets 
I evaluated two datasets.  First, I present the results when using a dataset limited to covered 
interventions, i.e., those subject to positive coverage decisions (Table 40).  Second, I present the 
results when using a dataset including interventions subject to either positive or non-coverage 
decisions (Table 41).  Results are presented separately when including interventions irrespective 
of the unit of health gain, and when including only interventions for which an estimate of 
incremental QALY gain was available. 
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7.3. Results 
Figure 21 shows the process taken to arrive at the final sample of interventions.  Only 
interventions with complete data were included.  Thirty-six of the 64 interventions associated 
with an estimate of cost-effectiveness were included in the final sample (Table 39).  Twenty-six 
of the 28 excluded interventions were excluded due to incomplete data, for which the most 
common reason was the inability to accurately identify the utilisation rate for the intervention in 
the indicated patient population.  For example, in the NCD for ultrasound stimulation for non-
union fracture healing, coverage of the intervention was restricted to patients with non-union bone 
fractures. (CMS 2005f)  However, despite identifying an ICD-9 code for non-union fracture 
healing (733.82) and for fractures of the relevant bones (tibial [823]; scaphoid [814]; radius 
[813]), it was not possible to identify beneficiaries with a combination of both codes in the 
Medicare claims database.  For other interventions, the appropriate patient population was 
unidentifiable in the Medicare claims database, an example being the NCD for intravenous 
immune globulin for autoimmune mucocutaneous blistering diseases. (CMS 2002a)  The 
appropriate patient population was identified for two of the three indications for which the 
intervention received a positive coverage decision (bullous pemphigoid and pemphigus vulgaris).  
For the third indication, pemphigus foliaceus, the Medicare claims database did not include 
beneficiaries that suffered from this condition (ICD-9 694.5) and thus this diagnosis and treatment 
combination was excluded from the final dataset.   
 
Two interventions were excluded as they were dominated by another intervention in the sample.  
The first was breast biopsy using stereotactic core needle image guidance, an intervention 
estimated to be dominated by ultrasound image guidance for the same indication. (Liberman et al. 
1998)  The second was screening immunoassay fecal-occult blood test (iFOBT) for colorectal 
cancer screening.  The iFOBT test was extendedly dominated by a second screening 
immunoassay fecal-occult blood test, Hemoccult II, and was thus excluded from the sample 
included here. (AHRQ 2003) 
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Table 39. Interventions eligible for reallocation 
Patient Dyad Characteristics Utilisation Cost-effectiveness 
Costs in year following first 
use 
Intervention Population 
Eligible 
patient 
population 
Received Tx 
for diagnosis 
Eligible but did 
NOT receive 
treatment 
Inc. cost 
Inc. 
QALY ICER 
Cost of 
intervention 
Cost of 
comparator 
Cost 
difference 
in yr1 
Ventricular Assist 
Devices 
Destination Therapy - 
Chronic end-stage heart 
failure patients that meet 
specified criteria 
1,474,420 20 1,474,400 $416,545 0.42 $986,630 $331,878 $65,177 $266,701 
Transmyocardial 
revascularisation 
Patients with severe angina 
(stable or unstable), which 
has been found refractory 
to standard medical 
therapy. 
143,180 40 143,140 $19,777 0.04 $489,417 $18,123 $4,086 $14,037 
Liver transplantation 
Patients suffering from 
hepatitis B 
14,320 40 14,280 $150,967 0.74 $204,186 $117,624 $8,558 $109,066 
Ocular Photodynamic 
Therapy with 
Verteporfin 
 Macular Degeneration - 
Predominately classic 
subfoveal CNV lesions 
73,400 1,200 72,200 $14,504 0.03 $195,566 $9,570 $0 $9,570 
Lung Volume Reduction 
Surgery 
Severe upper lobe 
emphysema 
109,180 120 109,060 $60,243 0.50 $120,460 $87,905 $28,727 $59,178 
Implantable 
Cardioverter 
Defibrillators (ICDs) 
Patients with documented 
familial or inherited 
conditions with a high risk 
of life-threatening 
ventricular 
tachyarrhythmias 
1,305,060 28,180 1,276,880 $21,102 0.16* $99,782 $92,783 $65,846 $26,937 
Pancreas transplantation 
Pancreas Transplants - 
Patients that meet the 
specified criteria (type 1 
diabetes etc) 
67,920 720 67,200 $198,351 2.20 $90,159 $227,788 $4,218 $223,570 
Positron Emission 
Tomography 
Esophageal Cancer 80,400 200 80,200 $5,598 0.07 $81,485 $4,192 $1,438 $2,755 
Implantable 
Cardioverter 
Defibrillators (ICDs) 
NIDCM, documented prior 
MI, Class II and III heart 
failure 
3,240 0 3,240 $77,113 1.01 $76,244 $37,474 $7,090 $30,384 
Deep Brain Stimulation  Parkinson's Disease 727,800 39,860 687,940 $47,121 0.72 $65,970 $53,853 $5,988 $47,864 
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Patient Dyad Characteristics Utilisation Cost-effectiveness 
Costs in year following first 
use 
Intervention Population 
Eligible 
patient 
population 
Received Tx 
for diagnosis 
Eligible but did 
NOT receive 
treatment 
Inc. cost 
Inc. 
QALY ICER 
Cost of 
intervention 
Cost of 
comparator 
Cost 
difference 
in yr1 
Implantable 
Cardioverter 
Defibrillators (ICDs) 
Documented sustained 
ventricular 
tachyarrhythmia 
959,060 28,040 931,020 $34,375 0.65* $39,971 $101,310 $73,912 $27,398 
Autologous Stem Cell 
Transplantation 
(AuSCT)  
Patients suffering from 
Multiple Myeloma 
1,600 80 1,520 $83,123 1.69* $37,275 $2,396 $106 $2,289 
Acupuncture Osteoarthritis 744,860 0 744,860 $536 0.02 $20,383 $97 $0 $97 
Lumbar Artificial Disc 
Replacement 
Back pain 140,700 0 140,700 $7,625 0.39 $18,939 $25,986 $16,547 $9,439 
Laparoscopic adjustable 
gastric banding (LAGB) 
- bariatric surgery 
Treatment of Morbid 
Obesity 
5,983,500 6,600 5,976,900 $8,100 0.45 $18,028 $3,366 $142 $3,224 
Cochlear implantation 
Post lingually hearing 
impaired patients 
32,340 1,120 31,220 $41,520 3.80 $11,653 $26,748 $0 $26,748 
Hyperbaric Oxygen 
Therapy 
Hypoxic Wounds and 
Diabetic Wounds of the 
Lower Extremities - 
Diabetic Wounds of the 
Lower Extremities 
1,240,600 43,800 1,196,800 $1,771 0.27 $6,649 $524 $0 $524 
Electrical Bioimpedance 
for Cardiac Output 
Monitoring 
Hypertension 1,429,060 0 1,429,060 $314 0.05 $6,408 $628 $515 $113 
External 
Counterpulsation (ECP) 
Therapy 
Various cardiac conditions 5,018,500 0 5,018,500 $820 0.26 $3,264 $5,343 $0 $5,343 
Positron Emission 
Tomography 
Head and Neck Cancers 576,000 800 575,200 $1,425 0.44 $3,224 $6,022 $4,597 $1,425 
Screening Immunoassay 
Fecal-Occult Blood Test 
-  Hemoccult II 
Screening for colon cancer 533,200 56,400 476,800 $400 0.13* $1,318 $5 $0 $5 
Ultrasound image 
guidance 
Breast cancer - Breast 
biopsy  
1,986,600 49,600 1,937,000 -$358 NA Dominates $613 $972 -$358 
Foot care 
Diabetic Peripheral 
Neuropathy with Loss of 
Protective Sensation 
473,600 400 473,200 -$386 0.05 Dominates $207 $0 $207 
   
 289
Patient Dyad Characteristics Utilisation Cost-effectiveness 
Costs in year following first 
use 
Intervention Population 
Eligible 
patient 
population 
Received Tx 
for diagnosis 
Eligible but did 
NOT receive 
treatment 
Inc. cost 
Inc. 
QALY ICER 
Cost of 
intervention 
Cost of 
comparator 
Cost 
difference 
in yr1 
Cardiac rehabilitation 
programs 
Acute Myocardial 
Infarction 
200,200 46,400 153,800 -$470 0.60 Dominates $69 $0 $69 
Cardiac rehabilitation 
programs 
Percutaneous Transluminal 
Coronary Angioplasty 
631,400 152,400 479,000 -$470 0.60 Dominates $69 $0 $69 
Positron Emission 
Tomography (FDG) 
Breast Cancer - Initial 
Staging of Axillary Lymph 
Nodes 
1,257,240 0 1,257,240 $609 NA Dominates $901 $0 $901 
Positron Emission 
Tomography 
Lung Cancer (non-small 
cell) 
838,400 3,000 835,400 -$698 NA Dominates $2,038 $2,736 -$698 
Positron Emission 
Tomography (FDG) 
Breast cancer - staging and 
restaging 
1,951,200 2,400 1,948,800 -$759 NA Dominates $953 $0 $953 
Ambulatory BP 
monitoring 
White coat hypertension 250,800 1,800 249,000 -$915 NA Dominates $110 $14 $96 
Positron Emission 
Tomography (FDG) 
Colorectal Cancer 605,000 800 604,200 -$892 NA Dominates $2,038 $2,929 -$892 
Positron Emission 
Tomography (FDG) 
Melanoma 388,600 600 388,000 -$906 NA Dominates $2,038 $2,943 -$906 
Cryosurgery Ablation 
Primary treatment for 
clinically localised prostate 
cancer. (Stages T1-T3) 
1,388,600 5,000 1,383,600 -$2,189 NA Dominates $6,017 $8,206 -$2,189 
Positron Emission 
Tomography (FDG)  
Ovarian cancer 230,500 0 230,500 -$3,467 NA Dominates $2,956 $0 $2,956 
Warm-Up Wound 
Therapy aka Noncontact 
Normothermic Wound 
Therapy NNWT  
Stage III and IV ulcers 1,119,120 0 1,119,120 -$14,706 0.12 Dominates $5,753 $8,431 -$2,678 
Intravenous Immune 
Globulin  
Bullous Pemphigoid 8,400 200 8,200 -$157,773 NA Dominates $44,613 $105,321 -$60,708 
Intravenous Immune 
Globulin  
Pemphigus Vulgaris 3,600 200 3,400 -$217,840 NA Dominates $102,656 $165,777 -$63,121 
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Figure 21. Process of identifying final set of coverage decisions for analysis 
  
7.4. Reallocation including only positive coverage decisions 
Prior to reallocation, 470,000 beneficiaries received one of the included interventions, at a cost of 
approximately $8 billion.  Findings of the hypothetical reallocation are reported when adjusting 
utilisation rates by 50% (range; 10% – 90%). 
 
First, a dataset including only positive coverage decisions was considered (Table 40).  When 
considering the net present value of future commitments and expenditures in the year following 
first use of the intervention, reallocating expenditures to maximise aggregate health while 
maintaining a net total expenditure change of zero resulted in approximately an additional 5.85 
140 decision memos
103 decision memos reviewed
15 non-
coverage decisions
49 positive 
coverage decisions
267 individual coverage decisions
37 decision memos excluded 
based upon exclusion criteria
64 coverage decisions with
a relevant  economic evaluation
203 coverage decisions - no 
relevant economic evaluation
20 decisions excluded 8 decisions excluded
29 positive coverage 
decisions in analysis
7 non-coverage 
decisions in analysis
   
 291
(1.17 – 10.5) million and 6.13 (1.23 – 11.04) million beneficiaries receiving the most effective 
available intervention, respectively.  This corresponded to gains in aggregate health of 
approximately 0.79 (0.16 – 1.42) million and 0.92 (0.18 – 1.65) million QALYs gained.  
Approximately 5.95 (1.19 – 10.72) million and 6.23 (1.25 – 11.22) million beneficiaries were 
affected by the reallocation, i.e., the reallocation changed the intervention they received, when 
considering the net present value of future commitments and expenditures in the year following 
first use of the intervention, respectively; corresponding to a per beneficiary gain of 0.13 QALYs 
and 0.15 QALYs.  The ICER of the marginal technology, autologous stem cell transplantation 
(AuSCT), was $37,275 per life year saved when considering the net present value of future 
commitments and expenditures in the year following first use of the intervention. 
 
When increasing the utilisation of dominant interventions, while maintaining the existing 
utilisation rate of interventions with positive ICERs, an additional 4.23 (0.85 – 7.62) million 
beneficiaries, approximately, received the dominant intervention (Table 40).  This approach 
yielded savings of approximately $4.71 ($0.94 - $8.48) billion and $1.94 ($0.39 – $3.50) billion 
when considering the net present value of future commitments and expenditures in the year 
following first use of the intervention, respectively.  Gains in aggregate health of approximately 
202,000 (40,000 – 363,000) QALYs were achieved.  Approximately 4.23 (0.85 – 7.62) million 
beneficiaries were affected by the reallocation, i.e., the reallocation changed the intervention they 
received, equating to a gain of approximately 0.05 QALYs per beneficiary.  Savings of $1,113 
and $459 per beneficiary were achieved when considering the net present value of future 
commitments and expenditures in the year following first use of the intervention, respectively. 
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Table 40. Reallocation including only positive coverage decisions 
 
 
 Net present value of future commitments Year following first use of intervention  
Reallocation 
Additional 
beneficiaries 
receiving care  
(50% [10-
90%]) 
Cost savings 
(millions) 
(50% [10-
90%]) 
QALY gain 
(50% [10-
90%]) 
Additional 
beneficiaries 
receiving care  
(50% [10-
90%]) 
Cost savings 
(millions) 
(50% [10-
90%]) 
QALY gain 
(50% [10-
90%]) 
All interventions – irrespective of unit of health 
outcome      
Maintaining 
existing levels of 
expenditure 
5,854,613 
(1,170,923 - 
10,538,304) 
NA 
790,392 
(158,078 – 
1,422,706) 
6,133,469 
(1,226,694 -  
11,040,245) 
NA 
 915,878  
(183,176 - 
1,648,580) 
Increase in 
utilisation of 
dominant 
interventions 
4,231,800 
(846,360 -
7,617,240) 
$4,709 
($942 - $8,476)
201,670 
(40,334 - 
363,006) 
4,231,800 
(846,360 -
7,617,240) 
$1,943  
($389 - 
$3,498) 
201,670 
(40,334 - 
363,006) 
        
Only interventions with incremental QALY gain data     
Maintaining 
existing levels of 
expenditure 
1,637,264 
(327,453- 
2,947,076) 
NA 
537,340 
(107,468 - 
967,211) 
1,775,312 
(365,802 - 
3,292,221) 
NA 
634,332  
(126,866 - 
1,141,797) 
Increase in 
utilisation of 
dominant 
interventions 
553,000 
(110,600 - 
995,400) 
$240 
($48 - $432) 
201,670 
(40,334 - 
363,006) 
553,000 
(110,600- 
995,400) 
-$70.86 
(-$14.17 –  
(-$128.56)) 
201,670 
(40,334 - 
363,006) 
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Table 40 also includes the findings of an analysis using a dataset restricted to interventions for 
which an estimate of incremental QALY gain was availablexviii.  Reallocating expenditures to 
maximise aggregate health while maintaining a net change in total expenditure of zero resulted in 
approximately an additional 1.64 million (330,000 – 2.95 million) and 1.78 (0.37 – 3.29) million 
beneficiaries receiving the most effective available intervention when considering the net present 
value of future commitments and expenditures in the year following first use of the intervention, 
respectively.  This corresponded to gains in aggregate health of approximately 0.54 (0.11 – 0.97) 
million and 0.63 (0.13 – 1.14) million QALYs.  Approximately 1.74 (0.35 – 3.12) million and 
2.56 (0.31 – 2.80) million beneficiaries were affected by the reallocation, i.e., the reallocation 
changed the intervention they received, when considering the net present value of future 
commitments and expenditures in the year following first use of the intervention, respectively; 
corresponding to a per beneficiary QALY gain of approximately 0.31 and 0.41.  The ICER of the 
marginal technology was $11,653 per QALY (cochlear implantation for post lingually hearing 
impaired patients) and $18,028 per QALY (bariatric surgery [LAGB] for the treatment of morbid 
obesity) when considering the net present value of future commitments and expenditures in the 
year following first use of the intervention, respectively. 
 
When increasing the utilisation of dominant interventions, while maintaining the existing 
utilisation rates of interventions with positive ICERs, an additional 553,000 (111,000 – 995,000) 
beneficiaries, approximately, received the dominant intervention (Table 40).  Cost-savings were 
estimated at approximately $240 ($48 - $432) million when considering the net present value of 
future commitments.  When considering expenditures in the year following first use of the 
interventions, dominant interventions were associated with an increased expenditure of $70.86 
($14.17 - $128.56) million.  This was because the included dominant interventions were 
associated with a positive expenditure in the year following their first use before yielding cost-
savings in future years. The aggregate health gain associated with this reallocation was 
approximately 202,000 (40,000 – 363,000) QALYs.  Per beneficiary incremental QALY gain was 
approximately 0.36 and per beneficiary savings approximately $434 when considering the net 
                                                 
xviii N.B. This dataset includes cost-effectiveness studies reporting cost-per life year gained estimates with incremental 
survival gain adjusted with a utility weight.  
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present value of future commitments.  When considering expenditures in the year following first 
use of the intervention, there was an additional expenditure of $128 per beneficiary.   
 
7.4.1. Reallocation including positive and non-coverage decisions 
A second set of analyses used a dataset that included both positive and non-coverage decisions 
(Table 41).   
 
Reallocating expenditures to maximise aggregate health while maintaining a net change in total 
expenditure of zero resulted in approximately an additional 11.12 (2.22 – 20.01) million and 6.73 
(1.35 – 12.11) million beneficiaries receiving the most effective available intervention when 
considering the net present value of future commitments and expenditures in the year following 
first use of the intervention, respectively.  This corresponded to approximately 1.86 (0.37 – 3.36) 
million and 580,000 (116,000 – 1.00 million) QALYs gained.  Approximately 11.22 (2.24 – 
20.19) million and 6.88 (1.38 – 12.38) million beneficiaries were affected by the reallocation, i.e., 
the reallocation changed the intervention they received, when considering the net present value of 
future commitments and expenditures in the year following first use of the intervention, 
respectively; corresponding to a per beneficiary incremental QALY gain of approximately 0.17 
and 0.08.  The ICER of the marginal technology was $18,028 per QALY (bariatric surgery 
[LAGB] for the treatment of morbid obesity) and $3,264 per QALY (External Counterpulsation 
(ECP) Therapy) when considering the net present value of future commitments and expenditures 
in the year following first use of the intervention, respectively. 
 
When increasing the utilisation of dominant interventions, while maintaining existing utilisation 
rates of interventions with positive ICERs, an additional 5.54 million (1.11 – 9.96 million) 
beneficiaries, approximately, received the dominant intervention (Table 41).  This approach 
yielded savings of approximately $12.95 ($2.59 – $23.32) billion and $2.54 ($0.51 – $4.56) 
billion when considering the net present value of future commitments and expenditures in the 
year following first use of the intervention, respectively.  Aggregate health gain was 
approximately 269,000 (54,000 – 484,000) QALYs.  Approximately 5.54 (1.12 – 9.96) million 
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beneficiaries were affected by the reallocation, i.e., the reallocation changed the intervention they 
received, equating to a per beneficiary QALY gain of approximately 0.05 QALYs.  Per 
beneficiary savings of $2,340 and $458 were achieved when considering the net present value of 
future commitments and expenditures in the year following first use of the intervention, 
respectively. 
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Table 41. Reallocation including positive and non-coverage decisions 
 
 Net present value of future commitments Year following first use of intervention 
Reallocation 
Additional 
beneficiaries 
receiving care  
(50% [10-
90%]) 
Cost savings 
(millions) 
(50% [10-90%]) 
QALY gain 
(50% [10-
90%]) 
Additional 
beneficiaries 
receiving care 
(50% [10-
90%]) 
Cost savings 
(millions) 
(50% [10-
90%]) 
QALY gain 
(50% [10-
90%]) 
All interventions – irrespective of unit of health outcome   
Maintaining 
existing levels of 
expenditure 
11,118,104 
(2,223,621 - 
20,012,587 
NA 
1,863,736 
(372,747 - 
3,354,725) 
6,729,994 
(1,345,999 - 
12,113,990) 
NA 
580,281 
(116,056 - 
1,044,506) 
Increase in 
utilisation of 
dominant 
interventions 
5,535,230 
(1,107,046 - 
9,963,414) 
$12,954 
 ($2,591 - 
$23,318) 
268,817  
(53,763 - 
483,871) 
5,535,230 
(1,107,046 - 
9,963,414) 
$2,535  
($507 - $4,563)
268,817 
(53,763 - 
483,871) 
        
Including only interventions with QALY data     
Maintaining 
existing levels of 
expenditure 
 6,141,655 
(1,228,331 - 
11,054,979) 
NA 
1,614,536 
(322,907 - 
2,906,165) 
2,100,071 
(420,014 - 
3,780,128) 
NA 
527,432 
(105,486 - 
949,377) 
Increase in 
utilisation of 
dominant 
interventions 
 1,112,560 
(222,512 -
2,002,608) 
$8,469 
($1,694 - 
$15,244) 
268,817 
(53,763 - 
483,871) 
1,112,560 
(222,512 -
2,002,608) 
$1,428 
($286 - $2,570)
268,817 
(53,763 - 
483,871) 
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Table 41 also includes the findings of an analysis of a dataset restricted to interventions for which 
an estimate of incremental QALY gain was available. xix  Reallocating expenditures to maximise 
aggregate health while maintaining a net change in total expenditure of zero resulted in 
approximately an additional 6.14 (1.23 – 11.05) million and 2.10 (0.42– 3.78) million 
beneficiaries receiving the most effective available intervention when considering the net present 
value of future commitments and expenditures in the year following first use of the intervention, 
respectively.  This corresponded to gains in aggregate health of approximately 1.61 (0.32 – 2.91) 
million QALYs and 530,000 (105,000 – 949,000) QALYs.  Approximately 1.74 (0.35 – 3.12) 
million and 2.56 (0.31 – 2.80) million beneficiaries were affected by the reallocation, i.e., the 
reallocation changed the intervention they received, when considering the net present value of 
future commitments and expenditures in the year following first use of the intervention, 
respectively; corresponding to a per beneficiary incremental QALY gain of approximately 0.31 
and 0.41.  The ICER of the marginal technology was $11,653 per QALY (cochlear implantation 
for post lingually hearing impaired patients) and $18,028 per QALY (bariatric surgery [LAGB] 
for the treatment of morbid obesity) when considering the net present value of future 
commitments and expenditures in the year following first use of the intervention, respectively.  
Approximately 6.24 (1.25 – 11.23) million and 2.20 (0.44 – 3.96) million beneficiaries were 
affected by the reallocation, i.e., the reallocation changed the intervention they received, when 
considering the net present value of future commitments and expenditures in the year following 
intervention implementation, respectively; corresponding to a per beneficiary QALY gain of 
approximately 0.26 and 0.24.  The ICER of the marginal technology was $18,028 per QALY 
(bariatric surgery [LAGB] for the treatment of morbid obesity) and $3,264 per QALY (External 
Counterpulsation (ECP) Therapy) when considering the net present value of future commitments 
and expenditures in the year following first use of the intervention, respectively. 
 
When increasing the utilisation of dominant interventions, while maintaining the existing 
utilisation of interventions associated with a positive ICER, approximately 1.11 (0.22 – 2.00) 
million additional beneficiaries received care (Table 41).  Cost-savings were approximately $8.47 
($1.69- $15.24) billion and $1.43 ($0.29 – $2.57) billion when considering the net present value 
                                                 
xix N.B. This dataset includes cost-effectiveness studies reporting cost-per life year gained estimates with incremental 
survival gain adjusted with a utility weight. 
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of future commitments and expenditures in the year following first use of the intervention, 
respectively.  Aggregate health gain associated with this reallocation was approximately 269,000 
(54,000 – 484,000) QALYs.  Per beneficiary incremental QALY gain was approximately 0.24, 
and per beneficiary savings were approximately $7,600 and $1,300 when considering the net 
present value of future commitments and expenditures in the year following first use of the 
intervention, respectively.   
 
7.4.2. Effect of reallocation on distribution of expenditures 
Using different criteria to allocate resources will inevitably have an effect on the distribution of 
expenditures across interventions and patient populations.  The effect of using a cost-effectiveness 
decision rule was evaluated by comparing the existing distribution of expenditures with the 
distribution following a 50% reallocation.  In each case, expenditures were reallocated to 
maximise aggregate health while maintaining a net change in total expenditure of zero.  To 
include the maximum number of interventions, the dataset that included positive decisions, non-
coverage decisions, and dominant interventions irrespective of measure of health outcome, was 
used.   
 
First, interventions were categorised into the following broad disease classifications: cardiology, 
oncology, and other (Section 4.7.5.7).  Prior to reallocation, approximately 55% of beneficiaries 
in the dataset received a cardiology-related intervention, approximately 25% oncology-related, 
with the remaining 20% other (Table 42).  Following reallocation, a greater proportion of 
beneficiaries received an oncology-related intervention (approximately 43%), with fewer 
receiving a cardiology-related intervention (approximately 34%) or other (approximately 24%).   
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Table 42. Effect of expenditure reallocation on distribution across broad disease 
classifications 
Disease area 
Prior to reallocation Following reallocation 
No. of 
beneficiaries 
Distribution 
No. of 
beneficiaries 
Distribution 
Cardiology 256,880 54.65% 3,893,420 33.60% 
Oncology 118,880 25.29% 4,937,110 42.60% 
Other 94,260 20.05% 2,757,594 23.80% 
  470,020 100% 11,634,101 100% 
 
Interventions were also categorised with respect to type.  Categories included Treatment, 
Diagnostic, and Other (Section 4.7.5.7).  Prior to reallocation, the majority of beneficiaries 
received an intervention categorised as Other (approximately 42%), with the remaining 
beneficiaries receiving interventions categorised as Treatment (approximately 33%) or Diagnostic 
(approximately 25%) (Table 43).  Following reallocation there was an increase in the proportion 
of beneficiaries receiving an intervention categorised as Treatment (approximately 50%) or 
Diagnostic (approximately 44%).  The proportion of beneficiaries receiving interventions 
categorised as Other decreased to approximately 7%. 
 
Table 43. Effect of expenditure reallocation on distribution across different types of 
interventions 
Type of 
intervention 
Prior to reallocation Following reallocation 
No of 
beneficiaries 
Distribution 
No of 
beneficiaries 
Distribution 
Treatment 155,220 33.0% 5,754,824 49.7% 
Diagnostic 115,600 24.6% 5,081,100 43.8% 
Other 199,200 42.4% 752,200 6.5% 
  470,020 100.00% 11,588,124 100.0% 
N.B. Type of intervention “Other” includes health education, preventative care, and mobility 
assistive equipment 
Interventions were categorised with respect to the size of the eligible patient population.  
Categories included Large (>1 million beneficiaries), Medium (50,000 – 1 million beneficiaries), 
and Small (<50,000 beneficiaries) (Section 4.7.5.7).  Prior to reallocation the majority of 
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beneficiaries (approximately 71%) received an intervention categorised as Medium, with 
approximately 29% and 0.3% of beneficiaries receiving an intervention classified as Large and 
Small, respectively (Table 44).  Following reallocation the majority of beneficiaries received an 
intervention categorised as Large (78%), with 21.8% and 0.2% of beneficiaries receiving an 
intervention that fell into the categories Medium and Small, respectively. 
  
Table 44. Effect of expenditure reallocation on distribution across patient populations of 
different sizes 
Size of untreated 
patient population 
Prior to reallocation Following reallocation 
No of 
beneficiaries 
Distribution 
No of 
beneficiaries 
Distribution 
Large 135,600 28.8% 9,034,894 78.0% 
Medium 332,780 70.8% 2,530,240 21.8% 
Small 1,640 0.3% 22,990 0.2% 
  470,020 100.00% 11,588,124 100.00% 
 
The impact of resource reallocation at the patient level with respect to incremental health gains 
and costs was evaluated.  For these analyses, the dataset that included only interventions with an 
associated estimate of incremental QALY gain was used.  First, the impact of expenditure 
reallocation on the distribution of health gains across Medicare beneficiaries was evaluated.  Prior 
to reallocation the estimated per beneficiary incremental QALY gain was 0.49 QALYs (95% CI 
0.53 – 1.05), compared to 0.29 (95% CI 0.18 – 0.75) following reallocation.  
 
The impact of expenditure reallocation on the average incremental cost per beneficiary was 
evaluated (Table 45).  Prior to reallocation the estimated average per beneficiary incremental cost 
was $7,711 (95% CI -$28,143 – $43,563), compared to $6,728 (95% CI -$12,874 – $13,500) 
following reallocation.   
 
The impact of expenditure reallocation on the average incremental cost per beneficiary in the year 
following first use of the intervention was evaluated (Table 45).  Prior to reallocation the 
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estimated average per beneficiary incremental annual cost of interventions was $7,800 (95% CI -
$26,700 - $42,200), compared to $1,600 (95% CI -$6,400 - $9,500) following reallocation.   
 
Table 45.  Effect of expenditure reallocation on distribution of resources at the patient level 
Average impact per beneficiary Prior to reallocation Following reallocation 
Incremental QALY gain 
0.49 QALYs 
(95% CI 0.53 – 1.05) 
0.29 QALYs 
(95% CI 0.18 – 0.75) 
Incremental cost 
$7,711 
(95% CI -$28,143 - $43,563) 
$6,728 
(95% CI -$12,874 - $13,500) 
Cost in year following first use 
of intervention 
$7,800 
(95% CI -$26,700 - $42,200) 
$1,600 
(95% CI -$6,400 - $9,470) 
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7.5. Discussion 
This research is an ambitious attempt to estimate the impacts of using a cost-effectiveness 
decision rule to allocate Medicare resources on overall expenditures and health outcomes.  To the 
best of my knowledge, this is the first research of its kind.  While frameworks for efficient 
resource allocation exist, e.g., mathematical programming, inhibitive data requirements reduce 
their practicality.  Studies considered in my literature review were of limited relevance to the 
methodological approach taken here and were limited in scope, i.e., they focused on a single 
indication or type of service. (Cromwell et al. 1998;Zaric & Brandeau 2001)  This empirical work 
has two objectives:  to estimate potential gains in aggregate health from reallocating expenditures 
using a cost-effectiveness decision rule in terms of the net present value of future commitments 
and expenditures in the 12 months following first use of an intervention; and, to estimate the 
impact of reallocation on the distribution of resources among disease areas and types of 
intervention. 
 
7.5.1. Summary of findings – Gains in efficiency 
The total cost of providing the included interventions in 2007 was estimated to be almost $8 
billion, approximately 1.8% of Medicare’s budget in that year (approximately $440 billion).  Prior 
to reallocation, approximately 470,000 Medicare beneficiaries received one of the included 
interventions. 
 
The first set of analyses used a dataset that included interventions subject to positive coverage 
decisions.  When including all dominant interventions, i.e., irrespective of reported unit of health 
gain, reallocating expenditures (50% reallocation) while maintaining a net change in total 
expenditure of zero resulted in almost 6 million additional beneficiaries receiving the most 
effective option, with a corresponding gain in aggregate health of almost 800,000 QALYs.  When 
using a dataset that included only interventions with an associated estimate of incremental QALY 
gain, findings remained substantial but were smaller in magnitude; 1.6 million additional 
beneficiaries received the most effective option, with an aggregate health gain of approximately 
550,000 QALYs.  Substantial gains were also achieved when increasing the utilisation (50% 
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decrease in unserved eligible population) of dominant interventions while maintaining existing 
utilisation rates of interventions associated with positive ICERs.  Increasing the utilisation of the 
12 included interventions estimated to be dominant allowed for approximately 4.2 million 
additional beneficiaries to receive the most effective option, with a corresponding gain in 
aggregate health of approximately 200,000 QALYs and savings of $4.8 billion.  
 
When considering expenditures in the year following first use of an intervention, findings were 
broadly consistent with the findings when considering the net present value of future benefits with 
respect to the number of additional beneficiaries receiving the most effective option and the 
corresponding gains in aggregate health.  This was because for the interventions considered here, 
the difference in expenditures between interventions and comparators when considering the 12 
months following first use of an intervention were proportionally similar to when considering the 
net present value of future commitments.  However, as the magnitude of the incremental cost in 
terms of net present value of future commitments was greater than the difference in expenditures 
between competing interventions in the year following first use of an intervention, cost-savings 
achieved when increasing utilisation of dominant interventions was greatest when considering the 
former ($4.8 vs. $1.9 billion).   
 
Interestingly, when considering the dataset that included only interventions with an associated 
estimate of incremental QALY gain, increasing the utilisation of dominant interventions while 
maintaining existing utilisation rates for interventions associated with positive ICERs resulted in a 
positive net expenditure in the year following first use of an intervention ($71 million).  This is 
because, despite being cost-saving when accounting for downstream costs, the included dominant 
interventions required a positive expenditure in the year following first use of an intervention.xx     
 
The pattern of findings was qualitatively similar when including interventions associated with 
non-coverage decisions in the dataset.  While CMS decided not to cover these interventions, they 
                                                 
xx These interventions include foot care for diabetic patients suffering from diabetic peripheral neuropathy 
(DPN) with loss of protective sensation, and cardiac rehabilitation programmes following acute 
myocardial infarction or percutaneous transluminal coronary angioplasty. 
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were included here to evaluate the impact of using cost-effectiveness as the only criterion for 
resource allocation.  However, while the pattern of findings was similar, the magnitude of each 
reported statistic was greater (Table 41).  This is because of the relatively favourable cost-
effectiveness estimates associated with non-covered interventions.  Three were estimated to be 
dominant, and the highest ICER of the remaining four was approximately $20,000 per QALY 
(acupuncture for osteoarthritis).  Also, as these interventions were associated with large potential 
eligible patient populations, their inclusion had a large impact on the results of the analysis.  
 
7.5.2. Summary of findings – Effect of reallocation on the distribution of resources 
It is inevitable that changing resource allocation criteria will affect the distribution of resources.  
The impact of using a cost-effectiveness decision rule to reallocate resources on the distribution 
of expenditures across disease areas, intervention type, and size of eligible patient population was 
evaluated.  The impact of reallocation at the patient level was also evaluated, with the average per 
patient incremental QALY gain, incremental cost, and cost in the year following first use of 
intervention considered.   
 
Following reallocation, a greater proportion of resources was directed to oncology-related 
interventions, and a lesser proportion was directed to those related to cardiology and other 
diseases (Table 42).  This may reflect the fact that many of the included oncology-related 
interventions were diagnostic imaging and tests rather than chemotherapies, which are generally 
accepted to be associated with high ICERs. (Greenberg et al. 2010)  With respect to intervention 
type, a greater proportion of resources were directed to treatments and diagnostics as opposed to 
‘other’ (Table 43) following reallocation.  This finding was expected as a number of the dominant 
interventions in the dataset were diagnostic imaging technologies and tests.  When considering 
size of the eligible patient population, a greater proportion of resources were directed to the most 
prevalent diseases (greater than one million eligible beneficiaries) following reallocation (Table 
44).  This is principally due to the fact that dominant interventions and those with favourable 
estimates of cost-effectiveness were indicated for diseases of high prevalence and largely 
underutilised.   
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As the reallocation disproportionately increased the utilisation of some interventions associated 
with lower than average incremental QALY gains, the average per beneficiary incremental QALY 
gain decreased from 0.49 to 0.29 QALYs.  Similarly, following reallocation the average per 
beneficiary incremental cost decreased from $7,700 to $6,700 when considering net present value 
and from $7,800 to $1,600 when considering the year following first use of the intervention. 
The limited number of interventions included in the hypothetical reallocation makes it difficult to 
draw meaningful conclusions from the findings.  The research demonstrates, however, that 
changing resource allocation criteria will likely affect the distribution of expenditures.   
 
7.5.3. Limitations and challenges 
Coverage decisions included in this research were identified in NCDs made from 1999 through 
2007.  As the minority of CMS’s coverage decisions are made through the NCD pathway and 
only coverage decisions associated with a cost-effectiveness estimate are included, this research is 
limited to a relatively select group of interventions.  Further, of the 64 coverage decisions 
associated with a cost-effectiveness estimate, complete information was available for only 36, 
with 28 ultimately excluded from the dataset.  Due to the relatively small sample of interventions 
included, it is possible that the included interventions are unrepresentative of those offered in the 
Medicare programme as a whole. Conclusions that can be drawn from the findings for objective 2 
are limited due to the small sample size.  However, despite only including 36 coverage decisions, 
the findings illustrate that reallocating resources is likely to have an effect on the distribution of 
expenditures across diseases and types of treatment. 
 
The data available for this analysis represented one of the largest challenges of this research.  
Ideally, the following data would have been available. 
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Cost data 
Ideal cost data for this analysis would be specific to Medicare claims data and have specifications 
that would facilitate potential legislative action based upon study findings, i.e., meet the standards 
of the Congressional Budget Office (CBO) and CMS’s Office of the Actuary. (CBO 2011;CMS 
2011b) Cost data should account for all implications of the intervention and comparator’s use and 
be available for each year through the relevant time horizon, i.e., year 1, year 2, year 3, etc.   
 
Effectiveness data 
Similarly, ideal effectiveness data for this research would be specific to the Medicare population, 
and would be reported in QALYs in order to facilitate comparison across conditions.  
Effectiveness data should be available for all competing interventions, and accrued QALYs 
should be reported for each year through the relevant time horizon, i.e., year 1, year 2, year 3, etc.  
Patient heterogeneity would be accounted for, with data available on the effectiveness of the 
intervention across the range of patients in the evaluated population.  
 
Patient level information 
Available patient-level information would be sufficient to allow accurate identification of 
beneficiaries that met the specifications of the coverage decision, i.e., ICD-9 codes would be 
reported comprehensively and would be supplemented with additional patient level data, 
including BMI, comorbidities, whether patient had failed alternative management approaches, etc.   
 
Epidemiological data 
Both prevalence and incidence data would be available, i.e., the total number of existing cases and 
the number of new cases each year.   
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If this data were available, the research presented here would have been more straightforward.  
Unfortunately, it was necessary to source the data from a number of different sources, each with 
its own limitations. 
 
I relied heavily on the cost-effectiveness literature for this research.  The process of identifying 
and selecting this literature is presented in Section 4.7.4.8.  Despite reviewing each study to 
ensure it was an appropriate match to the coverage decision, it is inevitable that there is variation 
between the included cost-effectiveness studies with respect to quality, perspective, country 
setting, framework, approach to estimating utility, etc.  This lack of consistency introduced 
uncertainty into the analysis, limiting the generalisability of the findings.  Also, I assumed that the 
comparator in the cost-effectiveness study was the only available alternative intervention.  While 
I ensured in each case that Medicare deemed the comparator to be appropriate (Section 4.7.4.9), it 
is likely that multiple alternative interventions were available.  Further, it may be that in some 
cases no treatment is the most clinically appropriate course of action, a management approach not 
accounted for here.   
 
When possible, cost data were extracted from the included cost-effectiveness study.  
Unfortunately, this was not possible for cost-effectiveness studies not performed in a US setting, 
and in these cases estimates were converted to US dollars and inflated to a 2007 valuation 
(Section 4.7.4.9).  The cost-effectiveness studies often proved insufficient as the source of 
estimates of the cost of interventions in the 12 months following first use.  In these cases, 
estimates were calculated from Medicare and physician reimbursement codes (Section 4.7.5.6). 
 
The cost-effectiveness literature was also the source of the effectiveness data.  Similar problems 
to those discussed for the cost data were seen here, i.e., a US study population was not always 
included, and there was variability with respect to how the data was calculated.  For example, 
while the majority of studies reported QALYs, the approaches to estimating utility were not 
consistent.  As a result, on four occasions, it was necessary to adjust reported incremental survival 
gain with a utility weight to gain an estimate of incremental QALY gain.  A further limitation was 
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that I used the published cost-effectiveness study to infer the effectiveness of the intervention and 
comparator for the average Medicare beneficiary, not accounting for patient heterogeneity.  
 
A fundamental part of this research was identifying both the number of Medicare beneficiaries 
currently receiving the intervention and the size of the unserved eligible patient population, i.e., 
beneficiaries eligible for the intervention in accordance with NCD specifications but who did not 
receive it.  I used ICD-9 codes reported in a 5% Medicare claims database to identify these groups 
of beneficiaries.  Although necessary for this research, basing eligibility solely on ICD-9 
diagnostic codes was a crude approach.  In clinical practice, a number of clinical factors not 
captured in ICD-9 diagnostic codes help guide management.  These may include disease severity, 
the presence of co-morbidities, patient preference, etc.  Also, factors related to disease 
management may influence coverage decisions, e.g., CMS may grant access to an intervention 
only after the failure of alternative treatment options.  Finally, I relied on ICD-9 codes to be 
accurately reported in the Medicare claims database.  Incomplete reporting of ICD-9 codes would 
affect the accuracy of the estimated number of unserved beneficiaries and those currently 
receiving the intervention.   
 
A Medicare claims database including 2007 data was used here.  It provided a ‘snapshot’ of the 
interventions received by Medicare beneficiaries over the one year period.  It does not, however, 
distinguish between incident and prevalent cases.  Without this information, determining whether 
a beneficiary is truly eligible for a particular intervention is challenging.  For example, identifying 
a Medicare beneficiary with Parkinson’s disease is insufficient to determine their eligibility for 
deep brain stimulation (DBS), as this treatment is reserved for use once pharmaceutical 
management is no longer effective.  For other interventions, this is less problematic. For example, 
foot care would always be an appropriate intervention for diabetic patients suffering from diabetic 
peripheral neuropathy with loss of protective sensation.   
 
Due to the crude approach for identifying eligible patients, it was deemed inappropriate to 
decrease utilisation of relatively low value interventions to zero, or to increase the utilisation of 
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relatively high value interventions to 100% of the eligible patient population.  Therefore, I used a 
maximum of a 50% change in utilisation to reallocate expenditures; when decreasing expenditure 
on relatively cost-ineffective interventions, utilisation was decreased by 50%, and when 
increasing expenditure on relatively cost-effective interventions, the size of the unserved eligible 
patient population was decreased by 50%.  The 50% value is arbitrary and, therefore, a range of 
10% through 90% was also reported.  As discussed below, the feasibility of such a shift in 
expenditures was not considered in this work.    
 
7.5.4. Policy significance 
This research is timely given the current fiscal challenges facing Medicare, and it asks important 
questions regarding the programme’s efficiency.  However, this research proved an ambitious 
task.  Data originated from a number of sources, including a Medicare claims database for 
utilisation rates and the size of the eligible patient population; the cost-effectiveness literature for 
estimates of incremental costs and benefits; and Medicare sources for reimbursement data.  The 
disparate nature of the data has implications for the accuracy of the estimates and, by extension, 
the policy significance of the study.  In particular, the included cost data are not up to the standard 
used by the CBO or the CMS’s Office of the Actuary, thus restricting the extent to which the 
findings presented here could be used for legislation action.  Nevertheless, the findings illustrate 
the broader benefits of using cost-effectiveness evidence, and, rather than an accounting 
framework, this research should be considered a technical exercise that estimates potential 
efficiency gains within a feasible range. 
 
Various findings of this research have particular policy relevance.  A notable finding is the 
relatively infrequent use of interventions with the highest ICERs, with interventions associated 
with ICERs greater than $100,000 per QALY having negligible utilisation rates (Table 39).  One 
potential reason for this may be related to reimbursement, i.e., the mode of reimbursement 
introduces financial incentives/disincentives that influences physician prescribing of these 
services. (Neumann, Rosen, & Weinstein 2005) 
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This research highlights the underutilisation of some dominant interventions, i.e., those that are 
health increasing and cost-saving.  One intervention for which this was the case was cardiac 
rehabilitation for patients recovering from an acute myocardial infarction or percutaneous 
transluminal coronary angioplasty.  Research suggests that despite documented evidence of the 
clinical and economic benefits of cardiac rehabilitation, it is an underutilised intervention.  
Suggested reasons for this underutilisation include a lack of referral by physicians, associated 
comorbidities, reimbursement factors, and perceived benefits of the intervention, among others. 
(Daly et al. 2002;Parkosewich 2008;Thomas 2007) 
 
For a number of dominant interventions, positive expenditure was required in the 12 months 
following first use even though cost-savings were estimated over the time horizon of the cost-
effectiveness analysis.  This was the case for cardiac rehabilitation and foot care for diabetic 
patients with neuropathy, two important drivers of study findings (Table 40).  This finding is 
important as it highlights that in some cases initial increased investment is required to yield cost-
savings downstream.  Policy makers should be aware of interventions for which this is the case 
and be prepared to prioritise resources accordingly, even if programme cost increases transiently 
in the year of use.  Further, this finding emphasises the importance of accounting for future costs 
and benefits when evaluating interventions; consideration of interventions over the short-term 
may not adequately account for the potential positive financial impact on the health care system. 
 
The apparent underutilisation of dominant interventions provides an opportunity for policy 
makers.  Increasing utilisation of dominant interventions would have a real positive impact on the 
Medicare programme, not only increasing aggregate health, but also generating additional 
resources that can be invested in other aspects of the Medicare programme. 
 
Few interventions were the principal drivers of efficiency gain in this analysis.  Unsurprisingly, 
efficiency gains were largest for interventions affecting the largest number of Medicare 
beneficiaries.  Low value interventions, i.e., those for which utilisation is reduced in expenditure 
reallocation, with high initial utilisation will have a large impact on results (e.g., deep brain 
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stimulation for Parkinson’s disease and Implantable Cardioverter Defibrillators (ICDs) for 
documented ventricular tachyarrhythmia).  Conversely, high value interventions that are 
associated with large unserved eligible patient populations, i.e., interventions with low 
penetration, have a large impact on results (e.g., cryosurgery for prostate cancer, image guidance 
for breast biopsy, and cardiac rehabilitation).  Though to a lesser extent than utilisation rate, the 
magnitude of the incremental cost and incremental QALY gain associated with interventions also 
impacts the results.  This finding suggests that interventions for which the largest potential gains 
are achievable should be targeted.  However, it is not necessarily the case that this approach 
would be most advantageous.  It would be unrealistic to expect that policy makers could impose 
disinvestment of deeply entrenched services without huge resistance.  In practice, a more 
manageable approach may be to target interventions for which it would be more feasible to 
implement a change in therapeutic management.   
 
Findings are presented in terms of the net present value of future commitments and year following 
first use of the intervention.  The findings presented in terms of net present value of future 
commitments are illustrative of potential efficiency gains.  However, they assume that 
unrestricted finance is available beyond the available annual budget to pay for interventions that 
yield cost savings in future years, a somewhat unrealistic assumption.  When considering the 12 
months following first use of the intervention, the findings are more conservative and account for 
the existing level of resources. 
 
The findings illustrate that using different criteria to allocate resources will have an effect on the 
distribution of resources across types of treatment and disease areas.  However, given the small 
number of included interventions, it is difficult to draw conclusions from the findings.  The 
findings do, though, draw into focus the fact that trade-offs between decision-making criteria will 
have to be made when allocating resources.  The objective of this research was to maximise 
aggregate health, though this may not be consistent with the preferences of the decision maker or 
society.  This research is important in that it provides insight into the maximum amount of health 
gain achievable, and thus the health-related opportunity cost of using alternative criteria to guide 
health care resource allocation.    
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7.5.5. Next steps 
Two broad alternative approaches can be taken to move this research forward.  First, scope of the 
research could be expanded to include additional interventions from a broad range of conditions.  
This approach would increase the complexity of this research and would likely suffer from many 
of the limitations laid out above in Section 7.5.3.  Second, the scope of the research could be 
reduced and focused on a more select group of interventions from a restricted set of conditions.  
Decreased model complexity may lend itself to different methodological approaches, e.g., integer 
programming.  These differing approaches would be relevant to two very different research 
questions.  The first approach would be consistent with the objective of the research described 
here, i.e., to estimate potential efficiency gains from using cost-effectiveness information to 
allocate resources in the Medicare programme.  The second approach would have a narrower 
objective and would be specific to a single condition or a set of few conditions. 
 
Regardless of the methodological approach, many steps could be taken to improve the model 
inputs.  With respect to the included cost-effectiveness evidence, the inclusion of additional 
studies would allow for a more comprehensive analysis and one that accounts for a greater 
proportion of the Medicare programme.  Also, with a sufficient sample size it may be possible to 
restrict cost-effectiveness studies included to those that both evaluate a Medicare population and 
include Medicare-specific costs and effectiveness data.  This, however, would be challenging 
since few cost-effectiveness studies included here meet these strict requirements.     
 
One of the challenges faced in this research was to identify the relevant patient population from a 
Medicare claims database.  In the absence of additional fields within the Medicare claims data to 
help characterise patients, one approach to improve the estimation of the size of the eligible 
patient population would be to seek clinical input.  For example, with input from physicians it 
would be possible to estimate the proportion of patients with a specific ICD-9 code that meet 
certain additional clinical criteria and thus the specifications of the NCD. 
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The small sample size prevented categorisation of interventions using as many intervention type 
or disease area categories as I would have liked.  With a larger sample it would be possible to 
better categorise interventions and understand the implications of resource allocation using a cost-
effectiveness decision rule.  For example, as society has been shown to have a preference towards 
the treatment of severe diseases, a variable to capture disease severity would be valuable (Coast 
2004;Dolan & Cookson 2000;Drummond et al. 2005;Nord et al. 1995;Ubel 2001)  However, as 
described in Section 4.7.4.12, generating such a variable proved difficult and input from health 
care practitioners may required for its inclusion.  By better understanding society’s preferences 
for resource allocation, the impact of alternative patterns of resource use could be evaluated in 
light of them.  Indeed, research to help evaluate whether the current distribution of expenditures is 
consistent with Medicare beneficiaries preferences would be valuable.   
 
The current analytic approach is essentially deterministic, one that does not account for parameter 
uncertainty.  An alternative approach would be to use a stochastic process to account for 
uncertainty in the parameter estimates.  Such an approach would require inclusion of additional 
information, which proved challenging when considering uncertainty in cost-effectiveness 
estimates, as shown in Section 4.7.4.9.  A stochastic process could be further developed to move 
towards a population model that accounts for disease incidence. 
 
Only interventions subject to NCDs, which comprise a small proportion of all CMS coverage 
decisions, were included in this research.  While NCDs are typically made for interventions 
deemed to have a significant impact on the Medicare programme, those considered here might not 
be those for which a reallocation of resources would yield the greatest efficiency gains.  Further, 
it is likely that if the sole purpose of NCDs were to increase programme efficiency, different 
interventions would be considered.  This research would benefit from including a broader range 
of interventions available in Medicare, not just those evaluated through the NCD pathway.  
Further, while interventions were included that were not subject to NCDs, i.e., those subject to 
LCDs, in the larger project conducted at Tufts Medical Centerxxi, the scope of the research did not 
                                                 
xxi See Acknowledgements  
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include the impact of reallocation on the distribution of resources or the cost of the interventions 
in the year of their first use.  
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7.6. Chapter summary  
The research in chapters 5 and 6 evaluated the relationship between coverage decisions made as 
part of NCDs and cost-effectiveness evidence.  The research presented in this chapter has a 
different set of objectives, i.e., to estimate potential gains in aggregate health from reallocating 
expenditures in terms of the net present value of future commitments and expenditures in the first 
12 months of use, and to estimate the impact of reallocation on the distribution of resources across 
disease areas and types of intervention.  Using the cost-effectiveness literature, a Medicare claims 
database, and Medicare reimbursement codes, I developed a dataset with which to perform this 
research.  To reallocate expenditures between interventions, utilisation of relatively cost-
ineffective interventions was decreased, and utilisation of more cost-effective interventions 
increased.  The findings estimate that substantial gains in aggregate health are achievable when 
reallocating expenditures to maximise health while maintaining a net change in total expenditure 
of zero.  Also, simply increasing the utilisation of dominant interventions increases aggregate 
health gains along with cost-savings.  When considering resource distribution, the findings show 
that allocating expenditures in a manner consistent with the cost-effectiveness evidence changed 
the distribution of expenditures across diseases and interventions.  
  
While this research highlights that efficiency gains may be achievable, a number of data 
limitations restrict the generalisability to current policy.  Further, the research did not account for 
the difficulty of changing established therapeutic practices, an aspect that would have a huge 
bearing on the success of the implementation of a policy consistent with this research. 
  
In the final chapter, I summarise each chapter contained in this thesis and present the key findings 
of my research.  Also, I discuss the limitations of this thesis, its policy relevance, and next steps.  
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8. Summary and Conclusions
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8.1. Context of thesis 
While health care affordability is a common challenge faced by developed countries, it is of 
particular concern in the US.  Health care spending in the US is currently greatly in excess of 
spending in other developed countries and is increasing at an unsustainable rate.  While steps 
have been taken to arrest this trend, the future affordability of health care in the US remains the 
subject of much debate and concern.  Despite substantially higher levels of spending, compared 
to other developed countries, the US health care system performs worse across a variety of key 
health metrics. 
 
In many countries, economic evaluation, or more specifically cost-effectiveness analysis, is an 
approach taken to prioritise scarce health care resources between competing interventions.  
However, despite the relatively poor return from health care spending, the US has been resistant 
to using economic evaluation to inform coverage decisions for medical interventions.  CMS’s 
stated position is that “Cost-effectiveness is not a factor CMS considers in making NCDs.  In 
other words, the cost of a particular technology is not relevant in the determination”. (CMS 
2010)   
 
This thesis considers the use of cost-effectiveness evidence in the US health care system.  The 
empirical work focuses on CMS national coverage determinations (NCDs).  National coverage 
determinations are reserved for interventions deemed particularly controversial or projected to 
have a major impact on the Medicare programme. (CMS 2003)  The empirical aspect of this 
thesis has two broad aims; first, to examine the relationship between cost-effectiveness and 
coverage decisions, and second, to estimate the potential benefits in terms of aggregate health 
gain of using cost-effectiveness evidence to inform the allocation of expenditures across 
interventions in the Medicare programme.  
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8.2. Background 
In Chapter 2, I summarised the use of economic evaluation to evaluate health care interventions 
and showed that it offers an approach to inform efficient resource allocation.  I presented the 
theory underpinning cost-effectiveness analysis and how the approach is consistent with an 
extra-welfarist framework.  Using a worked example I illustrated how, as long as certain 
assumptions hold, adherence to a cost-effectiveness decision rule will lead to efficient resource 
allocation across multiple health care programmes.  I discussed the limitations and criticisms of 
cost-effectiveness analysis and how the magnitude of required data limits the use of a league 
table or mathematical programming approach.  In the absence of full information on the costs 
and benefits of available interventions, a cost-effectiveness threshold is required to interpret cost-
effectiveness evidence.  Here I presented the various valuations of cost-effectiveness thresholds 
and various approaches to setting its value.   
 
In chapter 3, I examined the US health care system within the context of health care systems in 
other developed countries.  The US spends approximately 17% of GDP on health care, almost 
twice the average for OECD countries.  Despite this, the US has fewer physicians and hospital 
beds per capita than many other countries.  The US health care system performs poorly 
compared to health care systems in other developed countries and is associated with lower 
average life expectancy, higher infant mortality, and worse outcomes across certain diseases.  I 
chose the comparator countries included in Chapter 3 on the basis that they help illustrate 
different approaches to using cost-effectiveness evidence along with other factors in coverage 
and reimbursement decisions, or in recommendations for the efficient use of medical technology.  
The UK, Sweden, Australia, and Canada, while all using different processes, are countries in 
which cost-effectiveness evidence plays a fundamental role in decision-making.  In contrast, 
Germany and France are countries in which cost-effectiveness evidence, and economic evidence 
more generally, plays less of a role.  Cost-effectiveness analysis is used sparingly in the US 
health care system.  While some public and private payers claim to use cost-effectiveness 
evidence, the extent to which it informs decision-making is unclear.  Notably, CMS states that 
cost-effectiveness evidence is not relevant to NCDs.  To provide insight into why this resistance 
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exists, I described the failed attempts by Medicare and the state of Oregon’s Medicaid 
programme to incorporate cost-effectiveness evidence into resource allocation decision-making.  
Here I show that, despite an apparent need to increase the efficiency of the health care system, 
the US may reside at the end of the spectrum with respect to the extent that cost-effectiveness 
evidence plays a role in decision-making. 
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8.3. Introduction to empirical work 
In Chapter 4, I presented the research objectives, a review of the relevant literature, and the 
development of the database used for the empirical aspect of this thesis.  With respect to the 
database, 140 NCDs made from 1999 through 2007 were considered, and the accompanying 
decision memos reviewed.  One hundred and three decision memos met the inclusion criteria and 
were reviewed to extract relevant information into a database.  From the 103 decision memos, 
255 unique coverage decisions were identified.  For each coverage decision, a literature search 
was performed to identify relevant cost-effectiveness studies.  A relevant cost-effectiveness 
study was identified for 64 coverage decisions, 48 of which were positive coverage decisions and 
16 of which were non-coverage decisions.  This sample of coverage decisions with 
accompanying cost-effectiveness evidence was used for the empirical work presented in Chapter 
5. 
 
In addition to cost-effectiveness, the database included a number of variables pertaining to 
factors likely to have an effect on CMS’s coverage decisions.  These variables included the 
quality of the supporting clinical evidence, the availability of alternative interventions, 
intervention type, origin of the coverage request, and date of the decision.  These variables were 
used for the research presented in Chapter 6. 
 
A second smaller database was developed for the research presented in Chapter 7.  This database 
was restricted to coverage decisions associated with a relevant estimate of cost-effectiveness.  
The database included: the incremental cost and incremental effectiveness associated with the 
intervention; the cost of the intervention and comparator in the first year of its use; the existing 
utilisation rate of the intervention; and the size of the eligible patient population. 
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8.4. Key findings of empirical work 
8.4.1. Empirical Research:  Part 1 
The research presented in Chapter 5 had two objectives.  First, to examine NCD decision memos 
to determine if they are consistent with CMS’s stated position on the use of cost-effectiveness 
evidence, i.e., that cost-effectiveness is not a factor considered in NCDs.  Second, to determine if 
there is a difference between positive coverage decisions and non-coverage decisions with 
respect to cost-effectiveness. 
 
With respect to the first objective, I found that in the majority of cases CMS’s actions were 
consistent with their stated policy, i.e., that cost-effectiveness evidence did not feature in 
decision memos.  In some cases, however, CMS’s actions were inconsistent with their stated 
policy; for 14 coverage decisions, cost-effectiveness evidence was cited or discussed in the 
decision memo.  Interestingly, 12 of these coverage decisions were positive, with a favourable 
cost-effectiveness ratio in each case (maximum ICER of $27,161 per life year gained).  On one 
occasion, the decision memo for screening immunoassay fecal-occult blood test, a reference was 
made to the often-cited $50,000 per life year cost-effectiveness threshold.  On another occasion, 
for the NCD regarding PET for Alzheimer’s disease/dementia, the decision memo included 
discussion of QALYs.  While not discussed with respect to cost-effectiveness evidence, as a 
discussion of the intervention’s cost did not feature in the decision memo, it is notable that 
QALYS were used in this instance.  
 
With respect to the second objective, I used a Mann Whitney U test to determine that there was a 
statistically significant difference between positive coverage decisions and non-coverage 
decisions with respect to cost-effectiveness (p<0.05).  This finding suggests that interventions 
subject to positive coverage decisions tend to be more cost-effective than those subject to non-
coverage decisions.  However, the research showed that CMS cover a number of interventions 
that do not appear cost-effective by traditional standards; seventeen were associated with an 
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ICER greater than $50,000 per QALY, nine with an ICER greater than $100,000 per QALY, and 
three with an ICER greater than $500,000 per QALY. 
    
8.4.2. Empirical Research:  Part 2 
The findings of the research presented in Chapter 5 showed a statistically significant difference 
between positive coverage decisions and non-coverage decisions with respect to cost-
effectiveness.  However, the approach taken was insufficient to confirm that cost-effectiveness, 
or the availability of cost-effectiveness evidence, is independently associated with coverage.  
Therefore, the objective of the research presented in Chapter 6 was to determine if cost-
effectiveness is an independent predictor of coverage when controlling for other factors likely to 
have an effect on CMS’s coverage decisions. 
 
I used a binomial logistic regression for this analysis.  Independent variables included: quality of 
the supporting clinical evidence, availability of alternative interventions, intervention type, origin 
of the request for coverage, and the date of the decision.  The dependent variable was positive 
coverage or non-coverage.  The findings of the multivariate logistic regression showed that the 
following variables were either statistically significant or included at least one statistically 
significant category: quality of the supporting clinical evidence, availability of alternatives, the 
date of the decision, and cost-effectiveness. 
 
For Cost-effectiveness, compared to interventions estimated to be dominant, those with no 
associated estimate of cost-effectiveness were approximately five times less likely to be covered 
(approximately two thirds less likely when considering predicted probabilities).  This is an 
important finding, showing that the availability of cost-effectiveness evidence had an 
independent effect on the coverage decision.   
 
With respect to the quality of the supporting clinical evidence, interventions associated with 
good quality supporting evidence were six times more likely to be covered than those associated 
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with insufficient evidence (approximately twice as likely when considering predicted 
probabilities).  With respect to the availability of alternative interventions, compared to 
interventions with no available alternative, those with an available alternative were 
approximately eight times less likely to be covered (approaching half as likely when considering 
predicted probabilities).  Finally, with respect to the date of decision, coverage decisions made in 
2006-2007 were approximately 10 times less likely to be covered than those made in 1999-2001 
(half as likely when considering predicted probabilities).  Further, interventions subject to 
coverage decisions in more recent time periods were increasingly less likely to be covered. 
 
8.4.3. Empirical Research:  Part 3 
The findings of the research presented in Chapter 5 showed that CMS cover interventions that 
are not cost-effective by traditional standards.  Coverage of cost-ineffective interventions 
generates relatively little health gain for the expenditure and suggests that existing resources 
could provide greater benefits if directed towards alternative more cost-effective interventions.  
The research presented in Chapter 7 had two objectives.  First, to estimate potential gains in 
aggregate health from a hypothetical reallocation of expenditures using a cost-effectiveness 
decision rule.  Second, to estimate the impact of reallocation on the distribution of expenditures 
across disease areas (oncology, cardiology, and other) and types of intervention (treatment, 
diagnostic, and other). 
 
With respect to the first objective, reallocating expenditures, while maintaining a net change in 
total expenditure of zero, resulted in approximately 6 million additional beneficiaries receiving 
the most effective option.  This corresponded to a health gain of approximately 800,000 QALYs.  
Approximately 6 million beneficiaries were affected by the reallocation, i.e., the reallocation 
changed the intervention they received, and the average per beneficiary gained approximately 
0.13 QALYs.  The ICER of the marginal intervention, i.e., the intervention with the highest 
ICER for which utilisation was increased, was approximately $37,000 per life year saved 
(autologous stem cell transplantation).  Substantial gains in aggregate health were also estimated 
when increasing the utilisation of dominant interventions while maintaining existing utilisation 
  
324 
 
rates for interventions with positive ICERs.  Increasing the use of dominant interventions 
resulted in approximately 4.2 million additional beneficiaries receiving the most effective 
treatment option, corresponding to gains in aggregate health of approximately 200,000 QALYs 
and savings of $4.8 billion.  Approximately 4.2 million beneficiaries were affected by the 
reallocation, with an estimated average per beneficiary gain in health of 0.05 QALYs and per 
beneficiary cost savings of $1,113.  
 
With respect to the second objective, the reallocation resulted in a greater proportion of 
expenditures directed to oncology-related interventions, and a lesser proportion to cardiology and 
other diseases.  The reallocation also resulted in a greater proportion of expenditures directed to 
treatments and diagnostics, with less directed towards those categorised as other (e.g., health 
education, preventative care).  
 
The research highlighted that dominant interventions are often underutilised and that substantial 
gains in aggregate health and cost-savings are achievable.  While a number of interventions 
deemed cost-ineffective by traditional standards are covered, they appear to be utilised less 
frequently than more cost-effective interventions. 
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8.5. Limitations 
This thesis has a number of limitations.  First, I highlight limitations specific to the cost-
effectiveness evidence used for each piece of empirical work.  Second, I discuss the key 
remaining limitations for each piece of empirical work.  Third, I discuss some of the broader 
limitations of this research. 
 
8.5.1. Cost-effectiveness evidence 
Unlike agencies that conduct cost-effectiveness analyses internally, or require cost-effectiveness 
studies to be included in submissions to them, CMS do not perform, or require, a cost-
effectiveness analysis as part of their review.  While on occasion the included cost-effectiveness 
study originated in the decision memo, I predominantly relied on published estimates of cost-
effectiveness for much of this research.  Therefore, there was inevitable variation between 
studies across a range of aspects including: country setting, perspective, funding status, etc.   
 
While the majority of studies reported ICERs in terms of cost-per QALY gained, I also included 
studies reporting cost-per life year gained ratios, and those reporting cost-effectiveness ratios 
using disease specific units when the intervention was estimated to be dominant or dominated.  
While not directly comparable, cost-effectiveness studies reporting cost-per life year gained 
ratios were pooled with those reporting cost-per QALY ratios in the primary analyses in each 
piece of empirical work.  However, for the empirical work presented in Chapters 5 and 6, I 
reported findings of the analyses when cost-effectiveness studies reporting cost-per life year 
gained ratios were excluded from the dataset (Section 5.3.4 and Section 6.3.4.1).  For the 
empirical work presented in Chapter 7, for studies reporting cost-per life year gained, I adjusted 
survival gain with a utility weight to gain an, albeit imperfect, estimate of incremental QALY 
gain (Section 4.7.5.4).   
 
I did not account for uncertainty associated with the included cost-effectiveness estimates in the 
empirical aspects of this thesis.  Uncertainty was not consistently reported in the included cost-
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effectiveness studies and, although it was included in the review of the cost-effectiveness studies, 
it was ultimately excluded from the dataset (Section 4.7.4.9).  However, to more completely 
understand the influence of cost-effectiveness evidence on coverage decisions, it would be 
necessary to account for uncertainty.  
  
8.5.2. Empirical work presented in Chapter 5 
A minority of the coverage decisions featured in this research, approximately 25% (64 of 255), 
were associated with a cost-effectiveness estimate.  This raises the question of whether coverage 
decisions with an associated estimate of cost-effectiveness are truly representative of the total 
sample.  The fact that a large proportion of coverage decisions were not associated with cost-
effectiveness evidence, and thus unaccounted for in the empirical work presented in Chapter 5, is 
a limitation of the research.   
 
Also, in the instances when CMS did discuss or cite cost-effectiveness evidence in the decision 
memo, it was not possible to infer how the evidence influenced coverage decisions.   
 
8.5.3. Empirical work presented in Chapter 6 
The research presented in Chapter 6 was limited by data availability.  As noted in Section 
4.7.4.12, it was not possible to include a number of potentially relevant variables in the analysis.  
For example, including variables that accounted for the potential budget impact of the 
intervention and the prevalence of disease proved impractical.  Disease severity is another factor 
suggested to be of importance in decision-making. (Dolan, 2005)  However, accounting for 
disease severity proved difficult and was ultimately not accounted for in this research.   
 
As for Chapter 5, the cost-effectiveness variable was a source of a number of limitations of this 
research.  In the primary analysis, only 21% of coverage decisions were associated with evidence 
of cost-effectiveness at the time of the decision, though this increased to 30% when including 
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studies published after the NCD.  This was problematic when constructing the cost-effectiveness 
variable as I was restricted to the number of categories that I could include, i.e., for positive 
ICERs I was restricted to two categories, <$50,000 per QALY, and >$50,000 per QALY.  
Further, I was required to pool cost-effectiveness studies that estimated the intervention to be 
dominated with studies that estimated the intervention to have an ICER of >$50,000 per QALY.  
This is not an ideal approach, as interventions estimated to be dominated are less effective than 
their comparator, unlike those associated with positive ICERs.  
 
The variable capturing the quality of the supporting clinical evidence was limited in two key 
ways.  First, the USPSTF guidelines for grading evidence were used as the approach to 
characterise the evidence.  This approach is not ideal, as it requires that incremental benefit and 
the evidence quality to be accounted for simultaneously.  Second, the variable is subjective in 
nature.  The variable originated from a review of the evidence as presented in the decision memo 
by two researchers from Tufts Medical Center.  As the researchers relied on CMS’s presentation 
of the evidence base, rather than independently reviewing the individual studies, the variable is 
essentially subjective.  A potential approach to improving this variable is presented in Section 
6.4.5.   
 
As discussed in Chapter 6, there is a possibility that a number of the independent variables in the 
model may interact, i.e., that the combined effects of two independent variables are not a sum of 
their individual effects.  The presence of interaction effects make interpretation of model 
findings challenging, as a change in one variable will have unpredictable consequences on the 
result of the model.  While it was deemed that there was no significant interaction between the 
independent variables in the current model it will be important to retest future models as the 
dataset is extended and the volume of available data increases.   
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8.5.4. Empirical work presented in Chapter 7 
I had to make a number of necessary assumptions in the empirical work presented in Chapter 7.  
First, I assumed that every beneficiary included in the reallocation received some form of 
intervention.  Second, if the beneficiary did not receive the intervention under review, it was 
assumed that they received the comparator.  Third, when considering the net present value of 
future commitments, it was necessary to assume the availability of unrestricted finance.  
 
I included cost data from a variety of sources, including: the cost-effectiveness studies, costing 
studies, and Medicare reimbursement codes.  This variation in the source of the cost information 
is a limiting factor in this research.  The cost-effectiveness studies were also used as the source 
for the estimate of incremental health gain.  A consequence of this approach is that I inferred that 
the reported estimate of incremental health gain was accurate for the average Medicare 
beneficiary who received it.  The cost-effectiveness literature was insufficient to allow me to 
account for patient heterogeneity in the analysis.   
 
I relied on ICD-9 codes reported in the Medicare claims database to identify beneficiaries 
eligible for the intervention.  This is a crude approach as ICD-9 codes lacked the required 
precision to account for all clinical factors specified in NCDs.  On occasion ICD-9 codes were 
insufficient to identify Medicare beneficiaries eligible for an intervention, and the respective 
coverage decision was excluded from the analysis.  The Medicare claims database also prevented 
me from distinguishing between incident and prevalent cases.  This information is often 
necessary to determine whether a beneficiary is eligible for an intervention, e.g., when the 
management approach immediately following diagnosis differs from the long-term management 
of the condition.   
 
I did not account for the feasibility of implementing changes in patient care, i.e., changing the 
intervention received by the Medicare beneficiary.  It is likely that implementing a change will 
be challenging for interventions deeply entrenched in clinical practice.  I accounted for this by 
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implementing a change in utilisation of 50% (range 10-90%), rather than adjusting utilisation 
rates to 0% or 100%.  This change was, however, arbitrary. 
 
8.5.5. Broader limitations 
The empirical aspect of this thesis pertains to NCDs made from 1999 through 2007.  Updating 
the research to include NCDs made through 2011 would be useful, particularly given that for a 
number of recent NCDs CMS have cited or discussed cost-effectiveness evidence in the decision 
memo (Section 3.5.2). 
 
Although NCDs are arguably the most important of CMS coverage decisions, a minority of 
interventions are evaluated through this process.  Rather, the majority of coverage decisions are 
made by Medicare Administrative Contractors (MACS), often referred to as local coverage 
determinations (LCDs).  By excluding LCDs from this research, it is possible that the included 
coverage decisions are unrepresentative of CMS coverage decisions in general.   
 
The most evident limitation of this thesis is that it focuses solely on the Medicare programme. 
While Medicare is a dominant component of the US health care system, other public and private 
insurance bodies also play a major role.  To gain a more complete understanding of the role of 
cost-effectiveness evidence in the US health care system, this research could be broadened to 
include other payers. 
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8.6. Contributions of thesis  
In the US, health care is an emotive political issue.  This thesis is timely and is relevant to the 
ongoing debate regarding the cost, sustainability, and efficiency of the Medicare programme.  
Despite a real need to improve the value achieved from health care spending, the US remains 
largely opposed to the use of cost-effectiveness evidence in coverage decisions for medical 
technologies and interventions.  This thesis makes a number of important contributions and 
provides important evidence that fills significant gaps in the literature.   
 
The research presented in Chapter 5 is the first to systematically evaluate the cost-effectiveness 
of CMS’s coverage decisions, and to evaluate the consistency of CMS’s actions with its stated 
policy on the use of cost-effectiveness evidence.  I highlighted that, contrary to CMS’s stated 
position on the use of cost-effectiveness evidence, CMS has cited or discussed cost-effectiveness 
evidence on a number of occasions.  This research provides insight into the value of 
interventions offered in the Medicare programme, and shows that CMS cover a number of 
interventions that are not cost-effective by traditional standards.  Despite this, through this 
research I have established that there is a difference between positive coverage decisions and 
non-coverage decisions with respect to cost-effectiveness, suggesting that covered interventions 
tend to be more cost-effective than non-covered interventions.  It was possible to identify a cost-
effectiveness study for approximately 25% of coverage decisions and, therefore, this research 
illuminates the lack of knowledge with respect to the cost-effectiveness of the majority of 
interventions offered in the Medicare programme.   
             
The empirical work presented in Chapter 6 is the first to use regression analysis to evaluate 
coverage decisions made in CMS NCDs, providing an empirical insight into CMS’s coverage of 
medical interventions.  Given the lack of a formal interpretation of CMS’s reasonable and 
necessary coverage criteria, and the existing uncertainty regarding it, this research is an 
important contribution. (Foote 2002;Neumann, Rosen, & Weinstein 2005)  Encouragingly, the 
research suggests that CMS operate evidence-based decision-making, as coverage decisions 
appear to be broadly consistent with the supporting clinical evidence base.  I have also shown 
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that the availability of alternative interventions appears to be an important factor in coverage 
decisions and that value appears to play a role.  
 
Insight into CMS’s decision-making criteria is important, as NCDs are increasingly subject to 
debate and scrutiny.  The findings of the empirical work in Chapter 6 have the potential to reduce 
the uncertainty associated with CMS NCDs and provide a framework with which to understand 
CMS’s reasonable and necessary criteria.  The research presented in Chapter 6 provides a 
starting point for a future research agenda to better understand the evidence required for an 
intervention to be a covered benefit in the Medicare programme. 
 
While it is apparent that the Medicare programme has faced increasingly difficult fiscal 
challenges, no study has shown the impact this has had on coverage policy.  The research in 
Chapter 6 suggests that, when controlling for factors relevant in the decision making process, 
CMS has become increasingly restrictive with respect to the coverage of medical interventions 
over the considered time period, i.e., 1999 through 2007.   
 
It is claimed that Medicare is underperforming, with approximately 30% of administered care 
either inappropriate or unnecessary. (Bentley et al. 2008;Fisher et al. 2003;Garber, Goldman, & 
Jena 2007;Orszag 2008)  The research presented in Chapter 7 is the first to estimate the potential 
efficiency gains achievable from a hypothetical reallocation of resources in accordance with 
available cost-effectiveness evidence.  The findings show that substantial gains in aggregate 
health are potentially achievable.  
 
The research in Chapter 7 provides an insight into the relationship between the existing 
utilisation of interventions in the Medicare programme and their cost-effectiveness.  For 
example, the findings highlight the underutilisation of a number of interventions that are 
estimated to be dominant.  These interventions represent obvious targets for gains in aggregate 
health and cost-savings.  In addition, the research shows that although CMS cover a number of 
  
332 
 
interventions that are not cost-effective by traditional standards, these interventions are used 
infrequently, with few patients receiving them.   
 
The research in Chapter 7 also illustrates that using different resource allocation criteria will 
impact the distribution of resources across types of technology and disease, i.e., that 
implementation of a cost-effectiveness rule for resource allocation may result in resources being 
reallocated from one type of technology or disease area to another.  This research draws attention 
to the opportunity cost of coverage decisions and the necessary trade-offs that must be made 
when allocating scarce health care resources.  
 
A common finding across all empirical aspects of this thesis is the often-inadequate nature of the 
available evidence to perform this type of research.  While a number of coverage decisions were 
associated with estimates of cost-effectiveness, there was much variability between cost-
effectiveness studies with respect to quality, methods, perspective, etc.  This thesis serves to 
reinforce the need for the standardisation of cost-effectiveness studies to be relevant to US 
decision makers’ practice.  Further, the utilisation and cost data used in Chapter 7 illustrate the 
difficulties of using existing evidence to estimate the consequences of reallocating resources in 
terms of aggregate health gain. 
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8.7. Policy implications 
This thesis has a number of important policy implications.  These are presented below with 
respect to each piece of empirical work. 
 
8.7.1. Empirical Research:  Part 1 
The findings of the research presented in Chapter 5 should be highly relevant to policy makers.  
First, this research provides an insight into the value of a proportion of interventions evaluated 
through CMS NCDs.  It shows that CMS is covering interventions that are not cost-effective by 
traditional standards.  As noted above, offering these interventions generates relatively little 
health gain for the expenditure and suggests that resources could provide greater benefits if 
directed towards alternative interventions.  Second, it highlights the lack of knowledge regarding 
the value of many of the interventions offered by Medicare.  Without this knowledge, Medicare 
is limited to the extent it can make rational coverage decisions and account for value in coverage 
policy.  Third, in the majority of occasions, CMS have appeared not to consider relevant cost-
effectiveness studies available at the time of the NCD.  
 
8.7.2. Empirical Research:  Part 2 
The findings of the empirical work presented in Chapter 6 underscore that CMS has adopted 
evidence-based medicine in NCDs and illustrates a level of consistency in their decision-making.  
It is noteworthy that the availability of cost-effectiveness evidence is associated with coverage, 
in contradiction to CMS’s stated position.  The findings go some way to reveal CMS’s 
interpretation of the ‘reasonable and necessary’ criterion.  For example, the availability of 
alternative interventions is associated with coverage, which perhaps provides insight into what 
CMS considers necessary care.  This research has the potential to help the entire medical 
community better understand CMS’s evidence requirements, thus reducing uncertainty 
associated with CMS NCDs.  The study increases the transparency of coverage decisions, 
increasing CMS’s accountability.  The findings suggest that CMS has become more restrictive 
with respect to coverage over time, perhaps reflecting Medicare’s increasing fiscal challenges.   
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8.7.3. Empirical Research:  Part 3 
The research presented in Chapter 7 is particularly policy-relevant given the fiscal challenges 
currently faced by the Medicare programme.  As described above, CMS covers some very cost-
ineffective interventions, and thus there is opportunity for more efficient resource use.  The 
research illustrates the potential benefits in terms of aggregate health gains of using cost-
effectiveness evidence to inform resource allocation.  Indeed, substantial aggregate health gains 
are achievable from reallocating resources within the current level of expenditure.  Further, the 
research identifies the underutilisation of a number of dominant interventions.  This finding is 
concerning and suggests efficiency gains are readily achievable.  Lastly, the research highlights 
that the use of different resource allocation criteria will affect the distribution of expenditures 
across types of intervention and disease areas.  
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8.8. Next Steps 
8.8.1. Research scope 
As noted above, a limitation of this research is that it focuses solely on the Medicare programme.  
One potential starting point for future work would be to expand the scope of this research to 
included additional public and private payers.  In terms of public payers, the DoD or the VA may 
provide an appropriate place to start.  Both payers state that cost-effectiveness is considered in 
their decision-making, although their respective approach to its incorporation in the decision-
making process is unclear (Section 3.3.2.3).  An interesting study, given their different positions 
in the use of cost-effectiveness evidence, would be to compare coverage decisions made by 
CMS, the DoD, and the VA.  Unfortunately, the DoD and VA do not provide similar 
documentation to CMS’s decision memos and obtaining the necessary data for this research may 
be challenging. 
 
The majority of Americans (67.5%) obtain health insurance through private providers.  To gain a 
complete understanding of the relationship between cost-effectiveness evidence and coverage of 
interventions in the US health care system, it would be necessary to include private payers in 
future research.  As noted above for the DoD and the VA, this research would likely be limited 
by the absence of documentation providing details for each coverage/tiering decision.  While 
proprietary drug formularies are often publicly available, documentation supporting the 
coverage/tiering decision is typically unavailable. 
 
Also, as noted above, a limitation of this research is that it is limited to only NCDs.  Coverage 
decisions made by Medicare Administrative Contractors (MACs), local coverage determinations 
(LCDs) are the majority of coverage decisions made by Medicare.  Including LCDs in this 
research would provide a broader insight into the coverage of interventions in the Medicare 
programme.  The principal challenge of researching LCDs concerns the volume of policies.  In a 
study to assess variation in coverage across regional Medicare contractors, Foote et al. (2005) 
reviewed 5,213 individual coverage policies. (Foote, Halpern, & Wholey 2005)  The frequent 
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lack of supporting documentation for LCDs further complicates matters, a fact that would limit 
replication of the research presented here. 
 
8.8.2. Improving existing variables 
Cost-effectiveness 
One overarching means to enhance the empirical aspect of this thesis is to update it to include 
NCDs made through 2011.  This would increase the number of coverage decisions and provide a 
more up-to-date assessment.  As the number of NCDs with associated cost-effectiveness 
evidence increases, it may be possible to stratify the data by type of intervention.  This may 
prove informative when considering preventative care, a subset of NCDs for which cost-
effectiveness has been considered with some regularity in recent years (Section 3.5.2).  
 
A larger sample of coverage decisions would provide an opportunity to develop the cost-
effectiveness variable.  For the existing research, I was restricted to the number of categories I 
could include in the cost-effectiveness variable.  With a larger sample, I could increase the 
number of categories, capturing cost-effectiveness with more precision.   
 
For many coverage decisions, the medical literature proved insufficient to identify relevant 
estimates of cost-effectiveness.  Although the limitations of the medical literature unavoidable, 
one approach to supplement the literature searches would be to gain expert opinion into the cost-
effectiveness of the coverage decisions here.  
 
Quality of supporting clinical evidence 
The variable used to account for the quality of the supporting clinical evidence within the 
empirical work presented in Chapter 6 was limited due to its reliance on the USPSTF evidence 
grading criteria, and, as a result, its subjectivity.  The quality of the supporting clinical evidence 
could be captured more accurately using an objective review of the supporting evidence.  This 
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could be achieved by categorising the evidence base using a number of objective criteria, 
including:  study design (e.g., randomised studies, non-randomised study, retrospective study, 
etc); study outcomes (‘hard’ endpoints vs. surrogate endpoints); inclusion of active comparators; 
consistency of findings across studies; patient population (e.g., whether the study included 
Medicare beneficiaries); country of study (e.g., US-based vs. non-US-based); and recency of 
study publication.   
 
Availability of alternative therapies 
The variable accounting for the availability of alternative interventions is currently coded as a 
binary variable (alternatives available/no alternatives available).  Accounting for the number of 
available alternatives and coding the variable either continuously or categorically are potential 
approaches for developing this variable.  
 
Utilisation rate 
For the empirical work presented in Chapter 7, using ICD-9 diagnostic codes to estimate existing 
utilisation rate and size of the eligible patient population proved challenging.  Unfortunately, as 
ICD-9 codes were insufficient to identify eligible beneficiaries that met the specifications of the 
NCD, I had to exclude a number of interventions from the analysis.  Input from health care 
practitioners would be one approach to supplement the ICD-9 codes and provide estimates of the 
proportion of beneficiaries with a broad diagnosis that would meet the specifications of a NCD. 
 
8.8.3. Potential additional variables 
Adding a number of variables to the database would be useful.  As NCDs are typically made for 
interventions expected to have a significant impact on the Medicare programme, the inclusion of 
variables that characterise the budget impact and prevalence associated with an 
intervention/disease would be useful.  While the decision memos do not report this information, 
and the medical literature proved insufficient for these variables, it may be possible to include a 
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version of these variables in the database with input from health care practitioners or health 
services researchers.   
 
A variable that captures the nature of disease would be useful to include in the database.  Such 
variables could potentially account for disease severity or nature of clinical benefit.  While these 
variables proved difficult to include in this research (Section 4.7.4.12), input from health care 
practitioners may again be beneficial here.   
 
The empirical work presented in Chapter 7 found that the least cost-effective interventions were 
often underutilised.  I speculated that this might be related to how the intervention is reimbursed.  
One option to account for reimbursement would be include physician reimbursement rate as a 
variable in the dataset.  
 
Lastly, it is often the case that NCDs are controversial.  There is often a great deal of scrutiny on 
CMS with respect to NCDs, and it may be that political factors influence the outcome.  Although 
difficult to include, a variable that accounted for lobbying may prove insightful.  A potential 
proxy for this might be a tally of comments submitted to CMS during the NCD’s comment 
period.  Although a somewhat tenuous link to lobbying, this approach would at least account for 
the amount of public input into the decision.   
 
8.8.4. Alternative conceptual framework 
It would be valuable to engage members of the Medicare coverage group in future research.  I 
chose to use a ‘production function’ for the conceptual framework used in the research described 
in Chapter 6.  With insight from the decision makers, it may be possible to develop this research 
to account for the relative importance that they place on different aspects of the evidence base.  
For example, if it was the case that the quality of the clinical evidence was the dominant aspect 
of the evidence base, and evidence of value was considered secondarily, the regression model 
could be structured according using a hierarchical modelling framework. 
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8.8.5. Expanding scope of reallocation work 
The empirical research presented in Chapter 7 could be developed using two general approaches.  
First, the scope of the research could be broadened to include additional interventions available 
in the Medicare programme, i.e., those covered through LCDs.xxii  While this approach would 
include a greater proportion of interventions covered in the Medicare programme, the same 
challenges faced in the research presented in Chapter 7 would also likely be faced here.  
Nevertheless, estimated efficiency gains would be more reflective of the benefits of using cost-
effectiveness evidence in the Medicare programme as a whole.  The alternative approach would 
be to narrow the scope and focus the research on few interventions and conditions.  Research 
efforts could be focused on aspects of the Medicare programme in which data of sufficient 
quality was available.  However, the narrow scope of the work would make generalisations to the 
wider benefits of using cost-effectiveness analysis in the Medicare programme more difficult. 
 
The empirical work presented in Chapter 7 evaluated the impact of a hypothetical reallocation of 
expenditures using a cost-effectiveness rule on the distribution of expenditures between patient 
populations and types of intervention.  With a better understanding of society’s preferences, it 
would be possible to determine if the current distribution of expenditures is consistent with 
society’s preferences, and further, if using cost-effectiveness evidence moves us closer or further 
away from being in accordance with them. 
 
 
 
 
 
 
                                                 
xxii While the broader research project conducted at Tufts Medicare Canter did include interventions covered through 
LCDs, its scope was more limited compared to the empirical work in Chapter 7.  
  
340 
 
 
8.9. Moving towards value based policies – opportunities and challenges 
In the preceding sections, I have focused on the empirical aspects of this thesis.  In the remainder 
of this chapter, I will discuss the opportunities and challenges Medicare face in moving towards 
value-based policies. 
 
Medicare is an important component of the US health care system and is fundamental to its, and 
the country’s, financial future. (Chernew, Baicker, & Hsu 2010)  CMS’s role is to administer the 
Medicare programme and thus is responsible for its financial stability.  While the cost of 
Medicare has steadily increased, it is inevitable that a point will be reached when Congress will 
be unwilling to borrow or raise taxes to continue to fund the programme.  Medical technology is 
a major contributor to the increase in costs (Ginsburg 2004;Ginsburg 2008).  In 2008, the 
Medicare programme’s “Triple Aims” were announced: 1) improve the individual experience of 
care; 2) improve the health of populations; and 3) reduce per-capita costs of care for populations. 
(Berwick, Nolan, & Whittington 2008)  These aims reflect the rationale for using cost-
effectiveness analysis, i.e., to improve the health care quality while controlling costs.   
 
This thesis illustrates that using cost-effectiveness evidence to inform coverage decisions offers a 
potential approach for improving the quality of care that Medicare beneficiaries receive while 
curtailing the unsustainable growth in programme cost. 
 
8.9.1. Moving forward – Challenges, opportunities, and recommendations 
If CMS are to move towards a more value based coverage policy, there are a number of 
important hurdles to overcome.  In the following sections, I discuss some of the challenges 
facing Medicare and suggest how to overcome them. 
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8.9.1.1 Restricted authoritative capacity 
CMS’s role as Medicare’s administrator is limited both by its legal authority and a prevailing 
practice that inhibits its flexibility with respect to the coverage of medical technology.  This is 
illustrated by the recent NCD for sipuleucel-T (Provenge®), a vaccine-based treatment indicated 
for advanced prostate cancer approved by the FDA in 2010. (CMS 2011a;FDA 2010)  While 
sipuleucel-T is associated with estimated survival gains of 4.1 months compared to placebo, the 
cost of the treatment is notably high, $93,000 for a course of three treatments.  Prostate cancer is 
a prevalent disease in the Medicare population, and upon sipuleucel-T’s approval CMS were 
faced with the challenge of how to pay for an intervention that could potentially have huge 
implications for the cost of the programme.  Ultimately, after much debate and comment from 
stakeholders, CMS covered sipuleucel-T in accordance with the approved FDA indication.  This 
NCD serves as a useful case study of the limited flexibility that CMS has with respect to 
coverage.  Without the authority to negotiate on price, and with cost-effectiveness evidence 
effectively excluded from consideration, CMS’s only option is to closely scrutinise the clinical 
evidence base.  The NCD for sipuleucel-T shows that without the authority to consider cost-
effectiveness evidence, CMS have few options but to cover interventions that offer marginal 
incremental health benefits, irrespective of their cost.   
 
This lack of authority was exacerbated by Medicare recently losing its authority to use the long-
standing “least costly alternative” (LCA) policy.  Essentially a cost-minimisation strategy, the 
LCA policy allowed Medicare to pay the rate of the lowest cost alternative in situations where 
there was no evidence of clinical superiority between two products.  In December, 2009, 
Medicare lost a legal challenge on the grounds that Congress establishes payment policy and 
does not give Medicare explicit authority for LCA. (Hays v. Sebelius, 2009) 
 
CMS will inevitable face future difficult coverage decisions, particularly as highly expensive 
cancer treatments hit the marketplace.  Given its limitations, CMS face a significant challenge to 
balance the provision of new and expensive interventions while administering Medicare in a 
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fiscally responsible manner.  Payment reform should be accelerated to grant CMS the authority 
and flexibility to make coverage decisions consistent with these goals.   
 
8.9.1.2 Resistance to the use of cost-effectiveness evidence 
Resistance to the use of cost-effectiveness evidence in the US health care system is well 
established.  While the phenomenon of American exceptionalism, i.e., the general resistance to 
limit setting, is inherent throughout US society, it is maybe most visible in the political realm of 
health care.  With health care a contentious political issue, as exemplified by the debate 
surrounding, and resistance to, proposed changes in the recent health reform legislation, moving 
health care towards more value-based policies is likely to be hugely challenging.  Indeed, when 
considering the Medicare programme and the Oregon Health Plan, opposition from politicians 
contributed to previous failure to introduce cost-effectiveness considerations into decision-
making (Section 3.4.2). 
 
Cost-effectiveness analysis remains a difficult political sell.  Concerns that cost-effectiveness 
evidence may adversely affect the revenue streams of manufacturers, providers, insurers and 
health care professions are likely to hinder its future use.  Without politic support for its use, any 
change regarding the use of cost-effectiveness evidence remains unlikely.  However, at a time 
when the cost of health care is considered one of the most significant threats to the US’s fiscal 
wellbeing, perhaps the current environment is one in which there exists a political willingness to 
foster a change in health care.  Once there is a willingness on the part of politicians to accept that 
the health care system cannot offer all beneficial services regardless of cost, a debate can begin 
as to how best to implement the changes.   
 
8.9.1.3 Acceptance of limitations on health care 
In Chapter 2, I showed that to use cost-effectiveness evidence, there either must be a budget 
constraint or a cost-effectiveness threshold in operation; it is notable that CMS do not have either 
of these.  CMS do not have a fixed annual budget; rather, the cost of the programme increases 
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with the rising cost of care provision. The lack of a fixed budget is important as it has meant that 
CMS have not had to face considerations of opportunity cost in their coverage decisions.   
 
Setting an annual budget, or limiting spending growth, would help promote debate regarding the 
limits of the Medicare programme and the relative value of the services it provides.  Starting the 
debate as to how CMS should allocate scarce Medicare resources between services would 
perhaps provide a path to an open discussion among stakeholders with respect to relative value, 
opportunity cost, and cost-effectiveness. 
 
8.9.1.4 Ambiguity of decision-making criteria 
While the empirical work presented in Chapter 6 provides some insight into CMS’s decision-
making criteria, in the absence of a definition of how the ‘reasonable and necessary’ coverage 
criteria should be interpreted, much ambiguity remains.  Though there may be some benefit in 
CMS shielding decision-making criteria from public scrutiny if, as a result, outcomes are 
achieved that would not have been through a transparent process, it is unclear how this would be 
the case with respect to NCDs.   
 
Without explicit decision-making criteria, CMS maintains a degree of flexibility in their 
coverage decisions.  This flexibility, while beneficial to CMS, leads to uncertainty for 
manufacturers and the medical community as to the coverage of, and access to, medical 
technology, and prevents parties effectively negotiating with the CMS.  Further, a lack of a clear 
decision rule risks inequitable and inconsistent coverage decisions.   
 
Having clear coverage criteria would be beneficial.  It would decrease the uncertainty regarding 
CMS coverage among stakeholders and promote more consistent decision-making.  For 
manufacturers, explicit coverage criteria would help inform the evidence required to support 
positive coverage decisions, helping the design of clinical development programmes.   
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It would also have the effect of making transparent the trade-offs CMS make in their decision-
making and providing insight into how value factors into decision-making.  Currently, by virtue 
of the ambiguity of decision-making criteria CMS maintain the illusion that rationing does not 
occur in the Medicare programme.  However, this is evidently not the case.  Medicare does make 
rationing decisions, but it does so in a closeted manner, concealed behind coverage policies that 
are supposedly based solely on clinical evidence. (Fox 2010)  However, as the research presented 
in Chapter 7 suggests, not explicitly considering cost-effectiveness evidence comes at a cost, 
with resource allocation less efficient than would otherwise be achievable.  Further, because of 
the veiled nature of coverage decisions, it is impossible to determine their consistency with 
societal preferences for the coverage of medical technology.  
 
8.9.1.5 Learn from international experiences 
This thesis illustrates the benefits of using cost-effectiveness evidence to inform coverage of 
medical technology.  However, for the foreseeable future, it seems unlikely that cost-
effectiveness evidence will become as deeply integrated into the US health system as it has in 
other countries, e.g., the UK, Sweden, Australia, and Canada (3.3.1).  However, as described in 
Chapter 3, international experience shows that the introduction of cost-effectiveness evidence 
does not require a fundamental change in a health care system.  It is notable that it is in recent 
times economic evidence has been considered by institutions in Germany and France, and it has 
been incorporated in a manner that complements existing approaches to technology evaluation, 
with coverage decisions remaining principally grounded in the clinical evidence base. 
 
Also shown in Chapter 3 is that in no institution is cost-effectiveness the sole decision-making 
criterion.  While NICE operates an explicit threshold, the threshold exists over a range to allow 
for a range of other factors to be accounted for in decision-making (Section 2.6.3.2).   
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If there was the political will to consider cost-effectiveness evidence, CMS could learn from the 
various models used in other countries.  Experience illustrates that it is possible to include cost-
effectiveness evidence in coverage decisions in a transparent manner that would complement 
existing processes and institutional structures. 
 
8.9.1.6 Comparative effectiveness 
While great resistance to the use of cost-effectiveness evidence remains, comparative 
effectiveness evidence has recently been put under the spotlight as an approach to increase 
efficiency in the US health care system.  Recently, the PPACA legislation created the Patient 
Centered Outcomes Research Institute (PCORI) to coordinate comparative effectiveness research 
(CER) studies, assist in CER study funding, and to disseminate study findings. (PPACA 2010)  
While CER may prove sufficient to increase the value of care in some instances, i.e., identifying 
dominated interventions, the approach does account for the value of health gain, necessary when 
allocating scarce resources.  A proposed payment model incorporating CER would require 
Medicare to pay equally for interventions that provide comparable health outcomes, with higher 
payments set for interventions that have been demonstrated to provide superior health benefits. 
(Pearson & Bach 2010)  However, how to value additional health gain, and thus how to set 
prices, is unclear, and the approach does not satisfactorily circumvent the rationale for cost-
effectiveness analysis.  While not met with the same degree of resistance as cost-effectiveness 
evidence, not all stakeholders have embraced comparative effectiveness evidence, with 
opponents suggesting a negative impact on innovation and patient care. (Carrier, Pham, & Rich 
2010;Vernon & Goldberg 2011)   
 
Certainly, comparative effectiveness evidence is a step towards the consideration of value in 
decision-making.  Considering incremental benefits of competing treatments better informs 
decisions between competing interventions.  However, without consideration of cost, how to 
interpret the value of the incremental benefit is challenging.  
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8.10. Conclusions 
This thesis is timely and its findings have a number of important policy implications.  CMS 
NCDs are reserved for interventions deemed particularly controversial or projected to have a 
major impact on the Medicare programme and offer a valuable insight into CMS coverage of 
interventions.  This thesis aimed to evaluate the current use of cost-effectiveness analysis in 
Medicare, and to estimate the potential value of using it in terms of aggregate health gains.   
 
Despite their stated position on the use of cost-effectiveness evidence the empirical work 
highlighted that CMS have on occasion discussed or cited cost-effectiveness evidence in decision 
memos.  While I identified instances when CMS have covered interventions not cost-effective by 
traditional standards, I found that interventions subject to positive coverage decisions tend to be 
associated with more favourable cost-effectiveness evidence. 
 
The second piece of empirical work evaluated the role of cost-effectiveness evidence in CMS 
NCDs while controlling for other factors that are likely to have an effect on Medicare coverage 
decisions.  I determined that compared to interventions associated with cost-effectiveness 
evidence that estimated the intervention to be dominant; those with no associated estimate of 
cost-effectiveness were approximately five times less likely to be covered.  This finding again 
contradicts CMS’s stated position on the use of cost-effectiveness evidence.  The findings also 
illustrated that CMS operate use an evidence based approach for NCDs and that the availability 
of alternative interventions has a significant effect on the likelihood of coverage.  Lastly, the 
research showed that CMS have become more restrictive over time with respect to the coverage 
of medical interventions. 
 
The findings from the third empirical aspect of this thesis serve to highlight the potential benefits 
of considering value in Medicare coverage policy, suggesting that substantial aggregate health 
gains are achievable from using cost-effectiveness evidence to guide resource use. 
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While this thesis has shown that cost-effectiveness evidence has been discussed or cited on 
occasion, it is clear that it is not used, or acted upon, with regularity and, accordingly, the 
Medicare programme could be more efficient.  This is borne out by the research presented in 
Chapter 7 in which I estimated that substantial gains could be achieved from using cost-
effectiveness evidence. 
 
Rationing is an unavoidable reality in the Medicare programme.  CMS maintain, however, that 
cost-effectiveness is not a factor in decision-making, therefore suggesting that interventions with 
positive benefits are paid for, regardless of costs.  This closeted approach to rationing has proved 
insufficient and maintaining the current position on the use of cost-effectiveness has come at a 
cost in terms of efficiency.  Moving forward, CMS will have to decide if it is prepared to 
continue to trade-off the use of cost-effectiveness, and the associated gains in aggregate health, 
for the illusion that health care is unrationed. 
 
While politically difficult for the US government to set explicit limits on access to health care 
interventions, discouraging the use of cost-effectiveness evidence in Medicare is unfortunate.  
Only if full information of the relationship between the costs and benefits of interventions is 
available can a health care system be expected to work efficiently. (Neumann & Weinstein 2010)  
 
It seems certain that the Medicare will suffer from increasing fiscal difficulties.  It is inevitable 
that CMS will have to act to manage the financial sustainability of the programme as new 
expensive interventions become available.  What is uncertain is the approach CMS will take.  
Irrespective of the taken approach, the goal will be the same, i.e., to improve programme value.  
Despite the resistance to the use of cost-effectiveness evidence in the US health care system, as 
shown in this thesis, cost-effectiveness analysis offers one approach to inform efficient resource 
allocation.   
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If the political will to use cost-effectiveness evidence to inform resource allocation existed, CMS 
could learn from the experiences of other countries.  While to emulate the processes used in 
countries in which cost-effectiveness evidence plays a fundamental role in decision-making, e.g., 
the UK, Sweden, Australia, and Canada (Section 3.3.1), would require radical changes in the US 
health care system, lessons from Germany and France prove that cost-effectiveness can be 
incorporated without the need for radical overhauls.  As I described in Chapter 3, Germany and 
France are countries that have in recent times incorporated cost-effectiveness evidence into 
aspects of decision-making, while ensuring that existing process remained essentially unaltered.  
In Germany and France decision-making remains grounded in the clinical and comparative 
evidence with economic evidence incorporated in a manner to complement existing approaches 
to technology assessment. 
 
The fiscal challenges facing the Medicare programme, and the US health care system in general, 
are unlikely to diminish in the foreseeable future.  CMS face the challenge of balancing the 
provision of new and expensive interventions, while administering Medicare in a fiscally 
responsible manner.  This thesis shows that cost-effectiveness analysis is an approach that can 
achieve value based coverage policy.  What is required is the political will to make bold and 
likely hugely unpopular steps to shift coverage policy to one that is explicitly evidence and value 
based. 
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10.1.  Appendix 1 - Assigning monetary values to life – worked examples 
10.1.1. Compensating wage method (revealed preference) 
The compensating wage, or revealed preference, method can be used to estimate the value of a 
statistical life (VSL) can be estimated by multiplying the wage differential by the inverse of the 
difference in probability of death or injury. (Brannon 2005;Drummond, Sculpher, Torrance, 
O'Brien, & Stoddart 2005b)  A worked example is presented below: 
 
 
 
- VSL = Wage differential*Risk differential 
- VSL = 500*10,000 
- VSL = 5,000,000   
10.1.2. Contingent valuation  
Contingent valuation is another approach to estimating the VSL.  A worked example of CV is 
presented below (Drummond, Sculpher, Torrance, O'Brien, & Stoddart 2005b): 
- Current risk of a motorcyclist being killed in an accident = 50 in 100,000 
- Risk of a motorcyclist being killed in an accident with new safety feature = 25 in 100,000 
- Reduction in risk (dR) = 25 in 100,000 
- Maximum willing to pay for safety feature (dV) = £100 
- Implied value of life  = dV/dR 
    = £100/25 x 10-5 
    = £400,000 
 
 Wage Risk of death 
Job A 20,000 1/10,000 
Job B 20,500 2,10,000 
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10.2.  Appendix 2 – Email correspondence 
 
Email received from Prof. Christopher J.L. Murray (received January 29th, 2007). 
Dear James, 
The result is from an analysis by Jeff Sacks. It follows form a basic utility maximization model where 
healthy life years are effectively the integrand for U(c).  A log utility function yields something close to 3 
if I remember.  More concave utility functions would yield a higher multiplier. In fact, many plausible 
utility functions would argue that the multiplier of gdp per capita would increase as consumption 
increases.  I am not sure if the maths were ever published but they should be easy to replicate.   
Regards 
Chris Murray 
 
Email received from Prof. Jeffrey D. Sachs (received January 29th, 2007). 
Dear James, 
 
The standard of a DALY threshold at 3 times per capita income appears informally in several mentions in 
published articles.  The common US threshold of around $135,000 per DALY is an example. There is no 
deep-deep theory, but there are relevant articles by Alan Garber (and a co-author, whose name I don't 
recall for the moment), and value-of-life articles by Chicago economists, explaining why the benefit of an 
extra life year is equal in fact to three components: the direct effect, a curvature effect (more years to 
smooth the income), and a leisure effect.  Again, as I'm away from my office, I don't have references at 
hand. 
 
I would suggest that you also look at empirical cutoff points that are used in the U.S., U.K., and perhaps 
other high-income countries.  When I did that a few years ago, the 3x income level was roughly right. 
 
Please let me know what else you find, and I can take this up in more detail when I return from Africa. 
 
Best regards, 
Jeffrey Sachs 
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10.3. Appendix 3 - Review of NCD for Deep Brain Stimulation  
Comments 
One cost-effectiveness study set in the US was published prior to the decision memo. 
Number of decision/sub decisions available from this memo 
Two decisions were identified from the decision memo: first, positive coverage of DBS for 
Parkinson’s Disease (PD) patients that meet specified criteria; second non-coverage of DBS for 
PD patients that do not meet specified criteria 
Intervention:  
Deep Brain Stimulation (DBS) for Essential Tremor and Parkinson’s Disease 
Coverage criteria/decision: 
Medicare will cover unilateral or bilateral thalamic VIM DBS for the treatment of essential 
tremor (ET) and/or Parkinsonian tremor and unilateral or bilateral STN or GPi DBS for the 
treatment of Parkinson’s disease only under the following conditions: 
1. Medicare will only consider DBS devices to be reasonable and necessary if they are Food 
and Drug Administration (FDA) approved devices for DBS or devices used in accordance 
with FDA approved protocols governing Category B Investigational Device Exemption 
(IDE) DBS clinical trials. 
2. For thalamic VIM DBS to be considered reasonable and necessary, patients must meet all 
of the following criteria: 
a. Diagnosis of essential tremor (ET) based on postural or kinetic tremors of hand(s) 
without other neurologic signs, or diagnosis of idiopathic PD (presence of at least 
2 cardinal PD features (tremor, rigidity or bradykinesia) which is of a tremor 
dominant form  
b. Marked disabling tremor of at least level 3 or 4 on the Fahn-Tolosa-Marin 
Clinical Tremor Rating Scale (or equivalent scale) in the extremity intended for 
treatment, causing significant limitation in daily activities despite optimal medical 
therapy.  
c. Willingness and ability to cooperate during conscious operative procedure, as 
well as during post-surgical evaluations, adjustments of medications and 
stimulator settings. 
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3. For STN or GPi DBS to be considered reasonable and necessary, patients must meet all 
of the following criteria: 
a. Diagnosis of PD based on the presence of at least 2 cardinal PD features (tremor, 
rigidity or bradykinesia). 
b. Advanced idiopathic PD as determined by the use of Hoehn and Yahr stage or 
Unified Parkinson’s Disease Rating Scale (UPDRS) part III motor subscale. 
c. L-dopa responsive with clearly defined “on” periods. 
d. Persistent disabling Parkinson’s symptoms or drug side effects (e.g., dyskinesias, 
motor fluctuations, or disabling “off” periods) despite optimal medical therapy. 
e. Willingness and ability to cooperate during conscious operative procedure, as 
well as during post-surgical evaluations, adjustments of medications and 
stimulator settings. 
DBS is not reasonable and necessary and is not covered for ET or PD patients with any of the 
following: 
1. Non-idiopathic Parkinson’s disease or “Parkinson’s Plus” syndromes. 
2. Cognitive impairment, dementia or depression which would be worsened by or would 
interfere with the patient’s ability to benefit from DBS. 
3. Current psychosis, alcohol abuse or other drug abuse. 
4. Structural lesions such as basal ganglionic stroke, tumor or vascular malformation as 
etiology of the movement disorder. 
5. Previous movement disorder surgery within the affected basal ganglion. 
6. Significant medical, surgical, neurologic or orthopedic co-morbidities contraindicating 
DBS surgery or stimulation.  
Patients who undergo DBS implantation should not be exposed to diathermy (deep heat 
treatment including shortwave diathermy, microwave diathermy and ultrasound diathermy) or 
any type of MRI which may adversely affect the DBS system or adversely affect the brain 
around the implanted electrodes. 
 
DBS should be performed with extreme caution in patients with cardiac pacemakers or other 
electronically controlled implants which may adversely affect or be affected by the DBS system. 
  
392 
 
For DBS lead implantation to be considered reasonable and necessary, providers and facilities 
must meet all of the following criteria: 
1. Neurosurgeons must: (a) be properly trained in the procedure; (b) have experience with 
the surgical management of movement disorders, including DBS therapy; and (c) have 
experience performing stereotactic neurosurgical procedures. 
2. Operative teams must have training and experience with DBS systems, including 
knowledge of anatomical and neurophysiological characteristics for localizing the 
targeted nucleus, surgical and/or implantation techniques for the DBS system, and 
operational and functional characteristics of the device. 
3. Physicians specializing in movement disorders must be involved in both patient selection 
and post-procedure care. 
4. Hospital medical centers must have: (a) brain imaging equipment (MRI and/or CT) for 
pre-operative stereotactic localization and targeting of the surgical site(s); (b) operating 
rooms with all necessary equipment for stereotactic surgery; and (c) support services 
necessary for care of patients undergoing this procedure and any potential complications 
arising intraoperatively or postoperatively. 
Since long-term safety, effectiveness and optimal targeting for DBS have not been established, 
CMS will review the appropriateness of Medicare coverage as pertinent new evidence becomes 
available. This review will include clinical follow-up and targeting information from the 
ongoing, randomized VA/NINDS Cooperative Trial comparing best medical therapy with DBS 
of the STN and GPi for PD, as well as longer term clinical results from mandatory annual 
progress reports and final report to the FDA of Medtronic’s bilateral DBS PMA post-approval 
study. 
Is there an alternative treatment available? 
Yes. The following are excerpts from the decision memo: 
 
“Pharmacotherapy with propanolol (a beta-adrenergic blocker) and primidone (an 
anticonvulsant medication) are first line agents in the treatment of ET and may improve function 
by reducing the severity of tremor. However, certain patients do not adequately respond to or 
cannot tolerate these medications”. 
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“Treatments for PD include those which alleviate symptoms (symptomatic therapy), slow the 
loss of nerve cells (neuroprotective), and increase and/or improve cell function (restorative). 
Currently, symptomatic therapy - with medications, lesioning surgery or DBS - is the only 
available treatment for patients with PD”. 
“L-dopa is the oldest and most potent symptomatic drug treatment and remains the gold 
standard for relieving the symptoms of PD”. 
“Dopamine agonists (such as bromocriptine, pergolide, pramipexole and ropinirole), which 
directly stimulate dopamine receptors but are not as effective as L-dopa, are also used as an 
initial form of therapy in order to delay the need for L-dopa and its associated long-term adverse 
effects”. 
Type of treatment benefit 
As this treatment does not increase life expectancy it is determined that it has an “Increase in 
quality of life”. 
Is this an explicit decision in the decision memo? 
Yes 
Prevalence in Medicare population 
Not known. However, the following is an extract from the decision memo, “Parkinson’s Disease 
(PD) effects up to 1 million Americans”. 
Budget impact of this technology in the Medicare population 
Not known. 
First line? 
No.  The following text is extracted from the decision memo:  
“For patients who become unresponsive to pharmacological treatments and/or have intolerable 
drug side effects, lesioning surgeries and DBS may be helpful for carefully selected patients”. 
 
 
Economic evaluations (4): 
The study by Tomaszewski KJ and Holloway RG (2001) was ultimately included in the 
database.  It was assigned the highest grade of the four cost-effectiveness studies review (a ‘C’ 
grade). 
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The following studies were identified from the search strategy and reviewed.   
1. Tomaszewski KJ, Holloway RG.  Deep brain stimulation in the treatment of Parkinson's 
disease: a cost-effectiveness analysis.  Neurology. 2001 Aug 28;57(4):663-71. 
2. Charles PD, Padaliya BB, Newman WJ, Gill CE, Covington CD, Fang JY, So SA, 
Tramontana MG, Konrad PE, Davis TL.  Deep brain stimulation of the subthalamic 
nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord. 2004 
Dec;10(8):475-9. 
3. Meissner W, Schreiter D, Volkmann J, Trottenberg T, Schneider GH, Sturm V, Deuschl 
G, Kupsch A. Deep brain stimulation in late stage Parkinson's disease: a retrospective 
cost analysis in Germany. J Neurol. 2005 Feb;252(2):218-23. 
4. Valldeoriola F, Morsi O, Tolosa E, Rumià J, Martí MJ, Martínez-Martín P.  Prospective 
comparative study on cost-effectiveness of subthalamic stimulation and best medical 
treatment in advanced Parkinson's disease. Mov Disord. 2007 Nov 15;22(15):2183-91. 
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Appraisal of Tomaszewski KJ and Holloway RG, 2001 
 
Appraisal of Charles DP et al, 2004 
 
 
Assessment criteria: Comment: 
Year of study Price year 2000 
Perspective of study Societal 
Comparator Best medical management 
Country setting USA 
Study population Patients aged 50 years or older who are in the later stages of the 
disease (Hoehn and Yahr stage between 3 and 5) with intractable 
motor fluctuations. 
Incremental cost-effectiveness ratio 
(ICER) 
 Base case analysis - $49,000 
Uncertainty associated with reported 
ICER(s) 
As part of a sensitivity analysis the authors varied the efficacy in 
the treatment of DBS in terms of QALYs gained. This varied from 
DBS being dominated to $27,147 
The year study was published 2001 
The purpose of the  cost-effectiveness 
analysis 
The purpose of this economic evaluation appears to be for 
publication only 
Other comments The model time horizon is the remaining life expectancy of the 
patient.  
 
This economic evaluation was available at the time that the 
decision was made. The economic evaluation did use some 
theoretical input values; indeed, the author states the requirement 
for additional randomized controlled trials. 
Assessment criteria: Comment: 
Year of study Price year 2002 
Perspective of study Payer 
Comparator Standard care – no direct comparator was used. As this was a cost 
study it demonstrated how the cost of the technology was offset in 
subsequent years 
Country setting USA 
Study population US population, mean age of patients 57 years if age. 
Incremental cost-effectiveness ratio 
(ICER) 
Cost saving – only in relation to pharmacological treatment? 
Uncertainty associated with reported 
ICER(s) 
No estimate of uncertainty was presented 
The year study was published 2004 
The purpose of the  cost-effectiveness 
analysis 
The purpose of the economic evaluation was for publication only 
Other comments Small sample size 
 
The economic evaluation uses hypothetical increases in the cost of 
pharmacological treatment. Cost savings are in relation to 
pharmacological treatment only and does not take into account the 
cost of the procedure 
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Appraisal of Meissner et al. 2005 
 
 
 
 
 
 
 
 
 
 
  
Assessment criteria: Comment: 
Year of study Electrodes were implanted between May 1997 and December 
2000 – No price year us given 
Perspective of study Payer – Article states that no patients returned to work following 
the procedure 
Comparator Standard care 
Country setting Germany 
Study population German population - 58.6±1.0 years and mean disease duration 
was 16.0±0.7 years. 
Incremental cost-effectiveness ratio 
(ICER) 
  DBS was dominant after the 1st year 
Uncertainty associated with reported 
ICER(s) 
No estimate of uncertainty was presented 
The year study was published 2005 
The purpose of the  cost-effectiveness 
analysis 
The purpose of the evaluation appears to be for publication only 
Other comments The costs were assessed for one year before and two years after 
implantation of deep brain stimulators focusing on the charges for 
drug treatment, in-patient hospital care and outpatient care. All 
calculated costs are indicated in euros. 
  
397 
 
Appraisal of Valldeoriola F et al, 2007 
 
 
 
 
 
 
 
Assessment criteria: Comment: 
Year of study Price year not stated.  Appears that study was completed in 2006. 
Perspective of study Appears to be societal.  Authors state that only ‘Direct costs’ were 
included and these were divided into two categories: 
a. Direct medical costs, related to costs for goods and services used 
in the prevention, diagnosis, treatment, and rehabilitation of the 
illness (for example, costs for medical visits, hospitalization, and 
pharmaceuticals). 
b. Direct nonmedical costs, generally assumed by the patient, 
including expenses related to the disease (for example,  
transportation, social services, adaptation of accommodation and 
any kind of special equipment, facilities or orthopedic material). 
Comparator STN-DBS and best medical management in patients with advanced 
PD 
Country setting Spain 
Study population Yes.  Mean age of patients in STN-DBS grp  59.9 (SD 6.8), mean 
age of patients in BMT group  63.8 (SD 6.4) 
Incremental cost-effectiveness ratio 
(ICER) 
34,389€/QALY 
Uncertainty associated with reported 
ICER(s) 
Only basic sensitivity analyses were conducted.  
 
These included: 
Excluding the BMT patient group patient who had a prolonged 
hospitalization from the analysis - incremental cost per QALY was 
of 44,078€ (X1.3).  
 
Excluding patients treated with continuous apomorphine infusion, 
(an expensive therapy) - 62,148€ per QALY (X1.8). 
The year study was published 2007 
The purpose of the  cost-effectiveness 
analysis 
The purpose of the evaluation appears to be for publication only 
Other comments Open, prospective, longitudinal study 
 
EQ-5D used to estimate utility in the clinical trial.   
 
Study performed over a period of one year. 
